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Abstract  
Validation of Oral Fluid as a Matrix for Drug Detection 
Eva Maria Reichardt 
New testing procedures used as an aid for law enforcement are subject to intensive 
scrutiny in the courts.   In recent years in workplace drug testing there has been a shift 
away from using traditional specimens (i.e urine) for drug testing and monitoring and 
a move to employing less invasive testing using oral fluid.   
Whilst it is now widely accepted that drugs can be detected in oral fluid and devices 
are now available to facilitate analysis of drugs in this matrix, our understanding of the 
behaviour of drugs in the mouth and oral secretions is far from complete. Since the 
introduction of oral fluid drug testing in the late 1990’s it has been observed that some 
drugs appear to be present at higher than expected concentrations, often at 
concentrations that would be fatal if they were in blood. Clearly some extra process is 
occurring in addition to drugs entering the oral fluid by simple blood and saliva 
partitioning. Little is really known about the physiology of drugs in the mouth and 
limited understanding of drug elimination via the mouth poses a problem to forensic 
toxicologists with the interpretation of analytical results in relation to an individual’s 
drug use or the possible effects that the drug may be exhibiting on that individual.  
The work described in this thesis is aimed at increasing our understanding of the 
factors and processes concerning the deposition, secretion and detection of drugs in 
oral fluid and enhancing our ability to interpret the results of analysis in this matrix. 
The objective of this study was to explore how high drug concentrations can be 
deposited in the mouth tissues and oral fluid together with other factors that may 
influence drug detection in order to assist with the interpretation of testing results.  
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To test the hypothesis that drug depots form within the mouth, preliminary screening 
methods in combination with confirmatory techniques such as GC-MS and LC-
MS/MS were employed. The development of an immunohistochemical method was 
successfully demonstrated for the detection and visualisation of cocaine and opiates 
(heroin and morphine) in porcine and mouse tissue.  
The work undertaken in this thesis showed that elevated drug concentrations can be 
observed when drugs are consumed via oral administration either in form of an oral 
solution or smoking. Immunohistochemical analysis in combination with confirmatory 
techniques demonstrated that drugs such as cocaine and opioids can bind to oral tissue 
and be subsequently released over time, therefore has the potential to contribute to the 
drug concentration in oral fluid.  Although this is not an issue under legislation that 
forbids the presence of drugs or as a check for drug compliance or abstinence, it must 
be considered in relation to the interpretation of results in more complex forensic cases.  
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Chapter 1.0 - Background  
Workplace drug testing originated in the U.S. Navy when, in 1980, the U.S. 
Department of Defence launched a survey within the armed forces to investigate the 
extent of drug use and its effects on performance in the workplace. The Survey 
revealed that 47% of US Navy personnel admitted marijuana use in the 30 days prior 
to testing (Manno 1986, Cangianelli 1989). 
The enforcement of drug testing was considered following the 1981 crash of an 
aircraft on the aircraft carrier USS Nimitz resulting in several deaths.  Post-mortem 
results carried out on those killed in crash revealed traces of marijuana in seven 
members of the crew (Li et al 2011). As a consequence of the results obtained from 
the US Navy personnel survey and this aircraft incident, the US military developed a 
drug testing programme in which random urine specimen collections were enforced 
and disciplinary action imposed on those found positive for controlled drugs (Peat 
1995).   
In 1986, this drug testing scheme was extended to all federal agencies with the setup 
of the Drug Free Workplace Programme (Jacobson 2013). Since then, workplace 
drug testing has become an established procedure worldwide, particularly in safety 
related industries. Verstraete et al (2001) reported that in the United Kingdom, 40% 
of workplace drug testing took place in the military, 35% in prisons and 25% in all 
other companies.  
Urine was initially used for drug testing in the workplace because it is easy to obtain, 
is a relative simple matrix to analyse and drugs or their metabolites are normally 
present in significantly higher concentrations than alternative matrices such as blood. 
Following the widespread introduction of workplace drug testing, entrepreneurial 
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individuals manufactured and marketed a wide range of chemical agents to act as 
reagents to “Beat the Test”. As these substances became widely available via the 
internet workplace drug testing authorities introduced a number of guidelines for 
controlled specimen collection and testing in order to minimise adulteration of urine 
samples (Manno 1986, Winecker and Goldberger 1998, EWDTS 2009). The 
mandatory guidelines included observed specimen collection procedures and the 
introduction of laboratory tests to detect adulterants. Observed urine collection is not 
only unpleasant for the donor, but is also costly, hence suppliers of workplace drug 
testing services began to explore the use of alternative matrices such as oral fluid. 
Oral fluid is advantageous as a matrix for drug detection, as it is a fast and cost 
effective method for drug detection, but the technique is still in its relative infancy 
and there are many unknown factors, related to drugs in oral fluid that remain 
unresolved. One of the principal problems that remains to be tackled is related to 
explaining the exceptionally high drug concentrations that can be observed after use 
of some drugs and the implications that these may have on oral fluid testing and the 
interpretation of oral fluid drug concentrations. The work undertaken in this thesis 
aims to explore some of the issues mentioned above. 
1.1 Oral fluid 
Oral fluid, also commonly referred to as “whole saliva”, is principally composed of 
saliva, gingival fluid, bronchial and nasal secretions, serum, traces of blood, bacteria, 
viruses, epithelial cells, cellular components and food debris (Malamud et al 1993) 
Oral fluid is critical to oral hygiene and therefore its composition has been widely 
investigated and published in the literature. 
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The term oral fluid is used by many authors interchangeably with saliva but for the 
purpose of work undertaken in this thesis my measurements will refer to oral fluid 
rather than saliva.  
1.1.1 Composition of Oral Fluid 
1.1.1.1 Saliva 
Saliva is a clear, tasteless, odorless and viscous fluid formed in the salivary glands 
that plays an important role in maintaining dental health by removing bacteria and 
food from the mouth (van Niew Amerongen et al 2004). The main functions and 
constituents of saliva are summarised in Figure 1.1.  
 
Figure 1.1 represents the main functions of saliva on the teeth, food and microbes 
within the mouth. It also shows the main constituents of saliva to achieve those 
functions and processes (Amerongen et al 2004) 
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1.1.1.1.1 Salivary Glands 
Saliva is principally produced by the glandular parotis (parotid gland), glandular 
submandibularis (submandibular gland) and the glandular sublingualis (sublingual 
gland) (Figure 1.2). Saliva comprises approximately 99 % water and 1 % proteins 
and other constituents. 
 
Figure 1.2 Diagrammatic representation of the mouth showing the location of the 
principal salivary glands 1) parotid gland 2) submandibular gland 3) sublingual gland 
(Aps and Martens 2004) 
 
The parotid gland is the largest of the three main saliva glands. It is positioned in 
front of and below each ear (Figure 1.2). Controlled by the central nervous system, 
the parotid gland produces saliva at a flow rate of 0.3 mL/min, which is equivalent to 
around 65% of the total saliva secreted from all glands (Eisbruch et al 1999, Burlage 
et al 2005, Bhargava et al 2012). The submandibular gland is placed on the inner 
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sides of the lower mandible and produces saliva at a flow rate of around 0.26 
mL/min. Located below the tongue, the sublingual gland produces the lowest amount 
of saliva at a flow rate of 0.012 mL/min (Schneyer and Levin 1955).  
In addition to the three main salivary glands it has been estimated that there are 
between 450 and 750 minor accessory saliva glands situated on the tongue and 
buccal mucosa / palate which also produce saliva (Nieuw Amerongen et al 2007). 
Human salivary glands consist of acini consisting of small exocrine glands (Figure 
1.3).  Acini are made up of basophilic cytoplasm and large spherical nuclei.  Acinar 
excretion glands produce the saliva which is then excreted from an intercalated duct 
via the striated duct (excretory duct).  
 
Figure 1.3 Images showing the structure of salivary glands – the left column 
represents drawings whereas the right are images taken using a microscope (image 
taken from www.vetmed.vt.edu)  
Legend: SA =serous acini; MA = mucous acini; D= duct, SD = serous duct 
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1.1.1.1.2 Salivary pH 
The pH of saliva varies between pH 6.2 – pH 7.4 however the pH of saliva can 
change following the consumption of food. Meurman et al (1987) showed that 
salivary pH was affected by drinks such as sugary energy drinks and orange juice, 
with the pH dropping to a low of pH 3.8. Coffee and Cola resulted in a pH of 5.26. A 
study by Sanchez and Fernandez De Preliasco (2003) investigating salivary pH in 
relation to soft drink consumption in children also revealed that following the 
consumption of coca cola®, Sprite® and chocolate milk the pH of oral fluid dropped 
from pH 7.4 to pH 6.35, pH 6.20 and pH 7.17, respectively.  
Dawes and Macpherson (1992) investigated the effects of different chewing gums on 
salivary pH. As well as a tenfold increase in saliva flow rate, chewing gum 
containing organic acids resulted in decrease of pH 7.00 to pH 6.18 (unstimulated 
saliva is normally pH 6.95). Gum containing sugar as well as sugar free gum only 
resulted in a minor change in oral fluid pH.  
1.1.1.2 Lipids in oral fluid 
Larsson et al (1996) reported that the lipid concentration in saliva excreted from 
different salivary glands varied significantly. The paper showed that saliva excreted 
from the parotid gland contained lipids at a concentration of 0.21 mg/100 mL 
whereas submandibular and whole saliva displayed lipid concentrations of 0.89 
mg/100 mL and 1.31 mg/100mL respectively (Table 1.1). Neutral lipids such as 
cholesteryl esters, cholesterol, triglycerides, diglycerides and monoglycerides, were 
shown to be 99 % in the parotid saliva, 98 % in submandibular saliva and 96.4 % in 
whole saliva. Neutral lipids have been reported to make up around 70 - 95 % of 
lipids.  
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Table 1.1 Non-polar lipids in human saliva from different glands, pooled from 10 
individuals (Larsson et al 1996) 
 Parotid Saliva 
(mg/ 100mL). 
Submandibular 
saliva (mg/ 100mL). 
Whole saliva (Oral 
Fluid) (mg/100 
mL). 
Cholesteryl esters 0.03 0.26 0.43 
Triglycerides 0 0.19 0.29 
Diglycerides 0 0.05 0.26 
Cholesterol 0.09 0.17 0.13 
Monglycerides 0.07 0.15 0.10 
Total 0.19 0.82 1.21 
 
Polar lipids, consisting of phosphatidylcholine, phosphatidylethanolamine and 
sulphatides that are found in the membrane only accounted for around 1 to 5 % of the 
total saliva lipid concentration (Table 1.2).  
 Table 1.2 Polar lipids as percentages of the total amount of polar lipids in parotid, 
submandibular and whole saliva (Larsson et al 1996) 
 Parotid saliva 
Submandibular 
saliva 
Whole saliva 
Phosphatidylcholine 14 9 1 
Phosphatidylethanolamine 15 23 9 
Sulphatides 8 28 7 
Unidentified lipids 63 40 78 
% of non - polar lipids 0.8 2.0 3.6 
Lipids in oral fluid which result from contamination of food, consist of a wide range 
of neutral and polar lipids. Lipids in the mouth originating from food have been 
shown to alter drug absorption and bioavailability (Charman et al 1997, 
Humberstone and Charman 1997).  
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1.1.1.3 Proteins in oral fluid 
The primary function of the proteins and glycoproteins in saliva is to facilitate the 
retention of moisture in the gums, to act as a protective barrier and lubricant and to 
exert antimicrobial activity (Levine 1993) (Table 1.3).  
Table 1.3 Summary of the uses of the major salivary proteins (Levine 1993) 
Function Salivary component 
Anti-bacterial Amylases, cystatins, histatins, mucins, peroxidases 
Anti-viral Cystatins, mucins 
Anti-fungal Histatins 
Tissue coating 
Amylases, cystatins, mucins, proline-rich proteins, 
stratherins 
Lubrication and 
viscoelasticity 
Mucins, stratherins 
Mineralisation Cystatins, histatins, proline-rich proteins, stratherins 
Digestion Amylases, Mucins 
Buffering Carbonic anhydrase, histatins 
 
The proteins, which are located primarily on the gum surfaces, fall into four 
categories:  proline-rich proteins, stratherins, histatins and cystatins.  
Proline-rich proteins make up around 70% of the secretory proteins and play an 
important role in oral hygiene and oral health. Stratherins and histatin enzymes 
inhibit crystal growth of calcium phosphate salts and inhibit precipitation of calcium 
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phosphate, resulting in a build up of plaque, whereas cystatin proteins inhibit 
protease enzymes (Lamkin and Oppenheim 1993).  
Another vital protein present in saliva is amylase, which plays an important role in 
the digestion of food as well as conferring anti-microbial activity.  Lee et al (2007) 
reported the mean concentrations of a selection of proteins and carbohydrates in 
unstimulated and stimulated oral fluid obtained from 30 healthy volunteers (15 men 
and 15 women) with an age range of 20 – 26 years (mean age 23.3).  This is 
summarised in Table 1.4. 
Table 1.4 Mean concentrations of total protein, total carbohydrate, Immunoglobulin 
A, lactoferrin and sialic acid in unstimulated and stimulated oral fluid (Ahn et al 
2007, Lee et al 2007a, Lee et al 2007b) 
 Mean Concentration 
(µg/mL) 
Unstimulated Oral Fluid 
Mean Concentration 
(µg/mL) 
Stimulated Oral Fluid 
Total protein 785.6 646.2 
Total carbohydrate 26.3 23.2 
Immunoglobulin A 173.2 107.6 
Lactoferrin 1.3 1.0 
Sialic Acid 4.6 4.4 
 
Ferguson (1999) reviewed the composition of saliva produced by the human labial 
gland which is one of the many minor salivary glands and reported the organic 
components as summarised in Table 1.5.  The concentrations for total protein and 
immunoglobulin A (IgA) reported in Fergusson’s review fall within similar ranges to 
those reported by Lee et al (2007). 
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Table 1.5 Organic components of Labial gland saliva (Fergusson, 1999) 
 Concentration Concentration (µg/mL) 
Total protein 0.4 – 5.35 g/L 400 - 5350 
Amylase 1.0 – 12.0  mg/L 1.0 – 12 
Lysozyme 3.0 – 4.0   mg/L 3 – 4 
IgA 194     mg/L 194 
IgG 5mg/L 5 
IgM <1mg/L <1 
 
1.1.1.4 Electrolytes in oral fluid 
The main inorganic electrolytes of saliva are sodium, potassium, chloride, calcium, 
phosphate and bicarbonate. Calcium and phosphate are responsible for maintaining 
the integrity of the teeth by re-mineralising tooth surface following exposure to acids 
during consumption of foods and beverages.  
Bicarbonate, phosphate, histatins and carbonic anhydrase play a role in the buffering 
capacity of saliva which is influenced by storage conditions and may change if 
carbon dioxide loss occurs (Schipper et al 2007).  Neutral pH is optimal for the 
growth of micro-organisms associated with oral health (Bradshaw et al 1989, Marsh 
and Bradshaw 1990,  Bradshaw and Marsh 1998). The concentration of electrolytes 
is dependent on variables such as age and health. Nagler and Hershkovich (2001, 
2005b) compared the composition of electrolytes and proteins in a population of 23 
healthy 18 to 25 years olds (mean age 21.2 years) against a population of 22 healthy 
60-90 year olds (mean age 75.8 years) and reported significant differences in salivary 
composition (Table 1.6). Calcium secretion into saliva increases as the flow rate 
increases whilst potassium concentrations appear to be independent of flow rate.  
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Table 1.6 Salivary composition in young and elderly populations (Nagler and 
Hershkovich, 2005) 
Concentration 
Young (n=23) 
Mean concentration 
Elderly (n=22) 
Mean concentration 
Na+  (mmol/L) 9.52 12.56 
K+  (mmol/L) 19.2 27.78 
Cl (mmol/L) 19.7 29.50 
Ca2+           (mg/100mL) 3.45 5.15 
Protein     (mg/100mL) 49.8 93.4 
Amylase   (mg/l) 748 1476 
Lysozyme  (mg/mL) 10 26.3 
Albumin     (mg/100mL) 3.97 13.5 
IgA             (mg/100mL) 21.12 27.58 
IgG            (mg/100mL) 0.24 0.5 
 
The electrolyte concentrations in oral fluid reported by Nagler et al (2005a) and 
Shahar et al (2008) are compared against those summarised to be present in labial 
gland saliva (Ferguson 1999) in Table 1.7. 
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Table 1.7 Collated reported electrolyte concentrations in oral fluid  
Electrolyte 
Shahar 
et al, 
(2008) 
 
Nagler 
(2005a) 
 
Weismann et 
al (1972) 
(from 
Fergusson, 
1999) 
Dawes and 
Wood (1973) 
(from 
Fergusson, 
1999) 
Fergusson 
(1999) 
Phosphate 
(mmol/L) 
- - - 0.25 – 1.07 0.29 – 1.22 
Phosphate 
(mg/100mL) 
8 – 42.5 - - - - 
Na+ (mmol/L) - 9.5 – 12.6 4 – 15 3 – 38 30 - 125 
K+ (mmol/L) - 
19.2 – 
27.78 
12 – 30 10 – 30 4 – 20 
Cl (mmol/L) - 
19.7 – 
29.5 
- 16 – 54 - 
Ca2+ (mmol/L) - - - 1.6 – 3.2 2.4 – 5.8 
Ca2+ 
(mg/100mL) 
0.7 – 2.9 
3.45 – 
5.15 
- - - 
Mg2+ (mmol/L) - - 0.5 – 0.6 0.4 – 1.2 - 
Mg2+ 
(mg/100mL) 
0.4 – 1.3 - - - - 
 
 
1.1.2 Salivary flow rate 
The average person produces between 0.5 L to 1.5 L of saliva per day at a flow rate 
of approximately 0.6 mL/min (864 mL a per day) (Dawes 1987; Percival et al. 1994). 
However, the flow rate of saliva varies depending on different conditions such as 
smoking, drug use, climate and hydration. Smoking has been reported to cause a dry 
mouth by decreasing saliva flow rate and hence affecting oral fluid collection. 
(Anttila et al 1998, Axelsson et al 1998).  
Validation of Oral Fluid as a Matrix for Drug Detection – Chapter 1 
 
13 
 
Shannon (1966) reported that the production of saliva can be influenced by 
temperature and climate. A flow rate of 0.46 ml/min was reported in the winter and 
0.30 ml/min in warmer climates. A different study by Kavanagh et al (1998) who 
also investigated the effects of temperature and climate on saliva flow rate in great 
depth. Salivary flow rate can vary throughout the year with changing temperatures 
and that the flow rate increased with decreasing temperature (Shannon 1966, 
Kavanagh et al 1998). The change of the quantity of saliva production in warmer 
climates suggests that less saliva is produced as a result of dehydration. Additionally, 
salivary flow rate has been shown to decrease during exercise suggesting that this is 
a result of dehydration during exercise (Li and Gleeson 2004, Walsh et al 2004)  
1.1.3 Drug entry into oral fluid 
The original concept behind oral fluid drug testing  was that drugs circulating in the 
blood pass into the oral cavity via the saliva leading to a relationship between the 
concentration of drugs in the circulating blood and those that pass into the oral fluid 
(Kidwell et al 1998; Aps and Martens 2005). The transfer of drugs into oral fluid is 
dependent on lipid solubility of the drug, pH and molecular weight.  Following 
intravenous or tablet administration of many drugs it has been possible to calculate 
saliva:plasma (S/P) ratios (Spiehler 2011).  S/P ratios differ between drugs as a result 
of the variability of properties of different drugs (Table 1.8). 
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Table 1.8 Factors influencing the S/P Ratio of diffusible compounds (Haeckel 1993)  
1. Molecular Weight 
2. Lipid solubility 
3. pKa of ionized compounds 
4. Protein binding in plasma and saliva 
5. Flow rate of saliva 
6. Phenomenon of fluctuating arterial – venous differences 
7. Elimation kinetics  
 
Diffusion depends partly on the solubility of a compound, therefore lipophilic 
penetrate tissue easier than hydrophilic compounds. A theoretical S/P concentration 
can be calculated using the Henderson-Hasselbalch equation by applying the drug’s 
pKa, plasma and saliva pH and the amount of drug which has bound to the proteins 
within saliva and plasma (Haeckel 1993, Spiehler 2011). The legend is S=drug 
concentration in saliva; P=drug concentration in plasma; pKd=log of the ionisation 
constant for basic drugs; pHs=pH of saliva; pHp=pH of plasma, fp=fraction of drug 
protein bound in plasma and fs=fraction of drug protein bound in saliva   
 
𝑆 𝑃⁄ =
[1 + 10(𝑝𝐾𝑑−𝑝𝐻𝑠)]
[1 + 10(𝑝𝐾𝑑−𝑝𝐻𝑝)]
+
𝑓𝑝
𝑓𝑠
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This equation represents the calculation of the S/P ratio for acidic drugs.    
 
𝑆 𝑃⁄ =
[1 + 10(𝑝𝐻𝑠−𝑝𝑘𝑎)]
[1 + 10(𝑝𝐻𝑝−𝑝𝐾𝑎)]
+
𝑓𝑝
𝑓𝑠
 
 
The Henderson-Hasselbalch equation clearly shows that the S/P ratio is dependent on 
the saliva pH.  In section 1.1.1.1.2 the pH of saliva was discussed and it was shown 
that the average pH of saliva ranges between pH 6.2 – pH 7.4, dependent on the type 
external contamination. The variation of pH in saliva means that the S/P ratio can 
vary for each drug depending on the properties of saliva and plasma at the time of 
collection (Spiehler et al 2000). Additionally the quantity of drug detectable in saliva 
is subject to the flow rate. Variations in flow rate (section 1.1.2) may result in a 
larger dilution of the drug within the oral fluid decreasing the concentration detected 
(Haekel 1993, Woyceichoski et al 2013).   
1.1.4 Oral fluid collection 
Oral fluid may be collected by draining or spitting oral fluid into a tube, chewing on 
an absorbent material or placing an absorbent collection pad in the mouth and 
allowing the oral fluid to be absorbed. Oral fluid drug testing currently involves three 
stages: 1) oral fluid collection, 2) immunoassay screening and 3) confirmatory 
analysis of immunoassay positive samples using either gas chromatography/ mass 
spectrometry (GC-MS) or high performance liquid chromatography linked to a mass 
spectrometer (LC-MS). It is therefore essential that for oral fluid testing to be 
successfully achieved a) a sufficient flow of oral fluid is available for collection, b) 
there is sufficient drug present to be detected by the immunoassay and subsequent 
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confirmatory technique, c) the analytical testing steps are not affected by any non-
drug substances that might be present in the mouth e.g. foods or chemicals.  
A number of different types of oral fluid collection devices are commercially 
available however these differ markedly in their efficiency, the volume of oral fluid 
collected and whether an indicator is incorporated within the device to inform 
collection personnel when a sufficient quantity of oral fluid has been collected. Most 
oral fluid collection devices currently employed for workplace testing are based on 
the presence of some form of absorbent collection pad however they differ 
significantly in performance depending upon design, composition of the pad and also 
whether a chemical has been added to the pad (e.g. citric acid) to act as an oral fluid 
stimulant. Suggested factors which possibly affect the production of oral fluid in 
sufficient amounts for drug testing include diurnal rhythm, season of the year, the 
presence or thought of food, foods adulterants, smoking and the use of medications 
(Spiehler 2011).  
1.1.5 Workplace drug testing 
In 1986 the drug testing extended to all federal agencies in the USA under the Drug 
Free Workplace Programme (Jacobson 2003). Since then workplace drug testing has 
become an established procedure worldwide, particularly in safety related industries 
and guidelines have been established to provide guidance and ensure consistency for 
workplace drug testing.  
1.1.5.1 SAMHSA guidelines  
The Substance Abuse and Mental Health Services Administration (SAMHSA) was 
the first agency to publish mandatory guidelines for federal workplace urine drug 
testing in 1988 (SAMHSA 1994). There have been several edits to the drug testing 
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guidelines and in 2010 SAMHSA published their most recent guidelines which 
included oral fluid as a matrix for workplace drug testing (SAMHSA 2010). The 
purpose of these guidelines was to ensure the uniformity and reliability when testing 
for illicit drugs in the workplace (Bush 2008).  
1.1.5.2 UK workplace drug testing guidelines 
Guidelines have since also been established in the United Kingdom for the use of 
oral fluid drug testing in the workplace (Cooper et al. 2011). These guidelines were 
based on the SAMHSA guidelines but adapted for different drug use patterns. The 
guidelines were introduced in order to ensure the following:  
 consistency for workplace drug testing within the UK and between different 
workplace service providers 
 capability of legal scrutiny 
 providing a definition and guidance to laboratories for quality assurance and 
control  
 accreditation for participating laboratories 
The oral fluid workplace testing guidelines provide direction to UK based 
laboratories for oral fluid collection, laboratory confirmation, quality control and 
assurance and interpretation of results.  Additionally they offer guidance on 
challenges to the oral fluid drug testing results.  
1.1.5.2.1  Oral fluid collection guidelines 
The UK guidelines specify that the oral fluid collection systems should allow for an 
observed oral fluid collection, privacy of the collection, identification of the donor, 
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prevention of tampering and adulteration as well as ensuring that consent is obtained 
prior to collection of the oral fluid sample from the donor. 
1.1.5.2.2  Laboratory confirmation guidelines 
The guidelines also recommend that it should be compulsory for preliminary 
immunoassay screening to be confirmed via a confirmatory analytical technique such 
as GC-MS or LC-MS. For this, agreed cut offs were introduced to provide uniformity 
when reporting results such that any samples with drug concentrations greater than 
the cut off are regarded as positive and those  below the set cut off are reported as 
negative.  
1.1.5.2.3  Quality control and assurance guidelines 
All laboratories participate in workplace drug testing are recommended to be 
accredited using ISO 17025 accreditation which is provided by the United Kingdom 
Accreditation Service. The accreditation is designed to ensure that the correct chain 
of custody has been followed, correct screening, confirming, reporting and security 
of results. Additionally it is compulsory that all calibrators and controls are certified 
and all analytical methods fully validated before the use in workplace drug testing.  
1.1.5.2.4 European workplace drug testing guidelines 
In 2011, the European Workplace Drug Testing Society adapted the UK workplace 
drug testing guidelines for the use in all European laboratories (EWDTS 2011).  
1.1.6 Oral Fluid in the UK legal system  
Oral Fluid drug testing was first introduced into the UK Criminal Justice System in 
2001 with the amendment of Section 57 under the Criminal Justice and Court 
Services Act 2000. The main purpose of the amendments was to monitor opiate and 
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cocaine related crime and identify drug users for direction into drug rehabilitation 
programs.  
1.1.6.1 Roadside Testing of Oral Fluid  
1.1.6.1.1 Early legislation 
Established in 1930, the Road Traffic Act was the first statutory document that 
classed driving under the influence of drugs as an offence. Convictions were based 
on the level of impairment be shown in drivers.  The Act was later amended in 1960 
and 1962 to change the definitions of impairment to “under the influence drink or a 
drug to such an extent as to be incapable of having proper control of a motor 
vehicle”.  In addition to a change of the legislative wording, in 1962 the act allowed 
for the first time sample collections of urine, blood or breath for the identification of 
alcohol or other controlled substances (Road Traffic Act, 1962).  
1.1.6.1.2 Current legislation  
In order to enhance police officers ability to recognise and apprehend drivers whose 
performance may be impaired as a consequence of drug use, the UK Road Traffic 
Act 1988 was amended in 2003 by the Railways and Transport Safety Act 2003 to 
allow a preliminary oral fluid test to be carried out at the roadside.  In a similar 
manner to roadside breath testing, oral fluid drug testing in a driving under the 
influence of drugs (DUID) scenario offers police officers an immediate indication of 
whether a driver may have used drugs and provides support to the officer to execute 
an arrest. As oral fluid testing becomes more available and more robust, there is the 
potential for significant cost savings to police forces in relation to the development of 
evidential oral fluid testing devices since these would significantly reduce the 
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requirement for a forensic medical examiner to attend and collect blood specimens 
and may even in time reduce the need for costly laboratory analysis.  
Some other countries including Germany, Australia and the USA have already 
introduced oral fluid drug testing at the roadside as a preliminary screen in order to 
identify drivers that may be impaired by drug use. Oral fluid drug testing offers 
police officers the advantage of being rapid, easy to collect, less easy to adulterate 
and can be collected by individuals that require minimum training. Although oral 
fluid has been incorporated into the Road Traffic Act, it is not yet used at the 
roadside by police forces in the United Kingdom because a number of concerns exist 
in relation to the technique and the interpretation of oral fluid screening results. The 
UK parliament is scheduled to consider introducing the use of oral fluid testing of 
motorists in the near future. To date, following the collection of an oral fluid sample, 
a blood sample is collected for confirmation and in March 2014 the UK Department 
for Transport approved and published drug driving limits in blood for 16 drugs 
including eight illicit drugs and eight prescription drugs. The new drug driving limits 
means that it is an offence to drive over the recommended limit for each drug rather 
than relying on police officers to prove impairment by a drug in order to achieve a 
conviction (Department of Transport 2014). 
1.1.7 Variation of drug concentrations in oral fluid - the problem! 
The original belief underlying drug entry into oral fluid was based on a suggestion 
that drugs enter the oral cavity via the bloodstream and that this was dependent upon 
of the concentration of the drug not bound to proteins in circulating blood (section 
1.1.3). Studies have shown that drug concentrations in oral fluid can vary widely and 
in some cases may be significantly higher than would be expected if the concept of a 
simple blood : saliva ratio accounted for the presence of drugs in oral fluid. This lead 
Validation of Oral Fluid as a Matrix for Drug Detection – Chapter 1 
 
21 
 
to the postulation that drugs may form depots in mouth tissue subject to the mode of 
entry into the body (Osselton et al 2001, Crouch 2005, Drummer 2006, Samyn et al 
2007).   
Variation may be caused by a number of factors such as production and flow of 
saliva, contamination of the mouth cavity with drugs or other substances that may 
interfere with the drug test and the properties of the drugs consumed and their ability 
to cross from the blood into saliva i.e. is it parent drug or drug metabolite that enters 
the saliva and oral fluid. Additionally, deposition of drugs and their metabolites have 
been reported following exposure to drugs via nasal insufflation (snorting), 
inhalation (smoking) or oral consumption (Jenkins et al 1996, Osselton et al 2001). 
The problem may be illustrated by reference to two common classes of drugs that are 
tested for in the UK i.e. cocaine and opiates. Cocaine and opiates have subsequently 
been adopted as the principal compounds for study in this work.  
1.1.7.1 Cocaine 
Cocaine is an alkaloid principally sourced from the leaves of the Erythroxylum coca, 
but can also be synthesised from ecgonine. Incas and natives of South America have 
been using the leaves in religious ceremonies for over 2000 years. Leaves are widely 
chewed in the higher mountain regions of Peru to suppress and prevent altitude 
sickness and the low levels of cocaine within the leaves suppress hunger and thirst. 
In the lower non-mountainous regions of South American Countries such as Peru, the 
leaves are used to brew coca tea which is a well-practised social custom. 
Medicinally, cocaine was first used as a local anaesthetic during surgery in 1884 
when Carl Koller demonstrated the benefits of cocaine in ophthalmology 
(Grzybowski 2007). Cocaine was also applied for the use in local anaesthesia and 
nerve blocking during medical procedures. To date however, cocaine has decreased 
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in its popularity for medical use, as it showed signs of potentially harmful effects as 
well as risk of addiction.   
1.1.7.1.1 Effects of cocaine administration 
Cocaine is a stimulant producing effects such as euphoria, excitement, a profound 
sense of well-being, alertness and increased self-confidence. The increased self-
confidence may result in increased sociability and sexual stimulation. However, 
adverse behavioural effects such as insomnia, disorientation, paranoia, and violent 
tendencies have been reported in relation to higher doses of cocaine (Boghdadi and 
Henning 1997, Moffat et al 2011). Cocaine also exerts several physiological effects 
on the body such as the heart, brain, lungs and kidneys. Pulmonary complications 
related to the use of cocaine are bronchiolitis, pulmonary oedema or haemorrhage 
(Ettinger and Albin 1986, Bailey et al 1994, Glauser and Queen 2007).  Cocaine has 
also been linked to seizures as its can constrict blood vessels which increases blood 
pressure and results in cardiac dysrhythmia (White and Lambe 2003, Glauser and 
Queen 2007). Other cardiac effects from cocaine use include aortic aneurysms, 
infarction and arrhythmia (Boghdadi and Henning 1997, Pozner et al 2005).  
1.1.7.1.2 Cocaine Purity 
Cocaine as a street drug has decreased in purity over time. A report by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 2010 showed that 
the average purity of street samples seized in Europe ranged from 25 to 55 %. This 
report also stated that the reported purity decreased by 15% in comparison to the 
years 2005 – 2008. The report for 2011 showed that the average purity range in 
Europe had dropped to 25% -43%, with lowest values of 20% purity reported in 
England and Wales (EMCDDA 2010). In 2011 the Home Office also published data 
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on the purity of street drugs where the average purity of drug seizures analysed by 
the Forensic Science Service (FSS) reported increased from 21 % in 2009/2010 to 28 
% in 2010 / 2011 (Coleman 2011). In 2012 the EMCDDA reported on the purity of 
cocaine in the United Kingdom to be 23.8 % (EMCDDA 2012).  
1.1.7.1.3 Metabolism  
Cocaine is primarily metabolised in the liver, where it is hydrolysed into ecgonine 
methyl ester and benzoylecgonine, both of which are pharmacologically inactive. 
Benzoylecgonine and ecgonine methyl ester are both formed by the action 
carboxylesterase. The carboxylesterase hCE-1 causes the hydrolysis of cocaine to 
benzoylecgonine by demethylation (Fleming et al 1990, Pindel 1997). Ecgonine 
methyl ester is formed via the separation from the benzoyl group which is catalysed 
by the carboxylesterase hCE-2 (Pindel et al 1997).   Benzoylecgonine is further 
biotransformed into the minor metabolites norbenzoylecgonine, m-
hydroxybenzoylecgonine and p-hydroxybenzoylecgonine (Figure 1.4).  
A minor pathway results in the formation of norcocaine, which is part of the 
oxidative metabolism of cocaine.  During norocaine formation which is catalysed by 
the cytochrome (CYP) 450, cocaine is undergoes oxidation to remove a methyl 
group.  Norcocaine is then further metabolised by the CYP-450 enzyme to form N-
hydroxynorcocaine. N-hydroxynorcocaine has been reported to be hepatotoxic 
targeting the liver and thus resulting in drug induced liver disease (Figure 1.4).   
Anhydroecgonine methyl ester is a pyrolysis product of smoking “crack” cocaine and 
is formed by thermal degradation of cocaine. Anhydroecgonine methyl ester is then 
further metabolised into anhydroecgonine in the body.  
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Consumption of cocaine with alcohol results in the formation of cocaethylene, the 
ethyl ester of benzoylecgonine. Cocaethylene is formed as the addition of ethanol 
changes the path of the biotransformation of cocaine via in vivo transesterification 
catalyzed by hepatic carboxylesterase (hCE1) enzymes. During the formation of 
cocaethylene, the methyl ester group is replaced with an ethyl group. Cocaethylene is 
pharmacologically active and its pharmacological activity is similar to that of cocaine 
(Laizure et al 2003) (Figure 1.4). 
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1.1.7.1.4 Route of Administration 
Cocaine is consumed via three main routes of administration: intravenous injection, 
snorting or smoking. 
1.1.7.1.4.1  Intravenous injection 
Cocaine use via injection is the least common method of administering cocaine but 
can be achieved by combining cocaine powder with water, as cocaine is soluble 1 in 
600 of water. The solubility of cocaine increases to 1 in 270 of water if the water 
temperature is increased to 80 °C (Hudgins et al. 1995; Middleton et al. 2004; Moffat 
et al. 2011).   
Cocaine concentrations following intravenous use are dose dependant. Low doses 
such as a 32 mg and 40 mg resulted in peak plasma concentrations of 250 ng/mL (t = 
7.3 min) and 523 ng/mL (t = 10 min), respectively (Chow et al 1985, Kumor et al 
1989). Increased concentrations result in larger peak plasma concentrations. 
Following a 100 mg intravenous dose, (Barnett et al 1981) reported peak plasma 
concentrations of between 700 ng/mL and 1000 ng/mL (t = 5 min) whereas at the 
higher dose of 200 mg resulted in a peak plasma concentration of 2500 ng/mL (t = 5 
min) (Barnett et al 1982). The elimination half-life for cocaine when injected 
intravenously has been reported to be 41 min (range= 19 min – 64 min).  
1.1.7.1.4.2  Nasal insufflation (snorting) 
Cocaine hydrochloride is generally used when snorting cocaine.  Nasal insufflation 
or snorting of cocaine is relatively inefficient and results in low absorption of 
cocaine. The intranasal elimination half-life was shown to be 75 min (range = 70 min 
– 80 min) (Wilkinson et al 1980). There is a variation in the reported literature 
regarding time taken to reach peak plasma concentrations. Wilkinson et al (1980) 
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reported peak plasma concentration 35 min – 90 min whereas Javaid et al (1983) 
reported peak plasma concentrations between 120 min  - 160 min post cocaine 
insufflation.  
1.1.7.1.4.3  Oral ingestion 
Orally ingested cocaine is most commonly administered via coca tea drinking or 
coca leaf chewing. Studies have shown that the concentration of cocaine within the 
leaf is dependent on the species of the coca plant with the average cocaine 
concentration ranging between 0.39% and 0.5% (Blejerpr 1965, Hamner and 
Villegas 1969, Hannah and Hornick 1977, Negrete 1978, Holmstedt et al 1979, Paly 
et al 1980).  In addition to cocaine, the typical coca leaf contains a number of other 
structurally related compounds including benzoylecgonine and ecgonine methyl ester 
(Weil 1978, Penny et al 2009).   The amount of cocaine and its metabolites present in 
coca leave can vary depending on species and origin of the Erythroxylum plant 
(Jenkins et al 1996). The Peruvian Erythroxylum species contains 5.11 mg of 
cocaine, 0.11 mg of benzoylecgonine and 1.15 mg of ecgonine methyl ester in 1 g of 
leaf material (Jenkins et al 1996). 
Coca tea is commonly prepared from an infusion of the leaves obtained from the 
coca bush Erythroxylum coca. Coca tea is widely consumed in a number of South 
American countries, where its use is both legal and socially acceptable (Hamner and 
Villegas 1969, Hanna and Hornick 1977, Siegel et al 1986, Jenkins et al 1996, 
Turner et al 2005). Coca leaves have been used for over 2000 years and were widely 
used by the Incas of Peru in religious ceremonies (Martin 1970, Zapata-Oritz 1970, 
Allen 1981, Billman 1990).  
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In addition to the use of coca leaves during the preparation of coca tea, the custom of 
chewing coca leaves is still widely practiced today by people working at high 
altitude. Coca chewing alleviates adverse symptoms of pain, thirst, hunger and 
tiredness that are experienced by humans working or living at high altitude (Fuchs 
1978). Chewing coca can be advantageous in colder environments (Hanna 1971a). 
Chewers have been reported to consume on average 62.4 g and 51.1 g of coca leaves 
per day, respectively (Hanna 1974). Coca leaf chewing resulted in a mean 
concentration of 150 ng/mL of cocaine in plasma following chewing of 4.4g of coca 
leaves (Holmstedt et al 1979).   
1.1.7.1.4.4  Smoking 
Smoking of cocaine generally occurs in the form of “crack” cocaine. Cone et al 1994 
reported peak cocaine plasma concentrations immediately after smoking of “crack” 
cocaine before rapidly decreasing over time.  
This was further supported in a study reported by Jenkins et al (1996) who reported 
that the mean plasma concentrations during “crack” smoking occurred after 2 
minutes. The onset of physiological effects was reported 5 min after the smoking of 
“crack” cocaine.  Studies by Haney et al (2001a, 2001b) also reported cocaine 
concentrations in plasma following “crack” cocaine smoking in 10 individuals.  
Smoking of a 12 mg of “crack” resulted in cocaine plasma concentrations ranging 
between 30.6 mg/L and 88 mg/L (mean = 59.3 µg/mL).  In comparison, an initial 
dose of 50 mg of “crack” cocaine resulted in mean cocaine plasma concentrations 
ranging between 121.8 µg/mL and 166.4 mg/L (mean = 144.1 µg/mL).  
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1.1.7.1.5 Mechanism of action  
Cocaine acts on the neurotransmitters dopamine, norepinephrine and serotonin in the 
central nervous system. Neurotransmitters are chemical signals, which travel across 
the synaptic cleft and are responsible for initiating of a new electric signal in the post 
synaptic cell.  Cocaine inhibits the reuptake of these neurotransmitters by binding to 
the transporters which are responsible for removing excess neurotransmitter from the 
synaptic cleft (Ritz et al 1987, Volkow et al 1999).   
Serotonin is most potent in binding to the receptors followed by dopamine and 
norephedrine (Ritz et al 1990, Carroll et al 1992). The increased amount of dopamine 
within the synaptic cleft results in most of the behavioural effects observed with 
cocaine, such as euphoria and increased locomotor behaviour (Uhl et al 2002). The 
blocking of the re-uptake of serotonin results in rewarding effects by enhancing the 
mood, similar to  why serotonin blockers are commonly used during treatment for 
depression (Uhl et al 2002, Meyer and Quenzer 2005). However, the increased 
concentration of norepinephrine affects sensory functions, memory and can result in 
anxiety. As well as acting on neurotransmitters, cocaine reduces the sodium currents 
within nerve axons, which is the action responsible for the anaesthetic effects of 
cocaine (Crumb and Clarkson 1990, Warner 1993). 
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1.1.7.1.6 Tissue disposition 
The amount of drug that distributes into tissue is dependent on its volume of 
distribution (Vd). The reported Vd of cocaine is between 1 and 3 L/kg (Moffat et al 
2011). The disposition of cocaine in different body tissues has been thoroughly 
investigated. Poklis et al (1987a,  1987b) examined the disposition of cocaine in 
tissue in five cases of fatal poisoning. In two out of the five cases, additional drugs 
such as diazepam, nordiazepam and morphine were also detected and quantified. 
With the exception of urine, the highest concentrations of cocaine were observed in 
the kidney and spleen with mean concentrations of 39.4 µg/mL and 26 µg/mL 
respectively. An overview of the results in various tissues from Poklis et al (1987) 
can be seen in Table 1.9.  
Table 1.9 Disposition of Cocaine in Fatal Poisoning (µg/mL) (Poklis et al 1987) 
Specimens Cases  
 
1 2 3 4 5 Mean 
Blood 1.8 6.9 31.0 13.0 3.9 11.3 
Bile 10.0 18.0 - 25.0 3.2 14.1 
Brain 4.0 24.0 59.0 83.0 6.4 35.3 
Heart 6.1 - - - 5.3 5.7 
Kidney 26.0 26.0 58.0 53.0 34.0 39.4 
Liver 1.6 17.0 6.5 10.0 15.0 10.0 
Lung 3.4 - 69.0 24.0 27.0 30.9 
Spleen 22.0 25.0 42.0 - 15.0 26.0 
Skeletal muscle 6.1 - 48.0 30.0 - 28.0 
Adipose tissue 1.0 - 5.8 - 0.7 2.5 
Urine 39.0 41.0 270.0 - 27.0 94.3 
Vitreous 2.4 - - 14.0 - 8.2 
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Spiehler and Reed (1985) reported cocaine concentrations in the liver to be an 
average of 6.7 µg/mL. 
A different measure of lipophilicity is the partition coefficient (logP) of a drug. A log 
P value larger than 5, will favour sequestration into body fat. Therefore the lower the 
logP value, the easier the absorption into tissues. The reported logP value for cocaine 
is 2.3 whereas the logP value for heroin is 0.2 (Moffat et al 2011). 
 
1.1.7.1.7 Elimination of cocaine 
Wilkinson et al (1980) reported a plasma elimination half-life of 75 min (range = 70 
min - 80 min) following the snorting of cocaine in comparison to when the drug is 
consumed orally where the reported elimination half-life was reported at 48 min 
(range = 45 min – 51 min). Intravenous cocaine has a reported elimination half-life 
of around 78 min (Jeffcoat et al 1989).  The elimination half-life of benzoylecgonine 
and ecgonine methyl ester have been reported to be 5.1 hrs and 4.2 hrs, respectively 
(Ambre et al 1984).  
Reports have shown that following an intravenous dose of 120 mg of cocaine 
between 1 % and 9 % is excreted in the urine unchanged (Moffat et al 2011) in 
addition to 35 % to 55 % of its main metabolite benzoylecgonine. Similarly it has 
been reported that following snorting of a 1.5 mg/kg dose of cocaine resulted in 4% 
of cocaine to be excreted unchanged within the urine with 16% - 36 % of the dose 
excreted as benzoylecgonine (Moffat et al 2011).  Cone et al (1998) showed that 
following intravenous injection, snorting or smoking of cocaine 39 %, 30% and 16 % 
of the dose of cocaine was excreted via the urine. Additionally Cone et al (1998) 
reported that 18 %, 15 % and 8% of the administered dose was excreted as norcaine, 
benzoylnorcocaine, m-hydroxycocaine, p-hydroxycocaine, m-
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hydroxybenoyzlecgonine and p-hydroxylbenzoylecgonine. Anydroecgonine methyl 
ester has also been detected in the urine in trace amounts (~0.02 % of the dose 
administered) following the smoking of “crack” cocaine (Cone et al 1998). 
1.1.7.1.8 Toxicity 
Toxicity depends on each individual as regular users can build up a tolerance to 
cocaine. Reports on the lethal dose of cocaine vary in the literature. Trouve and 
Nahas (1990) reported the lethal dose at 60 mg/kg. In comparison, a study by Hearn 
et al (1991) reported the lethal toxicity of cocaine to be on average 93 mg/kg. In 
1998, Karch et al analysed blood concentrations in 48 cocaine related fatalities and 
reported a mean blood concentration of 1.12 mg/L (range 0.001 – 18.1 mg/mL) in 
comparison to a mean urine cocaine concentration of 40.1 mg/L (range 0.001 – 468 
mg/L), with mean benzoylecgonine concentrations reported at 1.54 mg/L (range = 
0.001 mg/L – 3.22 mg/L).  
Lethal cases of cocaine overdose are commonly seen in drug smuggling as a result of 
the rupture of a package in the gastro intestinal tract. Following rupture of packages 
Furnari et al (2002) reported peak blood concentrations of 4 mg/L of cocaine and 17 
mg/L of benzoylecgonine. Urine concentrations detected for cocaine and 
benzoylecgonine were 152 mg/L and 512 mg/L respectively. In comparison, Fineschi 
et al (2002) reported cocaine and benzoylecgonine concentrations following the 
rupture of a cocaine package of 98.1 mg/L and 86.1 mg/L in blood, and 10 mg/mL 
and 3.3 mg/L in urine, respectively.   
The most prominent toxic effect of cocaine is exhibited on the cardiac system. 
Cocaine can induce cardiac arrhythmias and myocarditis as well as pulmonary 
oedema, all of which can result in sudden death.  Cocaine also has major toxic effects 
Validation of Oral Fluid as a Matrix for Drug Detection – Chapter 1 
 
33 
 
on other organs such as the kidneys. When taken repeatedly cocaine can result in 
kidney damage and acute renal failure.  
Cocaine use also has toxic effects on the central nervous system such as psychosis, 
agitation and seizures. Cocaine users have been reported to be affected by cerebral 
aneurysms. Other toxic effects on the central nervous system include stroke and 
cardiovascular collapse.  
Lesser toxic effects of cocaine especially, when snorting cocaine, include damage of 
the nasal septum e.g. septal and avascular necrosis, tumours in the nasal chambers 
and ulcers.  
1.1.7.1.9 Elevated cocaine concentrations in oral fluid 
Jenkins et al. (1996) investigated concentrations of cocaine derivatives in oral fluid 
following smoking and intravenous administration. Cocaine concentrations in oral 
fluid after smoking ranged from 15.85 mg/L to 504.88 mg/L whereas concentrations 
following intravenous injection were significantly lower (0.43 mg/L to 1.93 mg/L). 
Jenkins also reported concentrations of anhydroecgonine methyl ester in saliva 
ranging from 0.56 mg/L to 4.37 mg/L. Anhydroecgonine methyl ester could not be 
detected in plasma following smoking.  
Although the phenomenon of elevated drug concentrations in oral fluid has been 
documented, little is known about the physiology of drugs in the mouth to explain 
the observations. The measurement of a high drug concentration in oral fluid could 
potentially be explained by recent drug use or by release of the drug from a drug 
depot. Limited understanding of drug elimination via the mouth poses a problem to 
forensic toxicologists since the toxicologist is required by the courts to interpret 
analytical results in relation to an individual’s performance.  Drug depot formation 
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has a clear implication on the interpretative value of oral fluid as a matrix in the 
workplace drug testing arena or  for prosecuting motorists since lawyers will argue 
that positive test results produced by  their clients will be a consequence of past drug 
use and not recent use that would be associated with impairment.  
1.1.7.2 Heroin 
Heroin or diacetylmorphine is synthesized from opium, a naturally occurring 
alkaloid. Opium is a product of the Papaver Somniferum L. Following the extraction 
of morphine, it undergoes acetylation with acetic anhydride to produce heroin. 
Heroin was originally produced as a commercial product to treat respiratory diseases 
(Hosztafi, 2001). This quickly changed when the addictive properties of heroin 
became apparent and drug users realised its euphoric properties. In the UK, heroin is 
listed and controlled as diamorphine under the Misuse of Drugs Act 1971 as a class 
A controlled drug.  
1.1.7.2.1 Effects of heroin administration  
The analgesic effects produced by heroin is on average three times more potent than 
morphine. Opioids, such as heroin, are narcotic analgesics that affect the central 
nervous system (CNS) and may produce pupillary constriction, euphoria and 
respiratory depression (Karch 2003). Short term effects of heroin include feelings of 
euphoria and “rush” followed by drowsiness. As a result of its suppressive effects on 
the CNS, heroin can lower heart and respiratory function which can ultimately result 
in death. In addicts/regular users, constant heroin use has been shown to cause liver 
and kidney disease as well as cardiac conditions (Paterna et al 1991). Additionally 
the repeated injection of heroin has been shown to result in collapsing of veins close 
to the injection site as well as causing abscesses.   
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1.1.7.2.2 Metabolism 
Heroin (diamorphine) is metabolised quickly into 6-monoacetylmorphine (6-MAM) 
by deacetylation of the 3-acetyl group.  6-MAM is then hydrolysed into morphine. 
The deacetylation of-heroin to 6-MAM occurs at an estimated half-life between 3 
minutes and 7.6 minutes whereas the hydrolysis to morphine is slower with the 
estimated half-life reported at 21.8 minutes (Rook et al 2006, Rentsch et al 2001, 
Moffat et al 2011). Heroin, metabolised in the liver is catalysed by carboxylesterases 
(Kamendulis 1996; Polettini et al 2005) – specifically human liver carboxylesterase 
form 1 (hCE-1) and human liver carboxylesterase from 2 (hCE-2). hCE-1 is 
responsible for removing the 3-acetyl group and has been shown to also the 6-acetyl 
link which results in the formation of 6-MAM from heroin (Pindel et al 1997, 
Redinbo et al 2003). hCE-2 catalyses the hydrolysis of the acetyl groups of heroin in 
the liver (Pindel et al 1997). hCE-2 has been shown to have a higher catalytic 
efficiency than hCE-1 for heroin (Kamendulis 1996, Pindel et al 1997, Satoh et al 
2002). In the blood, heroin is also metabolised via hydrolysis which is catalysed by 
the hydrolytic esterases butyrylcholinesterase and acetylcholinesterase (AChE). 
AChE then further catalyses the metabolism of 6-MAM to morphine (Lockridge et al 
1980, Salmon et al 1990) (Figure 1.5).  
Morphine is further metabolised into morphine-3-glucuronide and morphine-6-
glucuronide by the glucuronidation of a phenolic hydroxyl group at the third and 
sixth position, respectively. These glururonides are not further metabolised in the 
body but are excreted via the kidney. Morphine glucuronidation is catalysed by 
uridine – 5’ – diphosphate- glucuronosyltransferases (UGT), specifically UGT-2B7 
(Antonilli et al 2012, Eissing et al 2012). Although the main pathway for morphine 
glucuronidation is a hepatic pathway, gluruonidation has also been reported in the 
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kidneys, intestines and brain (Brunk and Delle 1974, Gerostamoulos and Drummer 
2000) (Figure 1.5). 
Morphine also undergoes N-demethylation to a lesser extent in order to form 
normorphine, which is also an active metabolite (Meadway et al 2002) (Figure 1.7).  
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Figure 1.5 Metabolic pathway of heroin (structures available on www.ncbi.nlm.nih.gov/strucutre [accessed 24/03/2014])
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1.1.7.2.3 Heroin Purity 
The Forensic Science Service reported a decrease in heroin purity from 44 % in 
2009/2010 to 30 % in 2010/2011. In 2011, heroin purity in the UK was reported by 
the EMCDDA to be much lower with a mean purity of 17.6 % (range = 1 % and 96 
%, median = 16 %) (EMCDDA 2011). It is most commonly cut with caffeine and 
paracetamol. However less common adulterants such as phenobarbitone and 
diazepam have also been reported.  
1.1.7.2.4 Routes of Administration 
1.1.7.2.4.1 Intravenous injection 
Intravenous injection is the most common route of administration of heroin during 
illicit drug use. However, as a result of a decrease in heroin purity over recent years 
and potential spreading of HIV and Hepatitis B, alternative routes of administrations 
increased (Strang et al 1992). Following intravenous injection of heroin, Jenkins et al 
(1994) reported the peak plasma concentration of heroin, morphine and 6-MAM. 
Heroin concentrations appeared in blood between 1 – 5 minutes post injection at 
concentrations of 141ng/mL but decreased rapidly. Morphine and 6-MAM 
concentrations resulted in concentrations of  151 ng/mL and 44 ng/mL, respectively.  
1.1.7.2.4.2 Nasal insufflation (snorting) 
The effects of nasal insufflation of heroin have been reported to be similar to effects 
when heroin is injected. However, as there is no trauma from a needle, snorting has 
become more popular. Cone et al (1996) reported peak blood concentration in plasma 
within 5 minutes of snorting of heroin. Following an intranasal dose of heroin of 6 
mg in 6 volunteers peak morphine blood concentrations of 2821 ng/mL (range = 
1174 ng/mL – 3455 ng/mL) and peak 6-MAM concentration of 34 ng/mL (range = 0 
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ng/mL – 81 ng/mL). Positive morphine and 6-MAM concentrations were detected 
for up to 23.9 hours and 1.8 hours respectively. In comparison, following a higher 
dose of 12 mg, morphine and 6-MAM were detected for 11.1 hours and 2.9 hours, 
respectively. Peak urine concentrations of morphine and 6-MAM were reported at 
6371 ng/mL (range = 3085 ng/mL – 10425 ng/mL) and 73 ng/mL (range = 0 ng/mL - 
183 ng/mL), respectively.  
1.1.7.2.4.3 Oral Ingestion 
Oral ingestion as a route of administration is not commonly reported for the use of 
heroin. Sawynok (1986) reported that orally ingested heroin is on average 1.5 times 
more potent than morphine. In comparison when heroin is administered via 
intravenous injection its potency is on average three times larger than that of 
morphine.   
1.1.7.2.4.4 Smoking 
Smoking heroin, commonly known as ‘Chasing the Dragon’, involves heating heroin 
on a foil and inhaling the smoke via a straw. Hendriks et al (2001) reported that the 
bioavailability of heroin was 35% - 45 % following smoking of 100 mg of heroin,   
Rook et al (2006) also reported the bioavailability of heroin following inhalation of 
smoke to be at a mean of 52 % (range = 44 % - 61%). Peak plasma concentrations 
following smoking were reported to be on average four times lower than following 
intravenous injection with a plasma mean concentration 1.70 mg/L (mean = 7.54 
mg/L) (Rook et al 2006).  
1.1.7.2.5 Mechanisms of action 
Heroin crosses the blood-brain-barrier quickly and freely to then interact with opioid 
receptors present within the brain. There are three main opioid receptors: mu (µ), 
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delta (δ) and kappa (κ) (Kieffer 1995).  The affinity to the µ-opioid binding sites is 
higher in comparison to the affinity to other receptors such as delta and kappa 
(Goldstein and Naidu, 1989, Pasternak 2001). These opioid receptors are present in 
the central nervous system as well as the gastrointestinal tract.  Heroin acts as an 
antagonist at the µ-opioid receptor which, as a result, inhibits the release of gamma-
aminobutyric acid (GABA) and hence increases the amount of dopamine produced. 
Increased dopamine activation then causes the effects felt during heroin use such as 
euphoria, feelings of wellbeing and intense pleasure.  
Heroin itself has a low binding affinity for µ-opioid receptors. Heroin is quickly 
metabolised to 6-MAM and morphine, both of which have a high affinity to bind to 
opioid receptors and hence exert maximum effects (Inturrisi, et al, 1983, Rossi et al 
1996, Selly et al 2001).  The presence of µ-opioid receptors within the 
gastrointestinal tract inhibits the intestines secretory activity leading to constipation 
(Holzer 2009).  
1.1.7.2.6 Tissue disposition 
The volume of distribution of heroin is not very documented, as it is metabolised 
quickly to 6-MAM and morphine within the body. Heroin is lipophilic, which results 
in large estimated volume of distribution ranging between 25 L/kg and 33.8 L/kg 
(mean = 29.5 L/kg) (Rook et al 2006, Baselt, 2011, Urso et al, 2012). The higher 
volume of distribution of heroin suggests that a larger amount of drug travels into the 
tissue. However, as a result of its rapid metabolism, heroin is rarely detected and 
reported to be present in biological specimens. In addition to heroin, 6-MAM is also 
lipophilic indicating that the drug can also freely travel across the blood-brain 
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barrier. The volume of distribution for 6-MAM has been reported to be similar to that 
of heroin (Rook et al 2006).  
The reported volume of distribution of morphine ranges between 3 - 5 L/kg (Moffat 
et al 2011). Morphine has been reported to cross the blood-brain barrier at a slower 
rate than heroin or 6-MAM. Moriya and Hashimoto (1997) reported a large quantity 
of morphine in the stomach contents, liver and lung at concentrations of 5220 ng/g, 
4200 ng/g and 2270 ng/g following an overdose of self-injected heroin. Following 
intravenous morphine injection morphine concentrations were reported in blood, 
brain, lung, liver and bile at concentrations of 670 ng/mL, 40 ng/mL, 210 ng/mL, 110 
ng/mL and 440 ng/mL, respectively (Cravey and Reed 1977). In comparison, Felby 
(1974) reported morphine concentrations following an intravenous overdose in 10 
cases to range between 200 and 2300 ng/mL (mean= 700 ng/mL) in blood, 100 
ng/mL and 2000 ng/mL (mean = 800 ng/mL) in muscle, 400 ng/mL and 18000 
ng/mL (mean = 3000 ng/mL) in liver and 14000 ng/mL and 81000 ng/mL (mean = 
52000 ng/mL) in urine. 
1.1.7.2.7 Elimination 
Heroin has a half-life of 10 - 15 minutes and thus is rapidly metabolised to 6-MAM 
and morphine in the body and is subsequently excreted as morphine-3-gluruondide 
and morphine-6-gluruconide.  As a result of this, the detection of heroin in biological 
specimens is uncommon. A study by Elliot et al in 1971 investigated urinary 
excretion of heroin and its metabolites following an intravenous dose. Elliot et al 
showed that following injection of 70 mg of heroin, 45 % of the dose was recovered 
in the urine in the form of total morphine and 6-MAM over the course of 40 hours. 
Smith et al (2001) reported the excretion half-life for both, morphine and 6-MAM, to 
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be 3.11 hrs (±0.3 hrs). Peak morphine urine concentrations were observed at 1392 – 
9250 ng/mL at 1.2 hrs – 6.2 hrs following an intravenous heroin dose of less than 7 
mg. An intravenously administered heroin dose above 10 mg, resulted in peak 
morphine concentrations at 2.3 hrs – 9.3 hrs ranging between 2065 ng/mL and 29030 
ng/mL. Peak 6-MAM concentrations in urine following a low dose (<7mg) were 
observed to be ranging between 6.1 – 298 ng/mL at 1.2 hrs- 5.1 hrs post injection. 
Following an intravenous dose larger than 10 mg, peak 6-MAM concentrations were 
observed 1.4 – 4.3 hours post injection at concentrations ranging between 13 – 598 
ng/mL (Smith et al 2001).  
Normorphine has also been reported to a lesser extent to be excreted in the urine 
(Yeh et al 1976). However, the amount of drug which is excreted via the urine is 
dependent on the route of administration of the drug. Orally consumed morphine 
undergoes extensive first pass metabolism resulting in a delayed absorption and 
hence slower excretion than morphine which is administered via injection (Brunk 
and Delle 1974, Rook et al 2006). 
1.1.7.2.8 Toxicity 
Heroin is three times more potent than morphine resulting in a lethal dose to average 
around 200 mg (Rob et al 1997, Moffat et al 2011). Regular drug users can build up a 
tolerance to opioids, resulting in a larger lethal dose. Users who use the drug 
regularly have a larger risk of overdose, as the difference between the heroin dose 
that achieves the desired effect and the dose that causes lethal respiratory depression 
is not great.  
Rop et al (1997) reported a lethal overdose following exposure to heroin. Although 
the quantity of heroin which was consumed was unknown, the blood concentrations 
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were 109 ng/mL, 168 ng/mL and 1140 ng/mL for heroin, 6-MAM and morphine, 
respectively. In a separate fatality reported by Winek et al 1999, the concentrations 
of morphine in blood and urine following heroin injection were 680 ng/mL and 490 
respectively.  Following the death of eight body packers who transported heroin from 
Columbia, concentrations of morphine in blood ranged between 4.4 µg/mL and 52.6 
µg/mL (Wetli et al 1997).  
One of the most commonly reported toxic effects of heroin is pulmonary disease 
(Warner-Smith et al 2001, Meyer and Quenzer 2005). Pulmonary disease is a 
condition of the lungs in which the breathing can be restricted and exacerbated 
leading to respiratory depression (White and Irvine 1999).  Heroin use has been 
associated with liver (hepatic) disease as a result of slower drug clearance from the 
liver (Torre, 1999, Warner-Smith et al 2001).  
Heroin also induces cardiac toxicity which results in cardiac arrhythmias. 
Additionally, heroin usages results in muscular effects and neurological effects, 
however none of the three previously mentioned factors are a direct cause for death 
following an overdose (Darke et al 2000, Ghuran and Nolan 2000).  
1.1.7.2.9 Elevated heroin and metabolite concentrations in oral fluid 
Jenkins et al. (1996) investigated drug concentrations in oral fluid following the 
controlled consumption of smoked heroin. Both blood and oral fluid samples were 
collected and screened for heroin, 6-monoacetylmorphine and morphine in order to 
compare results from these matrices. Heroin concentrations ranged from 3.53 μg/mL 
to 20.58 μg/mL following smoking 2.6 mg and 5.2 mg heroin respectively. 
Concentrations could be detected for up to 24 hours. Significant 6-
monacetylmorphine concentrations could be detected within a range of 1.12 μg/mL 
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(2.6 mg) and 3.58 μg/mL (5.2 mg) and could be detected for 30 minutes and 480 
minutes respectively. In comparison, concentrations of heroin in oral fluid following 
intravenous injection, ranged from 6 ng/mL (10 mg) to 22 ng/mL (5 mg) and could 
be detected for 30 minutes. 6-monoacetylmorphine was only detected at very low 
concentrations in saliva following intravenous injection ranging between 18 ng/mL 
(5 mg) and  40 ng/mL (10 mg). 
 
Data from the Forensic Science Service (Osselton et al  2001) has shown that oral 
fluid concentrations of opiates, with or without the combination of a second opiate, 
ranged from 0.023 μg/mL to 17.375 μg/mL for morphine, 0.003 μg/mL to 7.75 
μg/mL for codeine, 0.002 μg/mL to 66.93 μg/mL for 6-monoacetylmorphine and 
0.001 μg/mL to 274.27 μg/mL for dihydrocodeine A potential explanation for the 
elevated drug concentrations in oral fluid is that drug accumulate to form depots in 
mouth tissues.  
Although the phenomenon of elevated drug concentrations in oral fluid has been well 
documented, little is known about the physiology of drugs in the mouth to help 
explain the observations. The measurement of a high drug concentration in oral fluid 
could potentially be explained by recent drug use or by release of the drug from a 
drug depot. Limited understanding of drug elimination via the mouth poses a 
problem to forensic toxicologists since the toxicologist may be required by the courts 
to interpret analytical results in relation to an individual’s performance.  Drug depot 
formation has a clear implication on the interpretative value of oral fluid as a matrix 
for prosecuting motorists since lawyers will argue that positive test results produced 
by  their clients will be a consequence of past drug use and not recent use that would 
be associated with impairment.  
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Chapter 2.0 - Aims and Objectives 
2.1 Aims 
The research described in this thesis aimed to increase our understanding of the 
factors and processes concerning the deposition of drugs in oral fluid and to further 
enhance the ability of forensic toxicologists to interpret the results of analysis in this 
matrix.  
The work undertaken in this thesis aimed to test the following hypotheses: 
1. Foods and Adulterants can interfere with oral fluid collection systems and 
subsequently result in false positive screening results 
2. Drugs which are consumed orally either in form of an oral solution, via 
smoking or snorting can result in elevated oral fluid drug concentration which 
can subsequently affect the interpretation of oral fluid drug concentrations 
3. Microbleeding of the gums can contribute to elevated drug concentration by 
leaking blood, and hence drug, directly into the oral fluid 
4. Drugs, such as cocaine and heroin, can bind to tissue within the oral cavity 
and subsequently form drug depots in oral tissues 
5. Drug depots that formed within the oral cavity can subsequently be released 
into the oral fluid over time.  
2.2 Objectives  
The objective of this work was to enhance our knowledge and understanding of the 
behaviour of drugs in oral fluid and the mouth cavity by:  
1. Identifying possible chemical agents and adulterants that may interfere with 
 oral fluid drug testing systems in order to determine which collector will be 
 used in the experiment designed for the work planned in this thesis 
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2. Investigating how high drug concentrations are formed in oral fluid, 
 particularly with respect to opiates / opioids and cocaine by 
a. Detection and quantification of cocaine and its metabolites in oral 
 fluid following the consumption of coca tea  
b. Investigating and comparing drug concentrations from volunteers who 
consumed Codeine Linctus or Collis Browne’s Opium Tincture  
c. Investigating whether microbleeding may be the cause of elevated oral 
 fluid drug concentrations. This will be achieved by  
i. Investigating a relationship between transferrin (a marker of oral 
bleeding) and drug concentrations in oral fluid samples collected from 
drug clinics in the UK  
ii. Comparing drug concentrations in human volunteers following 
controlled administration of codeine tablets and comparing the results 
with codeine concentrations in volunteers who stimulated 
microbleeding following consumption 
d. Designing laboratory models to mimic exposure of mouth tissues to 
 drug solutions and smoking.  
3.  Investigate the nature of drug binding sites within the mouth (porcine tongue) 
 by developing an immunohistochemical visualisation technique to 
 demonstrate the localisation of drugs/components in situ. This was 
 achieved by  
a.  Developing an immunohistochemical staining technique using 
monoclonal antibodies for morphine and benzoylecgonine  
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b.  Applying staining techniques to porcine tongues which were exposed 
to smoke or solution of cocaine or heroin in order to identify the 
distribution of drug throughout the tissue and identify binding sites in 
tissue 
c.  Performing in-vivo studies in mice to identify a) whether drugs 
accumulate in mice salivary glands and b) are subsequently excreted 
during production of saliva 
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Chapter 3.0  - Investigation of the effects of common food and   
beverages on oral fluid drug detection  
3.1 Introduction 
Oral fluid drug testing is based on three main processes: 1) oral fluid collection, 2) 
immunoassay screening and 3) confirmatory analysis of immunoassay positive 
samples using either GC-MS or HPLC-MS.   It is essential for oral fluid testing that a 
sufficient flow of saliva is available for collection and that there is sufficient drug 
present to be detected by immunoassay and subsequent confirmatory technique in 
order to achieve successful testing. A further factor to take in to consideration when 
interpreting results is whether the testing processes are affected by any non-drug 
substances which might be present within the mouth i.e. foods or chemicals.  
The work described in this chapter investigates the effects of a variety of common 
foods, beverages and oral hygiene products on two oral fluid collection systems. The 
objective was to characterize the effects of common food and beverages on the oral 
fluid collection and screening systems, including their collection devices and 
immunoassays.  
A number of different types of oral fluid collection devices are commercially 
available each differing in efficiency, oral fluid collection volume and presence of an 
incorporated indicator within the device to inform the user when a sufficient quantity 
of oral fluid has been collected. Most oral fluid collection devices currently 
employed for workplace testing are based on the presence of an absorbent collection 
pad the performance of which is depending upon design, composition of the pad and 
also whether a stimulant chemical has been added to the pad (e.g. citric acid) to act 
as a stimulant of secretion of saliva (Navazesh 1993, Crouch 2005). 
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The Orasure Intercept and the AlereTM Certus collection systems are the two devices 
which are the most commonly used devices in the UK. The purpose of investigating 
the effects of foods and beverages on the two collection systems was to establish 
which one of the two collectors is more suitable for use in further experimental 
studies.  
 
3.1.1 Orasure Intercept collection system 
The Orasure Intercept system (Figure 3.1) is a well-established collection device 
comprising a small pad that is wiped around the inside of the mouth and is claimed 
by the manufacturer to collect approximately 0.4 ml of oral fluid (Cone et al 2002). 
The device is 510K cleared by the FDA as a medical device. The collection device 
does not incorporate any mechanism to indicate when sufficient oral fluid has been 
collected, however the manufacturers advise that 0.4 ml of oral fluid is collected 
within two to five minutes. Following collection of the oral fluid specimen, the 
Intercept collection pad is immersed into 0.8 ml of buffer / preservative provided in a 
sealable tube.  
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Figure 3.1 Image showing the Orasure Intercept Collector 
 
The performance of the Orasure Intercept device has been evaluated as reported in 
the literature and it was shown that the recovery of oral fluid ranged between of 
82.91 % and 88.18 %. Although the device showed a good recovery of 80 %, the use 
of the device is not pleasant for the volunteer (Langel et al 2008). Volunteers 
commented on the bitter taste and hence gave negative feedback on the collection 
device.  
3.1.2 AlereTM Certus collection system 
The AlereTM Certus collector was introduced onto the market during 2010 and is a 
Class I medical device. It comprises a small absorbent foam cylinder attached to a 
handle that incorporates a built-in sample adequacy indicator. This turns blue when 1 
mL of oral fluid has been collected (Figure 3.2). The Certus collector is provided 
with a sealable tube containing 3mL preservative / buffer into which the collected 
oral fluid specimen is placed for transport to the laboratory. 
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Figure 3.2 Image showing the AlereTM Certus Collector with colour indicator  
 
The operation of the Certus and Orasure collection devices differs significantly in 
that the Certus collection device collects a measured volume of oral fluid whereas the 
Orasure device collects an unspecified quantity of oral fluid by wiping the collector 
across the mucosal membranes inside the mouth. It is outside the scope of this thesis 
to discuss the detailed reasoning behind manufacturers’ preference for different 
collection methods and the two collection devices are both widely used 
internationally by drug testing industry.  It may be argued that if a measurement of 
drug concentrations in oral fluid is the desired outcome, which seems logical when 
positive and negative results are compared against agreed cut off concentrations, then 
there is a requirement to know the volume of oral fluid collected which is not 
possible with the Orasure collector.   
Both collection devices are immersed in buffer solution after oral fluid has been 
collected.  The composition of the buffer solutions used in both devices is 
Colour 
Indicator 
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commercially restricted, however in general terms the buffer solution serves to a) 
extract drugs from the collection device into a matrix from which they can be 
subsequently extracted and analysed, b) control the pH of the medium to minimise 
drug breakdown and c) to act as a microbial inhibitor and preservative for the 
sample. Although no known fixed volume of oral fluid is collected using the Orasure 
device however the manufacturers of the Certus device state that samples should not 
be submitted if the volume indicator does not turn blue.   
Although studies have been reported in relation to oral fluid drug detection and 
identification, little has been published in relation to the investigation of the effects 
of common beverages and food substances on oral fluid drug testing. In 2005, Wong 
et al investigated the effects of a range of foods on oral fluid testing and showed that 
Asian, Hispanic or American food did not interfere with the test results and neither 
did salt or sodium glutamate. Additionally, Wong et al (2005) showed that toothpaste 
and mouthwash also did not interfere with the analysis of the samples.  
Other common household products and foodstuff have been investigated (Niedbala et 
al 2001).  Sugar water, toothpaste, cranberry juice, baking soda, orange juice, cola, 
cough syrup and antiseptic water all resulted in no interference to the immunoassay 
testing system when added to negative oral fluid samples. Additionally these 
substances did not interfere with the detection of benzoylecgonine or its recovery 
(Niedbala et al 2001).    
3.2 Materials and Methods 
Two studies were performed that involved collecting oral fluid specimens. The first 
study involved volunteers consuming food, beverages and oral hygiene products.  
The second study focused on investigating the effect of a range of vinegar products 
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on the testing process.  Informed consent was obtained from all participants and the 
experimental procedures were approved in compliance with the University of 
Bournemouth ethical guidelines (Appendix A). Volunteers undergoing treatment 
with any prescribed drugs or medications were excluded from the experiments. 
Volunteers were aged between 22 and 64.  .  
3.2.1 Materials 
Orasure devices / kits were purchased from Orasure, Bethlehem, Pennsylvania, USA. 
AlereTM devices / kits were donated by AlereTM, Abingdon, Oxfordshire, UK. 
3.2.2 Methods 
3.2.2.1  Collection Methods 
3.2.2.1.1 Collection Method Study 1 – Effects of a range of foods and beverage 
on oral fluid collection methods 
Non-drug using human volunteers were invited to consume one apple, coffee, cola, 
cranberry juice, fried food (plate of fish, chips and mushy peas), 5 grapes, a stick of 
chewing gum, milk, alcohol free mouthwash, one whole orange, Red Bull® , five sour 
candy sweets, spicy food, five sugar coated candy sweets, tea with milk, toothpaste, 
vinegar and yoghurt.  
Ten volunteers sampled each test substance individually and in separate studies. 
Solid foods and beverages were totally consumed whilst liquids such as mouthwash 
and vinegar (n = 30 mL) were swirled around the mouth for 30 seconds and then 
discarded. Sufficient toothpaste to cover the brush of a toothbrush was dispensed. 
Oral fluid was collected on separate occasions using the Orasure Intercept and 
AlereTM Certus oral fluid collection devices a) immediately after mouth emptying 
and b) 10 minutes after mouth emptying. Oral fluid was collected in accordance with 
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each manufacturer’s instructions. The Orasure Intercept oral fluid collection device 
was allowed to remain in the mouth for 3 minutes in accordance with the 
manufacturer’s guidance after which it was removed and placed into the 
manufacturer’s collection tube containing buffer and sealed. 
 
   
Figure 3.3. Summary of the oral fluid collection process using the AlereTM Certus 
and Orasure Intercept device (image available from http://www.orasure.com) 
 
The AlereTM Certus oral fluid collection device was allowed to remain in the mouth 
until the dye indicator turned blue after which time the collector was removed and 
placed in the manufacturer’s tube, containing buffer, and sealed. Collected oral fluid 
samples were stored at -20oC until analysis. Collections using each device were made 
alternatively and randomly. The volume of oral fluid collected, time for collection of 
Collection device is 
placed between the 
cheek and teeth 
Intercept collection time 
= 3 min 
Certus collector has a 
built in indicator to show 
when sufficient sample 
has been collected  
Collection device is 
inserted into the tube 
and handle is snapped 
off  
Finally, the sample was 
send to AlereTM 
Laboratories, Abingdon for 
immunoassay analysis and 
confirmation by GC-MS 
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samples and pH were recorded.  pH was measured using a Minilab ISFET electronic 
pH probe. The volume of oral fluid was determined gravimetrically by weighing the 
collection devices pre- and post-collection whilst assuming a specific gravity of 1. 
Oral fluid samples were subsequently analysed using their respective supplier’s 
immunoassay reagents to observe whether the substances affected the immunoassay 
screening system.  
The dilution factor for the Intercept device has been reported as an average of 1:4 
(Niedbala et al 200). The Certus dilution factor is also 1:4. Cut off concentrations in 
neat oral fluid for opiates, cocaine, and methadone were the same for both Intercept 
and Certus at 40ng/ml. Intercept cut offs in neat oral fluid were higher than Certus for 
Amfetamines (100 versus 15 ng/mL) and methamfetamines (45 versus  15 ng/mL). 
3.2.2.1.2 Collection Method Study 2 - Effects of vinegar on oral fluid collection 
methods 
Drug-free human volunteers  (n=10) were asked to swirl 5mL of a selected range of 
vinegars around the mouth for a period of 30 seconds and then discard the vinegar  
into a waste collecting receptacle. The vinegars included malt vinegar, white distilled 
vinegar, balsamic vinegar, red wine vinegar and white wine vinegar. After exposure, 
oral fluid was collected using the Orasure Intercept or the new AlereTM Certus oral 
fluid collection devices a) immediately after mouth emptying and subsequently at 10, 
20 and 30 minute intervals after mouth emptying. The sample collection procedure 
employed was the same as for Experiment one. Each volunteer provided samples 
using both devices for all vinegars tested. Oral fluid volume, pH and time of 
collection were recorded. 
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3.2.2.2 Analytical Method  
Oral fluid samples were analysed for the presence of amfetamine, methamfetamine, 
cocaine, methadone and opiates using the Intercept and Certus oral fluid collection 
systems. Intercept samples were analysed in duplicate using Orasure microplates and 
the manufacturer’s recommended cut offs. Intercept samples were analysed on 
Orasure microplates run on a Dynex microplate reader read at 450 nm  whereas the 
Certus samples were analysed using the AlereTM homogeneous assays on an Ilab 650 
using the manufacturer’s recommended cut offs. The screening cut offs for Intercept 
and Certus were the same for opiates, cocaine and methadone (10 ng/ml). They 
differed for amfetamine (100 ng/ml and 15 ng/ml) and methamfetamine (45 ng/ml 
and 15 ng/ml) for Intercept and Certus respectively. All samples that indicated a 
positive immunoassay response were confirmed by extraction (solid phase using 
Bond Elut Certify 3mL) with suitable internal standard and analysis by GC/MS or 
LC-MS-MS. Identification of each analyte for GC-MS was confirmed by three 
characteristic mass ions and for LC-MS-MS by two MS-MS transitions. The limit of 
detection (LOD) for the drug groups cocaine, opiates, amfetamines and 
metamfetamines was 1 ng/ml and for methadone was 3 ng/ml. 
3.3 Results and Discussion 
3.3.1 Study 1 - Effects of a range of foods and beverage on oral fluid  collection 
methods 
The pH of oral fluid prior to consumption of food and adulterants ranged from pH 6.8 
to pH 7.3 (mean= 6.9; median= 6.9, SD = 0.2). Neither of the two devices showed 
large pH changes after the consumption of most foods or adulterants. Following the 
consumption of vinegar the pH of oral fluid decreased to a mean pH of 5.3 (range = 
pH 4.7 - pH 6, median = pH 5.2) (Table 3.1).  
  
5
7 
Table 3.1 Summary of oral fluid pH pre and post exposure of common foods, beverages and oral hygiene products  
 
Intercept Certus 
 
Mean 
pre-
exposure 
pH  
Standard 
Deviation 
pre-
exposure 
pH 
Mean pH 
post 
exposure 
Standard 
Deviation 
post-
exposure 
pH 
pH post 
exposure 
Mean 
pre-
exposure 
pH  
Standard 
Deviation 
pre-
exposure 
pH 
Mean pH 
post 
exposure 
Standard 
Deviation 
post-
exposure 
pH 
pH post  
exposure 
 
Min  Max Min Max  
Apples 6.8 0.2 7.4 0.4 6.5 7.9 6.9 0.2 7.5 0.4 6.5 7.8 
Coffee 6.9 0.3 7.1 0.3 6.2 8.2 6.9 0.3 7.2 0.5 6.2 8.2 
Coke 6.9 0.2 6.8 0.5 5.9 8.1 6.9 0.2 6.7 0.6 5.7 7.7 
Cranberry 
Juice 
6.9 0.1 6.5 0.4 5.9 7.3 6.9 0.1 6.3 0.7 4.5 7.5 
Fried Food 7 0.3 7.2 0.4 6.6 8.1 6.9 0.1 7.3 0.4 6.8 8 
Grapes 6.9 0.2 7.4 0.6 5.9 8.6 6.9 0.2 7.6 0.5 6.8 8.6 
Gum 6.9 0.3 7.6 0.5 6.5 8.1 7.1 0.2 7.7 0.5 6.7 8.1 
Juice 7 0.2 6.2 0.8 4.8 7.7 7.2 0.2 6.6 0.8 5.2 7.7 
Milk 6.9 0.2 7 0.3 6.5 7.3 6.9 0.2 6.9 0.3 6.2 7.3 
Mouthwash 7 0.2 7.3 0.4 6.5 7.9 6.9 0.2 7.1 0.4 6.3 7.8 
Oranges 6.9 0.2 6.6 0.7 5.1 7.9 7.1 0.3 7 0.6 5.9 7.9 
Red bull  6.9 0.2 6.6 0.7 5.7 8.2 6.9 0.2 6.7 0.6 5.7 8.2 
Sour Candy  7 0.3 7.2 0.5 6.2 7.9 6.9 0.2 6.9 0.9 4.7 8.4 
Spicy Food 7 0.2 7.5 0.5 6.4 8.7 6.9 0.1 7.1 0.2 6.8 7.5 
Sugar 
Coated 
Candy 
7 0.2 7.4 0.4 6.3 8.5 7 0.3 7.8 0.7 6.6 7.9 
Tea 7 0.1 7.2 0.2 6.6 7.4 6.9 0.1 7.3 0.3 6.6 7.8 
V
alid
atio
n
 o
f O
ral F
lu
id
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Intercept Certus 
 
Mean 
pre-
exposure 
pH  
Standard 
Deviation 
pre-
exposure 
pH 
Mean pH 
post 
exposure 
Standard 
Deviation 
post-
exposure 
pH 
pH post 
exposure 
Mean 
pre-
exposure 
pH  
Standard 
Deviation 
pre-
exposure 
pH 
Mean pH 
post 
exposure 
Standard 
Deviation 
post-
exposure 
pH 
pH post  
exposure 
 
Min  Max Min Max  
Toothpaste 7 0.1 7.4 0.2 6.9 7.8 7 0.1 7.3 0.3 6.5 7.7 
Vinegar  6.9 0.1 5.3 0.6 4.7 6 6.9 0.3 5.8 0.8 5.2 6.8 
Yoghurt 7 0.2 6.9 0.4 5.3 7.8 6.9 0.2 6.9 0.4 6.1 7.7 
Mean 
(n=380) 
6.9 0.2 7 0.5 6 7.9 6.9 0.2 7 0.5 6 7.8 
Median (n = 
380) 
6.9 0.2 7.2 0.4 6.2 7.9 6.9 0.2 7.1 0.5 6.2 7.8 
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Table 3.2 summarises the volume of oral fluid collected by the Orasure Intercept 
collection device using a fixed 3 minute collection time (as recommended by the 
manufacturer) ranged from 0.01 mL to 1.77 mL (mean = 0.58 mL, median = 0.57 
mL, SD = 0.2 mL). In comparison the AlereTM Certus device collected an average of 
1.19 mL (range = 0.42 mL - 1.96 mL, median = 1.20 mL, SD = 0.3 mL). The 
collection time of the Certus device ranged from 1.1 min to 1.9 minutes (mean = 1.6 
min, median = 1.5 min).  
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Table 3.2 Summary of the volume of oral fluid collected with the Orasure Intercept 
device and the AlereTM Certus device following the exposure to several substances 
 
Volume Collected (mL) 
 
Intercept Certus 
 Mean  
Standard 
Deviation  
Min Max Mean  
Standard 
Deviation  
Min Max 
 
Apples 0.57 0.2 0.18 0.86 1.18 0.3 0.84 1.68 
Coffee 0.59 0.2 0.31 0.93 1.15 0.4 0.54 1.87 
Coke 0.56 0.2 0.02 0.9 1.11 0.4 0.45 1.87 
Cranberry 
Juice 
0.56 0.2 0.04 0.8 1.15 0.3 0.73 1.71 
Fried Food 0.49 0.2 0.15 0.79 1.26 0.3 0.84 1.59 
Grapes 0.64 0.2 0.21 0.95 1.27 0.3 0.8 1.96 
Gum 0.65 0.2 0.25 0.95 1.13 0.3 0.66 1.71 
Juice 0.54 0.2 0.27 0.85 1.29 0.3 0.55 1.87 
Milk 0.66 0.8 0.1 0.86 1.26 0.3 0.92 1.6 
Mouthwash 0.58 0.2 0.14 0.83 1.2 0.3 0.66 1.54 
Oranges 0.54 0.2 0.22 0.9 1.22 0.3 0.67 1.71 
Red bull 0.65 0.4 0.01 1.77 1.27 0.3 0.82 1.96 
Sour Candy 0.55 0.2 0.19 0.87 1.07 0.4 0.42 1.73 
Spicy Food 0.61 0.2 0.13 0.94 1.14 0.3 0.43 1.63 
Sugar 
Coated 
Candy 
0.56 0.2 0.29 0.79 1.19 0.3 0.78 1.69 
Tea 0.52 0.2 0.26 0.77 1.2 0.4 0.78 1.43 
Toothpaste 0.65 0.2 0.3 0.86 1.22 0.2 0.86 1.66 
Vinegar 0.56 0.2 0.16 0.89 1.24 0.3 0.78 1.82 
Yoghurt 0.59 0.2 0.01 0.9 1.17 0.3 0.78 1.64 
Mean 
(n=380) 
0.58 0.2 0.18 0.92 1.19 0.3 0.7 1.72 
Median (n = 
380) 
0.57 0.2 0.18 0.87 1.2 0.3 0.78 1.71 
 
 
The buffer volume in the Intercept tube was 0.8 mL which yields a range of dilution 
factors from 1 in 81 for the smallest collected sample (0.01 mL) to 1 in 1.5 for the 
largest collected sample.   
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By comparison, the buffer volume in the Certus tube is 3 mL which yields a range of 
dilution factors from 1 in 8.1 for the smallest volume collected to 1 in 2.5 for the 
largest collected sample. 
No presumptive positive results were obtained using the combination of Certus 
collector and AlereTM immunoassay. Several screen positive results were observed 
using the Orasure Intercept oral fluid collector in combination with the Orasure 
immunoassays. These were confirmed as drug free by chromatography - mass 
spectrometry and as such were deemed presumptive positives. It was noted however 
that these were mainly observed at time 0 and therefore represent a worst case 
scenario. 
Intermittent presumptive positives (1 subject out of 10) were obtained with the 
Orasure combination after consumption of coffee, coke, fruit juice, oranges, spicy 
food and toothpaste (Table 3.3). In these cases the intermittent presumptive positive 
results were observed across the volunteers and not from one single subject. High 
numbers of presumptive positives were observed following the consumption of malt 
vinegar.  
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Table 3.3 Summary of false positive immunoassay results from Orasure combination 
following the exposure to a range of foods and beverages 
Substance Amfetamine Methadone Methamfetamine Opiate Cocaine 
Apples -ve -ve -ve -ve -ve 
Coffee 
+ve (n=1, 
t=0) 
+ve (n=1, 
t=0) 
-ve 
+ve 
(n=1, 
t=0) 
-ve 
Coke 
+ve (n=1, 
t=0) 
-ve -ve -ve -ve 
Cranberry 
Juice 
-ve -ve -ve -ve -ve 
Fried Food -ve -ve -ve -ve -ve 
Fruit juice -ve -ve -ve 
+ve 
(n=1, 
t=0) 
-ve 
Grapes -ve -ve -ve -ve -ve 
Gum -ve -ve -ve -ve -ve 
Milk -ve -ve -ve -ve -ve 
Mouthwash -ve -ve -ve -ve -ve 
Oranges 
+ve (n=1, 
t=0) 
-ve -ve -ve -ve 
Red Bull -ve -ve -ve -ve -ve 
Sour 
Sweets 
-ve -ve -ve -ve -ve 
Spicy food -ve 
+ve (n=1, 
t=0) 
-ve -ve -ve 
Sugar 
Coated 
Sweets 
-ve -ve -ve -ve -ve 
Tea (with 
milk) 
-ve -ve -ve -ve -ve 
Toothpaste 
+ve (n=1, 
t=0) 
+ve (n=1, 
t=0) 
-ve -ve -ve 
Vinegar 
+ve (n=20, 
t=0,10)) 
+ve (n=20, 
t=0,10)) 
-ve -ve 
+ve 
(n=20, 
t=0,10)) 
Yoghurt -ve -ve -ve -ve -ve 
Legend: +ve =positive immunoassay screening result, -ve = negative immunoassay 
screening results, n= number of positive samples out of 10, t= time after mouth 
emptying (min) 
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Vinegar, coffee, cola, fruit juice, oranges, spicy food and toothpaste are all capable of 
affecting the Orasure assay system to produce presumptive positive results. With the 
exception of vinegar positives occurred randomly in 1% of samples indicating that 
this result is not statistically significant. Since vinegar was shown to produce a 
significant effect on the Intercept device it was decided to explore this in more detail.   
3.3.2 Study 2 - Effects of vinegar on oral fluid collection methods 
Vinegar (all types) consistently produced positive screening results with the Orasure 
combination for amfetamine, methamfetamine and cocaine immunoassays (Table 
3.4). No screening positives were observed with the Orasure combination for opiate 
and methadone assays. The majority of screening test positives were observed at the 
early time points although a significant number were also observed out to 30 minutes. 
All screen positives were submitted for GC MS confirmation and found to be 
confirmation negative (false positives) i.e. screening presumptive positive results.  
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Table 3.4 Binding (%) in different oral fluid samples after vinegar exposure using the 
Intercept oral fluid collection device 
  Binding (%) 
  Time Amfetamine Methadone Methamfetamine Opiate Cocaine 
Cut 
Offs 
  28 13 23 13 52 
M
a
lt
 V
in
eg
a
r
 0 8 32 14 45 39 
10 4 31 22 46 43 
20 8 34 16 47 43 
30 27 46 43 62 64 
W
h
it
e 
W
in
e 
V
in
eg
a
r 
0 4 25 7 36 24 
10 3 23 5 31 20 
20 5 30 10 39 32 
30 11 37 21 49 45 
R
ed
 W
in
e 
V
in
eg
a
r 
0 3 25 6 34 26 
10 3 25 7 36 25 
20 7 34 15 45 37 
30 7 32 13 45 36 
B
a
ls
a
m
ic
 
V
in
eg
a
r 
0 2 22 5 29 14 
10 3 26 7 35 22 
20 12 38 22 54 44 
30 24 44 33 60 51 
Legend: Binding (%) for the timed vinegar samples was calculated by dividing the 
optical density obtained for the sample by that of the kit’s zero calibrator and 
multiplying by 100. Binding (%) for the cut off calibrator was calculated by dividing 
the optical density obtained for that calibrator by that of the kit’s zero calibrator and 
multiplying by 100. As it is a competitive immunoassay, any binding value less than 
the cut off calibrator is deemed presumptive positive and any binding value greater 
than the cut off calibrator is deemed negative. Highlighted values in the table 
represent presumptive positives relative to the cut off binding for that particular 
assay. Non-highlighted values represent screen negative results. For clarity, the table 
shows the response from single donors each time point being post vinegar exposure.  
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Of note was the depression in the binding response for most of the vinegar samples 
using the Intercept/Orasure combination. Due to the wide displacement between 
negative and cut off for the opiate and methadone assays, the vinegar samples did not 
trigger a positive response. The other Orasure assays have less displacement between 
negative and cut off which resulted in higher numbers of presumptive positive 
results. 
Depressed binding could clearly be shown for up to 75 minutes post vinegar 
exposure for methamfetamine, amfetamine and cocaine. Although samples were 
reported as negative and above the cut off for the percentage binding 30 minutes post 
exposure to a substance, binding was still found to be depressed post this period as 
can been in Figure 3.4, Figure 3.5 and Figure 3.6. This indicates that the vinegar  still 
affects the Orasure collection system after 30 minutes post consumption. These 
results should be borne in mind when interpreting forensic data as should the large 
difference in dilution factors observed between the devices.  
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Figure 3.4 Binding (%) for methamfetamine in samples taken after the consumption of malt, distilled, balsamic and red and white  
vinegar over 75 minutes collected using the Orasure Intercept® device. The red line (---) indicates the percentage binding 
 cut off for metamfetamine (23 %) 
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Figure 3.5 Binding (%) for Amfetamine in samples taken after the consumption of malt, distilled, balsamic and red and white vinegar over 75 
minutes collected using the Orasure Intercept® device. The red line (---) indicates the percentage binding cut off for amfetamine (28 %) 
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Figure 3.6 Binding (%) for cocaine in samples taken after the consumption of malt, distilled, balsamic and red and white vinegar over 75 minutes 
collected using the Orasure Intercept® device. The red line (---) indicates the percentage binding cut off for cocaine (52 %) 
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Although opiate and methadone sample did not result in a false positive result, 
depressed binding can still be shown in all types of vinegar for up to 75 minutes post 
exposure. Percentage binding could clearly be observed to be above the cut off.  
Opiate binding was initially depressed by 50 % but during the collections over 75 
minutes, depression quickly decreased. However, at t = 75 min depression still 
ranged between 80 % and 90 %. Although results were all above the cut off for 
percentage binding, depressed binding could still affect the concentration detected 
and hence the interpretation of the results (Figure 3.7).  
 
 
 
Figure 3.7 Binding (%) for opiates in samples taken after the consumption of malt, 
distilled, balsamic and red and white vinegar over 75 minutes collected using the 
Orasure Intercept® device. The red line (---) indicates the percentage binding cut off 
for opiates (13 %) 
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Similarly to opiate, methadone depression was observed in all oral fluid samples 
during the 75 minute collection. Binding was depressed by up to 70 % in the sample 
collected immediately post exposure. Depression only slowly decreased and in 
samples collected at t = 75 min depression was still observed ranging between 40 % 
and 60 % (Figure 3.8).  
 
 
Figure 3.8 Binding (%) for methadone in samples taken after the consumption of 
malt, distilled, balsamic and red and white vinegar over 75 minutes collected using 
the Orasure Intercept® device.  
The red line (---) indicates the percentage binding cut off for methadone (13 %) 
 
By comparison the Certus / AlereTM samples were negative for all vinegar types and 
time points. No visual changes to either buffer were observed in specimens that were 
tested following the use of vinegar. 
Vinegar proved to be a major interference to the immunoassay. Most manufacturers 
of oral fluid drug tests indicate that the effects of foods and beverages have dispersed 
from the mouth after 10 - 15 minutes (Spiehler 2011) and that after this time has 
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elapsed an oral fluid sample can then be collected with minimum risk of 
contamination. 
The results presented here clearly contradict this general guideline in relation to 
vinegar. Although no opiate or methadone presumptive positives results were 
observed, the antibody binding following the consumption of vinegar was reduced 
significantly (>50%) however results were still above the cut off and hence had to be 
reported as negative. There was no relationship between presumptive positive result 
and the variable dilutions. 
Vinegar (pH = 4.2) was the most acidic of the substances tested and it is possible that 
the acid pH of collection. Following the consumption of vinegar the pH of oral fluid 
decreased to a mean pH of 5.3 (range = pH 4.7 - pH 6) when collected using the 
Orasure Intercept device. In sample collected with the AlereTM Certus device the pH 
ranged between 5.2 and 6.8 (mean = 5.3).  
In comparison to the AlereTM Certus Collector, which is provided with 4 mL of 
buffer, the Orasure collection device contains a lower buffer volume of 3 mL.  Each 
collection buffer is designed to ensure sample stability and minimize the side effects 
of sample pH to immunoassay screening (Ericson and Bratthall, 1989). The 
effectiveness of a buffer or buffer capacity is determined by the concentration of acid 
which is added to the buffer solution. The weak base in the buffer is designed to 
neutralize acidic solutions, however if the acid/base ratio is too large, it can lead to a 
buildup of acid and hence lower the pH of the sample solution. Therefore the dilution 
factor plays an important role, when investigating false positive results, following the 
consumption of vinegar.  
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The Intercept collector has a much greater variation in the dilution factor than the 
Certus system. The buffer volume in the Intercept tube was 0.8 mL, which resulted in 
a range of dilution factors from 1 in 81 for the smallest collected sample to 1 in 1.5 
for the largest collected sample. Due to the lower dilution factor in the Intercept 
system, the acid/base ratio will be larger in comparison to the acid/base ratio in the 
Certus collector, hence lowering the pH of the solution and resulting in a false 
positive effect on the immunoassay. 
Additionally, the hypothesis that pH can affect antibody binding and hence lead to 
unreliable results is further supported in the literature. Kim et al (2003) discussed 
large amounts of false positives in samples collected using a Salivette collector using 
the Cozart Microplate EIA Cocaine Oral Fluid Kit have been reported in the 
literature (Kim et al 2003). The Salivette system is based on a cotton swab which is 
treated with citric acid to stimulate saliva flow. The citric acid results in a lower 
sample pH (mean pH 2.8) which has been shown to increase the amount of false 
reactions in immunoassay testing systems. Niedbala et al (2001) also investigated the 
effects of pH on the Cozart Cocaine EIA kit by adjusting oral fluid (pH 7.07) with 
aqueous sodium hydroxide or hydrochloric acid solutions to achieve a range of pH 
5.0 to pH 9.0 and applying this to the immunoassay. No interference from the pH on 
the Cozart Cocaine EIA kit was detected during testing.  
3.4 Conclusion 
The Orasure Intercept oral fluid collection device has limited buffering capacity and 
hence exhibited numerous presumptive positive immunoassay test results. This was 
particularly observed following the consumption of vinegar.  With the exception of 
vinegar, interferences from foods, common beverages and oral hygiene products 
were not observable after 10 minutes providing support for the widely held view that 
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foods should not be a problem after 10-15 minutes has elapsed. The interference by 
vinegar was not related to the pH of the sample or dilution factor when applied to the 
immunoassay. Use of the AlereTM Certus collection device did not provide any 
presumptive positive results by immunoassay. As a consequence of the improved 
performance of the Certus oral fluid collection device, this was used for collecting 
oral fluid samples in the experiments described in the following sections. 
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Chapter 4.0 - Concentrations of cocaine, benzoylecgonine and 
ecgonine methyl ester in oral fluid following the  consumption of 
coca tea 
4.1 Introduction 
It has been reported (Chapter 1) that orally consumed drugs can be deposited in the 
oral cavity and hence result in the detection of elevated concentrations in oral fluid 
above the contribution from drug passing into the blood stream and back into the 
mouth via saliva secretions (Cone 1996, Huestis and Cone 2004, Drummer 2006). 
Most scientific studies examining oral fluid cocaine appearance have been restricted 
to relatively small doses of drug for ethical and safety reasons. For the purpose of 
this study, oral fluid samples following the consumption of coca tea were collected in 
Lima, Peru.  
Coca tea is widely consumed in a number of South American countries where its use 
is both legal and socially acceptable. The tea is prepared from an infusion of the 
leaves obtained from the coca bush Erythroxylum coca (Hamner and Villegas 1969, 
Hanna and Hornick 1977, Siegel et al 1986, Jenkins et al 1996, Turner et al 2005). 
Coca leaves have been used for over 2000 years and were widely used by the Incas 
of Peru in religious ceremonies (Martin 1970, Zapata-Oritz 1970, Allen 1981, 
Billman 1990). 
In addition to the use of coca leaves during the preparation of coca tea, the custom of 
chewing coca leaves is still widely practiced today by people working at high 
altitude. Coca chewing alleviates adverse symptoms of pain, thirst, hunger and 
tiredness that are experienced by humans working or living at high altitude (Fuchs 
1978). Chewing coca can be advantageous in colder environments (Hanna 1971a). In 
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addition to cocaine, the average coca leaf contains a number of other structurally 
related compounds including benzoylecgonine and ecgonine methyl ester (Weil 
1978, Penny et al 2009).   The amount of cocaine and its metabolites present in coca 
leave can vary depending on species and origin of the Erythroxylum plant (Jenkins et 
al 1996). The Peruvian Erythroxylum species, as used by Jenkins et al, contains 5.11 
mg of cocaine, 0.11 mg of benzoylecgonine and 1.15 mg of ecgonine methyl ester in 
1 g of leaf material (Jenkins et al 1996). 
Elevated drug concentrations are reported to be caused by contamination of the oral 
mucosa following exposure to orally consumed drugs. Concentrations of cocaine in 
oral fluid following crack cocaine smoking ranged between 15.85 µg/mL to 504.88 
µg/mL in comparison to cocaine concentrations following injection that ranged 
between 0.43 µg/mL to 1.93 µg/mL (Jenkins et al 1996). These concentrations 
greatly exceed normal levels thus indicating possible depot formation. 
The experiments described in this section were designed to investigate the 
concentration of cocaine and related compounds that may be detected in oral fluid 
following consumption of coca tea. To identify whether elevated drug concentrations 
can be detected for extended time periods and hence interfere with the interpretation 
of results, oral fluid specimens were collected from volunteers following the 
consumption of coca tea over a 60 minute interval.  
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4.2 Materials and Methods 
4.2.1 Materials 
AlereTM Certus collectors were provided by Alere Toxicology, Abingdon, UK 
AlereTM Microplate EIA Kits for cocaine were used to screen for the presence of 
cocaine and its derivatives and were provided by Alere Toxicology, Abingdon, UK.  
Dried Coca leaves (500 g) were purchased in a local market in Lima, Peru.  
4.2.2 Methodology 
4.2.2.1 Preparation of coca tea 
Following local custom, coca tea was prepared by soaking 10 whole coca leaves in 
boiling water for 5 minutes prior to straining to remove the leaf tissues (Figure 4.1). 
 
Coca tea – prior to straining Coca tea following straining of leaves  
  
Figure 4.1. Coca tea preparation – Coca leaves were infused with boiling water (left), 
and subsequently strained (right) to yield a clear pale yellow infusion prior to 
drinking  
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4.2.2.2   Collection methods 
Twenty-five healthy volunteers, ranging in age between 21 and 88 (12 male, 13 
female) whom were resident in Lima, Peru, participated in this study. Informed 
consent was obtained from all participants prior to participation and the experimental 
procedures were undertaken in compliance with the University of Bournemouth 
ethical guidelines (Appendix B). All volunteers completed a questionnaire regarding 
prior use of cocaine/coca tea and stated that they had not consumed cocaine, coca tea 
or alcohol within the preceding 24 hours. Volunteers provided a blank control oral 
fluid sample immediately prior to drinking the coca tea for confirmation that no coca 
tea, cocaine or alcohol was consumed prior to participating in this study.  
Volunteers drank 1 cup (~250 mL) of coca tea immediately post straining of the 
leaves over a period of approximately 5 minutes and afterwards provided a sample of 
oral fluid immediately following completion of tea drinking. Oral fluid was 
subsequently collected at 15, 30, 45 and 60 minute intervals. Oral fluid collection 
was facilitated using the AlereTM Certus device and subsequently transferred to 
buffer of  pH 4.5 buffer since acidic buffers have been shown to reduce the 
hydrolysis of cocaine to benzoylecgonine (Kiszka et al. 2000). The collected 
specimens were stored at –20oC prior to transportation to the laboratory at Alere 
Toxicology, Abingdon, UK.  A period of 14 days elapsed between collection of the 
specimens and their subsequent analysis. Oral fluid samples were screened using a 
cocaine immunoassay prior to confirmation using LC-MS. 
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4.2.2.3 Immunoassay 
The AlereTM Microplate EIA Kit for cocaine metabolites was provided with four 
calibrators ranging between 0 ng/mL and 300 ng/mL. The manufacturers report cross 
reactivity of the assay with cocaine and cocaethylene as summarised in Table 4.1. 
Table 4.1. Summary of compounds cross-reacting with the AlereTM Microplate EIA 
Kit for cocaine (AlereTM, 2013)  
Compounds Cross 
Reactants 
Concentration 
ng/mL 
Apparent 
Benzoylecgonine 
Reactivity (%) 
Cocaine 
300 277.1 92.4 
50 46.4 92.8 
10 10.2 102.0 
Cocaethylene 
300 290.9 97.0 
50 59.9 119.7 
10 13.0 129.7 
 
All non-cross reacting compounds are summarised in Appendix C.  
 
The principal upon which this immunoassay is based relies on the fact that the wells 
of a microplate are coated with a benzoylecgonine antibody. Initially the sample is 
added to the wells in combination with an enzyme conjugate which is included in the 
immunoassay kit. The enzyme conjugate is a cocaine metabolite derivative labelled 
with horseradish peroxidase <0.1% (v/v) and diluted in a matrix with stabilers. 
During the incubation time, the analyte of interest competes with the enzyme 
conjugate for the binding sites of the antigen of the wells. The plates were then 
thoroughly washed using a DAS automated microplate washer to remove excess 
enzyme conjugate. A substrate solution which consists of a solution of <0.05% 
3,3’,5,5’-tetramethylbenzidine was then added. The substrate reagent is converted 
directly by the enzyme conjugate which has bound to the well antibody resulting in a 
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blue colour reaction. After a further incubation period, a stop solution of 1 mol/L 
sulphuric acid is added to stop the reaction and convert the colour reaction into a 
more readable yellow colour. The immunoassay plate is read at a wavelength of 450 
nm and secondary wavelength of 630 nm on a DAS 8 channel ELISA photometer.  
The procedure is summarised in below in Figure 4.2.  
25 µl of calibrator/sample added to each well
100 µL of cocaine enzyme conjugate added to each well
Incubation at room temperature for 30 minutes
Washed four times with 400 µL of wash buffer
100 µL of substrate solution added to each well
Incubation at room temperature for 30 minutes
100 µL of stop solution added to each well
Read plate within 15 minutes on DAS 8 channel microplate reader
 
Figure 4.2. Outline of the procedure for using the AlereTM immunoassay method for 
cocaine 
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4.2.2.4 Solid Phase Extraction (SPE) 
200 µL of 0.1M hydrochloric acid was added to 200 µL of the oral fluid samples. 
Extraction was performed using Oasis mixed-mode cation exchange (MCX) micro 
elution plates (Waters, Manchester, UK). Cartridges were conditioned with 200 µL 
of methanol and 200 µL of 0.1 M hydrochloric acid followed by addition of sample. 
The columns were washed with 200 µL of 0.1 M hydrochloric acid and 200 µL of 
30% methanol in water (70/30 v/v) and dried. Elution was achieved using 50 µL of 
5% ammonia in methanol. The sample was reconstituted in 50 µL of 0.1% formic 
acid in water and analysed on a Waters LC-MS system.  
4.2.2.5 Liquid Chromatography – Mass Spectrometry  
Extracted oral fluid samples were analysed at Alere Toxicology, Abingdon using 
LC-MS. Chromatographic analysis was carried out using a C18-ether column (3µ x 
50 mm x 2 mm) (Phenomenex, UK). An elution gradient at a flow rate of 0.25 
mL/min was used for a run time of 17 minutes. The Mobile Phase A was 0.1 % 
acetic acid and Mobile Phase B was 0.1 % acetic acid in methanol.  The HPLC 
column temperature was maintained at 40°C. To ensure the assay performance is fit 
for purpose, the following parameters were determined to validate the quantitative 
chromatographic methods used within the laboratory (Table 4.2):  
 Method linearity 
 Limit of Quantitation (LOQ) 
 Upper (ULOQ) and Lower (LLOQ) robustness of the assay 
 Stability of the analytes of interest 
 Recovery from collection device 
 Extraction efficiency  
 Matrix effects  
 Specificity 
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 Carryover 
 Bias (accuracy) 
 Reproducibility (precision) – within and between batches and the 
measurement of uncertainty  
 
  
8
2
 
Table 4.2 Parameters for the detection of cocaine and its metabolites by LC-MS 
Compound 
MRM transition 
(m/z) 
Retention 
Time 
(min) 
LOD 
(ng/mL) 
LLOQ 
(ng/mL) 
Analyte 
Bias (%) 
(n=79) 
Measurement of 
Uncertainty 
(%) 
Cocaine 
304→105 
304→182 
12.36 0.1 0.8 - 9 ± 46 
Cocaine-D3 307→185. 12.36 -- -- -- -- 
Benzoylecgonine 
290→168 
290→105 
11.43 0.1 0.8 + 22 ± 38 
Benzoylecgonine- D3 293→171 11.43 -- -- -- -- 
Ecgonine Methyl 
Ester 
200→182 
200→82 
2.45 0.33 0.8 - 13 ± 48 
Anhydroecgonine 
methyl ester 
182→118 
182→122 
5.94 0.66 0.8 + 25 ± 59 
Anhydroecgonine 
methyl ester – D3 
185→125 5.94 -- -- -- -- 
Cocaethylene 
318→150 
318→196 
13.41 0.33 0.8 - 1 ± 36 
Cocaethylene – D3 321→199 13.41 -- -- -- -- 
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4.3 Results and Discussion 
4.3.1 Immunoassay Results 
In toxicology, immunoassay is adapted as a fast, preliminary screening technique 
commonly used as an indicator to identify the presence or absence of a drug group, 
rather than a specific compound. The immunoassay results generated are only 
qualitative or semi-quantitative and require confirmation, usually by 
chromatography-mass spectrometry. Due to the limited amount of sample, the 
immunoassay was used in qualitative mode reporting as positive (+ve) or negative (-
ve) rather than perform multiple dilutions to obtain a value. The cut off 
recommended by the kit manufacturer was 50 ng/mL for the immunoassay below 
which the results were reported as negative. Table 4.3 summarises the results from 
the immunoassay screening of coca tea samples. None of the 25 volunteers indicated 
a positive result prior to participating in this study. All volunteers tested positive 
immediately post consumption of coca tea however, the immunoassay result showed 
that 20 volunteers out of the 25 tested did not test positive for cocaine or any of its 
cross-reacting compounds 60 minutes post consumption of coca tea.  
   
  
 
8
4 
Table 4.3. Summary of cocaine immunoassay results (ng/ml) in oral fluid obtained from 25 volunteers before and after the consumption of 
coca tea. -ve = negative result below the manufacturers recommended cut off (50 ng/mL) ; +ve = positive result above the manufactures 
recommended cut off for the immunoassay (50 ng/mL) 
ID 
Time 
(min) 
Concentration 
(ng/ml) 
ID 
Time 
(min) 
Concentration 
(ng/ml) 
ID 
Time 
(min) 
Concentration 
(ng/ml) 
ID 
Time 
(min) 
Concentration 
(ng/ml) 
ID 
Time 
(min) 
Concentration 
(ng/ml) 
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4.3.2 LC-MS results 
Mass spectra were unobtainable due to loss of data following a computer fault.  
4.3.2.1 Cocaine 
The SAMSHA guidelines for confirmatory analysis cut off for cocaine in oral fluid 
has been set at 8 ng/mL. Cocaine concentrations immediately after consumption of 
coca tea ranged between 14 ng/mL and 8,595 ng/mL (mean = 2,729 ng/mL, median 
= 1,807 ng/mL, SD = 2434 ng/mL) (Table 4.4). The interquartile range, which 
excludes low and high outliers within the results, was 2175 ng/mL.  
Table 4.4. Summary of the mean, median and range of concentrations (ng/mL) of 
cocaine analysed by LC/MS in oral fluid specimens collected from human volunteers 
following the consumption of coca tea  
n = 25 Concentration (ng/ml) 
Time (min) Mean  Median 
Standard 
Deviation 
(SD) 
Interquartile 
Range (IQR) Range 
 Min Max 
pre-dose 9 4 14 5 1 62 
0 2729 1808 2434 2175 14 8595 
15 368 184 444 365 25 1570 
30 138. 33 205 100 6 768 
45 44 25 52 35 5 186 
60 22 12 37 19 2 176 
 
 Cocaine concentrations dropped rapidly to a mean concentration of 368 ng/mL after 
15 minutes.  Mean concentrations at 30 and 45 minutes after tea drinking were 128.0 
ng/mL and 44 ng/mL respectively. In all 25 cases cocaine was still detectable at 60 
minutes with concentrations ranging between 1.9 ng/mL and 176 ng/mL (Figure 4.3). 
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Figure 4.3. Mean and Median concentrations (ng/mL) of cocaine in oral fluid 
following the consumption of coca tea in samples collected over 60 minutes.  Red 
line (---) indicates the SAMHSA cut off for cocaine in oral fluid (8 ng/mL) during 
confirmatory analysis 
 
Of note was the maximum concentration of cocaine in samples collected prior to 
consumption. Whilst no positives were reported from the immunoassay analysis due 
to the higher cut off, the concentrations of cocaine in pre-dose samples during 
confirmatory analysis ranged from 1 ng/mL to 62 ng/mL (mean = 9 ng/mL, median = 
4 ng/mL) (Figure 4.4). The difference between screening and confirmatory positives 
prior to consumption of tea is a result of the higher sensitivity of the LC-MS method.  
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Figure 4.4 represents the concentrations of cocaine in oral fluid in samples collected 
prior to consumption of coca tea shown by LC/MS. The red line (---) indicates the 
recommended SAMHSA cut off for cocaine in oral fluid of 8ng/mL 
 
Although volunteers were asked not to consume coca tea 24 hours prior to 
participating in this study, as with any human volunteer study, this could not be 
guaranteed. Drinking of coca tea prior to collection of the pre-dose sample may be 
the cause of positive results prior to drinking. Excluding the positive pre-dose 
samples which were above the 8 ng/mL cut off did not result in a significant change 
in mean, median, minimum or maximum concentrations. Concentrations observed 
when excluding anomalies are still above the recommended SAMHSA cut off of 8 
ng/mL for up to 60 minutes post consumption (Table 4.5).   
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Table 4.5. Summary of the mean, median and range of concentrations (ng/mL) of 
cocaine analysed in oral fluid specimens collected from human volunteers post 
consumption of coca tea following the exclusion of positive volunteers pre-drinking 
above the recommended SAMHSA cut off of 8ng/mL 
n = 20 Concentration (ng/ml) 
Time (min) Mean  Median  
Standard 
Deviation 
(SD) 
Interquartile 
Range (IQR) 
Range  
 Min Max 
pre-dose 3 3 2 4 1 7 
0 2959 1808 2631 3261 14 8959 
15 396 191 480 381 25 1570 
30 160 49 224 131 6 768 
45 50 25 57 51 5 186 
60 24 11 41 20 2 177 
 
4.3.2.2 Benzoylecgonine 
Concentrations of benzoylecgonine were detected above the recommended 
SAMHSA cut off for benzoylecgonine in oral fluid (8ng/mL) for up to 60 minutes 
post consumption of coca tea (Table 4.6).   
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Table 4.6. Summary of the mean, median and range of concentrations of 
benzoylecgonine analysed in oral fluid specimens collected from human volunteers 
following the consumption of coca tea 
n = 25 Concentration (ng/ml) 
Time (min) Mean  Median  
Standard 
Deviation 
(SD) 
Interquartile 
Range (IQR) Range 
 Min Max 
pre-dose 8 1 17 1 1 53 
0 174 146 113 138 11 452 
15 17 7 20 17 3 81 
30 12 7 14 10 2 66 
45 15 11 17 10 2 87 
60 15 10 15 11 3 73 
 
Concentrations of coca tea benzoylecgonine concentrations in oral fluid immediately 
post consumption of coca tea ranged between 11 ng/mL to 452 ng/mL (mean = 174 
ng/mL, median = 146 ng/mL, SD = 113 ng/mL, IQR = 138 ng/mL). Although the tea 
itself was not analysed during this study,  Jenkins et al (1996) reported presence of 
benzoylecgonine in Peruvian coca tea at concentrations of 440 ng/mL which 
indicated that immediately post consumption of coca tea, concentrations detected in 
oral fluid are likely to be reflecting the concentration in the coca tea rather than 
concentrations from oral fluid itself.    
Initially the concentration of benzoylecgonine dropped rapidly within 15 minutes to a 
concentration of 17 ng/mL (range = 3.0 ng/mL – 81 ng/mL, median = 7.3 ng/mL, SD 
= 20 ng/mL ). Following the initial 15 minutes the concentrations plateaued and no 
substantial concentrations change was observed over the next 45 minutes (Figure 
4.5).   
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Figure 4.5. Mean and Median concentrations (ng/mL) of benzoylecgonine in oral 
fluid following the consumption of coca tea in samples collected over 60 minutes. 
The red line (---) indicates the recommended SAMHSA cut off for benzoylecgonine 
in oral fluid of 8ng/mL 
 
At 60 minutes post consumption concentrations of benzoylecgonine were still above 
the recommended SAMHSA cut off of benzoylecgonine in oral fluid (8 ng/mL) 
ranging between 3 ng/mL and 73 ng/mL (mean = 15 ng/mL, median = 10 ng/mL, SD 
= 15 ng/mL, IQR = 11 ng/mL).  
Similarly to cocaine, positive results above the SAMHSA recommended cut off of 8 
ng/mL could be detected in samples from two volunteers collected prior to the 
consumption of coca tea. Concentrations ranged between 1 ng/mL and 53 ng/mL 
(mean = 8 ng/mL, median = 1 ng/mL, SD = 17 ng/mL). Only two volunteers were 
above the recommended SAMHSA cut off of 8ng/mL prior to participation in this 
study (Figure 4.6).  
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Figure 4.6. Concentrations of benzoylecgonine in oral fluid samples collected prior 
to consumption of coca tea. Benzoylecgonine was detected in 8 out of 25 samples, 
however only 2 were positive above the recommended SAMHSA cut off. The red 
line (---) indicates the recommended SAMHSA cut off for benzoylecgonine in oral 
fluid of 8ng/mL 
 
In order to identify whether mean and median concentrations were raised artificially 
by the outliers pre-drinking, the two volunteers were excluded. Concentrations 
following the exclusion of the two volunteers did not show a significant difference to 
the initial results and results were still reported above the recommended SAMHSA 
cut off of 8 ng/mL with a mean concentration of 175 ng/mL (median = 146 ng/mL, 
range = 11 ng/mL – 452 ng/mL, SD = 115 ng/mL) immediately post consumption. 
Concentrations of benzoylecgonine in the final samples 60 minutes post consumption 
ranged between 3 ng/mL and 37 ng/mL (mean = 12 ng/mL, median = 10 ng/mL, SD 
= 8 ng/mL). The interquartile range 60 minutes post consumption was 10 ng/mL 
(Table 4.7).  
 
 
0
10
20
30
40
50
60
0 1 2 3 4 5 6 7 8
C
o
n
ce
n
tr
a
ti
o
n
 (
n
g
/m
L
)
Volunteer Number
Validation of Oral Fluid as a Matrix for Drug Detection  - Chapter 4 
 
93 
 
Table 4.7. Summary of the mean, median and range of concentrations (ng/mL) of 
benzoylecgonine analysed in oral fluid specimens collected from human volunteers 
post consumption of coca tea following the exclusion of positive volunteers pre-
drinking above the recommended SAMHSA cut off of 8 ng/mL 
n = 23 Concentration (ng/ml) 
Time (min) Mean  Median  
Standard 
Deviation 
(SD) 
 Range  
Interquartile 
Range (IQR) 
Min Max 
pre-dose 1 1 0 0 1 1 
0 175 146 115 117 11 45 
15 16 7 20 16 3 81 
30 13 7 14 10 2 66 
45 12 11 7 7 2 29 
60 12 10 8 10 3 37 
 
4.3.2.3 Ecgonine Methyl Ester (EME) 
Ecgonine methyl ester was the compound observed with the highest concentration 
immediately after consumption of the tea with a mean concentration of 3,239 ng/mL 
(range = 24 ng/mL – 16,685 ng/mL, median = 2,246 ng/mL, SD = 3602 ng/mL, IQR 
1,946 ng/mL) (Table 4.8).   
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Table 4.8. Summary of the mean, median and range of concentrations of ecgonine 
methyl ester analysed in oral fluid specimens collected from human volunteers 
following the consumption of coca tea 
 Concentration (ng/ml) 
Time 
(min) 
Mean 
(n=25) 
Median 
(n=25) 
Standard 
Deviation 
(SD) 
Interquartile 
Range (IQR) Range (n = 25) 
 Min Max 
pre-dose 24 14 30 30 1 98 
0 3,239 2246 3602 1946 25 16,686 
15 257 144 280 219 39 1,209 
30 141 85 129 115 20 533 
45 137 92 143 100 17 675 
60 72 56 59 61 2 241 
 
The maximum concentration of ecgonine methyl ester observed in oral fluid samples 
immediately post consumption is at a four-fold increase above the reported 
concentration of 4,600 ng/mL found in  peruvian tea by Jenkins et al (1996). It is 
well known that cocaine and benzoylecgonine can both convert to form ecgonine 
methyl ester hence this may offer an explanation for the elevated concentration of 
ecgonine methyl ester in oral fluid samples immediately after tea drinking (Chapter 
1). Although an acidic buffer was used to slow down the degradation of cocaine to 
benzoylecgonine and ecgonine methyl ester during transportation, the samples 
underwent several freeze-thaw cycles prior to analysis, allowing a possible 
degradation to ecgonine methyl ester and resulting in increased concentrations of 
ecgonine methyl ester.  
Concentrations of ecgonine methyl ester rapidly decreased within the first 15 minutes 
post consumption of coca tea. Mean concentrations decreased from 3,239 ng/mL 
(range = 25 ng/mL – 16,686 ng/mL, median = 2,246 ng/mL, SD = 3602 ng/mL) to 
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257 ng/mL (range = 39 ng/mL – 1,209 ng/mL, median = 144 ng/mL, SD = 
280ng/mL). Concentrations of ecgonine methyl ester did not show a substantial 
decrease and plateaued resulting in concentrations ranging between 2 ng/mL and 250 
ng/mL (mean = 72, median = 56 ng/mL, SD = 59 ng/mL) 60 minutes post exposure 
(Figure 4.7).  
 
 
Figure 4.7. Mean and Median concentrations (ng/mL) of ecgonine methyl ester in 
oral fluid collected over 60 minutes following the consumption of coca tea  
 
There is currently no  SAMHSA cut off for ecgonine methyl ester in oral fluid, but 
the presence of  ecgonine methyl ester in oral fluid samples prior to consumption of 
coca tea followed a similar trend  to the pre-dose cocaine and benzoylecgonine 
samples with five samples showing high positive results in comparison to other 
volunteers (Figure 4.8).  
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Figure 4.8 Concentrations of ecgonine methyl ester in oral fluid samples collected 
prior to consumption of coca tea. Ecgonine methyl ester was detected in 15 out of 25 
samples. To date no cut off has been recommended by SAMHSA for the detection of 
ecgonine methyl ester in oral fluid 
 
Although there is no cut off for ecgonine methyl ester in oral fluid to date, when 
excluding pre-dose concentrations at a hypothetically cut off of 8 ng/mL, no large 
change in the mean, median, minimum and maximum concentration was observed. 
Large concentrations were still observed 60 minutes post consumption of coca tea 
ranging between 16 ng/mL and 241 ng/mL (mean = 77 ng/mL, median = 61 ng/mL, 
SD = 62 ng/mL) (Table 4.9).  
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Table 4.9. Summary of the mean, median and range of concentrations (ng/mL) of 
ecgonine methyl ester analysed in oral fluid specimens collected from human 
volunteers post consumption of coca tea following the exclusion of positive 
volunteers pre-drinking above a hypothetical cut off of 8 ng/mL 
n = 16 Concentration (ng/ml) 
Time (min) Mean  Median  
Standard 
Deviation 
(SD) 
Interquartile 
Range (IQR) 
Range  
 Min Max 
pre-dose 3 1 3 4 1 7 
0 3,965 2,761 2306 2463 56 16,685 
15 318 165 324 302 65 1209 
30 161 80 151 179 20 533 
45 160 87 169 132 17 675 
60 77 61 62 51 16 241 
 
4.3.2.4 Summary of cocaine, benzoylecgonine and ecgonine methyl ester 
concentrations 
Concentrations of cocaine, benzoylecgonine and ecgonine methyl ester all indicate 
that there is a potential for drugs to accumulate in oral tissues.  Concentrations were 
above the SAMHSA recommended cut off of 8 ng/mL (where applicable) up to one 
hour post consumption as measured by LC-MS/MS.  
In order to be able to collect a specimen from a driver suspected to have been driving 
whilst impaired through drug use the current United Kingdom Road Traffic Act 
requires, police offices to demonstrate that an offender is impaired and unfit to drive 
and that any potential impairment may be attributable to drugs. Drugs can affect 
different people in different ways and may even affect the same person in different 
ways on different occasions making it difficult to correlate impairment to a specific 
concentration range.  
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Volunteers, who were undertaking their normal work duties during participation in 
this study, were asked whether any stimulant effects were felt post consumption of 
coca tea. None of the volunteers described any stimulant effects after drinking just 
one single cup of coca tea. As regular coca tea drinkers, they may well have 
developed tolerance to the effects of cocaine and require higher doses of drug to gain 
an effect. By contrast, many of the published papers describe the effects of cocaine 
from low dose clinical studies conducted in healthy, non-drug using individuals. The 
elevated concentrations detected in oral fluid in this study are the first to be observed 
in a coca tea using population.  
Positive results in the blank  control sample that was collected pre-drinking, resulted 
in cocaine, could be explained by drinking of coca tea prior to collection of the pre-
dose samples. Although volunteers were asked not to consume coca tea 24 hours 
prior to participating in this study, as with any human volunteer study, this could not 
be guaranteed. When volunteers who tested positive for cocaine, benzoylecgonine or 
ecgonine methyl ester were excluded, no significant change in the mean, median, 
minimum or maximum concentrations were observed. Concentrations observed were 
still above the recommended SAMHSA cut off of 8 ng/mL for cocaine and 
benzoylecgonine for up to 60 minutes post consumption of coca tea.  
4.3.3 Unexpected results 
In addition to cocaine, benzoylecgonine and ecgonine methyl ester, the LC-MS/MS 
method used in this work to analyse the oral fluid samples collected in Peru also 
detects cocaethylene and anhydroecgonine methyl ester.    
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4.3.3.1 Cocaethylene 
Cocaethylene forms in the human body following the co-consumption of cocaine and 
ethanol was detected in a number of oral fluid samples.  All volunteers stated that 
they had not consumed alcohol for 24 hours prior to participating in this study. All 
pre-dose samples were confirmed to be negative for cocaethylene (Table 4.10).  
Table 4.10. Summary of randomly distributed positive results for Cocaethylene (CE) 
in oral fluid following the consumption of coca (V = Volunteer, ND = not detected) 
 Cocaethylene concentration (ng/ml) 
Time 
(min) 
V 1 V 2 V 3 V 4 V 5 V 6 
Pre-dose ND ND ND ND ND ND 
0 ND ND ND 3 ND ND 
15 14 ND 17 ND ND ND 
30 2 ND ND ND ND 10 
45 ND 29 86 ND 2 ND 
60 ND 61 ND ND ND ND 
 
Concentrations of cocaethylene detected ranged between 2 ng/mL to 86 ng/mL and 
the presence of cocaethylene was randomly distributed amongst samples analysed. 
The random distribution of cocaethylene positives mediated against the proposition 
that its presence could be explained by alcohol consumption prior to participating in 
the experiment. Additionally, participants were monitored throughout the study and 
therefore potential alcohol consumption during the collection can be excluded as a 
cause for unexpected presence of cocaethylene. 
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4.3.3.2 Anhydroecgonine Methyl Ester  
Anhydroecgonine methyl ester is a pyrolysis product formed during the smoking of 
crack cocaine and is commonly used as a biomarker for the use of crack cocaine.  
Anhydroecgonine methyl ester results were randomly distributed in a similar manner 
to cocaethylene indicating that the concentrations did not originate from smoking 
crack cocaine (Table 4.11).  
Table 4.11. Summary anhydroecgonine methyl ester concentrations detected in oral 
fluid following consumption of coca tea showing the random distribution of this 
compound (V=Volunteer, ND = not detected) 
 Anhydroecgonine methyl ester concentration (ng/ml) 
Time 
(min) 
V 1 V 2 V 3 V 4 V 5 V 6 V 7 V 8 V 9 
Pre-
dose 
ND ND ND ND ND ND ND ND ND 
0 257 ND ND 322 215 ND ND 118 ND 
15 ND ND ND ND ND ND 32.7 ND ND 
30 1 3 1 4 ND 1 40 5 20 
45 ND ND ND ND 5 ND ND ND ND 
60 ND ND ND ND ND ND ND ND 2 
 
Nine out of the twenty volunteers who participated in this study tested positive for 
anhydroecgonine methyl ester in at least one sample during the one hour collection 
period. Concentrations of anhydroecgonine methyl ester ranged between 1 ng/mL 
and 322 ng/mL with highest concentrations observed in samples collected 
immediately post consumption of coca tea.  
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Anhydroecgonine methyl ester has been reported to be present in some species of the 
Erythroxylum coca (Jenkins et al 1996). The hypothesis that anhydroecgonine methyl 
ester positives results from the presence of anhydroecgonine methyl ester in the leaf, 
can be dismissed due to the random manner at which the positives appear. In the 
event of a volunteer consuming coca tea containing anhydroecgonine methyl ester, 
positives for anhydroecgonine methyl ester should have been observed in all samples 
throughout the timed collection.   
All samples were subsequently reanalysed for cocaethylene and anhydroecgonine 
methyl ester one year post collection of the sample in order to assist with the 
explanation for the presence of these two compounds in such a random manner. The 
reanalysis of samples was intended to assist with the explanation for the presence of 
anhydroecgonine methyl ester and investigate the possibility that anhydroecgonine 
methyl ester concentrations were formed as the result of an instability of compounds 
present within the samples.  
Samples were analysed using the same method as in the initial analysis one year 
earlier (section 4.2.2.4, section 4.2.2.5).  
4.3.3.3 Reanalysis of samples containing cocaethylene and            
anhydroecgonine methyl ester  
4.3.3.3.1 Cocaethylene 
During the second analysis with the same method, cocaethylene was not detected in 
any of the oral fluid samples collected following the consumption of coca tea. One 
explanation for the disappearance of cocaethylene positives, could be a possible 
instability of cocaethylene in oral fluid. Only limited information is available in the 
literature on the stability of cocaethylene in oral fluid, Clauwaert et al (2004) stated 
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that cocaethylene is stable in oral fluid at -20 ºC for a minimum of six months. 
Concentrations of cocaethylene in sweat, a compositionally similar matrix to saliva 
due to its high water content, has been reported to decrease by 17 % after two weeks 
at a temperature of 4 ºC (Follador et al 2004).   Cocaethylene is an ester and therefore 
de-esterfication of cocaine to from cocaethylene can occur. Oral fluid contains 
esterases such as cholinesterases, pseudocholinesterase and cholesterol esterases 
(Finer and Santerre 2004). Therefore, a possible explanation is the de-esterification 
by salivary esterases of cocaine to from cocaethylene.  
4.3.3.3.2 Anhydroecgonine methyl ester 
An increased number of samples tested positive for anhydroecgonine methyl ester 
during the second analysis (Table 4.12). Samples positive during the initial analysis 
mostly decreased in concentration with some to the positives disappearing 
completely. An increased number of samples which had previously been confirmed 
to be negative, resulted in positive anhydroecgonine methyl ester concentration 
during the second LC-MS analysis one year post initial analysis.  
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Table 4.12. Concentrations (ng/mL) of anhydroecgonine methyl ester in oral fluid 
samples following consumption of coca tea. Samples were analysed initially in 2011 
and then reanalysed one year later (2012) to investigate the presence of 
anhydroecgonine methyl ester  
Time 
(min) 
Volunteer 
ID 
Analysis 
2011 
Analysis 
2012 
 
Time 
(min) 
Volunteer 
ID 
Analysis 
2011 
Analysis 
2012 
0 
1031 ND 8.7 
 
15 
1032 ND 9 
1032 ND 98.4 
 
28021 ND 5.1 
28021 256.8 59.4 
 
280211 ND 19.2 
280210 ND 27.9 
 
280212 ND 12.9 
280211 ND 25.2 
 
280213 ND 4.2 
280212 ND 53.1 
 
280215 32.7 34.8 
280213 ND 53.1 
 
280216 ND 3.6 
280214 ND 40.2 
 
28022 ND 2.1 
280215 ND 60 
 
28023 ND 51 
280216 ND 32.1 
 
28029 ND 9.3 
280217 ND 58.2 
 
30 
28021 1.23 ND 
280218 ND 22.5 
 
280210 0.96 ND 
28022 10.8 ND 
 
280215 40.2 17.4 
28022 ND 218.1 
 
28023 ND 6.3 
28022 ND 35.1 
 
28023 5.4 ND 
28022 ND 79.8 
 
28024 2.52 ND 
28023 ND 66.9 
 
28025 1.26 ND 
28023 ND 118.5 
 
28026 4.38 ND 
28024 ND 21.6 
 
28029 ND 8.1 
28025 ND 4.2 
 45 
280212 2.97 ND 
28026 321.6 54 
 
280215 ND 6.3 
28027 ND 14.7 
 
28029 5.25 ND 
28028 ND 22.5 
 
60 28023 1.77 ND 
28029 214.65 114.3 
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Samples collected immediately post consumption of one cup of coca tea showed the 
largest difference in positive results between the first and second analysis of oral 
fluid samples. The amount of positives increased significantly between the initial 
analysis in 2011 and second analysis in 2012 (Figure 4.9). Concentrations 
immediately post consumption ranged from 4.2 ng/mL to 218 ng/mL (mean = 52.5 
ng/mL, median= 37.64 ng/mL). 
 
Figure 4.9  Chart showing the presence of anhydroecgonine methyl ester in oral fluid 
samples immediately post consumption of coca tea in the initial analysis in 2011 
(t=0) and one year later (2012) 
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In comparison to the initial analysis where only one positive for anhydroecgonine 
methyl ester was observed for the 15 minute time point, the reanalysis resulted in ten 
anhydroecgonine methyl ester positives. Concentrations ranged from 2.1 ng/mL to 
51 ng/mL (mean = 14.1 ng/mL, median = 9 ng/mL) (Figure 4.10).  
 
Figure 4.10. Comparison of the presence of anhydroecgonine methyl ester in oral 
fluid samples 15 minutes post consumption of coca tea in the initial analysis (2011) 
and one year later (2012)  
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The number of samples containing anhydroecgonine methyl ester 30 minutes post 
consumption also increased with a mean anhydroecgonine methyl ester concentration 
of 52.3 ng/mL (median = 42.15, range = 6.3 ng/mL to 118.5 ng/mL) (Figure 4.11).  
 
Figure 4.11.  Comparison of the presence of anhydroecgonine methyl ester in oral 
fluid samples 30 minutes post consumption of coca tea in the initial analysis (2011) 
and one year later (2012) 
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At 45 minutes post exposure the two previously confirmed samples for 
anhydroecgonine methyl ester, tested negative for the anhydroecgonine methyl ester, 
whereas one volunteer showed an increase in concentration during the second 
analysis (Figure 4.12).  
 
 
Figure 4.12. Comparison of the presence of anhydroecgonine methyl ester in oral 
fluid samples 45 minutes post consumption of coca tea in the initial analysis (2011) 
and one year later (2012) 
 
Only one volunteer had tested positive for anhydroecgonine methyl ester in the first 
year at t = 60 min, however during the second analysis, no anhydroecgonine methyl 
ester positives were observed in the samples collected one our post consumption.  
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4.3.3.3.3 Summary of the results from the secondary analysis of samples to 
quantify anhydroecgonine methyl ester  
The repeat analysis one year post the initial analysis resulted in an increased number 
of samples testing positive for anhydroecgonine methyl ester. This indicates that 
anhydroecgonine methyl ester was formed within the sample during the one year of 
storage. The stability of anhydroecgonine methyl ester in oral fluid has not been 
documented in the literature, however Fandino et al (2002) reported on stability of 
anhydroecgonine methyl ester in plasma. During his work, anhydroecgonine methyl 
ester had fallen by 50 % to anhydroecgonine within 5 days at room temperature and 
within 13 days at 4 °C.  
In comparison to the study by Fandino et al (2002), the anhydroecgonine methyl 
ester positive results in the work described in this chapter showed an increase in the 
number of samples that tested positive, which suggests the increased amount of 
positive samples is due to a formation of anhydroecgonine methyl ester in oral fluid 
samples following the consumption of coca tea. Although anhydroecgonine methyl 
ester has been reported to form through thermal degradation of cocaine as a pyrolysis 
product of smoking crack cocaine, formation due to storage conditions or instability 
have not previously been reported in the literature (Jacob et al 1990, Kintz et al 1995, 
Kintz et al 1997, Toennes 1999).  
When considering the structure of cocaine a carbon-oxygen bond can be observed. 
Thermal decomposition has been suggested  to cause the scission of carbon-oxygen 
bonds (Chan et al 1976). This can be applied to the formation of anhydroecgonine 
methyl esters and ecgonine methyl ester. The decomposition of the carbon-oxygen as 
a result of the heating process during the preparation of the coca tea (highlighted at A 
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in Figure 4.13) would result in the formation of anhydroecgonine methyl ester from 
cocaine. Similarly, the scission the oxygen-carbon bond as highlighted at B in Figure 
4.13 would result in the formation of ecgonine methyl ester which could provide an 
explanation why the ecgonine methyl ester concentrations within in the oral fluid 
were significantly higher than those within the coca tea which was prepared from the 
teabag (section 4.3.2.3).  
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Figure 4.13 Metabolic pathway of cocaine highlighting the potential thermal 
decomposition of cocaine during the preparation of coca tea resulting in the 
formation of anhydroecgonine methyl ester (A) and ecgonine methyl ester (B) 
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A major drawback of this study was that it was not possible to analyses the coca 
leaves and tea itself due to importation restrictions of coca leaves and coca tea into 
the UK. Jenkins et al (1996) reported that 1 g of plant material contained 5.11 mg of 
cocaine, 0.11 mg of benzoylecgonine and 1.15 mg of ecgonine methyl ester which 
resulted in a cocaine dose of 4.14 mg per cup leading to concentration of 16.56 
µg/mL cocaine, 0.44 µg/mL benzoylecgonine and 4.6 µg/mL ecgonine methyl ester 
present in the tea.  
Following the anomalous results regarding cocaethylene and anhydroecgonine 
methyl ester, coca tea was prepared with tea bag which contained ground coca leaves 
and green tea. The Andes Spirit tea bag contained 1 g of Erythroxlum coca and green 
tea. There was no quantity provided on the amount of coca leaves present within the 
tea bag. The tea was prepared by adding a tea bag to 250 mL of boiling water and 
following soaking of 5 minutes, five samples were collected from the tea using the 
AlereTM Certus collector. Samples were analysed using the LC-MS method described 
in section 4.2.2.5. 
Results showed that cocaine detected in the five samples taken from the coca tea 
ranged between 16,404 ng/mL and 17,317 ng/mL (mean = 16,828 ng/mL). The mean 
benzoylecgonine concentration detected was 5,888 ng/mL (range = 5,539 ng/mL – 
6211 ng/mL) (Table 4.13).  
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Table 4.13. Summary of results from five samples collected from coca tea prepared 
from a ready-to-use teabag that contained ground coca tea leaves as well as green tea 
powder. 
 
Concentration (ng/mL) 
  COC BZE EME AEME CE 
Coca Tea 1  16404 6075 5947 54 ND 
Coca Tea 2 16436 5599 6050 51 ND 
Coca Tea 3 16745 5539 6476 66 ND 
Coca Tea 4 17241 6015 6202  58 ND 
Coca Tea 5 17317 6212 6005 54 ND 
Mean  16829 5888  6136 57 ND 
 
No cocaethylene was detected supporting the results from the second analysis of the 
oral fluid samples collected following consumption of one cup of coca tea. The 
analysis of the coca tea showed that anhydroecgonine methyl ester was present in all 
5 samples collected. Anhydroecgonine methyl ester ranged between 51 ng/mL and 
66 ng/mL (mean = 57 ng/mL). However the analysis had a number of limitations. 
The quantity of coca leaf within the tea bag was unknown and therefore it is difficult 
to compare the concentrations of cocaine and its metabolites within the tea from the 
tea bag with those observed in oral fluid following the consumption of coca tea. 
Additionally it is unknown whether the species of coca leaf was the same in both 
instances. Some species of the Erythroxylum coca plant have been reported to 
contain anhydroecgonine methyl ester within the leaf which could explain the 
presence of anhydroecgonine methyl ester within the analysed tea. Alternatively, the 
presence of anhydroecgonine methyl ester in the coca tea suggests that 
anhydroecgonine methyl ester is formed during the production of the coca tea, by the 
thermal degradation of cocaine during the boiling process The analysis of the tea 
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does not provide an explanation as to why anhydroecgonine methyl ester was 
detected at random time points in oral fluid throughout the initial analysis. However 
it does confirm that anhydroecgonine methyl ester is present within the tea which 
would subsequently be detected in oral fluid.  
4.4 Conclusion 
This experiment demonstrated that the consumption of coca tea can result in elevated 
concentrations of cocaine and its metabolites in oral fluid. High concentrations were 
detected as expected immediately after consumption of coca tea. However, the 
detection of positive concentrations of cocaine and its metabolites up to one hour 
post consumption of the tea supports the proposition that drug depots can be formed 
within mouth tissues. 
Additionally, cocaethylene and anhydroecgonine methyl ester were detected and 
quantified. The appearance of cocaethylene and anhydroecgonine methyl ester in oral 
fluid samples at random time points has not yet been fully explained and offers scope 
for further investigation. Differences in concentrations between the first and second 
analysis could be explained by instability of cocaethylene and anhydroecgonine 
methyl ester in oral fluid and further research is required to investigate this further.  
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Chapter 5.0  - Oral fluid opiate concentrations following oral 
consumption of Codeine Linctus® and Collis Browne’s® 
mixture 
5.1  Introduction 
The work described in Chapter 4 showed that elevated drug concentrations can be 
observed following the consumption of Peruvian coca tea with cocaine, 
benzoylecgonine and ecgonine methyl ester. Positive concentrations were still 
detected one hour post consumption of coca tea which strongly supported the 
hypothesis that drug depots can be formed within tissues when drugs are consumed 
orally i.e. via an oral solution.  
Looking at different routes of administration, Jenkins et al (1995) further supported 
this proposition. Jenkins et al (1995) reported elevated oral fluid concentrations 
following heroin smoking with concentrations of 3.53µg/mL and 20.58 µg/mL 
between 2 – 5 minutes post smoking of 2.6 mg and 5.2 mg respectively. Measurable 
concentrations were reported for up to 24 hours post the smoking of heroin. In 
comparison, concentrations in oral fluid 2 – 5 minutes post intravenous injection 
were much lower from 6 ng/mL (from a 10 mg dose) to 22 ng/mL (5 mg dose)  and 
were only detected in blood for 30 minutes (Jenkins et al 1995). 6-MAM is rarely 
detected in oral fluid following injection as it has short half-life and, when reported, 
has only been detected at very low concentrations; 18 ng/mL (dose = 5 mg dose) or 
40 ng/mL (dose = 10 mg). In contrast, when heroin was smoked, large concentrations 
of 6-MAM were observed in oral fluid with concentrations up to 1.12 µg/mL and 
3.58 µg/mL (Jenkins et al 1995). Additionally, Osselton et al 2001 showed that 
concentrations of opiates, with or without the combination of a second opiate, ranged 
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from 0.023 μg/mL to 17.375 μg/mL for morphine, 0.003 μg/mL to 7.75 μg/mL for 
codeine, 0.002 μg/mL to 66.93 μg/mL for 6-monoacetylmorphine and 0.001 μg/mL 
to 274.27 μg/mL for dihydrocodeine A potential explanation for the elevated drug 
concentrations in oral fluid is that drug accumulate to form depots in mouth tissues.  
The elevated concentrations of opiates in oral fluid following the smoking of heroin 
in comparison to lower concentration following injection of heroin suggest that 
deposition of drug in the mouth tissues can significantly contribute to opiate 
concentration measure in oral fluid.   
The above studies show that depending upon the mode of exposure, drugs coming 
into contact with mouth tissue can cause contamination of the oral cavity resulting in 
the measurement of elevated concentrations in oral fluid leading to easier detection 
using point of care or laboratory tests. However, it can also lead to difficulty in 
interpretation of S/P ratios in drug pharmacology. The purpose of the work described 
in this chapter was to examine drug deposition in oral fluid and potentially the 
surface of the mouth cavity by investigating concentrations of opiates following oral 
consumption of Codeine Linctus® and Collis Browne’s® ® mixture.  
The elevated drug concentrations in oral fluid over a prolonged period suggest that 
drugs such as cocaine and opioids can bind to oral tissue. Collected oral fluid can 
contain cell and food debris which can be collected by the abrasion of the collector 
against the oral tissues. The presence of drug depots in tissues suggests that the cell 
debris present in oral fluid also contains drugs, which can potentially contribute to 
and hence increase oral fluid concentrations.    
Validation of Oral Fluid as a Matrix for Drug Detection – Chapter 5 
 
116 
 
The work undertaken in this chapter aimed to investigate characteristics of deposition 
in the oral fluid using observed concentrations such as the length of time drug can be 
detected in oral fluid and the effect of cell abrasion during collection. 
5.2  Materials and Methods 
5.2.1 Materials 
5.2.1.1 Collection devices 
AlereTM Certus devices/kits were donated by Alere Toxicology, Abingdon UK.  
AlereTM  Microplate EIA Kits for opiates were provided by Alere Toxicology, 
Abingdon, UK.  
5.2.1.2 Collis Browne’s®  mixture 
Collis Browne’s®  mixture, manufactured by Thornton & Ross Ltd, Huddersfield, 
UK contains two principal active ingredients, morphine hydrochloride at a dose 
equivalent to 1.0 mg/5 mL anhydrous morphine and 1.5 µL/5mL of peppermint oil. 
Collis Browne’s®  mixture also contains ethanol, benzoic acid, sorbitol sucrose and 
fructose.  Collis Browne’s®  mixture is available for purchase as an over-the-counter 
medication.  
5.2.1.3 Codeine Linctus®    
Codeine Linctus®, Care+, Thornton & Ross Ltd, Huddersfield, UK, contains only 
one active drug ingredient, Codeine phosphate at a dose of 15 mg/5 mL. Other 
ingredients include citric acid monohydrate, ethyl and propyl 
parahydroxybenyzoates, sodium methyl, ethanol, sugars, food colourings and 
flavouring. Codeine Linctus® is available for purchase as an over-the-counter 
medication. 
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5.2.1.4 Methodology 
Informed consent was obtained from all participants prior to participation and the 
experimental procedures were undertaken in compliance with the University of 
Bournemouth ethical guidelines (Appendix D). All volunteers completed a 
questionnaire regarding prior use of medication which may interfere with the results. 
Volunteers provided a blank control oral fluid sample immediately prior to 
participating in this study for confirmation that medication – opioid based drug was 
consumed prior to commencing of the study. 
5.2.1.5 Collection Procedure 
5.2.1.5.1 Study 1 – Investigation into opiate oral fluid concentrations following 
the exposure to Collis Browne’s®  mixture and Codeine Linctus®  
Volunteers were invited to swirl 5 mL of Collis Browne’s® or Codeine Linctus® 
around the mouth for one minute before discarding the liquid from the mouth. The 
calculated dose for Codeine Linctus®  was 15 mg and 5 mg for Collis Browne’s®  
mixture. Oral fluid was subsequently collected at 15, 30, 45, 60, 90, 120, 150 and 
180 minutes after mouth emptying using the AlereTM Certus oral fluid collection 
device. Oral fluid was collected in accordance with the kit manufacturer’s 
instructions.  
5.2.1.5.2 Study 2- Investigation into opiate oral fluid concentrations following 
the exposure to Collis Browne’s®  mixture and Codeine Linctus®  
with two different collection methods 
Volunteers were invited to swirl 5 mL of Collis Browne’s® or Codeine Linctus® 
around the mouth for one minute before discarding the liquid from the mouth. The 
calculated dose for Codeine Linctus®  was 15 mg and 5 mg for Collis Browne’s®  
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mixture. Two oral fluid samples were collected following exposure. One oral fluid 
sample was collected following the collection procedure in 5.2.1.5.1 at 15, 30, 45, 
60, 90, 120, 150 and 180 minutes after mouth emptying.  In addition to the collection 
according to the manufacturer’s guidelines, a second AlereTM Certus collector was 
brushed against the oral cavity to identify whether the increased presence of cellular 
debris can increase the amount of drug detected in oral fluid. Brushing was 
undertaken until the adequacy indicator showed that sufficient oral fluid had been 
collected.  
5.2.1.6 Immunoassay (Study 2) 
The AlereTM Microplate EIA Kit is provided with five calibrators of 0 ng/mL, 10 
ng/mL, 100 ng/mL and 500 ng/mL. Samples which were detected above the highest 
calibrator of 500 ng/mL calibrator following analysis were diluted 1 in 10 and 
reanalysed. The manufacturers report cross reactivity of the assay with several 
compounds that are summarised in Table 5.1. Non cross reacting compounds are 
presented in Appendix B. 
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Table 5.1. Summary of compounds cross-reacting with the AlereTM Microplate EIA 
Kit for opiates 
 
 
  
Compounds 
Cross 
Reactants 
ng/mL 
Apparent 
Morphine 
Reactivity 
(%) 
Compounds 
Cross 
Reactants 
ng/mL 
Apparent 
Morphine 
Reactivity 
(%) 
6- 
Acetylmorphine 
100,000 442.86 0.4 
Meperidine 
100,000 74.33 0.07 
1,000 381.32 38.1 10,000 8.17 0.08 
500 96.1 18.2 1,000 <5 - 
100 81.16 81.2 
Morphine - 3 - 
Glucuronide 
100,000 403.3 0.4 
10 7.1 71 1,000 8.95 0.9 
Codeine 
100 398.9 398.9 500 5.1 1 
10 95.37 953.7 100 <5 - 
5 80.97 1619.4 
Nalorphine 
100,000 95.89 0.1 
Dextro- 
methorphan 
100,000 31.26 0.03 1,000 38.63 0.4 
10,000 <5 - 500 <5 - 
Dihydro-
codeine 
500 >500 - 100     
100 196.7 196.7 
Norcodeine 
100,000 >500 - 
10 73.43 734.3 1,000 37.26 3.7 
5 39.49 789.8 500 20.02 4 
Heroin 
500 98.29 19.7 100 <5 - 
100 58.17 58.2 
Normorphine 
100,000 363.74 0.4 
10 <5 - 10,000 62.8 0.6 
Hydro- codone 
500 82.17 16.4 1,000 <5 - 
100 82.69 82.7 
Oxycodone 
100,000 429.67 0.4 
10 9.38 93.8 1,000 8.51 0.9 
5 7.23 144.6 500 <5 - 
Hydro- 
morphone 
100,000 >500 - 
Oxymorphone 
100,000 161.51 0.2 
1,000 245.05 24.5 10,000 32.8 0.3 
500 78.56 15.7 1,000 <5 - 
100 50.29 50.3 
    10 <5 - 
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The immunoassay method used for the detection of opiates in oral fluid is 
summarised in Figure 5.1.  
10 µl of calibrator/sample added to each well
100 µL of opiate enzyme conjugate added to each well
Incubation at room temperature for 30 minutes
Washed four times with 400 µL of wash buffer
100 µL of substrate solution added to each well
Incubation at room temperature for 30 minutes
100 µL of stop solution added to each well
Read plate within 15 minutes on DAS 8 channel microplate reader
 
Figure 5.1. Outline of the procedure for using the AlereTM immunoassay method for 
opiates 
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5.3  Results and Discussion 
5.3.1 Study 1 - Investigation into concentrations of opiates in oral fluid 
following the exposure to Collis Browne’s®  and Codeine Linctus®  
5.3.1.1 Collis Browne’s®  mixture  
Following exposure to Collis Browne’s®  mixture highest opiate concentrations 
(ng/mL) were observed in the first timed collection after exposure, 15 minutes post 
exposure, in all volunteers. Concentrations then decreased steadily over the 
collection time of 180 minutes (Figure 5.2). 
 
Figure 5.2 Opiate concentrations (ng/mL) in oral fluid following consumption of 
Collis Browne’s®  in eight volunteers 
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All pre-dose samples were negative. In the initial sample, 15 minutes following 
exposure, opiate concentrations ranged between 330 ng/mL and 15,808 ng/ml (mean 
= 4,008 ng/mL, median = 2,284 ng/mL, SD = 5067 ng/mL). Opiate concentrations 
rapidly decreased to an average of 1,916 ng/mL at t = 30 min (range = 70 ng/mL – 
9798 ng/mL, median = 489 ng/mL, SD = 3277 ng/mL) and 357 ng/mL at t = 60 
minutes (range = 9 ng/mL to 1230 ng/mL, median = 216 ng/mL, SD = 415 ng/mL) 
(Table 5.2).  
  
 
1
2
3 
Table 5.2 Summary of opiate concentrations (ng/mL) including mean, median and range in oral fluid in eight volunteers following a 5 mg dose 
of Collis Browne’s®  mixture 
 
 
 
 
 
 
 
 Concentration (ng/mL) 
Time 
(min) 
V1 V2 V3 V4 V5 V6 V7 V8 Mean Median SD Min Max 
Predose -ve -ve -ve -ve -ve -ve -ve -ve -ve -ve -ve -ve -ve 
15 1456 330 666 2332 3484 15808 2236 5750 4008 2284 5067 330 15808 
30 271.4 70 277 1644 700 9786 270 2310 1916 489 3277 70 9786 
60 438 9 103 326 107 624 18 1230 357 216 415 9 1230 
90 30 12 18 197 33 542 8 379 152 32 205 8 542 
120 40 7 14 18 54 348 39 718 152 29 254 7 718 
150 19 5 10 18 22 348 14 185 78 18 125 5 348 
180 15 5 10 19 
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The opiate concentrations decreased even further at t= 90 ranging between 9 ng/mL 
and 542 ng/mL (mean = 152 ng/mL, median = 29 ng/mL, SD = 205 ng/mL). 
Following the last rapid decline, concentrations plateaued averaging 152 ng/mL 
(range = 7 ng/mL – 718 ng/mL, median = 29 ng/mL, SD = 254 ng/mL) at t = 120 
min, 78 ng/mL (range = 5 ng/mL – 348 ng/mL, median = 18 ng/mL, SD = 125 
ng/mL) at t = 150 min and 34 ng/mL (range = 3 ng/mL – 136 ng/mL, median = 15 
ng/mL, SD = 48 ng/mL) at t = 180 min.  
 
 
Figure 5.3. Minimum, Maximum and Mean concentrations (ng/mL) of opiates in oral 
fluid collected over 180 minutes following the consumption of Collis Browne’s®  
(dose = 5 mg) in eight volunteers
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5.3.1.2 Codeine Linctus®   
The exposure to Codeine Linctus®  resulted in highest opiate concentrations in oral 
fluid 15 minutes post exposure in all volunteers. Opiate concentrations then 
decreased steadily over 180 minutes (Table 5.4). 
 
Figure 5.4. Oral fluid Concentrations (ng/mL) of opiates in six volunteers (V1 – V6) 
following a dose of 15 mg Codeine Linctus®  
 
Samples of oral fluid collected prior to commencement of Codeine Linctus®  
swirling were all negative. Highest concentrations were observed at t = 15 min and t 
= 30 min with an average of 79,666 ng/mL (range = 17,876 ng/mL – 190,400 ng/mL, 
median = 74,630 ng/mL, SD = 59,776 ng/mL) and 31,161 ng/mL (range = 6104 
ng/mL – 114,456 ng/mL, median = 15,863 ng/mL, SD = 41,256 ng/mL) respectively 
(Table 5.3).  
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Table 5.3. Summary of opiate concentrations (ng/mL) including mean, median and range in oral fluid in six volunteers following a 15 mg dose 
of Codeine Linctus®  mixture 
 
 
 
 
 
 
 
 
 
 Concentration (ng/mL) 
Time     
(min) 
V 1 V 2 V 3 V 4 V 5 V 6 Mean  Median  SD Min  Max  
Predose -ve -ve -ve -ve -ve -ve -ve -ve -ve -ve -ve 
15 81720 17876 79920 190400 38740 69340 79666 74630 59776 17876 190400 
30 14118 17608 10704 114456 6104 23976 31161 15863 41256 6104 114456 
60 2734 10702 6412 14088 5588 22352 10313 8557 7132 2734 22352 
90 295 8874 195 7836 167 669 3006 482 4160 167 8874 
120 422 2862 620 4394 58 230 1431 521 1779 58 4394 
150 74 2112 481 3062 46 183 993 332 1280 46 3062 
180 69 378 239 1198 22 88 332 164 444 22 1198 
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One hour post consumption concentrations of opiates decreased to range between 
2,734 ng/mL and 22,352 ng/mL (mean = 10,313 ng/mL, median = 8,557 ng/mL, SD 
= 7,132 ng/mL). Over the course of the next hours concentrations further decreased, 
averaging at 3,006 ng/mL (range = 167 ng/mL – 8,874 ng/mL, median = 482 ng/mL, 
SD = 4,160 ng/mL) resulting in a mean concentration of 1,431 ng/mL (range = 58 
ng/mL – 4,394 ng/mL, median = 521 ng/mL, SD = 1,779 ng/mL). In the final hour of 
collection, samples ranged from 49 ng/mL to 3,062 ng/mL (mean = 993 ng/mL, 
median = 332 ng/mL, SD = 1,280 ng/mL) resulting in a final opiate concentration 
range of 22 ng/mL to 1198 ng/mL (mean = 332 ng/mL, median = 164 ng/mL, SD = 
444 ng/mL) (Figure 5.5). 
 
 
Figure 5.5. Minimum, Maximum and Mean concentrations of opiates in oral fluid 
collected over 180 minutes following the exposure to Codeine Linctus®  (dose =  15 
mg) in six volunteers 
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5.3.1.3 Summary of Study 1 
Opiate concentrations in oral fluid observed were highest in the first (t = 15 min) 
sample collected post exposure to Codeine Linctus® and Collis Browne’s® mixture, 
which was in agreement with the drug concentrations observed following 
consumption of coca tea (Chapter 4).   
Mean opiate concentrations 15 minutes post exposure to Collis Browne’s® mixture 
and Codeine Linctus® were 4,008 ng/mL to 79,666 ng/mL, respectively. Opiate 
concentrations following codeine use were much higher than morphine as a result of 
the difference in dose. This could be explained by the higher dose of 15 mg of 
Codeine Linctus® which was swirled around the mouth whereas Collis Browne’s® 
was swirled at a dose of 5 mg. The cross reactivity of codeine, which was assessed 
against morphine, in the opiate immunoassay has been reported to be 398.9% in 
Table 5.1. The high cross reactivity of codeine also has to be borne in mind when 
explaining the higher oral fluid concentrations observed 15 minutes post exposure to 
Codeine Linctus®.  
High opiate concentrations in oral fluid 15 minutes post exposure to either Collis 
Browne’s® mixture or Codeine Linctus® resulted from this method of 
administration. Both solutions were swirled around the mouth and not swallowed 
which indicates that observed concentrations in oral fluid are a result of oral 
contamination and did not originated from the blood to saliva transfer. Although 
information on the length of exposure is limited in the literature, contamination of 
the oral mucosa is reported to affect the correlation between saliva and blood 
concentrations for 30 – 60 minutes (Bosker and Huestis, 2009). 
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The rate of elimination of opiates from oral fluid differs between individuals as a 
result of variations of saliva production and flow. A larger saliva flow rate, which is 
dependent on age, sex, climate, hydration state or stimulation will dilute the 
contamination faster and hence result in lowered concentrations (Chapter 1). This 
may account for the large variations observed between volunteers.  
The principle of contamination suggests that an orally consumed solution lingers in 
the oral mucosa but also in cavities within the mouth. Participants were initially not 
requested to provide information on possible fillings or cavities. However, as a result 
of the variation of concentrations between volunteers, participants were asked 
retrospectively to provide this information.  Out of six volunteers sampled post 
Codeine Linctus® exposure, only one reported to have numerous cavities and 
fillings. High codeine concentrations of 191,400 ng/mL at t=15 min in comparison to 
the mean concentration of 79,666 ng/mL, would appear to support the theory that 
cavities result in higher contamination concentrations, but more work with a larger 
sample population would be required to further test this hypothesis.  
Additionally, manufacturers of Collis Browne’s® and Codeine Linctus® solution 
listed ethanol in their list of ingredients. Ethanol intake can alter the distribution of 
drugs into tissue, which could hence affect the interpretation of results (Sellers and 
Holloway 1978). The manufacturers for Collis Browne’s® and Codeine Linctus® 
did not provide information on the amount of alcohol present within each solution.  
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5.3.2 Study 2 - Investigation into concentrations in oral fluid following the 
exposure to Collis Browne’s® and Codeine Linctus® with two different 
collection methods 
5.3.2.1 Collis Browne’s® mixture 
During collection, the AlereTM Certus collector is inserted into the oral cavity and left 
there until sufficient oral fluid has been collected. For the purpose of this study, an 
additional collector was then brushed against the oral tissues in order to stimulate cell 
abrasion. Brushing did not result in significant larger concentrations in comparison to 
oral fluid collected with the conventional oral fluid method (Figure 5.6). 
 
Figure 5.6. Comparison of mean oral fluid concentrations following exposure to 
Collis Browne’s®  mixture over three hours collected with the Certus collector via 
the manufacturer’s recommended method and the scraping method ( 
 
The recommended collection method resulted in a mean oral opiate oral fluid 
concentration 15 minutes post exposure of 6,819 ng/mL (median = 2,617 ng/mL) in 
comparison to the mean concentrations of 8,070 ng/mL (median = 7,680 ng/mL) 
detected when using the collector to stimulate cell abrasion (Table 5.4).  
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Table 5.4 Mean and Median opiate concentrations (ng/mL) measured by 
immunoassay following the exposure of Collis Browne’s® . Oral fluid was collected 
with two different methods a) as recommended by the manufacturer and b) whilst 
scraping the collector hard against mouth tissues.  
 
Concentration (ng/mL) 
 
Oral fluid collection Oral fluid scraping 
Time (min) Mean  Median Mean  Median 
Predose <5 <5 <5 <5 
15 6,820 4617 8070 7680 
30 3,267 1505 3798 1315 
60 495 366 674 706 
90 241 206 174 187 
120 290 201 232 211 
150 142 104 153 109 
180 62 48 28 38 
 
Concentrations decreased quickly in the first 30 minutes resulting in concentrations 
of 3,266 ng/mL (median = 1,505 ng/mL) and 3,798 ng/mL (median = 1,315 ng/mL) 
with the conventional and scraping collection method, respectively.  
No large changes in concentrations were observed between the two methods of 
collection i.e. scraping or ordinary collection. Concentrations at the final 
concentrations decreased to 62 ng/mL (median = 48 ng/mL) with the manufacturers 
recommended method and 28 ng/ml (median = 38 ng/mL) when collected whilst 
scraping the collector. Results indicated that scraping the collector and hence 
increasing the amount of cellular debris within the sample did not cause a large 
difference in oral fluid opiate concentration following the swirling of Collis 
Browne’s®  solution.  
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5.3.2.2  Codeine Linctus®  
As observed with the results following the exposure of Collis Browne’s®, no 
significant changes were observed when applying the two different collection 
methods following the exposure to Codeine Linctus®  (Figure 5.7). 
 
Figure 5.7. Comparison of oral fluid concentrations following exposure to Codeine 
Linctus® solution over three hours collected with the Certus collector via the 
manufacturer’s recommended method and the scraping method  
 
 
Opiate oral fluid concentrations were much higher following Codeine Linctus®  
which may be explained by the difference in dose each volunteer swirled around the 
mouth. The dose of Collis Browne’s®  mixture was 5 mg whereas the dose of 
Codeine Linctus®  was a higher dose of 15 mg.  
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Mean opiate concentrations when collected with the manufacture recommended 
method and the scraping technique 15 minutes post exposure were detected at 55,406 
ng/mL (median = 38,480 ng/mL) and 58,230 ng/mL (median = 51,112 ng/mL) 
respectively.  
Table 5.5 Mean and Median opiate concentrations (ng/mL) following the exposure of 
Codeine Linctus® . Oral fluid was collected with two different methods a) as 
recommended by the manufacturer and b) whilst brushing the collector hard against 
mouth tissues. 
 Concentration (ng/mL) 
 
Oral fluid collection Oral fluid scraping 
Time (min) Mean  Median  Mean  Median  
Predose 7 1 9 3 
15 55406 38480 58230 51112 
30 19998 23324 18746 20492 
60 11277 6700 9840 5278 
90 2240 2570 2066 2558 
120 764 802 510 512 
150 405 389 419 459 
180 292 227 296 239 
 
Concentrations decreased rapidly in the first 30 minutes although high concentrations 
are still observed up to 90 minutes post exposure. Concentrations at 90 minutes had a 
mean concentration of 2,240 ng/mL (median = 2,570 ng/mL) when collected using 
the manufactures recommended method of collection. In comparison opiate 
concentrations in samples that were collected 90 minutes using the scraping method, 
were at a mean concentration of 2,066 ng/mL (median = 2,558 ng/mL). Opiate 
concentrations during normal collection and brushing continued to decrease and were 
still above the manufacturers cut off at 292 ng/mL (median = 227 ng/mL) and 296 
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ng/mL (median = 239 ng/mL). Results indicated that brushing the collector against 
the oral mucosa and hence increasing the amount of cellular debris does not result in 
elevated drug concentration following the use of an oral opiate solution.  
5.4   Conclusion 
The results from work undertaken in this chapter suggest, that elevated opiate 
concentrations can be observed following the exposure to Collis Browne’s®  and 
Codeine Linctus®  as a result of the deposition of drugs in the oral mucosa.  Both 
solutions were discarded from the mouth prior to collecting oral fluid samples and 
hence were not swallowed. That means that observed oral fluid concentrations were a 
result of oral contaminations rather than originating from the transfer of blood to 
saliva. Oral fluid drug concentrations were observed for up to three hours post 
exposure to the oral solution, but may extend beyond the final collection time. 
Results indicate that the consumption of an oral solution such as Codeine Linctus®  
or Collis Browne’s®  mixture has the potential to artificially elevate oral fluid 
concentrations and hence interfere with the interpretation of oral fluid drug 
concentrations.  Additionally, it was suggested from the results in this chapter that a 
large amount of cavities can increase the potential for drug depots when drugs are 
consumed orally as drugs can linger within the oral cavities.  
The hypothesis that drugs bind to tissue and thus cells, suggests that the presence of 
cellular debris within the oral fluid could increase elevated drug concentrations. 
However, no large variation in opiate concentration were observed between 
concentrations in oral fluid samples collected via the recommended manufacturer’s 
method and brushing the collector against the oral tissues indicating that increased 
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cellular debris within the oral fluid sample, does not contribute to elevated drug oral 
fluid concentrations.  
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Chapter 6.0 - Effect of microbleeding of the gums on oral fluid drug 
detection 
6.1 Introduction  
The work described in Chapter 4 showed that elevated cocaine and metabolite 
concentrations could be observed for up to one hour post consumption of one single 
cup of coca tea. Similarly, research undertaken in Chapter 5 showed that the elevated 
opiate concentrations were observed following the exposure to Collis Browne’s 
solution and Codeine Linctus. Oral fluid opiate concentrations were reported for up 
to three hours post exposure to either of the solution. The results presented in these 
previous sections suggest that drugs liquid formulations of drugs which are 
consumed orally have the potential to accumulate in mouth tissues.  
Oral contamination however cannot only be caused by drugs but also by other 
factors such as microbleeding of the gums. This led to the question whether 
microbleeding of the gums could be a contributing factor to elevated drug 
concentrations in oral fluid. This propositions has previously been raised in the 
literature (Schartz and Granger 2004) but has not been fully investigated. 
6.1.1  Microbleeding 
Microbleeding is a natural phenomenon in which blood is released from the gums 
into the mouth and may subsequently be present in oral fluid.  Several factors have 
been reported to cause microbleeding in the gums yet these factors do not appear to 
have been extensively explored in relation to oral fluid drug testing. The main causes 
for microbleeding are tooth brushing, chewing gum or gum disease (Fure et al 1998, 
Yaegaki et al 2002, Krause et al 2002, Pratibha et al 2006). The contamination of 
oral fluid by microbleeding could hypothetically increase drug concentrations in oral 
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fluid if the donor of the oral fluid specimen had consumed drugs and they were 
present in his / her circulating blood. Leao and Sheiham (1995) also reported that 
subjects with poor dental health, fillings and decaying teeth are prone to increased 
microbleeding of the gums.  
The work described in this chapter was undertaken to investigate whether 
microbleeding in the gums can contribute to elevated oral fluid concentrations. The 
original concept (Chapter 1) was that drugs enter oral fluid via the saliva from the 
circulating blood (Kidwell et al 1998, Aps and Martens 2005). If an individual has 
drugs in the blood microbleeding of the gums could hypothetically contribute to the 
overall oral fluid drug concentration. At the present time there are no reports in the 
available literature on studies which investigate the hypothesis that microbleeding 
can contribute to or influence the oral fluid drug concentration.  
6.1.2  Protein hormones in Saliva 
During microbleeding, large blood proteins such as transferrin are released into the 
oral fluid. Transferrin is present in oral fluid in trace amounts as it is present in the 
gingival fluid (Asman et al 1981, Curtis et al 1988). It binds tightly to the 
glycoproteins in blood plasma and hence has become a useful biomarker for blood in 
saliva with concentrations ranging between 0 mg dL and 5.5 mg/dL (mean = 3.7 
mg/dL) (Schwartz and Granger 2004). Transferrin concentrations in oral fluid are 
dependent on age and sex (Granger et al 2007). In 2004, a study by Kivlighan et al 
revealed that transferrin concentrations rise significantly when micro-injury occurs 
in the oral cavity. In comparison to healthy gums where mean transferrin 
concentrations were 0.37 mg/dL (range = 0.32 mg/dL – 0.49 mg/dL), concentrations 
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of transferrin immediately post injury rose to 0.75 mg/dL and then quickly decreased 
to 0.43 mg/dL over one hour.  
Saliva contains a wide variety of hormones including steroids, thyroid hormones and 
protein hormones (Vining and McGinley 1986). Hormones are passed into saliva by 
transfer from surrounding tissues. Salivary glands express enzymes responsible for 
the conversion of steroid hormones such as converting unbound cortisol into inactive 
cortisone (Boumba et al 1995, Smith et al 1996, Morineau et al 1997). The main 
functions of salivary hormones are immune response and inflammatory processes 
which contributes to wound healing and cell repair. Additionally, salivary hormones 
have been used as diagnostic tumour markers (Gröschl 2009).    
There are other methods for detecting blood in oral fluid. In addition to transferrin, 
haemoglobin has been proposed as a useful biomarker for blood in oral fluid 
(Hofman 2001, Kivlighan et al 2004), however, salivary peroxidases interfere with 
the haemoglobin test and can result in a  false positive test for haemoglobin hence 
making it an unsuitable marker for blood in saliva (Schwartz and Granger 2004). 
Therefore, transferrin was selected as a method for the detection of blood in oral 
fluid for the following research undertaken in this chapter.  
6.2 Materials and Methods 
6.2.1 Materials  
Transferrin immunoassay kits were purchased from Salimetrics Europe, Newmarket, 
UK. This immunoassay is optimised by the manufacturer to measure salivary 
transferrin, where there is a requirement to quantitate at low concentrations 
compared to analysis in blood where the levels are considerably higher. Elevated 
concentrations of transferrin in saliva indicate that contamination through blood has 
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occurred. The manufacturer, Salimetrics, recommends that saliva samples with 
transferrin concentrations higher than 0.5 mg/dL should be reported as contaminated.  
The kit has a mean recovery ranging between 96% and 117.7% with the lower limit 
of detection at 0.08 mg/dL. No cross reactivity has been reported with cortisol, 
testosterone, dehydroepiandrosterone, progesterone, melatonin, estradiol, secretory 
IgA and lactoferrin.  
6.2.2 Methods  
Two studies were performed during the investigation on the effect of microbleeding 
on oral fluid drug detection. The initial study focused on comparing oral fluid drug 
and transferrin concentrations in samples provided by drug using volunteers. The 
second study investigated the effects of the stimulation of microbleeding following 
the ingestion of a 15 mg dose of codeine. For the second study, volunteers 
undergoing treatment with any prescribed drugs or medications were excluded from 
this experiment. The experimental procedures were approved in compliance with the 
University of Bournemouth ethical guidelines.  
6.2.2.1 Study 1 - Sample collection 
Alere Toxicology Laboratories regularly screen oral fluid samples collected from 
regular drug users attending drug clinics as part of drug treatment programmes. Oral 
fluid samples were collected from 75 drug clinics throughout the UK and were then 
analysed by Alere Toxicology (Abingdon, UK) via immunoassay as part of their 
routine work. The samples were then anonymised and supplied to the University of 
Bournemouth for screening for transferrin. Prior to providing the oral fluid samples, 
drug users gave consent for additional testing on their provided samples as deemed 
appropriate by the laboratory.  
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6.2.2.2 Study 1 - Sample selection 
Alere Toxicology, Abingdon, UK provided 3,000 samples where the screening 
resulted in a positive, for cocaine, opiates or 6-MAM. Because of the high cost of 
purchasing the transferrin assay it was necessary to limit the number of samples for 
analysis. For the purpose of identifying possible microbleeding, samples were 
categorised into four groups (Table 6.1) a) below 100 ng/mL b) low concentration 
range, c) medium concentration range and d) high concentration range. 
Table 6.1. Concentration ranges (ng/mL) for each one of the four groups in which 
drug clinic samples were divided. Table summarises the ranges for cocaine, opiates 
and 6-MAM 
 
Concentration range (ng/mL) 
 
Cocaine Opiates 6-MAM 
Group 1 <100 <100 <100 
Group 2 100 – 150 100 - 200 100 - 250  
Group 3 150 - 240  201 - 320  250 – 450 
Group 4  >241 >321 >451 
 
The number of samples analysed using the transferrin immunoassay was restricted 
due to the high cost of the Salimetrics transferrin kits. As a result 120 samples in 
total were analysed, 40 per drug and 10 samples of each drug and group were 
selected to be screened for transferrin using the Salimetrics’ transferrin 
immunoassay. Samples were collected at random with every 15th sample in the list 
selected for analysis using a Salimetrics’ transferrin immunoassay.  
6.2.2.3 Study 1 - Transferrin Immunoassay 
The manufacturer’s recommended immunoassay cut off for transferrin in saliva is 
0.5 mg/dL. Calibrators ranged between 0.08 mg/dL and 6.6 mg/dL. 10 µL of sample, 
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50 µL of enzyme conjugate and 50 µL of antiserum were added to each well and 
incubated for 40 minutes. Wells were then washed four times with 400 µL of wash 
buffer provided with the kit. Samples were then incubated with 100 µL of 3,3’,5,5’ - 
tetramethylbenzidine (TMB) solution for 10 minutes in the dark before addition of 
the 100 µL of stop solution at reading the absorbance at 450 nm. The transferrin 
immunoassay method is summarised in Figure 6.1. 
10 µl of calibrator/sample added to each well
50 µL of transferrin enzyme conjugate added to each well
50 µL of antiserum added to each well
Incubation at room temperature for 40 minutes
Washed four times with 400 µL of wash buffer
100 µL of TMB solution added to each well
Incubation in the dark at room temperature for 10 minutes
100 µL of stop solution added to each well
Read plate at 450 nm within 15 minutes on DAS 8 channel microplate 
reader
 
Figure 6.1. Summary of method for the analysis of transferrin in oral fluid using the 
Salimetrics’ transferrin kit for blood contamination 
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6.2.2.4 Study 2 – Sample collection 
Eight non-drug using human volunteers (4 male, 4 female) were invited to swallow a 
15 mg codeine tablet. Volunteers ranged in age between 21 and 66. Volunteers were 
asked to provide a pre-dose sample of oral fluid immediately to participating in this 
study. Oral fluid was subsequently collected 15, 30, 45, 60, 90, 120, 150, 180 and 
240 minutes after consumption of codeine using the AlereTM Certus oral fluid 
collection device. Two groups of volunteers were formed. The first group ingested 
the codeine tablet and subsequently provided oral fluid. The second group stimulated 
microbleeding three hours post ingesting the codeine tablet. Oral fluid was collected 
in accordance with the AlereTM manufacturer instructions for the AlereTM Certus 
collection device.  
6.2.2.5 Study 2 -  Immunoassay 
For the detection of opiates, the AlereTM Opiate EIA kit was used as described in 
Chapter 5. 
6.3 Results and Discussion 
6.3.1 Study 1 -   Results  
Transferrin concentrations detected in samples in Group 1 (Table 6.1) ranged from 
0.2 mg/dL to 6.2 mg/dL (mean = 2.1 mg/dL, median = 1.2 mg/dL, SD = 1.6 mg/dL, 
IQR = 1.1 mg/dL). In the low and medium drug concentration groups mean 
transferrin concentrations were detected at 1.9 mg/dL (range = 0.1 mg/dL- 6.5 
mg/dL, median = 1.4 mg/dL, SD = 1.7 mg/dL, IQR = 1.3 mg/dL) and 1.7 mg/dL 
(range = 0.1 mg/dL – 6.2 mg/dL, median = 0.7 mg/dL, SD = 1.6 mg/dL, IQR = 1.6 
mg/dL), respectively. Similar concentrations were observed in samples with high 
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drug concentrations ranging between 0.1 mg/dL and 6.2 mg/dL (mean = 1.7 mg/dL, 
median = 0.1 mg/dL, SD = 1.9 mg/dL, IQR = 1.2 mg/dL) (Table 6.2).  
 
Table 6.2 Summary of transferrin concentrations (mg/dL) in cocaine, opiates and 6-
MAM positive samples collected from drug clinics in the UK 
 
Transferrin Concentrations (mg/dL) 
Min Max Mean Median 
Standard 
Deviation 
(SD) 
Interquartile 
Range (IQR) 
Group 1 0.2 6.2 2.1 1.2 1.6 1.1 
Group 2  0.1 6.5 1.9 1.4 1.7 1.3 
Group 3  0.1 6.2 1.7 0.7 1.6 1.6 
Group 4 0.1 6.2 1.7 0.1 1.9 1.2 
 
 
6.3.1.1 Cocaine 
Transferrin positive results were observed in all of the four groups. In the cocaine 
group 1 below 100ng/mL, transferrin concentrations ranged from 0.3 mg/dL to 6.2 
mg/dL (mean = 2.3 mg/dL, median = 1.6 mg/dL, SD = 2.0 mg/dL) with eight out of 
the ten samples in this group above the manufacturers recommended cut off (0.5 
mg/dL). 
In the cocaine group 2, six volunteers had extremely high levels of transferrin 
resulting in a mean concentration of 5 mg/dL (range = 0.1 mg/dL – 6.6 mg/dL, 
median = 4.2 mg/dL, SD = 2.3 mg/dL) (Table 6.3). Transferrin concentrations 
detected in cocaine group 3 were all above the manufacturers recommended 
transferrin cut off of 0.5 mg/dL cut off. Transferrin concentrations in this group 
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ranged between 1.0 mg/dL and 6.2 mg/dL (mean = 2.8 mg/dL, median = 1.8 mg/dL, 
SD = 1.9 mg/dL).  
In group 4 the cocaine concentrations were the highest detected in the oral fluid 
samples, however only seven samples were positive for transferrin with a mean 
concentration of 1.8 mg/dL (range = 0.1 mg/dL – 5.6 mg/dL, median = 1.9 mg/dL, 
SD = 2.1 mg/dL) (Table 6.3).  
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Table 6.3 Summary of cocaine concentrations (ng/mL) compared to transferrin 
results (mg/dL) – (Samples reported as ‘over’, were above the highest calibrator 
provided with the kit)  
  
Concentration 
(ng/ml) 
Transferrin 
(mg/dL)   
Concentration 
(ng/ml) 
Transferrin 
(mg/dL) 
B
el
o
w
 
59 1.4 
M
ed
 
176 4.4 
17 4.0 187 6.2 
29 1.4 209 1.0 
20  over 191 3.0 
10 0.6 206 1.7 
12 0.3 190  over 
55  over 204  over 
25 3.0 195 1.2 
60 6.2 169 over  
82 1.8 160 1.8 
Mean 36.9 2.3 Mean 188.7 2.8 
median 27 1.6 median 190.5 1.8 
Min  10 0.3 Min  160 1.0 
Max 82 6.2 Max 209 6.2 
SD 25.0 2.0 SD 16.2 1.9 
R2 0.0855 R2 0.1047 
L
o
w
 
100 0.7 
H
ig
h
 
249 0.7 
111 1.8 242 1.5 
110 0.1 246 0.1 
104 0.2 241 0.5 
109 over  236 5.4 
106 6.5 241 0.2 
110 0.8 234 2.7 
102 over  241 0.5 
108 over  244 5.7 
111 0.2 243 0.8 
Mean 107.1 1.5 Mean 241.7 1.8 
median 108.5 0.7 median 241.5 0.7 
Min  100 0.1 Min  234 0.1 
Max 111 6.5 Max 249 5.6 
SD 3.9 2.3 SD 4.4 2.1 
R2 0.0085 R2 0.1571 
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This indicated that the concentrations of cocaine are not in correlation with the 
concentration of transferrin detected in these samples. Samples which were below 
the cut off showed similar results to the samples analysed from the high cocaine 
concentration group indicating that the microbleeding cannot be a cause for the high 
drug concentrations detected. This was also supported by the coefficient of 
correlation (R2) which was 0.0855 for the concentrations below the cut off for 
cocaine. For the low, medium and high cocaine concentrations the R2 values were 
0.0085, 0.1047 and 0.1571, respectively (Figure 6.2). The closer the coefficient of 
correlation is to 1, the closer results correlate. However, the R2 value for cocaine vs 
transferrin concentrations were low, indicating that there is no correlation between 
elevated cocaine concentrations and transferrin concentration in oral fluid samples.  
 
Figure 6.2 Scatter graph showing the correlation between the cocaine concentration 
(ng/mL) against the transferrin concentration (mg/mL) observed in oral fluid 
collected from drug clinics 
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6.3.1.2 Opiates 
Transferrin concentrations in oral fluid samples which previously were confirmed to 
contain opiates also did not show good correlation between the opiate concentrations 
detected and the transferrin concentrations.   
In the Group 1 for opiates, 50% of all samples screened for transferrin, gave a 
positive results above the recommended transferrin cut off. Transferrin 
concentrations ranged from 0.2 mg/dL to 6.0 mg/dL (mean = 1.0 mg/dL, median = 
0.4 mg/dL, SD = 2.0 mg/dL). Transferrin concentration in Group 2 had a mean of 
1.8 mg/dL (range = 0.4 mg/dL – 5.2 mg/dL, median 1.2 mg/dL, SD = 1.7 mg/dL) 
with eight out of ten volunteers confirmed above the transferrin cut off.   
Similarly, medium and high opiate concentrations resulted in mean transferrin 
concentrations at 0.5 mg/dL (range = 0.1 mg/dL – 1.6 mg/dL, median = 0.3 mg/dL, 
SD = 0.5 mg/dL) and 2.4 mg/dL (range = 0.1 mg/dL – 6.2 mg/dL, median = 0.6 
mg/dL, SD = 2.5 mg/dL). In both, the medium and the high opiate concentration 
group, only three volunteers tested positive for transferrin using the Salimetrics’ 
transferrin kit (Table 6.4).   
 
 
 
 
 
 
Validation of Oral Fluid as a Matrix for Drug Detection - Chapter 6 
 
148 
 
Table 6.4. Summary of immunoassay opiate concentrations (ng/mL) compared to 
immunoassay transferrin results (mg/dL) – (ND = not detected) 
  
Concentration 
(ng/ml) 
Transferrin 
(mg/dL) 
  
Concentration 
(ng/ml) 
Transferrin 
(mg/dL) 
B
el
o
w
 
9 0.3 
M
ed
 
315 0.2 
12 1.2 300 over 
31 0.2 310 0.7 
62 6.0 309 0.5 
9 0.7 293 1.6 
29 0.6 288 over 
10 0.7 310 0.2 
16 0.3 301 0.2 
46 0.2 279 0.4 
20 0.2 313 0.1 
Mean  24.4 1.0 Mean  301.8 0.5 
Median 18 0.4 Median 305 0.3 
Min 9 0.2 Min 279 0.1 
Max 62 6.0 Max 315 1.6 
SD 18.9 2.0 SD 11.9 0.5 
R2 0.4557 R2 0.0222 
L
o
w
 
103 0.4 
H
ig
h
 
327 0.6 
103 2.9 332 0.1 
111 1.5 338 over 
104 0.6 329 over 
110 5.2 329 over 
110 0.5 353 0.2 
106 0.9 336 0.2 
104 0.6 333 4.1 
100 4.0 342 6.2 
113 1.8 342 5.3 
Mean  106.4 1.8 Mean  336.1 2.4 
Median 105 1.2 Median 334.5 0.6 
Min 100 0.4 Min 327 0.1 
Max 113 5.2 Max 353 6.2 
SD 4.3 1.7 SD 8.0 2.5 
R2 0.0002 R2 0.0851 
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The results for opiates also indicate that there is no relationship between the amount 
of drug present in saliva and the presence of microbleeding, which was also 
supported by the low R2 value obtained when comparing opiate concentration to 
transferrin concentration in oral fluid samples. . The R2 value for samples which 
were below the opiate cut off was 0.4557.  For the low, medium and high opiate 
concentrations the R2 values were 0.0002, 0.0222 and 0.0851, respectively (Figure 
6.3). The low R2 value for opiate vs transferrin concentrations indicating that there is 
no correlation between elevated opiate concentrations and transferrin concentration 
in oral fluid samples. 
 
Figure 6.3 Scatter graph showing the correlation between the opiate concentration 
(ng/mL) against the transferrin concentration (mg/mL) observed in oral fluid 
collected from drug clinics 
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6.3.1.3 6-monoacetylmorphine 
Transferrin concentrations in samples containing 6-MAM below 100 ng/mL ranged 
from 0.2 mg/dL to 1.7 mg/dL (mean = 0.9 mg/dL, median = 0.8 mg/dL, SD = 0.5 
mg/dL). Only two samples with concentration below the 100 ng/mL of 6-MAM gave 
a negative result for transferrin.  
Similarly, the analysis of group 2 and group 3 which contained 6-MAM resulted in 
negative results on the transferrin immunoassay. Low and medium drug 
concentrations mean at 1.4 mg/dL (range = 0.3 mg/dL – 5.0 mg/dL, median = 0.7 
mg/dL, SD = 1.4 mg/dL) and 1.5 mg/dL (range = 0.3 mg/dL – 5.2 mg/dL, median = 
0.7 mg/dL, SD = 1.5 mg/dL).  
High 6-MAM concentrations were associated with the lowest positivity rate for 
transferrin with only five samples testing above the manufacturers recommended 0.5 
mg/dL cut off.  A mean transferrin concentration of 0.6 mg/dL (range = 0.1 mg/dL – 
1.9 mg/dL, median 0.5 mg/dL, SD = 0.5 mg/dL) was detected in samples previously 
confirmed to contain a high 6-MAM concentration (Table 6.5).  
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Table 6.5. Summary of 6-monoacetylmorphine concentrations (ng/mL) compared to 
transferrin results (mg/dL) – (ND = not detected) 
  
Concentration 
(ng/ml) 
Transferrin 
(mg/dL)   
Concentration 
(ng/ml) 
Transferrin 
(mg/dL) 
B
el
o
w
 
25 0.55 
M
ed
 
349 2.18 
14  over 393 0.5 
13 0.18 383 0.34 
87 0.79 391 0.6 
10 0.71 393 5.16 
20 1.52 420 2.82 
16 0.87 394 0.68 
29 1.72 364 0.39 
81 0.52 423 0.68 
47 0.88 398 2.02 
Mean  34.2 0.86 Mean  390.8 1.54 
Median 22.5 0.79 Median 393 0.68 
Min 10 0.18 Min 349 0.34 
Max 87 1.72 Max 423 5.16 
SD 28.3 0.5 SD 22.3 1.5 
R2 0.0122 R2 0.0089 
L
o
w
 
108 2.12 
H
ig
h
 
472 0.7 
109 0.65 458 0.53 
108 0.32 459 0.6 
107 0.28 475 0.09 
107 0.69 459 0.18 
110 0.72 459 1.87 
113 1.83 459 0.41 
103 0.67 460 0.12 
101 1.23 493 0.1 
110 5.01 489 0.86 
Mean  107.6 1.35 Mean  468.3 0.55 
Median 108 0.705 Median 459.5 0.47 
Min 101 0.28 Min 458 0.09 
Max 113 5.01 Max 493 1.87 
SD 3.5 1.4 SD 13.4 0.5 
R2 0.0955 R2 0.0309 
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When 6-MAM concentrations in oral fluid increased, transferrin concentrations 
decreased leading the conclusion that blood contamination of saliva is not a 
contributing factor to the elevated oral fluid concentrations observed previously 
(Chapter 4, Chapter 5). Similarly, to cocaine and opiate concentrations, this was also 
supported by the low R2 value obtained when comparing 6 MAM concentration to 
transferrin concentration in oral fluid samples. . The R2 value for samples which 
were below the opiate cut off was 0.0122.  For the low, medium and high 6 MAM 
concentrations the R2 values were 0.0955, 0.0089 and 0.0309, respectively (Figure 
6.4). The low R2 value for 6 MAM vs transferrin concentrations indicating that there 
is no correlation between elevated 6 MAM concentrations and transferrin 
concentration in oral fluid samples. 
 
Figure 6.4 Scatter graph showing the correlation between the 6 MAM concentration 
(ng/mL) against the transferrin concentration (mg/mL) observed in oral fluid 
collected from drug clinics 
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6.3.1.4 Summary of Drug Clinic Data results 
During analysis of the drug clinic data, results showed that for cocaine, opiates and 
6MAM, high transferrin concentrations did not relate directly to high drug 
concentrations. Elevated transferrin concentrations were observed no matter what the 
concentration of the drug, i.e. below 100 ng/mL, low concentration, medium 
concentration or high concentration, which is supported by the low R2 value between 
drug and transferrin concentration. This further indicates that there is no correlation 
between concentrations of drug and concentration of transferrin in oral fluid.  
No information was available on the oral hygiene from oral fluid donors. However, it 
has been shown that periodontal disease can result in increased gingival fluid 
(Schenkein and Genco 1977, Genco et al 1985). As transferrin is present in gingival 
fluid, observed elevated transferrin concentrations could also be resulting as a cause 
of periodontal disease in the oral fluid donor.  
Results suggested that microbleeding was not a contributing factor to elevating drug 
concentrations in oral fluid. However this study has a number of limitations,  beyond 
control of this study as the samples were already collected before key information 
could be recorded such as:   
6.3.1.4.1 Route of administration 
As discussed in other chapters, the contribution to oral fluid drug levels is significant 
from smoking, intranasal and chewing routes of administration whilst 
intravenous/intramuscular use results in higher blood levels rather than oral fluid 
levels. It would have been advantageous to know the route of administration to 
further segregate the groups into oral versus injection routes. This would have 
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allowed to conclude whether observed elevated concentrations are related to the 
route of administration.  
6.3.1.4.2 Drug use 
It would have been beneficial to have known the time between last drug use and 
collection of sample. This information would have given some insight as to whether 
the sample was in early or late elimination phase. In early phase we would expect to 
see high oral fluid levels resulting from contamination of the mouth cavity whereas 
in late phase elevated concentrations might be relating to drug deposition within and 
release from the oral cavity.   
6.3.1.4.3 Drug dose 
The final missing information in this data set is dose of the drug consumed and drug 
purity. The missing detail on the dose hinders the correct interpretation of the oral 
fluid concentrations in relation to the drug consumed.  
Because of the large number of unknowns associated with the drug clinic data, a 
study was undertaken involving oral fluid collection under controlled conditions 
following the controlled consumption of a codeine tablet.  
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6.3.2 Study 2 - Results 
Following stimulation of microbleeding three hours post consumption of a 15 mg 
dose of codeine (as a tablet) by a group of eight volunteers, mean opiate 
concentrations 15 minutes post ingestion were 1,359 ng/mL (range = 70 ng/mL – 
2,811 ng/mL, median = 1,185 ng/mL, SD = 909 ng/mL). Peak concentrations were 
observed at 60 minutes post ingestion with concentrations ranging between 441 
ng/mL to 3,551 ng/mL (mean = 1,414 ng/mL, median = 1,098 ng/mL, SD = 1,002 
ng/mL) (Table 6.6).  
  
1
5
3 
Table 6.6 Summary of immunoassay opiate concentrations results from volunteers who stimulated microbleeding 3 hours post consumption of a 
15 mg codeine  tablet 
Time 
(min) 
Concentration (ng/mL) 
V1 V2 V3 V4 V5 V6 V7 V8 Min Max Mean Median SD 
15 1244 1126 70 1362 2811 631 2523 1108 70 2811 1359 1185 909 
30 102 1224 76 345 2904 474 1896 1463 76 2904 1060 849 1002 
60 441 3551 1188 514 1514 621 2483 1007 441 3551 1415 1098 1090 
120 608 700 197 588 451 471 1885 273 197 1885 647 530 528 
180 323 447 40 296 494 34 137 230 34 494 250 263 173 
180MB 463 290 27 41 571 31 125 21 21 571 196 83 219 
195 371 312 36 45 27 58 231 28 27 371 138 51 143 
210 345 298 36 51 40 106 423 38 36 423 167 78 161 
240 190 227 21 55 25 36 143 41 21 227 92 48 82 
 
Legend: V= Volunteer number, 180MB=Sample collected post stimulation of microbleeding at t=180 minutes 
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Microbleeding was stimulated at t = 180 min. Immediately before stimulation of 
microbleeding, the mean opiate concentration was 250 ng/mL (range = 34 ng/mL – 
494 ng/mL, median = 263ng/mL, SD = 173 ng/mL). Microbleeding was stimulated 
until blood was visible in the sample. Microbleeding did not result in an immediate 
increase in opiate concentration with concentrations ranging between 21 ng/mL and 
571 ng/mL (mean = 196 ng/mL, median = 83 ng/mL, SD = 219 ng/mL) at t = 180 
min (post microbleeding). No significant change in concentration could be detected 
in samples immediately following microbleeding. However, a delayed rise could be 
observed at t = 210 min in 5 out of the 8 volunteers participating in this study. Mean 
concentrations at t = 210 min rose to 167 ng/mL (range = 36 ng/mL - 423 ng/mL, 
median = 78 ng/mL, SD = 161 ng/mL) from 138 ng/mL (range = 27 ng/mL – 371 
ng/mL, median = 51 ng/mL, SD = 143 ng/mL) at t = 195 min (Figure 6.5). 
 
Figure 6.5. Comparison of codeine concentrations in eight volunteers following the 
consumption of a 15 mg dose of codeine. Microbleeding was stimulated 180 minutes 
post consumption and is indicated by the red arrow. V = Volunteer    
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Only two volunteers showed a slight increase in concentrations following 
microbleeding (Table 6.6 – V1, V5). However, concentrations then continue 
dropping at constant rate and showed no significant change in comparison to the 
other volunteers.  
Results from controlled exposure experiments support the results from drug clinics 
data and indicated that micro-microbleeding is not a significant contributory factor to 
the elevated drug concentrations observed in oral fluid.  
The amount of blood released during microbleeding has not been reported in the 
literature. Therefore calculations were based on an estimated volume of 
microbleeding ranging between a minimum volume of 5 µL and a maximum volume 
of 20 µL. The theoretical quantity of drug released from the blood into saliva can be 
calculated when applying the saliva/plasma ratio (S/P) for codeine. Although the S/P 
ratio for codeine has been variously reported, the mean S/P ratio applied during 
calculation in this study is 3.32 (Sharp et al 1983, Schramm et al 1992, Cone 1993, 
O’Neal et al 1999, Kim et al 2002) (Table 6.7). 
Table 6.7 Summary of saliva plasma ratios for codeine as reported in the literature 
Saliva/Plasma Ratio Source 
3.7 O'Neal et al 1999 
3.3 Cone 1993 
3.3 Kim et al 2002 
3 Schramm et al 1992 
3.3 Sharp et al 1983 
3.32 Mean S/P ratio 
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Microbleeding during this study was stimulated three hours post exposure however, 
concentrations of opiates in the oral fluid in the literature are reported only at 2 hours 
or 4 hours. Following an oral dose of 30 mg of codeine, O’Neal et al (1999) reported 
a mean opiate concentration of 34 ng/mL at 2 hours post exposure and 18 ng/mL at 4 
hours post exposure. When applying the mean S/P ratio to the plasma concentration 
at 2 hour and 4 hour, the amount of drug which would pass into oral fluid during 
microbleeding can be calculated. 
Based on the plasma concentration reported by O’Neal et al (1999) the mean 
quantity of drug contaminating saliva at 2 hours with a minimum of a 5 µL 
microbleed would be 0.17 ng. At four hours post consumption the quantity of drug 
contaminating the saliva decreased to 0.09 ng. This is a minimal contamination of 
oral fluid through drug caused by microbleeding.  
Even when considering the highest quantity of microbleeding reported, the amount 
of drug contaminating the oral fluid would only have a theoretical quantity of 0.68 
ng and 0.36 ng at 2 hours and 4 hours post consumption, respectively. This quantity 
would also not elevate opiate concentrations in oral fluid significantly during this 
study when comparing to the observed mean oral fluid concentration of 250 ng/mL. 
6.4 Conclusion 
This chapter examined the hypothesis that microbleeding of the gums could 
contaminate the oral fluid. However, the work undertaken in this chapter showed that 
no relationship between elevated drug concentration and transferrin concentrations 
could be observed during the comparison of drug and transferrin concentrations in 
samples collected at drug clinics indicating that elevated drug concentrations are not 
a result of microbleeding of the gums.  
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Additionally, microbleeding did not result in an immediate rise of opiate oral fluid 
concentrations when bleeding was stimulated following the consumption of a 15 mg 
dose of codeine.  A delayed response was however observed at t = 210 min, half an 
hour post stimulation of microbleeding. Concentrations then continued to decrease 
over the following 30 minutes.   
The low response to microbleeding was explained by the low quantity of drug 
present within the microbleed when assuming that the average microbleed is 
between 5 µL to 20 µL. When applying the average S/P ratio of 3.32 to the average 
plasma concentration reported following a dose of 30 mg/mL, it results in the 
quantity of drug leaking into the oral fluid to range between 0.17 ng and 0.68 ng. 
This amount is insignificant when considering the much higher concentration of 250 
ng/mL of opiates at three hours post consumption on one 15 mg dose of codeine. 
Therefore when considering both the results from the drug clinics and the results 
from the controlled codeine exposure study, microbleeding can be ruled out to be a 
contributing factor to elevated drug concentrations.  
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Chapter 7.0  - Development of an immunohistochemical method for 
the visualisation of cocaine and heroin in tissues with a 
benzoylecgonine or morphine antibody 
7.1 Introduction  
Immunohistochemistry (IHC) is a technique commonly used in pathology and 
morphological studies to identify specific cells or cultures. Although the technique is 
widely used for the visualisation of tumours, only a few papers are available where 
the technique has been applied to the visualisation of drugs in tissue. Kajitani et al 
(1989) demonstrated that immunohistochemical techniques could be applied in order 
to localise methamphetamine in salivary glands of mice. Additionally, Yotsu-
Yamashita et al (2013) described the use of immunohistochemistry for the 
visualisation of puffer fish toxin in tissue and Wehner et al (2000) for visualising 
methadone in human brain.  It was postulated that this method could be used to 
enable the detection of cocaine and opioids bound within cells and tissues to be 
visualised by the use of an antibody-antigen reaction.  
The aim of the work undertaken in this chapter was to explore whether an 
immunohistochemical method could be developed to show the presence of cocaine 
and heroin and/or their metabolites in oral tissues after exposure to these drugs and 
the formation of drug depots. Immunohistochemical techniques are based on four 
main processes: a) fixation, b) processing, c) antigen retrieval methods and d) 
staining. The principals of these processes are described below.  
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7.1.1 Fixation 
Fixation is a process that is designed to prevent tissue autolysis and bacterial 
decomposition. It also coagulates the tissue to prevent loss of easily diffusible 
substances and protects the tissue against from damage due to the effect of any 
subsequent stages in the tissue preparation (Bozzola and Russel 1999). Strong fixing 
can destroy protein based antigens and therefore compromise this technique. 
Additionally, fixation should leave the tissue in a condition which allows for 
subsequent staining (Karnovsky 1965).  
7.1.2 Processing 
Following fixation, the tissue sections need to be processed into an embedding 
medium. The two most common embedding media used during 
immunohistochemical staining are glycol methyl acrylate (GMA) resin or paraffin 
wax. Both embedding media differ in the approach needed for the immuno-reaction 
with antibody. GMA is a water miscible acrylic resin and has been reported to give 
the best resolution when locating cells. In comparison to techniques such as paraffin 
wax or freezing, GMA does not require dehydration of the tissue prior to staining, it 
prevents shrinkage and the resin does not need to be removed for subsequent staining 
procedures. GMA has a low viscosity, which allows easy penetration of the tissue. 
Other advantages of GMA include good antigen preservation, excellent morphology 
and localisation of antigens and no antigen retrieval is required. Good antigen 
preservation allows specialised fixation and low temperature processing which 
would be advantageous for drug detection in tissue. A major disadvantage of GMA 
resin as an embedding medium is that sections should be no larger than 2mm x 2mm. 
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GMA resin could be beneficial for the detection and visualisation of drugs as the 
high sensitivity allows for detection of low quantity of drugs in tissue.  
In comparison to GMA resin, paraffin wax is commonly used to embed larger 
sections for immunohistochemical staining. However, tissue embedded  in paraffin 
wax has been reported to lose some of its sensitivity and resolution as a result of de-
paraffinisation and de-hydration steps during the following staining methods which 
are needed during the staining procedure.  
7.1.3 Antigen retrieval methods 
Fixation using neutral buffered formalin and embedding using paraffin wax causes 
links to form between tissue proteins. During the antigen retrieval step, the protein 
links are broken to unmask the antigen sites and enhance specific staining. The 
antigen retrieval methods vary depending on the antigens/epitopes of interest. For 
drug detection appropriate methods could include microwave treatment, pronase 
treatment or no pre-treatment.  
7.1.4 Staining Principle 
Tissue sections contain endogenous peroxidases and biotin in addition to the antigen 
of interest. Enzyme activity and biotin can interfere with the staining process by 
causing non-specific binding of the antibody. Thus, they must be inhibited during the 
staining process.  Next, a culture medium needs to be applied consisting of amino 
acids, glucose, salts and vitamins to block additional non-specific binding sites.. 
Once all blocking steps are completed, a primary monoclonal or polyclonal antibody 
is applied which has been raised to bind directly to the antigen of interest. The 
working antibody concentration is calculated by dividing the antibody neat 
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concentration by an appropriate dilution factor. The formula for calculating the 
antibody working concentration is presented below: 
 
Antibody working concentration (mg/mL) =
Antibody neat concentration  (mg/mL)
Dilution Factor
 
 
After a short incubation, any excess primary antibody is washed from the tissue and 
a secondary antibody added. This secondary antibody is one that has been raised 
against the primary antibody and is labelled with a moiety to allow it to act as a 
reporter antibody. Typically for a mouse monoclonal primary antibody (for example 
mouse anti-benzoylecgonine) a good choice of secondary antibody would be 
biotinylated rabbit-anti-mouse antibody. Biotinylation is the process of linking biotin 
directly onto the secondary antibody and has the benefit that it amplifies the signal.  
Signal amplification comes from using avidin biotin-peroxidase complexes (ABC). 
ABCs were first developed for immunohistochemistry techniques in 1981 (Hsu 
1990). Since then, they have become an established tool in chemistry, diagnostics 
and immunohistochemistry (Wilcheck and Bayer 1990). Avidin is a glycoprotein 
with great binding affinity for the vitamin biotin. When mixed together, avidin will 
bind to the biotinylated secondary antibodies (which are already bound to the drug 
within the tissue) and biotin-peroxidase forming a complex. Finally, 3, 3’ 
diaminobenzidinetrahydrochloride (DAB) was applied as a substrate for the 
peroxidase enzyme bound within the ABC. Conversion of the substrate results in a 
brown chromagen and specific staining within the tissue sections.  This process is 
shown in Figure 7.1. Sections are then rinsed and cover slips applied.  
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Figure 7.1 Avidin - Biotin staining principle applied during the 
immunohistochemical detection of drugs ( 
 
7.1.5 Tris-buffered saline (TBS) controls 
Tris-buffered saline (TBS) controls act as blanks throughout the staining process. 
During staining of tissue sections, TBS is applied to a second tissue section instead 
of the primary antibody which acts a control to ensure that no non-specific binding 
occurs.  
Drug Antigen 
Primary Antibody 
Avidin-Biotin 
Complex with DAB 
(  = biotin,      = 
avidin,  = DAB) 
Endogenous 
peroxidases and 
endogenous biotin 
Secondary Antibody 
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7.1.6 Isotype Controls 
In addition to TBS controls, isotype controls are used. These are a type of negative 
control designed to show any signal due to non-specific binding and need to be 
included for each experimental test. Typically mouse primary antibodies will bind 
non-specifically to receptors present on the cell surface and this can be inhibited with 
an Immunogloblulin G (IgG) isotype control.  Isotype controls are used to ensure the 
specificity of the primary antibody as well as ruling out any non-specific binding of 
the primary antibody to unwanted receptor or cellular proteins. 
In order to prevent the tissue sections from drying out over night the sections are 
covered by microscope slides. TBS controls were incubated in TBS only. The 
appropriate isotype dilution is calculated by dividing the isotype neat concentration 
by the antibody working concentration. The formula for calculating the appropriate 
isotype dilution is presented below: 
 
Isotype dilution = 
Isotype neat concentration (mg/mL)
Antibody working concentration (mg/mL)
 
 
7.2 Materials and Method Development 
7.2.1 Materials 
Artificial Salvia was prepared according to the Cozart biosciences protocol for the 
production of synthetic saliva (Appendix C).  
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In vitro experiments involved the use of porcine tongues due to its physiological and 
anatomical similarities to human tissue (Simon and Maibach 2000). Porcine tongues 
were purchased from The Village Butcher, Kingsclere, UK. 
7.3 Method Development 
7.3.1 Exposure and sectioning of tongues 
Porcine tongues were exposed to solutions of cocaine or heroin at concentrations of 
100 ng/mL and 10 µg/mL in artificial saliva for 10 minutes. This allowed the 
determination of the sensitivity of the antibody to a low and high concentration of 
drug. Following exposure to a drug solution, a 0.5 cm thick transverse cross section 
was removed from the porcine tongue (Figure 7.2).  
 
Figure 7.2. Image representing the position of the transverse cross section which was 
removed for immunohistochemical analysis 
 
7.3.2 Glycol methyl acrylate 
7.3.2.1 Sectioning 
Tissue sections used for GMA resin fixation should be no larger in size than 2mm x 
2mm. Since the transverse cross sections of porcine tongue were significantly larger 
than 2mm x 2mm in size, 12 biopsy size samples were taken from a transverse cross 
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section of the tongue as depicted in Figure 7.3.  The sections were removed using a 
biopsy stance to keep the size of the samples consistent as variable sample volume 
could affect the fixing stage.  
 
Figure 7.3 Transverse cross section of tongue showing the position of removal of 12 
biopsy size samples for GMA immunohistochemical staining 
 
7.3.2.2 Fixation 
Initially, tissue sections were fixed overnight at -20°C in a solution of ice cold 
acetone (Fisher Scientific, UK) containing 2mM phenylmethylsuphonyl fluoride 
(Sigma and Aldrich, UK) and 20 mM iodoacetamine (Sigma and Aldrich, UK). 
Following overnight fixing of tissue sections, the fixative solution was replaced with 
acetone for 15 minutes prior to incubation in benzoate for a further 15 minutes. Next, 
the tissue sections were infiltrated with a 5% methyl benzoate in GMA solution A 
(JB-4 Embedding Kit; Polysciences, Inc.) at 4°C for 6 hours. The 
infiltration/processing solution was chosen to be similar to the final embedding 
solutions as it saturates the tissue and builds a supporting structure for the following 
processing steps. GMA Solution A (JB4 embedding Kit, Polysciences, Inc., UK), 
part of the final embedding solution which was also used in the previous processing 
step, comprises the following range of constituents (1,4 Dioxane, 2-Hydroxyethyl 
1 2 3 
4 5 6 7 8 
9 10 11 
12 
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methacrylate, 4-Methoxyphenol, Acetaldehyde, Ethylene oxide, Formaldehyde, 
Poly(ethylene oxide).  
In addition, to GMA Solution A the embedding kit contains benzoylperoxide and 
GMA Solution B (JB-4 Embedding Kit; Polysciences, Inc.). Benzoylperoxide acts as 
a plasticiser whereas Solution B acts as the catalyst in this process.  Solution B 
contains 2,4,6(1H,3H,5H)-Pyrimidinetrione,5-phenyl-1-(phenylmethyl) and 
Poly(ethylene oxide).  
Tissue sections were placed in flat bottom tubes and the freshly prepared embedding 
solution (solution B) was added to the brim of the tube prior to placing the samples 
in the fridge to polymerise at 4°C. Following 48 hours polymerisation time, samples 
were then safely stored at -20°C until cutting.  
7.3.2.3 Cutting of sections 
Fixed tongue sections were cut at a thickness of 2 µm using a Reichert – Jung 2050 
SuperCut Programmable Microtome and floated onto water containing 1 % ammonia 
solution for 1 to 1.5 minutes to avoid shrinking and creasing of the tissue sections. 
Floating sections were picked up onto labelled poly-L-lysine coated microscope 
slides.  Samples were next dried for at least one hour at room temperature before 
commencing the staining process.  
7.3.2.4 Primary antibody Titration 
7.3.2.4.1 Cocaine 
The antibody used to visualise the presence of cocaine in tissue was a monoclonal 
benzoylecgonine antibody at a stock concentration of 3.5 mg/mL (AlereTM, 
Abingdon, UK). Several dilutions of the primary monoclonal antibody were prepared 
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to determine the best working antibody concentration. Dilution factors and working 
antibody concentrations were summarised in Table 7.1.  
Table 7.1 Summary of dilution factors and working antibody concentrations used to 
determine best resolution within the tissue section 
Neat antibody 
concentration 
Dilution factor 
Working antibody 
concentration 
3.5 mg/mL 
1 : 50 70 µg/ml 
1 : 100 35 µg/ml 
1 : 200 17.5 µg/ml 
1 : 400 8.75 µg/ml 
1 : 800 4.38 µg/ml 
1 : 1600 2.19 µg/ml 
 
In addition to sections which were stained using antibodies, a second section of each 
tongue was covered using TBS which acted as control.  
7.3.2.5 Isotype Controls 
For the purpose of the work undertaken in this chapter, IgG was selected as the 
isotype antibody. The stock solution of the isotype IgG had a concentration of 1 
mg/mL. Dilution factors, working antibody concentrations and subsequent isotype 
dilutions are summarised in Table 7.2.  
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Table 7.2. Summary of dilution factors, working antibody concentrations and isotype 
concentrations used during isotype testing in paraffin for porcine tongue sections 
previously exposed to cocaine 
Neat antibody 
concentration 
Dilution factor 
Working antibody 
concentration 
Isotype dilution 
3.5 mg/mL 
1 : 50 70 µg/ml 1 :14 
1 : 100 35 µg/ml 1 : 28 
1 : 200 17.5 µg/ml 1 : 57 
1 : 400 8.75 µg/ml 1 : 114 
1 : 800 4.38 µg/ml 1 : 228 
TBS control Control Control 
 
7.3.2.6 Staining Method 
The staining method applied for the detection of cocaine and heroin and their 
metabolites is summarised in Figure 7.4.  
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Block endogenous biotin by incubating slides for 30 minutes using 0.1% sodium 
azide and 0.3 % hydrogen peroxide
Wash sections using TBS three times for 5 minutes
Apply avidin block for 20 minutes
Wash sections using TBS three times for 5 minutes
Apply biotin block for 20 minutes
Wash sections using TBS three times for 5 minutes
Apply Dulbecco modified Eagles blocking medium for 30 minutes 
Apply primary antibody at appropriate dilutions and incubate at room temperature 
overnight
Wash sections using TBS three times for 5 minutes
Apply secondary antibody for 2 hours
Wash sections using TBS three times for 5 minutes
Apply DAB for 10 minutes
Wash sections under Tap water
Counterstain using Mayer's Haemotoxylin reagent
Drain slides and bake at 80 °C until dry
Mount coverslips using pertex
 
Figure 7.4. Summary of immunohistochemical staining method for the detection of 
cocaine and heroin in porcine tissue samples embedded in GMA resin  
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7.3.3 Paraffin Wax embedding 
7.3.3.1 Sectioning  
Full transverse cross sections were used for immunohistochemical staining when 
paraffin was used as an embedding medium.  
7.3.3.2 Fixation 
Initially, transverse cross sections were fixed in 10% formalin for 24 hours however 
it was observed that tissue sections were not completely fixed after 24 hours and that 
the centre of the sections were soft and unusable for processing into paraffin. The 
time and amount of fixation can vary depending on the density of the tissue. Muscle 
tissue is dense and hence the infiltration of the fixation agent was slower. The 
fixation time was subsequently extended to 48 hours allowing complete penetration 
of the fixative into the section of tongue. On completion of the fixation stage, tongue 
sections were processed into paraffin wax prior to sectioning.  
7.3.3.3 Cutting of sections 
In comparison to GMA resin, tissue sections embedded in paraffin wax were cut at a 
thickness of 4 µm using a Leica rotary microtome.  Sections were floated on to a 40 
ºC water bath for a minimum of one minute in order to avoid shrinking and creasing 
of the tissue sections. Floated sections were picked up using labelled 3-
aminopropyltriethoxysilane (APES) coated microscope slides to improve adhesion 
of tissue to the slides. It is recommended that slides then need to be incubated for 24 
hours at 37 ºC, however due the large size of the tongue sections used in the in-vitro 
studies, slides were incubated for 48 hours.  
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7.3.3.4 De-Paraffinisation 
Prior to staining the sections needed to be de-waxed in clearene twice for five 
minutes. This removed the embedding media, as non-removal of excess media could 
result in non-specific binding and reduced resolution within the section. Sections are 
then re-hydrated in different strengths of alcohol (up to 70% v/v) for five minutes 
each.  
7.3.3.5 Antigen Retrieval Methods 
7.3.3.5.1 Microwave treatment 
During microwave pre-treatment de-waxed sections were placed in a 0.01 M citrate 
buffer (pH of 6) then placed in an 800W SHARP microwave for 25 minutes at 50% 
power and heated to unmask the epitopes of interest.  
7.3.3.5.2 Pronase treatment 
During pronase pre-treatment samples were covered with a pronase solution which 
was  prepared by adding 0.1 mL of 1% pronase stock to 1.9 mL of TBS. Slides were 
then incubated at room temperature for approximately 10 minutes.  
7.3.3.5.3 No pre-treatment 
Slides not undergoing pre-treatment were covered using TBS to prevent dehydration 
of the sections whilst performing pre-treatments on the remaining slides.  
7.3.3.6 Primary antibody Titration 
7.3.3.6.1 Cocaine 
The antibody used to visualise the presence of cocaine and its metabolites in tissue 
was a monoclonal benzoylecgonine antibody at a stock concentration of 3.5 mg/mL 
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(Alere Toxicology, Abingdon, UK). The cross reactivity of the antibody is 
summarised in Appendix D. Several dilutions of the primary monoclonal antibodies 
were prepared to determine the best working antibody concentration. Dilution factors 
and working antibody concentrations for the optimization of the monoclonal 
benzoylecgonine antibody for use with paraffin sections are summarised in Table 
7.3. 
Table 7.3 shows the a summary of the working antibody concentrations tested during 
optimisation of monoclonal benzoylecgonine antibody for immunohistochemical 
staining with paraffin as the embedding medium 
Antibody concentration  Dilution factor 
Working antibody 
concentration 
3.5 mg/mL 
1 : 100 35 µg/ml 
1 : 200 17.5 µg/ml 
1 : 400 8.75 µg/ml 
1 : 800 4.38 µg/ml 
TBS control Control 
 
7.3.3.6.2 Heroin 
The antibody used to visualise the presence of heroin and its metabolites in tissue 
was a monoclonal morphine antibody at a stock concentration of 5.47 mg/mL (Alere 
Toxicology, Abingdon, UK). The cross reactivity data of the morphine antibody is 
summarised in Appendix E. This was at a higher concentration than the monoclonal 
benzoylecgonine antibody and as a result the dilution factor of 1 in 50 was not tested 
during the antibody titration process. Dilutions factors and working antibody 
concentrations for the optimization of the monoclonal morphine antibody in paraffin 
are summarised in Table 7.4. 
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Table 7.4 Summary of the working antibody concentrations tested during 
optimisation of monoclonal morphine antibody for paraffin wax embedded sections 
Antibody concentration Dilution factor 
Working antibody 
concentration 
5.47 mg/mL 
1 : 100 54.7 µg/ml 
1 : 200 27.4 µg/ml 
1 : 400 13.7 µg/ml 
1 : 800 6.8 µg/ml 
TBS control Control 
 
7.3.3.7 Isotype Controls 
7.3.3.7.1 Cocaine 
Benzoylecgonine antibody concentrations were calculated from the stock antibody 
concentration of 3.5 mg/mL (Table 7.5)  
Table 7.5. Summary of dilution factors, working antibody concentrations and isotype 
concentrations in paraffin used during isotype testing in paraffin for porcine tongue 
sections previously exposed to cocaine  
Antibody 
concentration 
Dilution factor 
Working antibody 
concentration 
Isotype dilution 
3.5 mg/mL 
1 : 100 35 µg/ml 1 : 28 
1 : 200 17.5 µg/ml 1 : 57 
1 : 400 8.75 µg/ml 1 : 114 
1 : 800 4.38 µg/ml 1 : 228 
TBS control Control Control 
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7.3.3.7.2 Heroin 
Monoclonal morphine antibody concentrations were calculated from the stock 
antibody concentration of 5.47 mg/mL (Table 7.6).  
Table 7.6. Summary of dilution factors, working antibody concentrations and isotype 
concentrations used during isotype testing in paraffin for porcine tongue sections 
previously exposed to heroin 
Antibody 
concentration 
Dilution factor 
Working antibody 
concentration 
Isotype dilution 
5.47 mg/mL 
1 : 100 54.7 µg/ml 1 : 18 
1 : 200 27.35 µg/ml 1 : 36 
1 : 400 13.68 µg/ml 1 : 73 
1 : 800 6.84 µg/ml   1 : 146 
TBS control Control Control 
 
 
7.3.3.8 Staining method 
The staining method applied for the detection of cocaine and heroin and their 
metabolites is summarised in Figure 7.5. 
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Block endogenous biotin by incubating slides for 10 minutes using methanol 
containing 0.5 % hydrogen peroxide
Wash sections using TBS three times for 2 minutes
Apply avidin block for 20 minutes
Wash sections using TBS three times for 2 minutes
Apply biotin block for 20 minutes
Wash sections using TBS three times for 2 minutes
Apply blocking medium for 30 minutes 
Apply primary/isotype antibody at appropriate dilutions and incubate at 4°C 
overnight
Wash sections using TBS three times for 5 minutes
Apply secondary antibody for 30 minutes
Wash sections using TBS three times for 5 minutes
Apply ABC complex for 30 minutes
Wash sections using TBS three times for 5 minutes
Apply DAB for 5 minutes
Wash sections under Tap water
Counterstain using Mayer's Haemotoxylin reagent
Dehydrate using ethanol and clearene
Mount coverslips using pertex
 
Figure 7.5. Summary of immunohistochemical staining method for the detection of 
cocaine and heroin in porcine tissue samples embedded in Paraffin wax  
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7.3.4 Visual Examination – GMA and Paraffin 
Slides were visually examined on a Leica microscope which was fitted with a Nikon 
Coolpix camera for photographing transverse cross sections. 
7.3.5 Quantification of staining – GMA and Paraffin 
 For the quantification of staining Alere Toxicology provided the AlereTM DDS 
software which uses a colour filter to highlight all pixels given within the colour 
range brown before quantifying it as the ration of highlighted pixels over the total 
number of pixels within a section. The result is then given as a percentage staining 
within the section.  
7.4 Results and Discussion 
7.4.1 GMA 
7.4.1.1 Antibody titration 
The presence of drug was indicated by a brown colour which is a result of the 
reaction between DAB and the peroxidase from the avidin-biotin complex.  Higher 
antibody concentrations resulted in non-specific binding of other cells whereas the 
lowest concentration showed weak staining that was barely visible under the 
microscope (Figure 7.6). No dark brown staining indicated samples were negative 
and do not show any binding. 
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Negative result for cocaine Positive result for cocaine 
  
Figure 7.6. Comparison between negative and positive sections which were stained 
using a monoclonal benzoylecgonine antibody (8.75 µg/mL). A positive is indicated 
by brown pigmentation (magnification x25) 
 
TBS controls were negative and hence did not show any brown staining which 
indicated that no non-specific binding occurred (Figure 7.7). 
 
 
  
 
 
 
 
Figure 7.7 Visual results of TBS control in porcine tongue tissue (magnification x 
25) 
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Staining results showed that in the largest dilution (1: 600) no drug was detected as 
the working antibody concentration (2.16 µg/mL) was too weak. Staining increased 
with decreasing dilution factor. In the lowest dilution (1:50) staining was observed to 
be present throughout the tissue indicating that the antibody concentration (70 
µg/mL) was too high and that staining was non-specific. Optimal staining was 
observed in sections staining with an antibody working concentration of 8.75 µg/mL 
as staining was clear but specific to selected structures within the tissue (Figure 7.8). 
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Figure 7.8 Visual results of porcine tongue tissue which was stained 
benzoylecgonine antibody at selected working antibody concentrations 
(magnification x25) 
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7.4.1.2 Isotype Controls 
Sections of porcine tongues previously exposed to cocaine and stained using a 
monoclonal benzoylecgonine antibody showed positive brown staining for cocaine 
or cocaine related compounds. Isotype, as well as TBS controls, did not result in a 
positive stain for cocaine. Negative isotype controls confirmed that the primary 
antibody is specific and that positive staining observed is not a result of non-specific 
binding to unwanted receptor or cellular proteins. Therefore, the benzoylecgonine 
antibody was shown to be specific for the detection of cocaine and its metabolites 
when applied during the GMA immunohistochemical staining technique (Figure 
7.9).  
 Antibody stained Isotype control 
a 
  
b 
  
Figure 7.9 Summarisation of results for isotype controls and antibody stained 
sections in tongues exposed to 100 ng/mL (a) and 1000 ng/mL (b) of cocaine which 
were embedded in GMA resin (magnification x25) 
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7.4.1.3 Summary of results from the application of the staining method 
The GMA method showed promising results when staining for cocaine ensuring the 
specificity of the antibody. Isotype controls and TBS controls were both negative, 
confirming that the positive staining which was observed within stained sections, 
was a result of the presence of the drug and was not non-specific binding. However, 
during visual examination of the slides, it was noted that important features, such as 
blood vessels and epithelium were destroyed during the removal of the biopsy 
samples from the transverse cross sections. Features, such as blood vessels were vital 
to identify whether the drug is able to easily travel across the blood vessel wall and 
hence contaminate the blood. Therefore, GMA was deemed an unsuitable embedding 
medium for the measurement of drug distribution. 
7.4.2 Paraffin Wax 
7.4.2.1 Antigen Retrieval methods 
Best immunohistochemical results were achieved when no antigen retrieval methods 
were applied. The heating process during microwave treatment caused the sections to 
float off the slides. This was a result of the large size of the tissue section and the 
large surface area needed for the section to stick. Pronase pre-treatment resulted in 
clear staining similarly to sections not treated with any antigen retrieval method. As 
results did not differ significantly between the pronase method and when no pre-
treatment was applied, for the ease of the method, in all later staining no antigen pre-
treatment method was applied. 
Validation of Oral Fluid as a Matrix for Drug Detection – Chapter 7 
182 
 
7.4.2.2 Antibody Titration 
7.4.2.2.1 Cocaine 
Best resolution of staining was achieved at an antibody concentration of 35 µg/ml (1 
in 100 dilution).  
Lowest antibody concentration resulted in weak staining in tongues exposed to a 
lower cocaine concentration of 100 ng/mL.  
High antibody concentrations resulted in non-specific staining as excess antibody 
increases non-specific reactions within the tissue which therefore resulted in 
background staining. In the antibody titrations the highest antibody concentrations 
tested of 70 µg/ml, lost resolution and increased background staining at higher 
concentration of drug and hence making it an unsuitable dilution of antibody. Results 
are summarised in Figure 7.10. 
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Figure 7.10 Visual summary of antibody titration of a benzoylecgonine antibody (3.5 
mg/mL) for the detection of cocaine and its metabolites in porcine tongue tissues 
which were exposed to 100 ng/mL or 1000 ng/mL of cocaine (magnification x25) 
 
7.4.2.2.2 Heroin 
Opioid staining was observed to be more intense in color than the staining observed 
following exposure to cocaine. The optimum result of concentration for morphine in 
paraffin wax sections was achieved at a dilution of 1 in 800 resulting in a working 
antibody concentration of 6.8 µg/ml. Antibody titration results for heroin in paraffin 
wax immunohistochemistry are observed in Figure 7.11. 
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Figure 7.11 Visual summary of antibody titration of a monoclonal morphine 
antibody (5.47 mg/mL) for the detection of heroin and its metabolites in porcine 
tongue tissues which were exposed to 100 ng/mL or 1000 ng/mL of heroin 
(magnification x25) 
 
7.4.2.3 Isotype Controls 
Similarly to GMA, isotypes and TBS controls were negative when applied to porcine 
tongue sections which were embedded in paraffin wax for both, sections stained for 
cocaine or heroin.  Therefore, the benzoylecgonine (Figure 7.12) and morphine 
(Figure 7.13) antibodies were shown to be specific for the detection of cocaine/ 
heroin and its metabolites when applied to during the paraffin wax 
immunohistochemical staining technique.  
Adipose Tissue 
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Figure 7.12 Summarisation of results for isotype and antibody stained sections in 
tongues exposed to different concentrations of cocaine which were embedded in 
paraffin resin (magnification x25) 
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Figure 7.13 Summarisation of results for isotype and antibody stained sections in 
tongues exposed to different concentrations of heroin which were embedded in 
paraffin resin (magnification x25) 
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7.4.2.4 Summary of results from the application of the staining method 
The paraffin wax staining method resulted in specific staining for both heroin and 
cocaine. Isotype controls and TBS controls were both negative, confirming that the 
positive staining which was observed within stained sections, was a result of the 
presence of the drug and was not non-specific binding.  The main advantage for the 
use of paraffin wax as an embedding medium is that the entire transverse cross 
section of the porcine tongue tissue could be embedded allowing the drug 
distribution throughout the tongue to be observed. Paraffin wax has been reported to 
have less resolution during immunohistochemical analysis than GMA resin. 
However, the work undertaken in this chapter showed that for both cocaine and 
heroin, the paraffin immunohistochemical staining method was specific for tongues 
exposed to 100 ng/mL of either drug as well as the higher concentrations of 10 
µg/mL. Overall, the paraffin wax immunohistochemical staining method was a more 
suitable matrix for the detection of drugs in porcine tongue tissue and was 
subsequently adopted for further investigation of oral tissues.  
7.4.2.5 Quantification of staining 
The staining could not be quantified as the staining counter-software was not specific 
enough to identify all the staining during image analysis. The software is based on a 
filter by which it quantifies the brown pixels in the image and simultaneously 
translates them into red pixels which are then identified by the software. However, 
the identification of the brown pixels is dependent on the light intensity used in the 
microscope, the magnification employed and intensity of staining. Additionally, the 
software accounts for staining at low and high intensity, and quantifies both in the 
same manner hence cannot differentiate between the low and the high drug 
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concentrations. These factors resulted in the quantification method being deemed 
unsuitable for use (Figure 7.14).  Visual and non-quantitative analysis was 
subsequently adopted using a Leica DMLB microscope.  
Stained section Stained section - quantified 
  
  
  
Figure 7.14 Images represent how the staining software cannot quantify the brown 
staining correctly due to factors such as microscope lighting, magnification and 
intensity (magnification x63) 
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7.5 Conclusion 
The immunohistochemical methods for GMA resin and paraffin wax both resulted in 
good precise staining for cocaine and in the case of paraffin wax, heroin. However, 
quantification using the AlereTM method was not suitable for this technique as results 
were not specific and hence unreliable.  Although GMA immunohistochemistry 
staining was specific, important histological features such as blood vessels and 
epithelium were destroyed during the removal of the biopsy samples from the 
transverse cross sections. In comparison, paraffin wax allowed the embedding of 
whole transverse cross sections and hence should be the preferred method for any 
further analysis.  
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Chapter 8.0  - In vitro investigations of concentrations of cocaine and 
heroin in porcine tongue tissue  
8.1 Introduction 
Previous chapters of this thesis showed that contamination of the oral mucosa can 
occur following the oral consumption of drugs. High concentrations of cocaine and 
its derivatives have been shown to be present in oral fluid for 1 hour following the 
consumption of a single cup of coca tea (Chapter 4). Additionally, large 
concentrations of opiates were also observed when swirling Collis Browne’s mixture 
and Codeine Linctus around the mouth for one minute (Chapter 5).  
The work described in this chapter aimed to test the hypothesis that drugs which 
were consumed orally via solution or smoking can build up in oral tissue and form 
depots resulting in a slow release of drug over time. 
Most manufacturers of oral fluid drug tests indicate that the effects of contamination 
have dispersed from the mouth after 10 - 15 minutes (Spiehler 2011) and that after 
this time has elapsed an oral fluid sample can then be collected with minimum risk of 
interference (Chapter 3). Previous results presented in this thesis clearly contradict 
this guideline following the exposure to oral solutions containing cocaine and 
opiates.  
The amount of drug which distributes into tissue is dependent on its volume of 
distribution amongst other factors. The reported volume of distribution for cocaine is 
1 -3 L/kg (Moffat et al 2011). The volume of distribution for heroin is not very well 
documented as it is rapidly metabolised to 6-MAM and morphine. Heroin is more 
lipophilic than cocaine resulting in a much higher estimated volume of distribution of 
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heroin 25 L/kg (Baselt 2011, Urso et al 2012). The higher volume of distribution of 
heroin suggests that a larger amount of drug travels into the tissue. The reported 
volume of distribution of morphine is between 3 - 5 L/kg (Moffat et al 2011). A 
second measure of lipophilicity is the partition coefficient (logP) of a drug. A log P 
value larger than 5 does not absorb easily into tissues. Therefore the lower the logP 
value, the easier the absorption into tissues. The reported logP value for cocaine is 
2.3 whereas the logP value for heroin is 0.2 (Moffat et al 2011). 
The experiments described in this chapter aimed to investigate the possible formation 
of drug depots in oral tissue by designing an in vitro model to model the exposure of 
drugs to porcine tongues either via solution or smoke.  
8.2 Materials and Methods 
8.2.1 Materials 
Certus oral fluid collectors were provided by Alere Toxicology plc, Abingdon, UK.  
Artificial saliva was prepared as described in Appendix D.  
Street heroin and crack cocaine were provided by John Ramsey, TICTAC 
communications, St Georges Medical School, University London.  
In vitro experiments involved the use of porcine tongues due to their physiological 
and anatomical similarities to human tissue (Simon and Maibach 2000). Porcine 
tongues were purchased from The Village Butcher, Kingsclere. 
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7.2.1.2.  Porcine Tongue Histology 
The tongue is the floor of the mouth and is made of skeletal muscles which is 
covered by mucous membrane. The primary function of the tongue is to detect taste 
and to assist chewing and swallowing of food. 
The top/dorsal surface of the tongue is made of two parts which are the anterior part 
and posterior part of the tongue, also known as the body and root of the tongue and  
are separated by a membrane - the sulcus terminalis. The outside layer of the tongue 
is a layer of oral mucosa with the addition of taste buds. This special mucosa forms 
papillae. Papillae are projections of the lamina propria which are covered with 
stratified squamous epithelium. The tongue contains 4 different types of papilliae, the 
filiform, fungiform, circumvallate and foliate. As well as papillae the tongue contains 
taste buds, which contain receptor cells to communicate with the taste pore. The 
structure of porcine tongue is shown in Figure 8.1. 
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Figure 8.1 shows the structure of porcine tongue tissue 
 
8.2.2 Methods 
8.2.2.1 Tongue preparation methods 
8.2.2.1.1 Tissue exposure to drug solutions of cocaine and heroin 
Tongues were immersed in 50 mL artificial saliva containing cocaine or heroin at 
concentrations of 100 ng/mL, 250 ng/ml, 500 ng/mL, 1000 ng/mL and 10 µg/mL for 
10 minutes whilst being stirred on magnetic stirrer (Figure 8.2).  
Epithelium 
Muscle Fibre 
Connective Tissue 
Blood Vessel Nuclei 
Muscle Fibre 
Connective Tissue 
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Figure 8.2 Model for exposure of porcine tongues to either cocaine or street heroin 
spiked into artificial saliva at concentration of 100 ng/mL, 250 ng/mL, 500 ng/mL, 
1000 ng/mL or 10 µg/mL 
 
After 10 minutes exposure to the drug solution, tongues were removed and washed in 
50 mL of artificial saliva for 1 minute whilst being stirred on a magnetic stirrer. This 
process was repeated seven times. The wash steps were introduced in order to mimic 
the constant washing of the oral cavity with oral fluid in the mouth. Then a Certus 
collector was pre-wetted with artificial saliva and then brushed against the washed 
porcine tongue following the last wash.  
8.2.2.1.2 Tissue exposure to smoking from either crack cocaine or street heroin 
Tongues were individually suspended in a smoking chamber. In order to ensure that 
tongues were all treated the same way they were suspended at the same height during 
Porcine tongue 
Magnetic stirrer 
Clamps to hold 
porcine tongue in 
place 
Artificial saliva 
containing cocaine 
or heroin  
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each exposure run. Crack cocaine or street heroin was heated using a Bunsen burner 
whilst a vacuum at the other end of the smoking chamber provided sufficient suction 
to mimic smoking conditions. The vacuum created airflow was measured using a 
kestrel 3000 and was detected to be 0.5 m/s. Exposure was performed until smoking 
ceased, but for no more than 5 minutes. Following exposure to cocaine or heroin, 
samples were immersed in 10 % neutral buffered formalin in preparation for 
subsequent immunohistochemical analysis (Figure 8.3).  
 
  
Figure 8.3. Model for the smoke exposure of crack cocaine or street heroin at a dose 
of either 100 mg or 200 mg 
 
Porcine Tongue 
Tongues suspended at 
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8.2.2.1.3 Investigation into drug release from tongue tissue over time 
Tongues were immersed in artificial saliva containing cocaine or heroin at a low and 
high concentration of 100 ng/mL or 1000 ng/mL for 10 minutes with vigorous 
stirring on magnetic stirrer. This was in keeping with the previous laboratory model 
for the exposure of porcine tongues to a solution (Figure 8.2). Following exposure to 
either cocaine or heroin, tongues were suspended in artificial saliva for either 1 hour, 
6 hours, 24 hours or 48 hours. Irrespective of the time exposed after the first hour, 
the artificial saliva wash was changed to prevent the tongues being exposed to 
potentially drug-rich artificial saliva resulting from the drug being initially washed 
off the tongue.  
8.2.2.2 Immunohistochemical methods 
The immunohistochemical method for paraffin embedding developed and described 
in Chapter 7 was applied for the work undertaken in this chapter (Figure 8.4).  
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Block endogenous biotin by incubating slides for 30 minutes using 0.1% sodium 
azide and 0.3 % hydrogen peroxide
Wash sections using TBS three times for 5 minutes
Apply avidin block for 20 minutes
Wash sections using TBS three times for 5 minutes
Apply biotin block for 20 minutes
Wash sections using TBS three times for 5 minutes
Apply Dulbecco modified Eagles blocking medium for 30 minutes 
Apply primary antibody at appropriate dilutions and incubate at room temperature 
overnight
Wash sections using TBS three times for 5 minutes
Apply secondary antibody for 2 hours
Wash sections using TBS three times for 5 minutes
Apply DAB for 10 minutes
Wash sections under Tap water
Counterstain using Mayer's Haemotoxylin reagent
Drain slides and bake at 80 °C until dry
Mount coverslips using pertex
 
Figure 8.4 Summary of immunohistochemical staining method for the detection of 
cocaine and heroin in porcine tissue samples embedded in GMA resin 
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8.2.2.3 Analytical Methods 
8.2.2.3.1 Homogenisation 
Following removal of transverse tissue sections from the tongue, sections were 
divided further into five individual parts for homogenisation (Figure 8.5).  
 
Figure 8.5. Diagram of sectioning of the transverse cross section of the tongue for 
homogenisation 
 
Each tissue section was homogenised using a hand-held Potter homogeniser by 
adding 3 mL of pH 6 phosphate buffer to 1 g of tissue until the sample was smooth 
and homogenous.  
8.2.2.3.2 Solid Phase Extraction  
200 µL of 0.1M hydrochloric acid was added to 200 µL of the oral fluid samples or 
tissue extracts. Extraction was performed using Oasis MCX micro elution plates 
(Waters, Manchester, UK). Cartridges were conditioned with 200 µL of methanol 
and 200 µL of 0.1 M hydrochloric acid followed by addition of sample. The columns 
were washed with 200 µL of 0.1 M hydrochloric acid and 200 µL of 30% methanol 
Section 1 
Section 2 
Section 3 
Section 4 
Section 5 
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in water (70/30 v/v) and dried. Elution was achieved using 50 µL of 5% ammonia in 
methanol. The sample was reconstituted in 50 µL of 0.1% Formic Acid in Water and 
analysed on a Waters LC-MS/MS system.  
8.2.2.3.3  LC-MS/MS method 
Samples were analysed using LC-MS/MS at AlereTM Toxicology, Abingdon, UK.  
After sample extraction 5 µL was injected onto the LC-MS/MS system (Waters 
Acquity® TQD) which consisted of a tandem quadrupole mass spectrometer fitted 
with a Z-Spray ion interface coupled to a Waters Acquity UPLC® system. Analytes 
were separated on an Acquity UPLCTM BEH C18 column (130Å, 1.7µm, 1mm x 
100mm) (Waters, Manchester, UK) using gradient elution with 0.1% Formic Acid in 
Water (solvent A) and Acetonitrile (solvent B). The flow rate was 0.4 mL/min and 
the gradient is summarised in Table 8.1. 
Table 8.1. Summary of the gradient for the elution for LC-MS/MS method  
Time Solvent A Solvent B 
0 min 98 % 2 % 
1.5 min 90 % 10 % 
3.5 min 80 % 20 % 
5 min 60 % 40 % 
6.5 min 20 % 80 % 
6.55 min 98 % 2% 
8 min 98 % 2%  
 
Positive electrospray ionisation was used and all analyses were performed in multiple 
reaction monitoring (MRM) mode with 2 transitions for each analyte as shown below 
in table 8.2. To ensure the assay performance is fit for purpose the following 
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parameters were determined to validate the quantitative chromatographic methods 
used within the laboratory (Table 8.2): 
 Method linearity 
 Limit of Quantitation (LOQ) 
 Upper and Lower robustness of the assay 
 Stability of the analytes of interest 
 Recovery from collection device 
 Extraction efficiency  
 Matrix effects  
 Specificity 
 Carryover 
 Bias (accuracy) 
 Reproducibility (precision) – within and between batches and the 
measurement of uncertainty  
 
  
 
2
0
3
 
 
Table 8.2 Parameters for the detection of cocaine, heroin and their derivates by LC-MS/MS 
Compound 
MRM transition 
(m/z) 
Collision 
energy (v) 
Retention 
Time 
(min) 
LOD 
(ng/mL) 
LLOQ 
(ng/mL) 
Analyte 
Bias (%) 
(n=40) 
Measurement of 
Uncertainty 
(%) 
Cocaine 
304.1→105.1 
304.1→182.1 
30 
20 
4.21 0.031 0.5 - 17 ± 10.6 
Cocaine-D3 307.1→185.1 20 4.21 -- -- -- -- 
Benzoylecgonine 
290.1→179.1 
290.1→168.1 
30 
20 
3.60 0.125 0.5 - 14 ± 30.1 
Benzoylecgonine- D3 293.1→171.1 20 3.60 -- -- -- -- 
Norcocaine 
290.1→136.1 
290.1→168.1 
25 
25 
4.39 0.063 1 - 21 ±17 
Anhydroecgonine 
methyl ester 
182.1→118.14 
182.1→122.1 
25 
20 
1.96 0.031 0.5 + 1.5 ±12.8 
Anhydroecgonine 
methyl ester – D3 
185.1→125.1 25 1.96 -- -- -- -- 
Cocaethylene 
318.1→82.1 
318.1→196.1 
25 
20 
4.75 0.031 0.5 - 9.6 ±7.7 
Cocaethylene – D3 321.1→199.1 20 4.75 -- -- -- -- 
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Compound 
MRM transition 
(m/z) 
Collision 
energy (v) 
Retention 
Time 
(min) 
LOD 
(ng/mL) 
LLOQ 
(ng/mL) 
Analyte 
Bias (%) 
(n=40) 
Measurement of 
Uncertainty 
(%) 
Heroin 
370.1→211.1 
370.1→268.1 
25 
25 
4.15 0.5 0.5 + 19 ± 10 
Heroin – D9 379.1→272.1 25 4.12 -- -- -- -- 
Morphine 
286.1→153.1 
286.1→201.1 
40 
24 
1.96 0.063 0.5 - 2.97 ± 9.5 
Morphine –D3 289.1→153.1 40 1.96 -- -- -- -- 
6-
monoacetylmorphine 
328.1→165.1 
328.1→211.1 
40 
30 
2.82 0.063 0.063 - 27.3 ± 23.9 
6- 
monoacetylmorphine –
D6 
334.1→165.1 40 2.80 -- -- -- -- 
6-Acetylcodeine 
342.1→165.1 
342.1→225.1 
40 
25 
4.08 0.063 0.5 - 25.2 ± 14.5 
Codeine 
300.1→153.1 
300.1→165.1 
45 
45 
2.52 0.25 0.5 + 12.1 ± 12.1 
Dihydrocodeine 
302.1→199.1 
302.1→245.1 
35 
25 
2.47 0.031 0.25 + 8.41 ± 12 
Dihydorcodeine – D6 308.1→202.1 35 2.46 -- -- -- -- 
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8.3 Results and discussion 
8.3.1 Immunohistochemical results 
8.3.1.1 Results from controlled exposure to drug solutions of either cocaine or 
heroin  
Transverse cross sections which were stained using immunohistochemical techniques 
were examined using a Leica DMLB microscope fitted with a Nikkon Coolpix 
camera at 12 points throughout the cross-section of the porcine tongue (Figure 8.6). 
 
Figure 8.6 represents the position of each of the photographs taken of the stained 
cross section of each porcine tongue previously exposed to cocaine or heroin 
 
Both cocaine and heroin staining resulted in brown staining when tissue was positive 
for opioids (heroin, 6-MAM, and morphine) and cocaine (cocaine and 
benzoylecgonine). Staining in porcine tongues exposed to lower concentrations of 
drug resulted in lower intensity staining in tissue sections than in tissue sections 
which were exposed to higher concentrations. Duplicate tongues were exposed to 
each cocaine or heroin solution in order to test the reproducibility of the exposure 
and staining methods. As a large number of images were taken throughout the 
analysis, only pictures of sections 2, 6, 10 and 12 are represented in this thesis. 
1 2 3 
4 5 6 7 8 
9 10 11 
12 
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However, all images taken were visually analysed and showed similar results to 
those represented in this thesis.  
8.3.1.1.1 Cocaine 
Sections were assessed visually, as the staining counter software proved to be 
unsuitable for quantifying the amount of staining present as described in chapter 7.  
Porcine tongues exposed to a lower concentration of cocaine (100 ng/mL cocaine) 
showed less intense staining than the tongues exposed to a higher concentrations 
(500 ng/mL, 1000 ng/mL, 10 µg/mL). The observed differences in intensity between 
staining in tongues exposed to 100 ng/mL and 250 ng/mL was not markedly 
different. A larger intensity increase can be observed at 500 ng/mL, 1000 ng/mL and 
10 µg/mL (Figure 8.7, Figure 8.8, Figure 8.9, Figure 8.10, Figure 8.11). 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.7 Images of porcine tongues exposed to 100 ng/mL of cocaine solution. 
Porcine tongues were exposed in duplicate (tongue 1 / tongue 2). Only images 2, 6, 
10 and 12 are represented in this table (Figure 8.6) (magnification x25) 
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  Image - position 2 Image - position 6 
  
Image - position 12 Image position 10 
  
Figure 8.8 Images of porcine tongues exposed to 250 ng/mL of cocaine solution. 
Porcine tongues were exposed in duplicate (tongue 1 / tongue 2). Only images 2, 6, 
10 and 12 are represented in this table (Figure 8.5) (magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.9 Images of porcine tongues exposed to 500 ng/mL of cocaine solution. 
Porcine tongues were exposed in duplicate (tongue 1 / tongue 2). Only images 2, 6, 
10 and 12 are represented in this table (Figure 8.5) (magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.10 Images of porcine tongues exposed to 1000 ng/mL of cocaine solution. 
Porcine tongues were exposed in duplicate (tongue 1 / tongue 2). Only images 2, 6, 
10 and 12 are represented in this table (Figure 8.5) (magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.11 Images of porcine tongues exposed to 10 µg/mL of cocaine solution. 
Porcine tongues were exposed in duplicate (tongue 1 / tongue 2). Only images 2, 6, 
10 and 12 are represented in this table (Figure 8.5) (magnification x25) 
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The positive staining in the porcine tissue which was observed following the 
exposure to solution of cocaine indicated that cocaine and/or benzoylecgonine can 
enter the oral tissue by ways other than via the circulating blood. When visualising 
the tissue sections with a higher power (x 63) magnification, it can be observed that 
with increasing concentration of cocaine the drug travels further into the muscle 
bundles (Figure 8.12).  
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Figure 8.12 Images to representing the difference of penetration of cocaine into 
tongue muscle at a magnification of x 63 depending on the concentration to which 
each tongues were exposed 
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Only a small difference in staining intensity between tissue exposed to 100 ng/mL 
and 250 ng/mL was observed. However, over the concentration range, staining 
clearly increased and when directly comparing the lowest (100 ng/mL) and highest 
(10 µg/mL) cocaine exposure, the difference in staining intensity is more readily 
observed (Figure 8.13).  
 
100 ng/mL of cocaine 10 µg/mL of cocaine 
  
Figure 8.13 Direct comparison of tongues exposed to 100 ng/mL and 10 µg/mL of 
cocaine. Images taken at power x63 show the difference of penetration between the 
two different cocaine concentrations 
 
Prior to embedding porcine tongues in paraffin and immediately post exposure to 
cocaine, porcine tongues were washed seven times to wash off any excess cocaine 
from the surface of the tongue. The presence of cocaine and/or benzoylecgonine in 
tongue tissue after the washes clearly indicates that drugs can enter and bind into 
tissue and form depots.  
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8.3.1.1.2 Heroin 
In a similar manner to the results observed after cocaine exposure, tongues exposed 
to heroin also showed increased staining as concentrations of drug increased (Figure 
8.14, Figure 8.15, Figure 8.16, Figure 8.17, Figure 8.18).  
 
Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.14 Images of porcine tongues exposed to 100 ng/mL of heroin solution. 
Porcine tongues were exposed in duplicate (tongue 1 / tongue 2). Only images 2, 6, 
10 and 12 are represented in this table (Figure 8.5) (magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.15 Images of porcine tongues exposed to 250 ng/mL of heroin solution. 
Porcine tongues were exposed in duplicate (tongue 1 / tongue 2). Only images 2, 6, 
10 and 12 are represented in this table (Figure 8.5) (magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.16 Images of porcine tongues exposed to 500 ng/mL of heroin solution. 
Porcine tongues were exposed in duplicate (tongue 1 / tongue 2). Only images 2, 6, 
10 and 12 are represented in this table (Figure 8.5) (magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.17 Images of porcine tongues exposed to 1000 ng/mL of heroin solution. 
Porcine tongues were exposed in duplicate (tongue 1 / tongue 2). Only images 2, 6, 
10 and 12 are represented in this table (Figure 8.5) (magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.18 Images of porcine tongues exposed to 10 µg/mL of heroin solution. 
Porcine tongues were exposed in duplicate (tongue 1 / tongue 2). Only images 2, 6, 
10 and 12 are represented in this table (Figure 8.5) (magnification x25)
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Heroin and/or its metabolites were also shown to enter the tongue tissue. The 
intensity of staining was shown to increase with increasing heroin exposure 
concentration which indicated that more drug has entered the tissue.  
Additionally when visualising the tissue sections with a higher magnification (x63), 
it can be observed that with increasing concentration of heroin, more drug appears to 
penetrate into the muscle bundles (Figure 8.19). 
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Figure 8.19 Images to representing the difference of penetration of heroin into tongue 
muscle at a magnification of x 63 depending on the concentration to which each 
tongues were exposed 
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Porcine tongues were washed seven times following a 10 minute drug exposure time; 
however drug was still present in the tissue following this extensive wash process. 
This indicates that drug can enter and bind to the tissue and hence form depots.  
8.3.1.1.3 Summary of results from controlled exposure to drug solutions of 
either cocaine or heroin  
The immunohistochemical methods developed (Chapter 7) resulted in successful 
staining for cocaine and heroin including their metabolites following the exposure of 
porcine tongues to cocaine and heroin solutions demonstrating that drugs can enter 
tissues and bind in a manner that could represent the formation of a tissue depot. The 
presence of cocaine or heroin in the tissue after sequential washing gave negative 
result for the presence of drugs adds further support to the proposition that drugs can 
be absorbed into, and subsequently be retained, in oral tissue.  Drugs have been 
shown to enter the tissue for concentrations ranging between 100 ng/mL and 10 
µg/mL.  
In comparison to cocaine staining, the staining of heroin appeared to be significantly 
more intense in all tongues suggesting that the drug binds more readily to the tissue 
than cocaine. This was most noticeable in tissue sections which were exposed to 
higher concentrations of drug (10 µg/mL) (Figure 8.20, Figure 8.21).   
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Cocaine Heroin 
  
Figure 8.20 Comparison of images of tongues exposed to 100 ng/mL concentration 
of cocaine or heroin (magnification x63) 
 
 
Cocaine Heroin 
  
Figure 8.21 Comparison of images of tongues exposed to 10 µg/mL concentration of 
cocaine or heroin (magnification x63) 
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 Additionally, it was observed that no positive staining was observed for either 
cocaine or heroin within the blood vessel wall tissue (Figure 8.22). The lack of 
staining in the walls of blood vessels indicated that neither cocaine nor heroin binds 
to these vessels. However some staining was observed in the centre of the blood 
vessels which could indicate that the drug did cross the blood vessel wall.  
 
Figure 8.22. Image of a tongue exposed to 10 µg/mL of cocaine showing the staining 
around the blood vessel and the negative staining of the blood vessel wall 
(magnification x25) 
 
Of note was the staining presence around the epithelium (Figure 8.23). The 
epithelium stained was positive on the outside of the tongue. However, no staining 
was observed on the inside of the epithelium in tongues exposed to either cocaine or 
heroin. The inside layer of the epithelium showed an increased number of nuclei. The 
cluster of nuclei, which were blue in colour, resulted in a negative appearance on the 
inside of the epithelium.  
Blood vessel wall 
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Figure 8.23. Image of epithelium from a porcine tongue exposed to a cocaine 
solution clearly showing the negative stain on the inside of the epithelium whereas 
the outside of the epithelium is positively stained (magnification x25) 
 
 
8.3.1.2 Results from the prolonged washing study of porcine tongues to 
investigate the drug release from tongue tissue by 
immunohistochemical staining 
Results presented in Chapter 5, have shown that contamination from orally 
consumed drugs can occur for up to four hours post consumption of either Collis 
Browne’s mixture or Codeine Linctus. Additionally, it has been reported in the 
literature that drugs in oral fluid can be detected for up to 96 hours post consumption 
(Osselton et al 2001).  
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Positive staining on 
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The development of the immunohistochemical method has showed that drugs can 
enter the oral tissue via external contamination, be incorporated into tissue and hence 
form depots within the tissue.  
The drug which has bound to the tissue can subsequently be released over time. 
During the investigation into drug depots, porcine tongues were exposed to a 
concentration of 100 ng/mL and 1000 ng/mL of cocaine or heroin. Tongues were 
then soaked in artificial saliva for either 1 hour, 6 hours, 24 hours or 48 hours.  
The staining procedure showed that drug was present in tongues washed for 1 hour, 6 
hours, 24 hours and 48 hours following exposure to either 100 ng/mL or 1000 ng/mL 
of cocaine or heroin. Staining intensity weakened with increasing washing time. This 
was most noticeable around the epithelium of the porcine tongue. Staining in the 
muscle tissue was less intense but still prominent. Similarly to the previous exposure 
experiments, the staining for heroin appeared to be more intense in all tongues 
(Figure 8.24, Figure 8.25, Figure 8.26, Figure 8.27).  
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Figure 8.24 Images representing staining in tongues exposed to 100 ng/mL or 1000 
ng/mL to either cocaine or heroin and followed by washing each tongue for 1 hour 
(magnification x25) 
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Figure 8.25 Images representing staining in tongues exposed to 100 ng/mL or 1000 
ng/mL to either cocaine or heroin and followed by washing each tongue for 6 hours 
(magnification x25) 
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Figure 8.26 Images representing staining in tongues exposed to 100 ng/mL or 1000 
ng/mL to either cocaine or heroin and followed by washing each tongue for 24 hours 
(magnification x25) 
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Figure 8.27 Images representing staining in tongues exposed to 100 ng/mL or 1000 
ng/mL to either cocaine or heroin and followed by washing each tongue for 48 hours 
(magnification x25) 
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When sections were photographed using a higher magnification (x63) the decrease of the 
intensity of staining of drugs from porcine tongue muscle became more apparent. 
Previously, it was shown that the drug penetrated deep into the muscle bundles especially 
at higher concentrations. This was also shown when investigating drug release which also 
showed that results from the immunohistochemical staining method are reproducible. The 
most intense staining was observed following the 1 hour wash following exposure to 1000 
ng/mL. A decrease in the intensity of staining could be observed in tongues exposed to 
heroin and cocaine with prolonged washing with artificial saliva (Figure 8.28, Figure 8.29, 
Figure 8.30, Figure 8.31).  
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Figure 8.28 Summary of porcine tongues at magnification x 63 stained using an 
immunohistochemical technique following the exposure to either 100 ng/mL or 1000 
ng/mL of either cocaine or heroin and washing for 1 hour 
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Figure 8.29 Summary of porcine tongues at magnification x 63 stained using an 
immunohistochemical technique following the exposure to either 100 ng/mL or 1000 
ng/mL of either cocaine or heroin and washing for 6 hours 
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Figure 8.30 Summary of porcine tongues at magnification x 63 stained using an 
immunohistochemical technique following the exposure to either 100 ng/mL or 1000 
ng/mL of either cocaine or heroin and washing for 24 hours 
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Figure 8.31 Summary of porcine tongues at magnification x 63 stained using an 
immunohistochemical technique following the exposure to either 100 ng/mL or 1000 
ng/mL of either cocaine or heroin and washing for 48 hours 
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Drug can be visualised in muscle bundles for up tp 48 hours. Although the change between 
1 hour and 6 hours was small, when tongues were soaked for 24 hours, cocaine showed 
loss of staining at both exposure to 100 ng/mL and 1000 ng/mL. A slight loss of staining 
following the 24 hours washing was also observed following the exposure of 100 ng/mL or 
1000 ng/mL of heroin. However, in comparison to cocaine, the staining in the muscle 
bundles for heroin was more intense and was still detected throughout the muscle 48 hours 
post exposure.  
Results indicated that drug depots are capable of being formed in the porcine tongue tissue, 
which may be slowly released over time. A slow release of drug over a time period could 
potentially interfere with oral fluid drug detection by elevating the concentration and 
prolonging the detection of drugs in oral fluid. Although this is an issue when applying to 
roadside laws as toxicologist would be required to state if someone’s impairment was due 
to the drug concentration, it also allows for a greater detection window for drugs in oral 
fluid which could be beneficial in other areas such as workplace drug testing and drug 
treatment programmes. Both heroin and cocaine were still clearly visible 48 hours post 
exposure. Longer wash times would be beneficial to ascertain a point at which no drug 
staining could be seen. However when tongues were washed for 96 hours post exposure, 
the tongue tissue had started to decompose and when embedded in paraffin, the muscle 
structure had broken up and hence was not useable for immunohistochemical staining.  
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8.3.1.3 Detection of cocaine and heroin in porcine tissue following controlled 
exposure to crack cocaine and heroin smoke 
Tongues were exposed to either crack cocaine or heroin smoke following heating of 
100mg or 200 mg of each drug for 5 minutes. The presence of cocaine and heroin could be 
visualised using immunohistochemical staining techniques following smoking of either 
drug (Figure 8.32, Figure 8.33, Figure 8.34, Figure 8.35, Figure 8.36, Figure 8.37, Figure 
8.38, Figure 8.39).  
Image - position 2 Image - position 6 
  
Image - position 12 Image position - 10 
  
Figure 8.32 Images of porcine tongues (1) exposed to smoke from a dose of 100 mg 
cocaine. Only images from position 2, 6, 10 and 12 are represented in this figure 
(magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.33 Images of porcine tongues (2) exposed to smoke from a dose of 100 mg 
cocaine. Only images from position 2, 6, 10 and 12 are represented in this figure 
(magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.34 Images of porcine tongues (1) exposed to smoke from a dose of 200 mg 
cocaine. Only images from position 2, 6, 10 and 12 are represented in this figure 
(magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image position 10 
  
Figure 8.35 Images of porcine tongues (2) exposed to smoke from a dose of 200 mg 
cocaine. Only images from position 2, 6, 10 and 12 are represented in this figure 
(magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.36 Images of porcine tongues (1) exposed to smoke from a dose of 100 mg 
heroin. Only images from position 2, 6, 10 and 12 are represented in this figure 
(magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.37 Images of porcine tongues (2) exposed to smoke from a dose of 100 mg 
heroin. Only images from position 2, 6, 10 and 12 are represented in this figure 
(magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.38 Images of porcine tongues (1) exposed to smoke from a dose of 200 mg 
heroin. Only images from position 2, 6, 10 and 12 are represented in this figure 
(magnification x25) 
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Image - position 2 Image - position 6 
  
Image - position 12 Image - position 10 
  
Figure 8.39 Images of porcine tongues (2) exposed to smoke from a dose of 200 mg 
heroin. Only images from position 2, 6, 10 and 12 are represented in this figure 
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Images presented in Figure 8.39 show that drug entered the tongue tissue following 
exposure to both heroin and cocaine smoke. Tongues exposed to smoke from 100 mg 
of crack cocaine were demonstrated to enter into the tongue. Staining for cocaine 
was present in the epithelium; however it was not obvious in the muscle bundles and 
was mainly retained in the connective tissue surrounding the muscle bundles.  
Similarly heroin was detected in the epithelium following the generation of smoke 
from a 100 mg dose of street heroin. In comparison to cocaine, heroin appeared to 
have entered the muscle bundles as well as the connective tissue at the low dose.  
The high dose of cocaine resulted in more intense staining which seemed to be 
starting to enter the muscle bundles but the largest amount of staining and the most 
intense staining was still observed within the connective tissue.  
Higher doses of heroin showed more intense staining in the muscle of the tongue 
than exposure to lower doses of heroin. Heroin was clearly visible in the muscle 
bundles although a comparison at higher power magnification allows for a better 
comparison of the penetration of each drug.  
When visualising the sections of porcine tongues with a higher magnification (x63) 
the results support the initial statement that tongues exposed to cocaine smoke from a 
100 mg dose do not enter the muscle bundles at all and is only detected in the 
connective tissue (Figure 8.40). Following smoking of 200 mg dose of crack cocaine, 
it was seen to start to enter the muscle bundles with weak staining visual surrounding 
the muscle bundles. Cocaine was also visible in the connective tissue.  
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Crack cocaine (100 mg)   Crack cocaine (200 mg)  
  
Figure 8.40 Image representing the presence of cocaine in porcine tongue tissue 
following exposure to smoke from a 100 mg or 200 mg dose of crack cocaine 
visualised by an immunohistochemical technique. (magnification x63) 
 
In comparison following the exposure to smoke from 100 mg of heroin the drug can 
be seen to be weakly entering the muscle bundles with the outside of the bundles 
showing stronger binding.  
Following smoke exposure from a dose of 200 mg of heroin the drug has entered the 
muscle bundles and staining can be clearly strongly observed all the way through the 
muscle bundles (Figure 8.41).   
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Heroin   (100 mg) Heroin (200 mg) 
  
Figure 8.41 Image representing the presence of cocaine in porcine tongue tissue 
following exposure to smoke from a 100 mg or 200 mg dose of heroin visualised by 
an immunohistochemical technique (magnification x63). 
 
 
The presence of drugs, visualised by immunohistochemical staining in tissue 
following smoking also strongly supports the hypothesis that drugs can enter the oral 
fluid via routes other than via the surrounding blood. Drugs enter the muscle and 
form depots within the tissue when smoked which indicates that they can linger in 
the tissue and subsequently be released over time. Due to time restrictions during this 
project, no studies were undertaking to investigate the release and its detecting time 
for smoked tongues.  
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8.3.2  Analytical results 
8.3.2.1  Tissue exposure to drug solutions of cocaine and heroin 
8.3.2.1.1  Cocaine 
8.3.2.1.1.1  Cocaine and benzoylecgonine concentration detected in   
 the artificial saliva washes using LC-MS/MS 
 
LC-MS results showed how concentrations of cocaine and benzoylecgonine in 
artificial saliva washes decreased throughout the washes 1 –7 (W1 – W7) following 
exposure to cocaine at concentration in solution of either 100 ng/mL, 250 ng/mL, 
500 ng/mL, 1000 ng/mL or 10 µg/mL. With the exception of the highest exposure 
concentration of 10 µg/mL, all washes were no longer detectable at wash 7. 
Analytical results for cocaine and benzoylecgonine are summarised in Table 8.3.  
Table 8.3 Concentrations (ng/mL) of cocaine and benzoylecgonine in wash 1 to wash 
7 (W1 – W7) from tongues exposed cocaine concentrations of either 100 ng/mL, 250 
ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL (ND – not detected) 
Concentration 
(dose) 
Tongue 
No. 
Wash 
No.  
Concentration (ng/mL) 
Cocaine Benzoylecgonine 
1
0
0
 n
g
/m
L
 
1 
W1 ND ND 
W2 ND ND 
W3 ND ND 
W4 ND ND 
W5 ND ND 
W6 ND ND 
W7 ND ND 
2 
W1 ND ND 
W2 ND ND 
W3 ND ND 
W4 ND ND 
W5 ND ND 
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Concentration 
(dose) 
Tongue 
No. 
Wash 
No.  
Concentration (ng/mL) 
Cocaine Benzoylecgonine 
W6 ND ND 
W7 ND ND 
2
5
0
 n
g
/m
L
 
1 
W1 3 1 
W2 1 2 
W3 ND 1 
W4 ND 2 
W5 ND ND 
W6 ND ND 
W7 ND ND 
2 
W1 1 3 
W2 0 3 
W3 ND 0 
W4 ND 2 
W5 ND 1 
W6 ND ND 
W7 ND ND 
5
0
0
 n
g
/m
L
 
1 
W1 1 3 
W2 ND 1 
W3 ND 0 
W4 ND 1 
W5 ND 1 
W6 ND ND 
W7 ND ND 
2 
W1 3 2 
W2 ND 0 
W3 ND 0 
W4 ND 1 
W5 ND 3 
W6 ND ND 
W7 ND ND 
1
0
0
0
 n
g
/m
L
 
1 
W1 68 54 
W2 6 5 
W3 5 5 
W4 1 4 
W5 1 3 
W6 2 2 
W7 ND ND 
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Concentration 
(dose) 
Tongue 
No. 
Wash 
No.  
Concentration (ng/mL) 
Cocaine Benzoylecgonine 
2 
W1 45 33 
W2 11 11 
W3 4 4 
W4 2 3 
W5 2 3 
W6 4 3 
W7 ND ND 
1
0
 µ
g
/m
L
 
1 
W1 109 65 
W2 54 39 
W3 23 24 
W4 9 9 
W5 9 11 
W6 16 11 
W7 8 9 
2 
W1 198 104 
W2 60 29 
W3 26 18 
W4 11 10 
W5 10 8 
W6 15 9 
W7 13 3 
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Most manufacturers of oral fluid drug tests indicate that the effects of contamination 
have dispersed from the mouth after 10 - 15 minutes (Spiehler 2011) and that after 
this time has elapsed an oral fluid sample can then be collected with minimum risk of 
contamination. Tongues were washed during the work undertaken in this chapter as 
in the mouth saliva is constantly renewed and oral tissue washed with new fresh 
saliva at an average rate of 0.5 mL/min to 1 mL/min. The results supported the 
hypothesis that some drug had loosely bound to the tongue surface which was gently 
and progressively removed, potentially leaving significant binding and transfer to the 
tissue itself.    
Immunohistochemical results of the tongue tissue which was processed following 
wash 7, showed significant staining in all tongue tissue which previously exposure to 
cocaine at concentration in solution of either 100 ng/mL, 250 ng/mL, 500 ng/mL, 
1000 ng/mL or 10 µg/mL. This indicated that although no drug was being released 
during the wash steps, drug was still present within the tissue and hence bound to the 
oral tissue.   
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Figure 8.42 shows how concentrations of cocaine and benzoylecgonine in artificial saliva washes decreased throughout the washes 1 – 
washes 7 (W1 – W7) following exposure to cocaine at concentration in solution of either 100 ng/mL, 250 ng/mL, 500 ng/mL, 1000 
ng/mL or 10 µg/mL 
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8.3.2.1.1.2  Collectors 
After tongues were washed with artificial saliva a pre-wetted AlereTM Certus 
Collector was brushed against the tongue, in order to determine whether the use of 
the collector against the tongue would be able to collect cocaine from the tissue of 
the tongue. Previous results showed that during washing, no cocaine or 
benzoylecgonine could be detected in the last wash (wash 7), with the exception of 
tongues exposed to the highest concentration of cocaine of 10 µg/mL (Table 8.2).  
When Certus collectors were brushed against the tongue, both cocaine and 
benzoylecgonine could be detected in the collected samples which had been exposed 
to either 100 ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL (Table 8.4). 
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Table 8.4. Concentrations (ng/mL) of cocaine and benzoylecgonine that were 
brushed against the porcine tongues which had previously been exposed to cocaine at 
concentrations of either 100 ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL or 10 
µg/mL and washes seven times. Samples were collected using a pre-wetted AlereTM 
Certus Collector.  
Concentration (dose) 
Tongue 
No. 
Concentration (ng/mL) 
Cocaine BZE 
Mean 
Cocaine 
Mean 
BZE 
100 ng/mL 
1 2 10 
4 12 
2 6 14 
250 ng/mL 
1 22 24 
10 16 
2 34 32 
500 ng/mL 
1 8 14 
28 28 
2 12 18 
1000 ng/mL 
1 46 44 
38 39 
2 30 34 
10    µg/mL 
1 78 70 
76 70 
2 74 70 
 
Mean concentrations of cocaine and benzoylecgonine from tongues surfaces which 
were exposed to 100 ng/mL of cocaine solution were 4 ng/mL and 12 ng/mL, 
respectively. Following exposure to 250 ng/mL of cocaine solution, the mean 
cocaine and benzoylecgonine concentration detected in samples, collected with the 
AlereTM Certus collector, was 10 ng/mL and 16 ng/mL. Exposure to 500 ng/mL of 
cocaine solution resulted in a mean concentration of 28 ng/mL for both cocaine and 
benzoylecgonine. Brushing the Certus collector against porcine tongues which had 
been exposed to 100 ng/mL of cocaine solution resulted in mean concentration of 
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cocaine and benzoylecgonine of 28 and 39 ng/mL, respectively. The highest cocaine 
solution of 10 µg/mL resulted in mean concentrations of 76 ng/mL and 70 ng/mL for 
cocaine and benzoylecgonine respectively, in samples collected by brushing a pre-
wetted AlereTM Certus collector. Figure 8.43 summarises how cocaine and 
benzoylecgonine increased with increasing concentration of exposure.  
 
 
Figure 8.43. Mean cocaine and benzoylecgonine concentrations in samples collected 
by brushing the AlereTM Certus Collector against porcine tongues which were either 
exposed to 100 ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL. The red 
line (---) indicates the SAMHSA cut off for cocaine of cocaine and benzoylecgonine 
in oral fluid) 
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The recommended SAMHSA cut off for cocaine and benzoylecgonine in oral fluid is 
8 ng/mL (Chapter 4). The brushing of the collector against the tongue clearly 
removed cocaine and benzoylecgonine at concentrations which were significantly 
above the SAMHSA cut off. The presence of cocaine and benzoylecgonine in 
samples collected using a pre-wetted AlereTM Certus collector following seven 
washes after the original exposure to various concentrations of cocaine solution, 
indicated that the brushing the collector against the tongue can potentially extract 
drug from the oral tissue. The seventh wash was negative for cocaine and 
benzoylecgonine when exposed to cocaine spiked into artificial saliva, with the 
exception of the 10 µg/mL dose, indicating that all excess external contamination of 
cocaine had been washed off by wash seven. Therefore the presence of cocaine and 
benzoylecgonine in samples collected with the Certus collector, are not a direct result 
of external contamination, but the drug must have been released from the oral tissue.  
The extraction of cocaine and benzoylecgonine by simply brushing the collector 
against the porcine tongue has the potential to artificially elevate concentrations of 
cocaine and benzoylecgonine detected in an oral fluid drug test and hence can 
interfere with the interpretation of oral fluid testing results for toxicologist that look 
at saliva:plasma ratios. This could therefore affect oral fluid collection in individuals 
where samples were collected using any device that is designed to be rubbed or 
scraped over the mouth tissues. Expectorated samples may assist to fully avoid 
artificially elevated concentration through the use of a collector.  On the other hand it 
may assist in cases where it is necessary to check for drug compliance or abstinence 
where it is not relevant where the drug has come from.  
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8.3.2.1.1.3 Tissue Drug Concentrations  
Homogenates were prepared by analysing 1 g of tissue from five sections of tongue 
tissue (section 8.2.2.3.1).  
 
Figure 8.44. Diagram of sectioning of the transverse cross section of the tongue for 
homogenisation 
 
 
Both cocaine and benzoylecgonine were detected in tongue tissue following 
exposure to either 100 ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL of 
cocaine in artificial saliva. The mean cocaine concentration detected in tongues 
which were exposed to 100 ng/mL of cocaine solution was 12.8 ng/mL (range = 6– 
25 ng/mL) with the lowest cocaine concentration observed in the centre of the tongue 
(section 3).  
Following exposure to a cocaine solution of 250 ng/mL in artificial saliva mean 
cocaine concentrations detected in tongue tissue ranged between 7 ng/mL and 39 
ng/mL (mean = 19.8 ng/mL). The lowest mean cocaine concentration detected in 
Section 1 
Section 2 
Section 3 
Section 4 
Section 5 
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tissue was again in the centre of the tongue with a mean cocaine concentration 
between tongue 1 and tongue 2 of 7 ng/mL.  
Concentrations of cocaine which were detected in the transverse cross section of the 
tongue ranged between 6 ng/mL and 44 ng/mL (mean = 27.2 ng/mL). Largest 
concentrations were observed in section 1 and section 5 with 36 ng/mL and 44 
ng/mL, respectively. The lowest mean cocaine concentration was observed in section 
3 in the centre of the tongue at 6 ng/mL (Table 8.5).  
Table 8.5. Cocaine concentration (ng/mL) resulting from the analysis of 
homogenates from porcine tongues which were previously exposed to either 100 
ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL and 10 µg/mL of cocaine in artificial 
saliva 
Spiked 
Concentration 
Section 
Cocaine 
Concentration 
(ng/mL) Mean Cocaine 
concentration 
(ng/mL) 
Tongue 
1 2 
1
0
0
 n
g
/m
L
 
S1 4 22 13 
S2 10 8 9 
S3 2 10 6 
S4 6 44 25 
S5 2 20 11 
2
5
0
 n
g
/m
L
 
S1 24 32 28 
S2 10 22 16 
S3 12 2 7 
S4 42 36 39 
S5 12 6 9 
5
0
0
 n
g
/m
L
 
S1 34 38 36 
S2 12 46 29 
S3 4 8 6 
S4 30 12 21 
S5 34 54 44 
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Spiked 
Concentration 
Section 
Cocaine 
Concentration 
(ng/mL) Mean Cocaine 
concentration 
(ng/mL) 
Tongue 
1 2 
1
0
0
0
 n
g
/m
L
 S1 132 10 71 
S2 20 40 30 
S3 28 52 40 
S4 24 40 32 
S5 96 20 58 
1
0
 µ
g
/m
L
 
S1 88 322 205 
S2 14 96 55 
S3 34 34 34 
S4 360 188 274 
S5 354 190 272 
 
Cocaine concentrations detected in transverse cross section of the tongue did not 
show a large increase between tongues exposed to 100 ng/mL, 250 ng/mL and 500 
ng/mL which supported the immunohistochemistry staining result.  
Following the exposure of porcine tongues to 1000 ng/mL of cocaine solution, the 
mean concentration observed in the transverse cross section was 46.2 ng/mL (range = 
32 ng/mL – 71 ng/mL). The mean cocaine concentration in the centre of the tongue 
(section 3) was 40 ng/mL which was a large increase from cocaine concentration 
detected following exposure to 500 ng/mL cocaine solution indicating that cocaine 
has travelled further into the porcine tongue.  
Exposure of porcine tongue to 10 µg/mL of cocaine solution resulted in large mean 
cocaine concentrations ranging between 34 ng/mL and 274 ng/mL (mean = 168 
ng/mL). Lowest mean cocaine concentration was observed at 34 ng/mL in section 3 
which was removed from the centre of the tongue.  
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Results showed that there was large variation in cocaine concentration (ng/mL) 
measured in each section between the duplicate tongues exposed to either 100 
ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL and 10 µg/mL of cocaine in artificial 
saliva (Figure 8.45). Porcine tongues varied in size during this experiment as tongues 
are proportionate to the size of the animal it was removed from. As tongues were 
provided directly by the butcher there was no way to individually selecting each 
tongue depending on its size. Therefore the large variations in concentrations 
between two tongues exposed to the same cocaine concentrations could be a direct 
result of the difference in size between tongues. The butcher received the tongues 
from an abattoirs and it was therefore not known how long the tongues were stored 
frozen before the use in the work undertaken in this chapter. Immunohistochemical 
analysis however showed that the tissue structure was intact in all tongues, 
confirming that the tongues were suitable for the use in the work undertaken in this 
chapter.   
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Figure 8.45. Comparison between cocaine concentrations (ng/mL) in duplicate tongues following exposure to either 100 ng/mL, 250 
ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL of cocaine in artificial saliva 
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Following exposure to a cocaine solution of 100 ng/mL in artificial saliva mean 
benzoylecgonine concentrations detected in tongue tissue ranged between 20 ng/mL 
and 35 ng/mL (mean = 24.2 ng/mL). The lowest mean benzoylecgonine 
concentrations detected in porcine tongue tissue was in sections 2 and 3 at a 
concentration of 20 ng/mL. Only little difference was observed between 
concentrations observed following exposure to 100 ng/mL, 250 ng/mL and 500 
ng/mL which supported the immunohistochemical results as no large difference in 
the intensity of staining had been observed between those concentrations (Table 8.6). 
 
Table 8.6 Benzoylecgonine concentration (ng/mL) resulting from the analysis of 
homogenates from porcine tongues which were previously exposed to either 100 
ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL and 10 µg/mL of cocaine in artificial 
saliva 
Spiked 
Concentration 
Section 
Benzoylecgonine 
Concentration (ng/mL) Mean 
Benzoylecgonine 
concentration 
(ng/mL) 
Tongue 
1 2 
1
0
0
 n
g
/m
L
 
S1 22 22 22 
S2 22 18 20 
S3 18 22 20 
S4 30 40 35 
S5 18 30 24 
2
5
0
 n
g
/m
L
 
S1 28 42 35 
S2 12 22 17 
S3 16 12 14 
S4 34 46 40 
S5 20 26 23 
5
0
0
 n
g
/m
L
 S1 28 26 27 
S2 12 28 20 
S3 8 16 12 
S4 36 30 33 
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Spiked 
Concentration 
Section 
Benzoylecgonine 
Concentration (ng/mL) Mean 
Benzoylecgonine 
concentration 
(ng/mL) 
Tongue 
1 2 
S5 32 38 35 
1
0
0
0
 n
g
/m
L
 S1 170 38 104 
S2 142 42 92 
S3 52 58 55 
S4 80 56 68 
S5 238 40 139 
1
0
 µ
g
/m
L
 
S1 158 146 152 
S2 50 60 55 
S3 52 22 37 
S4 156 102 129 
S5 276 118 197 
  
 
Following the exposure of porcine tongues to 1000 ng/mL of cocaine solution, the 
mean benzoylecgonine concentration observed in the transverse cross section was 
91.6 ng/mL (range = 55 ng/mL – 139 ng/mL). The mean benzoylecgonine 
concentration in the centre of the tongue (section 3) was 55 ng/mL which was a large 
increase from benzoylecgonine concentration detected following exposure to 500 
ng/mL cocaine solution indicating that more drug has penetrated the tissue.  Cocaine 
has been known to breakdown to benzoylecgonine in aqueous solution and the 
presence of benzoylecgonine suggests an instability of cocaine and hence the 
breakdown of the cocaine to benzoylecgonine.  
Following exposure to a cocaine solution of 10 µg/mL in artificial saliva mean 
benzoylecgonine concentrations detected in tongue tissue ranged between 37 ng/mL 
and 197 ng/mL (mean = 114 ng/mL). The lowest mean cocaine concentration 
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detected in tissue was again in the centre of the tongue with a mean cocaine 
concentration between Tongue 1 and Tongue 2 of 37 ng/mL.  
Benzoylecgonine concentrations, like cocaine concentrations, also showed large 
variation between the duplicate tongues were exposed to either 100 ng/mL, 250 
ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL of cocaine in artificial saliva (Figure 
8.46). This further supported the theory that variations in drug concentration in 
tongue tissue can be caused by a difference in size of the tongue and hence the 
amount of drug accumulating in tongue tissue is proportionate to its size.  
  
  
 
2
6
4 
 
 
Figure 8.46. Comparison between benzoylecgonine concentrations (ng/mL) in duplicate tongues following exposure to either 100 
ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL of cocaine in artificial saliva 
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Mean concentrations of cocaine and benzoylecgonine (ng/mL) detected in transverse 
cross sections of tongues increased as the concentrations of drugs to which tongues 
were exposed increased. Both cocaine and benzoylecgonine concentrations detected 
were lowest when exposed to 100 ng/mL. Although there was small increase in 
cocaine and benzoylecgonine concentrations from 100 ng/mL to 250 ng/mL and 500 
ng/mL, the largest increase was observed when porcine tongues were exposed to 
1000 ng/mL and 10 µg/mL (Figure 8.47).  
The increasing mean cocaine and benzoylecgonine concentrations with increasing 
exposure dose suggest that the larger the exposure concentration, the further the drug 
can travel into the tissue and hence the larger the potential that drug depots can be 
formed within the tissue.  
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6 
 
 
Figure 8.47. Mean concentrations of benzoylecgonine (ng/mL) detected in transverse cross sections of the tongue following the 
exposure to either 100 ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL of cocaine in artificial saliva 
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Highest benzoylecgonine and cocaine concentrations were observed in homogenates 
of sections 1, 2, 4 and 5. Although sections 1 and 5 were removed from the same 
position of the tongue, a large difference of concentration of benzoylecgonine and 
cocaine could be observed in tongues which were exposed to cocaine concentrations 
of 1000 ng/mL and 10 µg/mL (Figure 8.48).  
Mean concentrations of cocaine and benzoylecgonine were shown to be lowest in 
section 3 taken from the centre of the tongue (Figure 8.48).   
  
  
  
2
6
8
 
 
Figure 8.48. Mean concentrations of cocaine and benzoylecgonine (ng/mL) detected in transverse cross sections of the tongue following 
the exposure to either 100 ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL of cocaine in artificial saliva. The red arrow 
represents the centre section (S3) of the transverse cross section of the tongue n, where observed concentration of cocaine and 
benzoylecgonine were lowest (n = 2) 
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8.3.2.1.2   Heroin 
8.3.2.1.2.1   Washes 
No heroin was detected in any of the 7 washes following exposure to heroin 
solutions from 100 ng/mL to 10 µg/mL. Morphine and 6-MAM could be detected in 
washes following exposure to 500 ng/mL of heroin. No positives were detected in 
wash 7 following exposure to any of the heroin concentrations (Table 8.6).  
Table 8.7 Concentrations (ng/mL) of heroin, morphine and 6-MAM in wash 1 to 
wash 7 (W1 – W7) from tongues exposed heroin concentrations of either 100 ng/mL, 
250 ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL (ND – not detected) 
Concentration 
(dose) 
Tongue 
No. 
Wash 
No.  
Concentration (ng/mL) 
Heroin Morpine  6-MAM  
1
0
0
 n
g
/m
L
 
1 
1 ND ND ND 
2 ND ND ND 
3 ND ND ND 
4 ND ND ND 
5 ND ND ND 
6 ND ND ND 
7 ND ND ND 
2 
1 ND ND ND 
2 ND ND ND 
3 ND ND ND 
4 ND ND ND 
5 ND ND ND 
6 ND ND ND 
7 ND ND ND 
2
5
0
 n
g
/m
L
 
1 
1 ND ND ND 
2 ND ND ND 
3 ND ND ND 
4 ND ND ND 
5 ND ND ND 
6 ND ND ND 
7 ND ND ND 
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Concentration 
(dose) 
Tongue 
No. 
Wash 
No.  
Concentration (ng/mL) 
Heroin Morpine  6-MAM  
2 
1 ND ND ND 
2 ND ND ND 
3 ND ND ND 
4 ND ND ND 
5 ND ND ND 
6 ND ND ND 
7 ND ND ND 
5
0
0
 n
g
/m
L
 
1 
1 ND 40 2 
2 ND ND ND 
3 ND ND ND 
4 ND ND ND 
5 ND ND ND 
6 ND ND ND 
7 ND ND ND 
2 
1 ND 35 3 
2 ND ND ND 
3 ND ND ND 
4 ND ND ND 
5 ND ND ND 
6 ND ND ND 
7 ND ND ND 
1
0
0
0
 n
g
/m
L
 
1 
1 ND 1 2 
2 ND 1 2 
3 ND ND ND 
4 ND ND ND 
5 ND ND ND 
6 ND ND ND 
7 ND ND ND 
2 
1 ND 1 1 
2 ND 0 0 
3 ND ND ND 
4 ND ND ND 
5 ND ND ND 
6 ND ND ND 
7 ND ND ND 
1
0
 
µ
g
/
m L
 
1 1 ND 43 41 
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Concentration 
(dose) 
Tongue 
No. 
Wash 
No.  
Concentration (ng/mL) 
Heroin Morpine  6-MAM  
2 ND 45 12 
3 ND 1 ND 
4 ND ND ND 
5 ND ND ND 
6 ND ND ND 
7 ND ND ND 
2 
1 ND 55 19 
2 ND 38 3 
3 ND 2 ND 
4 ND ND ND 
5 ND ND ND 
6 ND ND ND 
7 ND ND ND 
 
 
Following exposure to all concentrations of heroin solution, no opioids were detected 
in any of the washes after the 3rd wash however the drug had clearly been 
incorporated into the tissue as shown by immunohistochemical staining (section 
8.3.1.1.2).  
During immunohistochemical staining, it was observed that the staining for morphine 
in heroin exposed tongues was more intense in colour compared to the staining of 
cocaine, indicating that heroin binds more readily to the tissue. This is further 
supported by the analytical results of the washes. During the wash steps it was shown 
that cocaine was released and hence detected in several washes, indicating that some 
of the drug is released from the tissue. Heroin in comparison did not result in large 
concentration in the washes indicating that the drug was not released from the tongue 
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resulting in larger concentrations of drug in the tissue and hence resulting in more 
intense staining of the tissue during histochemical analysis.  
In a living organism the amount of drug which distributes into tissue is dependent on 
its volume of distribution. The reported volume of distribution for cocaine is 1 -3 
L/kg (Moffat et al 2011). The volume of distribution for heroin is not very well 
documented as it metabolises quickly to 6-MAM and morphine. Heroin is more 
lipophilic than cocaine resulting in a much higher estimated volume of distribution of 
heroin 25 L/kg (Baselt 2011, Urso et al 2012). The higher volume of distribution of 
heroin suggests that a larger amount of drug travels into the tissue. The reported 
volume of distribution of morphine is between 3 - 5 L/kg (Moffat et al 2011). This is 
further supported when comparing the logP value for cocaine and heroin. Heroin has 
a much lower logP value suggesting that the drug distributes more freely into the 
tissue than cocaine. Although the work undertaken in this chapter was carried out 
with in vitro tissue, the concept of the drugs crossing membranes still applies in that 
the microscopy of tissue sections showed the tissue to be intact and therefore drug 
still had the ability to cross membranes and accumulate in the tissues.   
8.3.2.1.2.2   Collectors 
After tongues had been washed seven times for 1 minute, a pre-wetted AlereTM 
Certus Collector that had been wetted using artificial saliva was brushed against the 
tongues.   Analytical results of the seven artificial saliva washes, showed that no 
heroin was present in any of the washes and although morphine and 6 MAM were 
detected and quantified. Heroin and its metabolites were no longer detected after 6 
washes.   
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No diacetylmorphine or morphine was detected when AlereTM Certus collectors were 
brushed against the tongue following completion of the washing process from 
tongues previously exposed to all heroin solutions (Table 8.8). 
A trace of 6-MAM (2ng/mL) was detected in tongues exposed to heroin at a 
concentration of 1000 ng/mL in solution but not at lower concentrations. A slight 
increase was observed in tongues which were dipped into 10 µg/mL, with 
concentrations of 8 ng/mL (Tongue 1) and 6 ng/mL (Tongue 2). 
Table 8.8. Concentrations (ng/mL) of heroin, morphine and 6-MAM in samples 
collected using the AlereTM Certus collectors that were brushed against the porcine 
tongues which had previously been exposed to heroin concentrations of either 100 
ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL or 10 µg/mL and washes seven times. 
Samples were collected using a pre-wetted AlereTM Certus Collector. (ND – not 
detected) 
Concentration (dose) Tongue No. 
Concentration (ng/mL) 
Heroin Morphine 6-MAM 
100 ng/mL 
1 ND ND ND 
2 ND ND ND 
250 ng/mL 
1 ND ND ND 
2 ND ND ND 
500 ng/mL 
1 ND ND ND 
2 ND ND ND 
1000 ng/mL 
1 ND ND 2 
2 ND ND 2 
10    µg/mL 
1 ND ND 8 
2 ND ND 6 
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The lack of heroin, morphine and 6-MAM in collectors suggest that the collector 
does not gather either of the compounds from the oral tissue and hence does not 
interfere with oral fluid interpretation. This further supports the proposition that 
opioids bind tightly to the tissue, as immunohistochemical staining resulted in 
intensive staining throughout the tissue (section 8.3.1.1.2). The recommendations (in 
draft) for the SAMHSA cut off for 6 MAM in oral fluid is 5 ng/mL. Although 6-
MAM was detected and quantified when collectors were brushed against the tongue 
following exposure to 1000 ng/mL and 10 µg/mL of heroin, concentrations above the 
SAMHSA cut off were only observed following exposure to 10 µg/mL.  
8.3.2.1.2.3  Tongue Homogenates 
Both morphine and 6-MAM were detected in tongue tissue which had previously 
been exposed to heroin. Concentrations of morphine are summarised in Table 8.9.  
Table 8.9. Morphine concentration (ng/mL) resulting from the analysis of five 
sections of porcine tongue homogenates which were previously exposed to either 100 
ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL and 10 µg/mL of heroin in artificial 
saliva 
Spiked 
Concentration 
Section 
Morphine 
concentration 
(ng/mL) Mean Morphine 
concentration 
(ng/mL) Tongue 
1 2 
100 ng/mL 
S1 39 43 41 
S2 16 16 16 
S3 8 20 14 
S4 23 86 55 
S5 44 39 42 
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Spiked 
Concentration 
Section 
Morphine 
concentration 
(ng/mL) Mean Morphine 
concentration 
(ng/mL) Tongue 
1 2 
250 ng/mL 
S1 94 63 78 
S2 39 43 41 
S3 47 41 25 
S4 64 70 67 
S5 47 42 44 
500 ng/mL 
S1 99 74 87 
S2 35 90 62 
S3 12 16 14 
S4 87 23 55 
S5 99 106 102 
1000 ng/mL 
S1 411 390 401 
S2 87 78 83 
S3 62 102 82 
S4 75 78 76 
S5 299 200 250 
10 µg/mL 
S1 351 330 340 
S2 136 188 162 
S3 56 66 61 
S4 143 368 255 
S5 422 371 397 
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Morphine concentrations detected in transverse cross section of the tongue did not 
show a large increase between tongues exposed to 100 ng/mL, 250 ng/mL and 500 
ng/mL which supported the immunohistochemistry staining result. Morphine 
concentrations then increased following exposure to 1000 ng/mL and 10 µg/mL of 
heroin. Lowest morphine concentrations were observed in section 3 which was 
removed from the centre of the tongue.  
Similar to cocaine results, concentrations showed that there was large variation in 
morphine concentration (ng/mL) measured in each section between the duplicate 
tongues which were exposed to heroin solutions. Porcine tongues varied in size 
during this experiment as tongues are proportionate to the size of the animal it was 
removed from. As tongues were provided directly by the butcher there was no way to 
individually selecting each tongue depending on its size. Therefore the large 
variations in concentrations between two tongues exposed to the same morphine 
concentrations could be a direct result of the difference in size between tongues.  
In addition to morphine, 6-MAM was also detected in tongue tissue which was 
exposed to heroin solutions at different concentrations. Concentrations of 6-MAM 
are summarised in Table 8.10. 
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Table 8.10. 6-MAM concentration (ng/mL) resulting from the analysis of 
homogenates from porcine tongues which were previously exposed to either 100 
ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL and 10 µg/mL of heroin in artificial 
saliva 
Spiked 
Concentration 
Section 
6-MAM 
Concentration 
(ng/mL) Mean 6-MAM 
concentration 
(ng/mL) Tongue 
1 2 
1
0
0
 n
g
/m
L
 
S1 68 73 70 
S2 68 59 64 
S3 53 64 59 
S4 93 132 113 
S5 56 99 77 
2
5
0
 n
g
/m
L
 
S1 87 139 113 
S2 37 73 55 
S3 34 25 29 
S4 105 152 129 
S5 62 86 74 
5
0
0
 n
g
/m
L
 
S1 87 86 86 
S2 47 92 70 
S3 23 53 38 
S4 112 99 105 
S5 99 125 112 
1
0
0
0
 n
g
/m
L
 
S1 264 251 257 
S2 220 277 249 
S3 81 383 232 
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Spiked 
Concentration 
Section 
6-MAM 
Concentration 
(ng/mL) Mean 6-MAM 
concentration 
(ng/mL) Tongue 
1 2 
S4 124 370 247 
S5 369 264 317 
1
0
 µ
g
/m
L
 
S1 490 482 486 
S2 155 198 177 
S3 109 73 91 
S4 242 337 289 
S5 428 390 409 
 
 
Lowest 6-MAM concentrations were detected in sections 3 which had been removed 
from the centre of the tongue.  
The presence of morphine and 6-MAM in tissue which was exposed to a heroin 
solution, suggest that heroin was broken down to morphine and 6-MAM during the 
preparation of the samples either during exposure, storage, extraction or analysis.  
The large variation between the duplicate tongues which were exposed to heroin in 
artificial saliva further supported the theory that variations in drug concentration in 
tongue tissue can be caused by a difference in size of the tongue and hence the 
amount of drug accumulating in tongue tissue is proportionate to its size (Figure 
8.49).  
  
2
7
9 
 
Figure 8.49. Mean concentrations of morphine and 6-MAM (ng/mL) detected in transverse cross sections of the tongue following the 
exposure to either 100 ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL and 10 µg/mL of heroin in artificial saliva (n =2) 
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Highest morphine and 6-MAM concentrations were observed in homogenates of 
sections 1, 2, 4 and 5. Although sections 1 and 5 were removed from the same 
position of the tongue, a large difference of concentration of morphine and 6-MAM 
could be observed in tongues which were exposed to heroin concentrations of 1000 
ng/mL and 10 µg/mL (Figure 8.50). Similar, to the difference in concentration of 
morphine and 6-MAM between duplicate tongues in section 1 and Section 5 can be 
explained by the variations of size in each tongue.   
Mean concentrations of morphine and 6-MAM were shown to be lowest in section 3 
as indicated by the arrow in Figure 8.50. Section 3 was the removed from the centre 
of the tongue indicating that the tongue travels to the centre of the tongue, however is 
not as concentrated in the centre of the tongue.  
  
 
2
8
1 
 
Figure 8.50. Mean concentrations of morphine and 6-MAM (ng/mL) detected in transverse cross sections of the tongue following the 
exposure to either 100 ng/mL, 250 ng/mL, 500 ng/mL, 1000 ng/mL and 10 µg/mL of heroin in artificial saliva. The red arrow represents 
the centre section (S3) of the transverse cross section, where observed concentration of morphine and 6-MAM were lowest. (n=2) 
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8.3.2.2     Tissue exposure to crack cocaine and exposure to street heroin smoke 
8.3.2.2.1  Crack cocaine smoke 
Cocaine, benzoylecgonine and anhydroecgonine methyl ester were detected in all 
five sections which were homogenised from a transverse cross section of the tongue.  
Following the exposure to smoke from a 100 mg dose of crack cocaine, mean 
concentrations of cocaine, benzoylecgonine and anhydroecgonine methyl ester were 
187 ng/mL, 1082 ng/mL and 4574 ng/mL, respectively, in section 1 of the samples 
taken for homogenisation of the transverse cross section of the tongue. The largest 
increase in concentration following smoke from a 200 mg dose of crack cocaine was 
observed with cocaine and anhydroecgonine methyl ester where the mean 
concentration detected were 870 ng/mL and 8902 ng/mL, respectively. 
benzoylecgonine showed a small decrease in concentration in section one dropping 
from 1,082 ng/mL to 836 ng/mL following smoke from a 100 mg and 200 mg dose 
of crack cocaine, respectively (Table 8.11).  
Section 2 of the tissue samples taken from porcine tongues did not show a large 
increase between the 100 mg dose or the 200 mg dose with mean concentrations 
observed of 484 ng/mL and 494 ng/mL respectively. Similarly to concentrations in 
Section 1, concentrations of benzoylecgonine decreased from 1,383 ng/mL when 
exposed to a 100 mg dose to 662 ng/mL following a 200 mg dose of crack cocaine. 
Anhydroecgonine methyl ester concentrations did not increase significantly from 
section 1 with mean concentrations detected of 4,396 ng/mL and 8,899 ng/mL 
following exposure to smoke from a 100 mg or 200 mg dose respectively (Table 
8.11).  
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Table 8.11. Concentrations (ng/mL) of cocaine, benzoylecgonine and 
anhydroecgonine methyl ester detected in five sections (s1 – s5) the tongue following 
the exposure to smoke from either a 100 mg or 200 mg dose of crack cocaine 
Section Dose 
Tongue 
No. 
Concentration (ng/mL) 
Mean concentration 
(ng/mL) 
COC BZE AEME COC BZE AEME 
S1 
100 mg 
1 184 124 4468 
187 1082 4575 
2 190 2040 4682 
200 mg  
1 426 454 3180 
870 836 8902 
2 1314 1218 14624 
S2 
100 mg 
1 468 648 5678 
484 1383 4396 
2 500 2118 3114 
200 mg  
1 14 194 6780 
494 662 8899 
2 974 1130 11018 
S3 
100 mg 
1 6 68 1190 
25 111 1124 
2 44 154 1058 
200 mg  
1 156 152 1162 
115 127 2036 
2 74 102 2910 
S4 
100 mg 
1 160 128 4210 
230 248 4772 
2 300 368 5334 
200 mg  
1 126 344 5830 
415 689 7355 
2 704 1034 8880 
S5 
100 mg 
1 932 590 6594 
722 516 8008 
2 512 442 9422 
200 mg  
1 140 320 10278 
80 242 20652 
2 20 164 31026 
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Lowest concentrations of cocaine, benzoylecgonine and anhydroecgonine methyl 
ester were observed in section 3 which was removed from the centre of the tongue. 
Following the exposure to smoke from a 100 mg dose of crack cocaine, mean 
concentrations of cocaine, benzoylecgonine and anhydroecgonine methyl ester were 
25 ng/mL, 111 ng/mL and 1124 ng/mL in section 3 of the samples taken for 
homogenisation of the transverse cross section of the tongue. Concentrations for all 
three compounds (cocaine, benzoylecgonine, anhydroecgonine methyl ester) 
increased with the increasing dose of crack cocaine (200 mg) to mean concentrations 
of 115 ng/mL, 127 ng/mL and 2036 ng/mL, respectively (Table 8.11).  
Concentrations of cocaine, benzoylecgonine and anhydroecgonine methyl ester also 
increased in section 4 when exposed to smoke from a dose of 200 mg rather than 100 
mg from 230 ng/mL, 248 ng/mL and 4,772 ng/mL to 415 ng/mL, 689 ng/mL and 
7,355 ng/mL respectively.  
In section 5, both concentrations of cocaine and benzoylecgonine were lower in 
tongues which were exposed to smoke from a 200 mg dose rather than a 100 mg 
dose of crack cocaine. Cocaine and benzoylecgonine concentrations following a 100 
mg dose were 722 ng/mL and 516 ng/mL respectively, whereas concentrations of 
cocaine and benzoylecgonine following a 200 mg dose were 80 ng/mL and 242 
ng/mL. Anhydroecgonine methyl ester showed a larger concentration when exposed 
to smoke from 200 mg of crack cocaine rather than smoke from 100 mg. The mean 
concentration of anhydroecgonine methyl ester increased from 8,008 ng/mL to 
20,652 ng/mL following a 200 mg dose rather than 100 mg dose.  
Lowest concentrations for cocaine, benzoylecgonine and anhydroecgonine methyl 
ester were observed in section 3, which was removed from the centre of the tongue 
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indicating that although the drug penetrated the tissue section all the to the centre of 
the tongue, less drug reached the centre than on the external sections of the tongue.  
Although sections 1 and 5 were removed from the same position from the left and 
right side of the tongue, a large difference in concentration for cocaine, 
benzoylecgonine and anhydroecgonine methyl ester could be observed in tongues 
which were exposed to smoke to a dose of 100 mg or 200 mg. (Figure 8.51). There 
are two possible explanations for this phenomenon. The size of the porcine tongues 
throughout the smoking of crack cocaine could not be guaranteed. Therefore some 
drug may infiltrate slimmer tongue sections faster than porcine tongues which were 
larger. Additionally, when tongues were suspended in the smoking chamber, it was 
observed that the smoke travelled upwards in a spiral motion, which could hence 
result in potentially uneven exposure to crack cocaine smoke. No noticable 
difference was observed between the exposure to smoke from either a 100 mg or a 
200 mg dose of crack cocaine.  
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Figure 8.51. Mean concentrations of cocaine, benzoylecgonine and anhydroecgonine methyl ester (ng/mL) detected in five sections (s1 
– S5) the tongue following the exposure to smoke from either a 100 mg or 200 mg dose of crack cocaine. The red arrow represents the 
centre section (S3) of the transverse cross section of tongue, where observed concentration of cocaine, benzoylecgonine and AEME 
were lowest.  (n=2) 
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8.3.2.2.2 Heroin Smoke 
Sections removed from tongues which were exposed to smoke from either 100 mg or 
200 mg of street heroin were positive for both morphine and 6-MAM.  
When tongues were expose to smoke from 100 mg of heroin, mean concentration of 
morphine and 6-MAM were 360 ng/mL and 290 ng/mL in comparison to 
concentrations following the exposure to 200 mg of heroin which were 569 ng/mL 
and 367 ng/mL, respectively (Table 8.12).  
Mean morphine concentrations in section 2 were 391 ng/mL and 872 ng/mL 
following tongue exposure to either 100 mg or 200 mg of heroin, respectively.  Mean 
concentrations of 6-MAM were 872 ng/mL when exposed to smoke from 100 mg 
heroin and 781 ng/mL following exposure to smoke from 200 mg heroin.  
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Table 8.12. Concentrations (ng/mL) of morphine and 6-MAM detected in five 
sections (s1 – S5) the tongue following the exposure to smoke from either a 100 mg 
or 200 mg of heroin 
Section Dose 
Tongue 
No. 
Concentration 
(ng/mL) 
Mean 
concentration 
(ng/mL) 
MOR 6-MAM MOR 6-MAM 
S1 
100 mg 
1 336 222 
369 290 
2 402 357 
200 mg 
1 447 375 
569 367 
2 691 358 
S2 
100 mg 
1 855 535 
391 599 
2 889 662 
200 mg 
1 350 742 
872 781 
2 432 820 
S3 
100 mg 
1 65 192 
73 237 
2 80 281 
200 mg 
1 285 342 
228 310 
2 172 277 
S4 
100 mg 
1 411 618 
419 645 
2 428 672 
200 mg 
1 860 1213 
862 1551 
2 863 1888 
S5 
100 mg 
1 1046 743 
236 775 
2 935 807 
200 mg 
1 256 904 
990 954 
2 217 1003 
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Lowest concentrations of morphine and 6-MAM were observed in section 3 which 
was removed from the centre of the tongue. Following the exposure to smoke from a 
100 mg heroin, mean concentrations of morphine and heroin were 73 ng/mL and 237 
ng/mL in section 3 of the samples taken for homogenisation of the transverse cross 
section of the tongue. Concentrations for morphine and 6-MAM increased with the 
increasing dose of heroin (200 mg) to mean concentrations of 228 ng/mL and 310 
ng/mL, respectively (Table 8.12). Concentrations of morphine and 6-MAM also 
increased in section 4 when exposed to smoke from a dose of 200 mg rather than 100 
mg from 419 ng/mL and 645 ng/mL to 862 ng/mL and 1551 ng/mL respectively. In 
section 5 concentrations of morphine and 6-MAM in tissue following exposure to 
smoke from 100 mg of heroin were 236 ng/mL and 775 ng/mL whereas 
concentrations following exposure to smoke from 200 mg of heroin were 990 ng/mL 
and 954 ng/mL, respectively.    
Similarly to exposure to cocaine, lowest concentrations for morphine and 6-MAM 
were observed in section 3, which was removed from the centre of the tongue 
indicating that although the drug penetrated the tissue section all the way to the 
centre of the tongue, less drug reached the centre than on the external sections of the 
tongue (Figure 8.52).  
Just like sections removed from tongue exposed to smoke from crack cocaine, 
variations in concentration between sections 1 and 5 were observed, although 
sections 1 and 5 were removed from the same position of the tongue. Similarly to 
tongues which were exposed to solutions of cocaine or heroin, the size of the porcine 
tongues throughout the smoking of heroin could not be guaranteed. Therefore some 
drug may infiltrate slimmer tongue sections faster than porcine tongues which were 
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larger. No significant difference was observed between the exposure to smoke from 
either a 100 mg or a 200 mg of heroin.  
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Figure 8.52. Mean concentrations of morphine and 6-MAM (ng/mL) detected in five sections (s1 – S5) the tongue following the 
exposure to smoke from either a 100 mg or 200 mg of heroin. The red arrow represents the centre section (S3) of the transverse cross 
section, where observed concentration of morphine and 6-MAM. (n = 2) 
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8.3.2.3 Prolonged washing of porcine tongues to investigate the drug release 
from tongue tissue using LC-MS/MS 
8.3.2.3.1 Cocaine 
Following exposure to concentration of 100 ng/mL or 1000 ng/mL of cocaine in 
artificial saliva, tongues were soaked in artificial saliva for 1 hour, 6 hours, 24 hours 
or 48 hours prior to homogenisation and extraction for analysis using LC-MS/MS 
(section 8.2.2.3).  
After 1 hour soaking of the tongue cocaine concentration ranged between 8 ng/mL 
and 15 ng/mL after the exposure to 100 ng/mL and 13 ng/mL and 28 ng/mL 
following exposure to 1000 ng/mL. Benzoylecgonine concentrations detected were 
lower ranging between 3 ng/mL to 7 ng/mL for a dose of 100 ng/mL and 3 ng/mL 
and 9 ng/mL for exposures to 1000 ng/mL (Table 8.13). 
When tongues were soaked for a longer time (6 hours), no significant difference 
concentrations were observed. Concentrations in tongues which were exposed to 100 
ng/mL ranged between 11 ng/mL and 28 ng/mL for cocaine and 6 ng/mL and 8 
ng/mL for benzoylecgonine. Exposure to cocaine of 1000 ng/mL resulted in higher 
concentrations which ranged between 12 ng/mL and 63 ng/mL for cocaine and 6 
ng/mL and 11 ng/mL for benzoylecgonine.  
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Table 8.13. Results from prolonged washing of porcine tongues to investigate the 
drug release from tongue tissue by immunohistochemical staining following the 
exposure to cocaine at concentrations of either 100 ng/mL and 1000 ng/mL and 
washing for either 1 hour, 6 hours, 24 hours or 48 hours 
Time Concentration (ng/mL) Section 
Concentration (ng/mL) 
Cocaine Benzoylecgonine 
1
 h
o
u
r 
100 
S1 15 6 
S2 12 5 
S3 8 3 
S4 9 6 
S5 15 7 
1000 
S1 27 8 
S2 20 6 
S3 13 3 
S4 14 7 
S5 28 9 
6
 h
o
u
rs
 
100 
S1 20 8 
S2 16 7 
S3 11 6 
S4 13 6 
S5 22 8 
1000 
S1 60 11 
S2 39 9 
S3 12 6 
S4 21 7 
S5 63 11 
2
4
 h
o
u
rs
 
100 
S1 12 6 
S2 18 6 
S3 1 6 
Validation of Oral Fluid as a Matrix for Drug Detection – Chapter 8 
 
294 
 
Time Concentration (ng/mL) Section 
Concentration (ng/mL) 
Cocaine Benzoylecgonine 
S4 6 6 
S5 8 6 
1000 
S1 29 8 
S2 12 7 
S3 8 2 
S4 13 6 
S5 25 7 
4
8
 h
o
u
rs
 
100 
S1 ND 3 
S2 ND 2 
S3 ND ND 
S4 ND 3 
S5 ND 4 
1000 
S1 ND 5 
S2 ND 5 
S3 ND 5 
S4 ND 5 
S5 ND 5 
 
Following 1 hour soaking of the tongue cocaine concentrations ranged between 1 
ng/mL and 18 ng/mL after the exposure of 100 ng/mL and 8 ng/mL and 29 ng/mL 
following exposure to 1000 ng/mL. Benzoylecgonine concentrations detected were 6 
ng/mL for a dose of 100 ng/mL and 2 ng/mL and 7 ng/mL for exposures to 1000 
ng/mL (Table 8.13). 
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Tissue samples removed from tongues exposed for 48 hours to 100 ng/mL of cocaine 
solution did not result in any detectable cocaine and only concentrations of 
benzoylecgonine were observed.   
Overall, when tongues were exposed to 100 ng/mL of cocaine in artificial saliva, 
cocaine and benzoylecgonine did not result in significant changes with different 
wash times (Figure 8.53). Although cocaine was not detected following 48 hours 
post exposure, benzoylecgonine was still detected at low concentrations. This was in 
keeping with the immunohistochemical results which showed that, although weak, 
positive staining was still observed 48 hours post exposure to 100 ng/mL of cocaine 
in solution.   
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Figure 8.53. Concentrations of cocaine and benzoylecgonine in sections 1 – 5 of tongues which were exposed to a 100 ng/mL solution 
of cocaine in artificial saliva and washed for either 1 hour, 6 hours, 24 hours or 48 hours 
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In comparison, tongues exposed to cocaine solution of 1000 ng/mL resulted in 
positive concentration of cocaine and benzoylecgonine for up to 48 hours.   
When tongues were exposed to 1000 ng/mL, no significant difference in 
benzoylecgonine concentrations were observed between the different wash times 
(Figure 8.54). Cocaine concentrations did not result in significant changes in the first 
24 hours, but decreased following 48 hours of washing. Similarly to cocaine 
concentration in tissue following exposure to 100 ng/mL, results following exposure 
to 1000 ng/mL were in keeping with the immunohistochemical results which showed 
that positive staining was still observed 48 hours post exposure to 1000 ng/mL of 
cocaine in solution (Figure 8.23).   
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Figure 8.54. Concentrations of cocaine and benzoylecgonine in sections 1 – 5 of tongues which were exposed to a 1000 ng/mL solution 
of cocaine in artificial saliva and washed for either 1 hour, 6 hours, 24 hours or 48 hours 
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8.3.2.3.2 Heroin 
Following exposure to concentration of 100 ng/mL or 1000 ng/mL of heroin in 
artificial saliva, tongues were soaked in artificial saliva for 1 hour, 6 hours, 24 hours 
or 48 hours and homogenized and extracted for analysis using LC-MS/MS (section 
8.2.2.3).  
Results showed that morphine and 6-MAM was detected in all tongues for up to 48 
hours. When tongues were soaked for 1 hour post exposure to solutions of heroin, 
morphine concentration detected ranged between 23 ng/mL and 41 ng/mL after the 
exposure to 100 ng/mL of heroin and 58 ng/mL and 113 ng/mL following exposure 
to 1000 ng/mL. 6-MAM concentrations detected were lower ranging between 9 
ng/mL to 24 ng/mL for a dose of 100 ng/mL and 14 ng/mL and 38 ng/mL for 
exposures to 1000 ng/mL of heroin (Table 8.14). 
Following soaking of exposed tongues for 6 hours, no significant changes in 
concentration for morphine or 6-MAM were observed. Concentrations in tongues 
which were exposed to 100 ng/mL ranged between 34 ng/mL and 69 ng/mL for 
morphine and 25 ng/mL and 35 ng/mL for 6-MAM. Exposure to heroin of 1000 
ng/mL resulted in higher concentrations which ranged between 24 ng/mL and 125 
ng/mL for morphine and 17 ng/mL and 30 ng/mL for 6-MAM.  
 
 
 
 
Validation of Oral Fluid as a Matrix for Drug Detection – Chapter 8 
 
300 
 
Table 8.14. Results from prolonged washing of porcine tongues to investigate the 
drug release from tongue tissue by immunohistochemical staining following the 
exposure to heroin at concentrations of either 100 ng/mL and 1000 ng/mL and 
washing for either 1 hour, 6 hours, 24 hours or 48 hours 
Time Concentration (ng/mL) Section 
Concentration (ng/mL) 
Morphine 6 MAM 
1
 h
o
u
r 
100 
S1 40 21 
S2 33 16 
S3 23 9 
S4 24 19 
S5 41 24 
1000 
S1 115 32 
S2 85 26 
S3 58 14 
S4 61 30 
S5 119 38 
6
 h
o
u
rs
 
100 
S1 61 35 
S2 49 28 
S3 34 25 
S4 39 25 
S5 69 35 
1000 
S1 121 29 
S2 78 25 
S3 24 17 
S4 42 18 
S5 125 30 
2
4
 h
o
u
rs
 
100 
S1 35 18 
S2 54 19 
S3 3 17 
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Time Concentration (ng/mL) Section 
Concentration (ng/mL) 
Morphine 6 MAM 
S4 18 17 
S5 23 18 
1000 
S1 52 17 
S2 26 33 
S3 5 16 
S4 105 20 
S5 60 18 
4
8
 h
o
u
rs
 
100 
S1 19 9 
S2 15 6 
S3 9 4 
S4 11 7 
S5 21 9 
1000 
S1 19 14 
S2 10 13 
S3 2 14 
S4 39 13 
S5 22 13 
 
 
Following 24 hour soaking of the tongue morphine concentration ranged between 1 
ng/mL and 20 ng/mL after the exposure of 100 ng/mL and 2 ng/mL and 39 ng/mL 
following exposure to 1000 ng/mL. 6-MAM concentrations detected ranged between 
4 ng/mL and 9 ng/mL for a dose of 100 ng/mL of heroin in solution and 2 ng/mL and 
7 ng/mL for exposures to 1000 ng/mL (Table 8.14). 
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Tongues which were exposed to 100 ng/mL of heroin in artificial saliva did not result 
in large changes in the morphine and 6-MAM concentrations in tissue. Both 
compounds were still detected 48 hours post washing with artificial saliva. This was 
in keeping with the immunohistochemical results which showed that, although weak, 
positive staining was still observed 48 hours post exposure to 100 ng/mL of cocaine 
in solution.  Detected morphine and 6-MAM concentrations were higher following 
exposure to 100 ng/mL of heroin than cocaine concentrations observed following 
exposure to 100 ng/mL of cocaine solution which further supports the results from 
the immunohistochemical staining as observed staining of heroin was more intense 
than positive staining for cocaine (Figure 8.55).  
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Figure 8.55. Concentrations of morphine and 6-MAM in sections 1 – 5 of tongues which were exposed to a 100 ng/mL solution of 
heroin in artificial saliva and washed for either 1 hour, 6 hours, 24 hours or 48 hours 
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In comparison, tongues which were exposed to a higher concentration of heroin 
solution of 1000 ng/mL resulted in the detection more significant concentrations of 
morphine and 6-MAM for up to 48 hours.   
Exposure to 1000 ng/mL of heroin in artificial saliva resulted in detection of 
morphine and 6-MAM  for up to 48 hours although over the first 24 hours no 
significant changes were observed between different wash times (Figure 8.56). 
Similarly to morphine and 6-MAM concentration in tissue following exposure to 100 
ng/mL, results following exposure to 1000 ng/mL were in keeping with the 
immunohistochemical results which showed that positive staining was still observed 
48 hours post exposure to 1000 ng/mL of heroin in solution (Figure 8.23).  
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Figure 8.56. Concentrations of morphine and 6-MAM in sections 1 – 5 of tongues which were exposed to a 1000 ng/mL solution of 
heroin in artificial saliva and washed for either 1 hour, 6 hours, 24 hours or 48 hours 
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Results indicated that drug (i.e. cocaine and its metabolites and heroin and its 
metabolites) which enters the tongue, can penetrate and bind tightly to the tissue. 
Drug was still visible via immunohistochemical staining and detected in tissue using 
LC-MS for up to 48 hours of washing using artificial saliva. Although the amount of 
drug detected decreased with prolonged washing, benzoylecgonine, morphine and 6-
MAM were still detected 48 hours post the exposure to either cocaine or heroin 
solution at concentrations of either 100 ng/mL or 1000 ng/mL. Drug which has 
bound to the tissue can subsequently be released over time and hence affect the 
interpretation of drug concentrations in oral fluid.  
8.4 Conclusion 
The work undertaken in this chapter has demonstrated the successful application of 
the immunohistochemical staining method developed in Chapter 7. 
Immunohistochemical staining in combination with toxicological analysis 
demonstrated that cocaine and heroin may penetrate into porcine tongue tissue 
following exposure to either drug in solution or following simulated smoking. 
Analysis of transverse cross sections of the tongue demonstrated that following 
exposure of tongues to cocaine, both cocaine and benzoylecgonine were observed in 
the analysed sections. Following exposure to heroin, morphine and 6-MAM were 
detected in tissue sections.   Repeated washing of tongues exposed to cocaine and 
heroin was capable of removing surface contamination however after repeated 
washes were shown to be negative for drugs, immunochemical staining and tissue 
analysis revealed that drugs had accumulated well into the tissue offering evidence 
that the formation of drug depots is possible. More cocaine and its metabolites were 
observed in washes than heroin and its metabolites, indicating that heroin binds more 
tightly into the oral tissue. Wiping tongue tissue with an oral fluid collection device 
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demonstrated that cocaine and benzoylecgonine, but not morphine or 6-MAM could 
be released from washed tongue tissue. Sufficient cocaine and benzoylecgonine 
could be removed by an oral fluid swab from washed tongue surfaces to exceed the 
positive cut-off concentrations recommended by SAMHSA.  Immunohistochemical 
staining results showed that the staining intensity in tongue sections increased with 
increasing drug exposure concentration. Staining following heroin exposure was 
observed to be more intense than following cocaine exposure indicating that more 
heroin had entered into and bound to tissue than cocaine.  The increased amount of 
cocaine within the washes suggested that less cocaine had entered the tissue and 
hence less intense staining is observed during immunohistochemical staining. Lowest 
concentrations of cocaine, benzoylecgonine, 6-MAM and morphine were detected in 
the centre of the tongue showing that the drugs penetrated the centre of the tongue 
following both routes of exposure.   
In a separate study the release of drugs from tongue tissue was investigated. Tongues 
were exposed to either 100 ng/mL or 1000 ng/mL of cocaine or heroin and then 
washed for 1 hour, 6 hours, 24 hours or 48 hours in artificial saliva with continuous 
mechanical stirring. Cocaine was detected for 24 hours post exposure whereas 
benzoylecgonine, 6-MAM or morphine were detected for up to 48 hours post 
exposure. This was in keeping with the immunohistochemical results of the 
transverse cross sections of the tongues which showed that positive staining was 
observed for up to 48 hours following exposure to cocaine or heroin at 
concentrations of either 100 ng/mL or 1000 ng/mL.  
To summarise, the work undertaken in this chapter showed that drugs have the 
ability to enter the oral tissue and form drug depots. Drugs which have previously 
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bound to tissue can subsequently be released over time and hence interfere with the 
interpretation of drug concentrations in oral fluid when investigating saliva:plasma 
ratios. However, the vast majority of oral fluid testing is carried out for two reasons 
a) under legislation that forbids the presence of drugs in oral fluid or b) as a check for 
drug compliance or abstinence. In both oral fluid testing procedures it is not 
necessary to identify whether the drug resulted from contamination, contribution 
from depots or from the salivary gland in which case the interpretation of oral fluid 
drug concentrations would not be affected by the work undertaken in this chapter.  
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Chapter 9.0- In Vivo and in vitro investigation into the detection of 
morphine in salivary gland and tongue tissue in mice using 
immunohistochemical staining techniques 
9.1 Introduction 
The in vitro investigation of opioid and cocaine distribution in porcine tongues 
(Chapter 7) discussed the application of an immunohistochemical technique to 
visualise the presence of opioids and cocaine in tongue tissue. The technique 
demonstrated extensive incorporation of drugs into tongue tissue that had previously 
been exposed to cocaine or heroin either via exposure to a solution of the drug or to 
simulated smoking. Results from work undertaken in Chapter 8 indicated that drugs 
which were administered orally either via smoke or solution, have the potential to 
enter the mouth tissue by mechanisms other than via the circulating blood thus 
providing support for a proposition that drugs can enter tissue via external 
contamination and may subsequently form depots in oral tissue from which they may 
be released over time.  
The challenge with any in vitro study is determining whether the propositions being 
tested would also be applicable in an in vivo model. The research described in this 
chapter investigated the application of the immunohistochemical staining method 
developed in chapter 7 on an in vivo model whereby mice were injected with 
morphine prior to removal of the tongue and subsequently comparing the result to in 
vitro mice tongues and salivary glands that were exposed to heroin smoke.  
The experiments described in this chapter aimed to investigate whether morphine can 
be detected in oral tissues (tongue and salivary glands) from circulating blood 
following entry into the body via peritoneal injection.  
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9.1.1 Anatomy of the mouse mouth: salivary glands 
Mice, like humans, have three main salivary glands – the parotid gland, the 
submandibular gland and the submaxillary gland. The histological structure of mouse 
salivary glands is similar to that in humans such that all glands consist of small acini, 
a structure consisting of small exocrine glands (Chapter 1, section 1.1.1.1.1).  Acini 
are made up of basophilic cytoplasm and large spherical nuclei.  Acinar excretion 
glands produce the saliva which is then excreted from an intercalated duct via the 
striated duct (excretory duct). The excretory ducts join up to form one single 
excretory duct via which saliva is excreted (Figure 9.1).  
 
Figure 9.1. Images showing the main structures including exocrine gland, blood 
vessels, ecretionary duct within mice salivary gland tissue  
 
Blood vessel 
Intercalated 
duct 
(excretionary 
duct) 
Septum 
Acini 
(exocrine 
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9.2 Materials and Methods 
9.2.1 Materials 
In vivo: Live mice and morphine solution used for the experiments were provided 
and conducted at the School of Physiology & Pharmacology, University of Bristol.  
In vitro: Frozen mice used for the exposure of tongues to simulated heroin smoking 
were obtained from Pets Corner, Pet supplies, Wallisdown, Bournemouth.  
For the purposes of staining for morphine in mouse salivary glands and tongues, a 
polyclonal morphine-3-glucuronide antibody (Ig-Innovations) was selected. This 
antibody was raised by repeated immunisation of sheep with purified antigen of 
interest and had been conjugated to keyhole limpet haemocyanin (KLH). KLH is a 
carrier protein responsible for carrying the antibody to the morphine. 
9.2.2 Methods 
9.2.2.1 Preparation of mice injected with morphine solution 
9.2.2.1.1 Dose calculation and preparation of mice  
Mice were divided into three groups each comprising of 6 mice as follows: a) a 
saline control group b) a group injected with a low dose of morphine and c) a group 
injected with a high dose of morphine. The three groups of mice averaged at 29.8 g, 
30.1 g and 30.3 g in body weight, therefore the average animal weight was taken to 
be 30 g. The intended dose for each group was 10 mg/kg for the low group and 30 
mg/kg for the high group with saline injections acting as a control.   
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The concentration of drug needed for injection was calculated with the animal 
weight, intended dose and volume of injecting in mind. The formula for calculating 
the volume of injection is summarised below: 
 
Volume of injection (mL) =  
animal weight (kg)×intended dose ( mg kg⁄ )
concentration of drug ( mg mL)⁄
  
 
The injection volume for all mice was 0.1 mL resulting with an injection 
concentration of 3 mg/mL of the low group of mice and 9 mg/mL for the high group 
of mice.  
 
9.2.2.1.2 Dissection 
Mice were killed humanely by cervical dislocation (Cook 1965) 30 minutes post 
injection prior to the removal of the tongue, submandibular, submaxillary and the 
parotid glands.  (Figure 9.2).  
 
Figure 9.2 shows the position of the individual salivary glands in mice (Cook 1965). 
For the purpose of this study the sub-lingual gland (a), parotid gland (b) and 
submaxillary gland (c) were removed.  
(a) 
(b) 
(c) 
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All glands are located in clusters below fat tissues and submandibular lymph nodes. 
Upon removing all fat tissues the salivary gland, the cluster becomes clearly visible. 
Following removal of salivary gland, teeth were removed from the oral cavity to 
allow for the removal of the mice tongues. Salivary glands and tongues were then 
fixed and processed for immunohistochemical analysis as described in section 
9.2.2.3.  
9.2.2.2 Preparation methods of mice tongues exposed to heroin smoke 
Tongues were removed from frozen mice (Pets at Home), after thawing, in the same 
manner as from live mice (section 9.2.2.1.2). Following removal, tongues were 
immediately suspended in the smoking chamber using micro fishing hooks (Figure 
8.3). Mice tongues were exposed to smoke from a 100 mg dose of heroin for either 
30 seconds or 60 seconds and then fixed immediately for further analysis using 
immunohistochemical methods.  
9.2.2.3 Immunohistochemical methods 
9.2.2.3.1 Fixation and Processing  
Mice salivary glands and tongues were placed into 10 % formalin immediately post 
removal from each animal in the case of injected mice or after exposure to heroin 
smoke in the smoke exposure experiment. In comparison to the porcine tongues, 
mice salivary glands and tongues were much smaller and were therefore only fixed in 
10 % formalin for 24 hours to avoid over-fixing of the tissue. Following complete 
fixation, samples were processed at Southampton Histochemistry Research Unit 
using the methods previously described in chapter 7.  
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9.2.2.3.2 Antibody selection 
Tissue used for the in vivo study originated from a mouse donor hence the use of the 
monoclonal antibodies employed in the porcine studies was not viable (Chapter 7, 
Chapter 8), since they had been raised as mouse monoclonal antibodies. The use of a 
mouse monoclonal antibody would result in a larger amount of non-specific binding 
as the secondary anti-mouse antibody can bind to endogenous mouse tissue and other 
compounds (Lu and Partridge 1998). Therefore the monoclonal antibody used in 
chapter 8 could no longer be used and a polyclonal antibody was sourced. The 
polyclonal antibody was a morphine-3-glururonide antibody. The Morphine-3-
glucuronide antibody had not yet been tested for the use in any particular technique 
and therefore needed to be titrated to establish the optimum antibody working 
concentration.  
9.2.2.3.3 Titration 
For the purposes of titration, one section of the salivary gland from each group (low 
and high dose of morphine and saline control) of mice was selected. A saline control, 
low and high concentration was exposed a range of dilutions of morphine-3-
glucuronide antibody as summarised in Table 9.1.  
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Table 9.1. Summary of dilution factor and working antibody concentration for the 
titration of the morphine-3-glucuronide stock antibody of 5mg/mL 
Neat antibody 
concentration  
Dilution factor 
Working antibody 
concentration 
5 mg/mL 
1 : 50 100 µg/ml 
1 : 100 50 µg/ml 
1 : 200 25 µg/ml 
1 : 400 12. 5 µg/ml 
1: 600 8.3 µg/ml 
1 : 800 6.25 µg/ml 
TBS Negative control  
 
9.2.2.3.3.1 Titration results 
All TBS controls were negative indicating that no non-specific binding had occurred. 
An optimum antibody concentration was observed at a dilution of 1 in 600 which 
resulted in a primary antibody concentration of 8.3 µg/ml. Lower dilution factors 
resulted in non-specific binding whereas a larger dilution factor resulted in staining 
with very little intensity. Results are summarised in Figure 9.3 and Figure 9.4.  
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Figure 9.3 Summarised visual results from antibody optimisation at different dilution 
factors from mice injected with a low (3 mg/mL) concentration of morphine 
(magnification x25) 
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Figure 9.4 Summarised visual results from antibody optimisation at different dilution 
factors from mice injected with a high (9 mg/mL) concentration of morphine 
(magnification x 25) 
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9.2.2.3.4 Secondary antibody 
The secondary antibody also had to be adapted to match the polyclonal antibody. As 
this antibody was raised in sheep, the secondary antibody selected was a biotinylated 
rabbit-anti-goat antibody (Dako). The secondary antibody was applied at a 
concentration of 2.67 µg/mL.  
9.2.2.3.5 Staining method 
The principle staining method in paraffin from Chapter 7 was adapted as a 
consequence of the nature of secondary antibody. As rabbit anti-goat can generate 
more non-specific binding, 1% of Tween 20 detergent was added to all TBS washes 
performed during the staining procedure. Tween 20 is designed to promote more 
effective washings as it promotes reagent spreading, resulting in a decrease of non-
specific background staining.  
Following blocking of endogenous peroxidases by applying a solution of 0.5 % 
hydrogen peroxide to the slides for 10 minutes, all slides were washed with TBS/ 
Tween 20 three times for two minutes. Slides were then drained and an avidin 
blocking solution was applied and incubated for 20 minutes each prior to washing 
with TBS / Tween 20 three times for two minutes. Biotin was then applied to all 
sections and incubated for 20 minutes. Together, the avidin and biotin blocking steps 
block all of the endogenous avidin and biotin binding sites which can be present in 
tissues and thus prevent non-specific binding at those sites.  
On completion of the avidin and biotin steps, a further wash step was performed 
three times for 2 minutes. The rabbit-anti-goat antibody had a tendency to cause non-
specific binding and therefore the Dulbecco’s Culture Medium (Chapter 6) was 
Validation of Oral fluid as a Matrix for Drug Detection – Chapter 9 
 
319 
 
ineffective to prevent non-specific binding. Instead of the Dulbecco’s culture 
medium, the slides were incubated in a 5% rabbit serum solution for 30 minutes. 
Following incubation with the primary antibody (in TBS containing 1% BSA) 
overnight at 4 ºC the slides were washed three times using TBS for five minutes. The 
slides were then drained and the biotinylated secondary antibody was applied at a 
concentration of 2.67 µg/mL and incubated for 30 minutes. Following another three 
washes for five minutes each, the avidin biotin-peroxidase complexes (ABC) were 
applied for 30 minutes before repeating the wash steps. The solution should only be 
used if a sufficient amount of time was given for these complexes to form.  Slides 
were then drained and the DAB substrate applied for five minutes. After rinsing in 
water for 5 minutes to remove the DAB, sections were counterstained with Mayer’s 
haematoxylin before being washed in running tap water.  
Finally sections were dehydrated through graded alcohols, cleared in clearene solvent 
(Leica Biosystems) and mounted in Pertex. The method is summarised in Figure 9.5.  
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Block endogenous biotin by incubating slides for 10 minutes using methanol 
containing 0.5 % hydrogen peroxide
Wash sections using TBS containing 1% Tween 20 three times for 2 minutes
Apply avidin block for 20 minutes
Wash sections using TBS containing 1% Tween 20 three times for 2 minutes
Apply biotin block for 20 minutes
Wash sections using TBS containing 1% Tween 20 three times for 2 minutes
Apply 5% rabbit serum for 30 minutes 
Apply primary/isotype antibody at appropriate dilutions (containing 1% BSA) and 
incubate at 4°C overnight
Wash sections using TBS containing 1% Tween 20 three times for 5 minutes
Apply secondary antibody for 30 minutes
Wash sections using TBS containing 1% Tween 20 three times for 5 minutes
Apply ABC complex for 30 minutes
Wash sections using TBS containing 1% Tween 20 three times for 5 minutes
Apply DAB for 5 minutes
Wash sections under Tap water
Counterstain using Mayer's Haemotoxylin reagent
Dehydrate using ethanol and clearene
Mount coverslips using pertex
 
Figure 9.5 Summary of immunohistochemical staining method for the detection of 
morphine in mouse tissue samples embedded in GMA resin 
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9.3 Results and Discussion 
9.3.1 Results mice injected with a saline solution  
Six mice which were injected with a saline solution to act as a negative control, did 
not result in any positive brown staining confirming a lack of non-specific binding 
(Figure 9.6). A full set of images for each of the mice is available in Appendix D.  
Mouse tongue (magnification x10 ): Mouse salivary gland (magnification x 25): 
  
Figure 9.6. Image showing the negative staining in salivary glands in mice which 
were injected with a saline solution to act as a control  
 
9.3.2 Results from salivary glands and tongues from mice injected with a low 
dose (3 mg/mL) of morphine 
9.3.2.1 Mice Tongues 
Specific staining was observed in tongues from mice injected with a low 
concentration of morphine. Clear staining was observed around the connective tissue, 
and in all muscle tissue (Figure 9.7, Figure 9.9, Figure 9.10, Figure 9.11, Figure 9.12, 
Figure 9.12). Staining was uniform throughout the section with no visual difference 
observed in the intensity of staining between the outside of the muscle tissue to the 
centre of the tongue.  
Blood vessel  
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Figure 9.7 Images of stained slides of a mouse tongue from mice injected with a 
3mg/mL (low) dose of morphine using an immunohistochemical technique  (Mouse 
1 of 6) (magnification x10) 
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Figure 9.8 Images of stained slides of a mouse tongue from mice injected with a 
3mg/mL (low) dose of morphine using an immunohistochemical technique  (Mouse 
2 of 6) (magnification x10) 
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Figure 9.9 Images of stained slides of a mouse tongue from mice injected with a 
3mg/mL (low) dose of morphine using an immunohistochemical technique (Mouse 3 
of 6) (magnification x10) 
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Figure 9.10 Images of stained slides of a mouse tongue from mice injected with a 
3mg/mL (low) dose of morphine using an immunohistochemical technique  (Mouse 
4 of 6) (magnification x10) 
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Figure 9.11 Images of stained slides of a mouse tongue from mice injected with a 
3mg/mL (low) dose of morphine using an immunohistochemical technique  (Mouse 
5 of 6) (magnification x10) 
 
 
 
 
 
 
 
 
 
Validation of Oral fluid as a Matrix for Drug Detection – Chapter 9 
 
327 
 
  
  
Figure 9.12 Images of stained slides of a mouse tongue from mice injected with a 
3mg/mL (low) dose of morphine using an immunohistochemical technique (Mouse 6 
of 6) (magnification x10) 
 
 
Staining was observed throughout the sections and at a higher power (x 63) visual 
analysis it was observed that morphine was present throughout the tongue tissue 
penetrating the muscle bundles fully (Figure 9.13).  
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Figure 9.13. Image showing staining in muscle bundles of mice tongues following 
injection of mice with a low (3 mg/mL) dose of morphine (magnification x63) 
 
The epithelium was stained positively on the outside of the tongue; however it 
showed negative staining on the inside of the epithelium in all six mice which were 
injected with a low concentration of morphine. Staining of the epithelium in porcine 
tongue, showed areas of non-drug staining that were attributed to the epithelium rate 
of repair and renewal of tissue in response to abrasion in the mouth (Chapter 8). A 
similar pattern of staining was also observed in mouse tongue tissue (Figure 9.14). 
Light positive staining was also observed in the blood vessel walls indicating that the 
drug travelled from the blood through the blood vessel wall into the tissue.  
Nuclei  Muscle fibre  
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Figure 9.14. Image shows a stained section of mouse tongue following injection of 
low dose morphine (3 mg/ml). Negative staining on the "inside" of the epithelium is 
clearly illustrated as also observed in porcine tongues (magnification x25) 
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9.3.2.2 Salivary glands 
Following injection of 3 mg/mL of morphine, all three salivary glands resulted in 
positive staining for morphine (Figure 9.15, Figure 9.16, Figure 9.17, Figure 9.18, 
Figure 9.19, Figure 9.20).  
  
Figure 9.15 Images of stained slides of mice salivary glands injected with a 3 mg/mL 
(low) dose of morphine (Mouse 1 of 6) (magnification x10) 
 
  
Figure 9.16 Images of stained slides of mice salivary glands injected with a 3 mg/mL 
(low) dose of morphine (Mouse 2 of 6) (magnification x10) 
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Figure 9.17 Images of stained slides of mice salivary glands injected with a 3 mg/mL 
(low) dose of morphine (Mouse 3 of 6) (magnification x10) 
 
  
Figure 9.18 Images of stained slides of mice salivary glands injected with a 3 mg/mL 
(low) dose of morphine (Mouse 4 of 6) (magnification x10) 
 
  
Figure 9.19 Images of stained slides of mice salivary glands injected with a 3 mg/mL 
(low) dose of morphine (Mouse 5 of 6) (magnification x10) 
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Figure 9.20 Images of stained slides of mice salivary glands injected with a 3 mg/mL 
(low) dose of morphine (Mouse 6 of 6) (magnification x10) 
 
Staining was present in parotid, submandibular and sublingual gland. Although the 
composition of the glands differ slightly, applying the immunohistochemical 
technique resulted in staining in the intercalated and interlobular ducts as well as the 
blood capillaries and vessel in each gland. However, no staining could be detected in 
the acini of each of the glands (Figure 9.21).  
 
Figure 9.21. Image showing the positive staining about the excretion ducts and blood 
vessels following an injection of 3 mg/mL of morphine (magnification x63) 
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9.3.3 Results from salivary glands and tongues from mice injected with a high 
dose (9 mg/mL) of morphine 
9.3.3.1 Tongues 
Significant positive staining was also observed following a much higher dose of 9 
mg/mL. In comparison to the tongues from the mice injected with the low 
concentration of morphine, the tongues from the higher concentration showed 
staining that was more intense in colour. All six mice showed positive staining in 
tongue tissue following an injection of 9 mg/mL of morphine (Figure 9.22, Figure 
9.23, Figure 9.24, Figure 9.25, Figure 9.26, Figure 9.27).  
  
  
Figure 9.22 Images of stained slides of a mouse tongue injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 1 of 6) 
(magnification x10) 
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Figure 9.23 Images of stained slides of a mouse tongue injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 2 of 6) 
(magnification x10) 
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Figure 9.24 Images of stained slides of a mouse tongue injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 3 of 6) 
(magnification x10) 
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Figure 9.25 Images of stained slides of a mouse tongue injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 4 of 6) 
(magnification x10) 
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Figure 9.26 Images of stained slides of a mouse tongue injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 5 of 6) 
(magnification x10) 
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Figure 9.27 Images of stained slides of a mouse tongue injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 6 of 6) 
(magnification x10) 
 
 
When the drugs are visualised with a higher powered microscope (x63) it can be 
observed that the drug penetrated the muscle bundles fully (Figure 9.28). Staining 
was intense in colour suggesting high concentrations of morphine present in the 
muscle.   
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Figure 9.28. Image showing staining in muscle bundles following injection of mice 
with a 9 mg/mL dose of morphine (magnification x63) 
 
Tongues from mice that had been injected with a 9 mg/mL of morphine showed a 
similar effect to the one injected with a 3 mg/mL in that the epithelium showed a 
negative stain on the inside (muscle side). The staining on the outside of the 
epithelium is stained more intensely than in the low dosed mice tongues. Staining 
can also be observed in the blood vessel walls (Figure 9.29).  
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Figure 9.29. Image shows a stained section of mouse tongue following a high dose 
injection of morphine. This picture highlights negative staining on the "inside" of the 
epithelium and positive staining in the blood vessels (magnification x25) 
 
9.3.3.2 Salivary glands 
Following injection of 9 mg/mL of morphine, all three salivary glands resulted in 
positive staining for morphine (Figure 9.30, Figure 9.31, Figure 9.32, Figure 9.33, 
Figure 9.34, Figure 9.35). Staining observed was more intense in colour than in 
salivary glands which originated from mice injected with a lower dose of morphine.  
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Figure 9.30 Images of stained slides of mice salivary glands injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 1 of 6) 
(magnification x10) 
  
Figure 9.31 Images of stained slides of mice salivary glands injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 2 of 6) 
(magnification x10) 
  
Figure 9.32 Images of stained slides of mice salivary glands injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 3 of 6) 
(magnification x10) 
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Figure 9.33 Images of stained slides of mice salivary glands injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 4 of 6) 
(magnification x10) 
  
Figure 9.34 Images of stained slides of mice salivary glands injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 5 of 6) 
(magnification x10) 
  
Figure 9.35 Images of stained slides of mice salivary glands injected with a 9 mg/mL 
(high) dose of morphine using an immunohistochemical technique (Mouse 6 of 6) 
(magnification x10) 
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Mice injected with a low dose of morphine, salivary glands obtained from mice 
injected with a higher dose of 9 mg/mL of morphine resulted in staining in the 
intercalated and interlobular ducts as well as the blood vessel. However, no staining 
was observed in the acini of any of the salivary glands (Figure 9.36).  
 
Figure 9.36. Image showing the positive staining about the excretion ducts and blood 
vessels following an injection of 9 mg/mL of morphine (magnification x63) 
 
9.3.4 Summary of in vivo study results 
The morphine-3-glucuronide polyclonal antibody was a suitable antibody for the use 
as a stain to visualise the presence of drugs in mouse tissues. Binding was specific 
for morphine and TBS controls did not show any staining. Mice injected with a 
saline solution acted as a second control and did not result in any positive brown 
staining.  
In the low (3 mg/mL) and the high (9 mg/mL) morphine dose group, significant 
staining could be observed in the tongue tissue. Tongues showed staining in the 
muscle bundles and blood vessels. As mice were injected with morphine, no external 
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oral contamination occurred. Therefore positive staining for morphine can only have 
originated via diffusion from the blood into muscle tissue.  
In both concentration groups the epithelium had a negative stain on the inside layer. 
The epithelium in the mouth is continuously exposed to abrasions. Therefore, it has a 
fast rate of repair, which results in a constant reproduction of cells on the inside layer 
of the tongue to repair the damaged cells. This is seen as a dense layer of nuclei in 
developing tissue. Nuclei did not stain positive and therefore a large amount of 
nuclei on the inside layer of developing epithelium cells creates the appearance of 
total negative stain.  
As mice were killed 30 minutes post injection, drug may have entered the saliva 
during that time from the surrounding blood and that re-absorption could have 
occurred from excreted saliva.  
When tissue sections were examined using a magnification of x63, it was observed 
that following injection of a low dose of morphine the staining within the muscle 
bundle was less intense than the staining in mice that were injected with a higher 
dose, suggesting that more drug has penetrated into the muscle and bound to the 
tissue (Figure 9.37, Figure 9.38).   
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Figure 9.37 Images representing morphine penetration into the tissue following a 3 
mg/mL (low dose) of morphine in live mice (magnification x63) 
 
  
Figure 9.38 Images representing morphine penetration into the tissue following 9 
mg/mL (high) dose of morphine in live mice (magnification x63) 
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The higher the dose consumed, the more likely drug depots are in oral tissues and 
suggests that when drugs travel further into tissue, it subsequently takes longer for 
the drug to be released / eliminated from the tissue.   
Additionally staining for morphine was observed in the blood vessel walls for both 
concentration groups, indicating that the drug travels through the blood vessel walls 
to the connective and muscle tissue. In comparison, in chapter 8.2 it was shown that 
when oral contamination occurred through external contact such as solution or 
smoking the blood vessel walls are negative and hence to do not penetrate the blood 
vessels and migrate into the blood.  
The parotid, submandibular and submaxillary glands were successfully removed 
from the mice and the immunohistochemical method applied to salivary glands. 
Opioid staining was observed in all three salivary glands for mice injected with either 
3 mg/mL (low) or 9 mg/mL (high). Staining was present in the excretory ducts as 
well as the blood vessels. However, no staining could be observed in the acini of the 
salivary glands. Acini are the secretory units mainly consisting of epithelial cells.  
The presence of morphine in the salivary ducts strongly supports a  hypothesis that 
drug is excreted from the salivary gland during production and excretion of saliva 
into the oral cavity hence contributing to the elevated drug concentrations observed 
in oral fluid.  
9.3.5 Exposure or mice tongues to smoke produced from heating 100 mg 
heroin  
Mice tongues were exposed to smoke produced by heating 100 mg of heroin. In 
comparison to the porcine tongues (Chapter 7), mice tongues were only exposed to 
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the smoke for 30 seconds and 60 seconds in order to prevent overheating and hence 
deterioration of the tissue as tongues were significantly smaller in size. 
Two tongues were exposed to heroin smoke for 30 seconds. Both tongues showed 
significant staining within the tissue; however staining appeared to be weak which 
was noticeable in the muscle and the epithelium (Figure 9.39, Figure 9.40).  
 
  
  
Figure 9.39 Images show the staining in mice tongues exposed to smoke from 100 
mg of heroin for 30 seconds (Tongue 1 of 2) (magnification x10) 
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Figure 9.40 Images show the staining in mice tongues exposed to smoke from 100 
mg of heroin for 30 seconds (Tongue 2 of 2) (magnification x10) 
 
 
When examining the tissue sections which were exposed to heroin smoke at a 
magnification of x 63, it was observed that the muscles bundles were fully penetrated 
(Figure 9.41). However, staining was weak, indicating that little drug was present 
within the bundles.  
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Figure 9.41. Image showing the staining in mice tongues following the expose to 
smoke from a 100 mg dose of heroin (magnification x63) 
 
Tongues exposed to smoke from a 100 mg dose of heroin for 60 seconds showed a 
greater density of staining in comparison to tongues exposed for 30 seconds (Figure 
9.42, Figure 9.43). Staining was observed throughout the entire cross section of the 
tongue.  
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Figure 9.42 Images show the staining in mice tongues exposed to a dose of 100 mg 
heroin smoke for 60 seconds (Tongue 1 of 2) (magnification x10) 
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Figure 9.43 Images show the staining in mice tongues exposed to a dose of 100 mg 
heroin smoke for 60 seconds (Tongue 2 of 2) (magnification x10) 
 
 
When visualising the sections at a magnification of x 63, staining was intense and 
muscle bundles were fully penetrated. This suggested that the significant amount of 
drug travelled into the muscle bundles (Figure 9.44). The staining pattern indicates 
that drug depots can be formed within tissue and that dose and exposure time can 
contribute to the amount of drug incorporation into tissue.  
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Figure 9.44. Image showing the staining in mice tongues following the exposure to 
smoke from a 100 mg dose of heroin for 60 seconds (magnification x63) 
 
When the tongues were exposed to smoke from heating 100 mg of heroin for 60 
seconds, the epithelium was fully saturated with drug and in comparison to mice 
which were injected with morphine, no negative staining was observed on the inside 
of the epithelium (Figure 9.45).   
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Figure 9.45.  Image showing the staining in epithelium of mice tongues following the 
exposure to smoke from a 100 mg dose of heroin for 60 seconds (magnification x25) 
 
Tissue exposed to smoke under conditions that simulated smoking showed that 
heroin can fully penetrate mice tongues. Tongues exposed for 30 seconds only 
showed weak staining whereas tongues exposed for 60 seconds showed intense 
staining. The intensity of staining following smoking of heroin was similar to that of 
mice injected with a high dose of morphine (Figure 9.46).  
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Figure 9.46. Images comparing staining in a stained tongue section from mice 
injected with a high dose of morphine (9 mg/mL) (left image) and a low dose of 
heroin smoke (100 mg) (right image) (magnification x63) 
 
Morphine has a volume of distribution of between 3 - 5 L/kg. Heroin is more 
lipophilic than cocaine resulting in a much higher estimated volume of distribution of 
heroin 25 L/kg (Moffat et al 2011, Urso et al, 2012). The higher the volume of 
distribution the larger the amount of drug which travels into the tissue offering an 
explanation  why a low dose of smoked heroin resulted in similar staining to a high 
injected dose of morphine.  
9.4 Conclusion 
The research described in this chapter showed that the proposition tested in the in 
vitro studies in chapter 7 and chapter 8 is also applicable in this in vivo study.  
Morphine administered to mice via peritoneal injection at concentrations of 3 mg/mL 
and 9 mg/mL was demonstrated to enter into tongue and salivary gland tissue. In 
comparison to porcine tongues exposed to external contamination in vitro, drug was 
detected in the walls of the blood vessel suggesting it diffuses from the blood into the 
tissue. The presence of drug was shown in all tongues as well as in the parotid, 
submandibular and submaxillary gland. The presence of morphine in the excretion 
ducts of the salivary glands, strongly supports  a hypothesis that drug can enter the 
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salivary glands and be excreted simultaneously to saliva. This is a major source for 
oral fluid drug concentrations that do not rely on oral contamination such as 
intravenous, intramuscular, trans-dermal and suppository.  
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Chapter 10.0  -  Discussion and Conclusion 
Oral fluid is gaining popularity as a matrix for drug testing as it is relatively simple 
and quick to collect and is non-invasive. Testing procedures for on-site and 
laboratory screening are inexpensive and no specially trained personnel are required 
for the collection of oral fluid. 
Oral fluid sampling is commonly used in the workplace, hospitals and drug treatment 
programmes. Recently, countries such as Germany, Belgium, Holland, France, 
Spain, Italy and Australia have adopted oral fluid sampling at the roadside as a 
preliminary drug screening method. In the United Kingdom, the Road Traffic Act 
1988, Section 5A was amended to allow police officers to employ roadside testing 
devices although this requires devices to have met Type Approval (Department for 
Transport 2014). The first device for testing within police stations, the Draeger Drug 
Test 5000, was approved in December 2012 for tetrahydrocannabinol (THC) only 
(Home Office 2013). The implementation of a point of care (PoC) testing system 
enables an inexpensive and rapid way to obtain a preliminary result at the roadside. 
The UK government is now planning to introduce oral fluid collection on the 
roadside as an initial screening by the autumn 2014, later followed by evidential 
testing on a blood sample. Whilst PoC testing systems are not suitable for evidential 
drug testing, they can act as an aid for law enforcement, supporting a Police Officer’s 
Drug Recognition test.  In March 2014 the UK Department for Transport approved 
and published drug driving limits for 16 drugs including 8 illicit drugs and 8 
prescription drugs in blood. The new drug driving limits means that it is an offence 
to drive over the recommended limit for each drug rather than relying on police 
officers to prove impairment due to a drug in order to achieve a conviction 
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(Department of Transport 2014). The embryonic issue facing the UK system is the 
assumption that a drug positive oral fluid screen will always result in a drug positive 
blood sample. Type approval for roadside screening for oral fluid cocaine has been 
set at 30 ng/mL whilst the recommended threshold limit in blood (without alcohol 
present) is 80 ng/mL (Home Office 2012). The saliva:plasma concentration ratio for 
cocaine is generally accepted to be 3 which would indicate that using blood as a 
confirmation method, would need a threshold of 90 ng/mL or an oral fluid cut off at 
240 ng/mL. The work presented in this thesis has shown the potential contribution of 
drug from tissues -  depending on route of administration, this will contribute to a 
better understanding in modifying these cut offs. In addition to roadside drug testing, 
the potential build-up of drugs in the oral tissue can affect workplace drug testing as 
well as testing as part of drug treatment centres. The vast majority of oral fluid 
testing is carried out for two reasons: a) under legislation that forbids the presence of 
drugs or b) as a check for drug compliance or abstinence. For both of these 
processes, it is not relevant where the drug has come from, just that the drug is 
present.  
Oral fluid drug testing is based on three main processes i.e. 1) oral fluid collection, 2) 
immunoassay screening and 3) confirmatory analysis of immunoassay positive 
samples. For oral fluid collection, numerous collection systems are commercially 
available. One of the questions raised in this thesis was whether the testing systems 
are affected by common foods, beverages and oral hygiene products and whether 
those can result in false results during the testing process (Chapter 3). Most 
manufactures recommend that the effect of foods and beverages have dispersed from 
the mouth after 10 -15 minutes following exposure and that after this time an oral 
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fluid sample can be collected with a minimum risk of contamination. These effects 
were investigated on the Orasure Intercept and AlereTM Certus collection devices.  
The Orasure Intercept device yielded several positive results in combination with its 
matched immunoassay screen (the Orasure Microplate system), which were 
confirmed to be false positives when analysed by GC-MS.  Coffee, Coca Cola, fruit 
juice, oranges, spicy food and toothpaste were all capable of interfering with the 
Orasure testing system, whereas no interferences were observed with the AlereTM 
Certus collector and associated immunoassay screen. The Orasure false positives 
appeared immediately post consumption and no positives were observed 10 minutes 
post consumption of each substance (Table 3.4). Therefore, when adhering to the 
manufacturing guidelines most of the substances tested should not interfere with the 
oral fluid drug test systems when collected 10 - 15 minutes post 
consumption/exposure.  
This general guideline was invalidated when vinegar was tested. Vinegar resulted in 
numerous false positives in samples collected with the Orasure Intercept device for 
up to 30 minutes post exposure to malt, distilled, balsamic, red and white wine 
vinegars. Vinegar was shown to interfere with the Orasure Microplate testing system 
for methamfetamine, amfetamine and cocaine. No false positives were observed 
when oral fluid was analysed on the methadone or opiate assays. Although no false 
positives were observed after 30 minutes post exposure, the percentage binding was 
still shown to be significantly depressed for methamfetamine, amfetamine and 
cocaine for up 75 minutes post exposure. Similarly, although no opiate and 
methadone positive were observed on the Orasure Microplate testing system, a 
depression of the percentage binding of up to 50% could still be observed for 
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samples up to 75 minutes post collection (Table 3.5). Although results were all still 
above the recommended manufacturer’s cut off for percentage binding, depressed 
binding can still affect the concentration detected and hence also interfere with the 
interpretation of the results. Vinegar was the most acidic of the substance tested and 
it is possible that the buffer capacity of the Orasure device is too low as the Orasure 
device yielded a much larger dilution factor range with the largest being 1 in 81 and 
the lowest 1 in 1.5. This indicated that the pH of the oral fluid samples can interfere 
with the Orasure Intercept system and hence affect the interpretation of results. 
Therefore, for the purpose of investigating drug depots during this thesis, the AlereTM 
Certus collector were used as it did not yield any false positives following the 
exposure to foods, beverages and oral hygiene products.  
Elevated drug concentrations have been reported in combination with contamination 
of the mouth as a result of the exposure of drugs to the oral cavity during 
consumption. Literature information is limited on elevated drug concentrations as a 
result of drug depots and length of detection window. During the investigation into 
concentrations of cocaine and its metabolites in oral fluid following consumption of 
coca tea, concentrations for cocaine and its metabolites were above a recommended 
SAMHSA cut off (8 ng/mL) and were observed for up to 60 minutes post 
consumption of coca tea (Table 4.3, Table 4.4, Table 4.7). The detection of elevated 
concentrations for cocaine and its derivatives over the course of an hour supports the 
proposition that drug depots can be formed within mouth tissues. In addition to 
cocaine, benzoylecgonine and ecgonine methyl ester, cocaethylene and the pyrolysis 
product anhydroecgonine methyl ester were also identified and quantified following 
the consumption of coca tea. Cocaethylene is only formed when cocaine and ethanol 
are consumed simultaneously (Table 4.9, Table 4.10).  
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 The presence of cocaethylene in oral fluid samples collected over the course of one 
hour following the consumption of coca tea was randomly distributed and therefore 
could not be explained by alcohol consumption (Table 4.9). Samples were therefore 
reanalysed one year post collection of coca tea oral fluid samples.  During the second 
analysis, no cocaethylene positives were observed in any of the oral fluid samples 
collected. This could be explained by a potential instability of cocaethylene in oral 
fluid. Studies in the literature only report stability in oral fluid at -20 °C for up to 6 
months (Clauewaert et al 2004). Stability of cocaethylene in oral fluid for a longer 
time period has not been reported in the literature and should be researched further. 
A secondary cause for the presence of cocaethylene could be the presence of 
esterases in oral fluid such as cholinesterases, pseudocholisterase and cholesterol 
esterase. Cocaethylene can be formed by the transesterfication of cocaine and hence 
has the potential to be formed by the esterases present in oral fluid. However, 
although the presence of esterases in oral fluid has been reported in the literature, the 
effects on cocaine and its potential formation to cocaethylene have not yet been 
reported.  
In addition to cocaethylene, anhydroecgonine methyl ester was also quantified during 
the investigation into concentrations of cocaine and its derivatives in oral fluid 
following the consumption of coca tea (Table 4.10). Anhydroecgonine methyl ester 
is a pyrolysis product of smoking crack cocaine as it is formed by the thermal 
degradation of cocaine. Although it has been reported to be present in some species 
of the Erythroxylum coca, similarly to cocaethylene, the presence of 
anhydroecgonine methyl ester positives was randomly distributed throughout 
collected samples. This indicated that positive samples did not result from the 
presence of anhydroecgonine methyl ester within the coca leaf as the results would 
Validation of Oral Fluid as a Matrix for Drug Detection – Chapter 10 
 
361 
 
be less random and instead be detected throughout each volunteers 60 minute 
collection timeline. Additionally, the production of anhydroecgonine methyl ester as 
a result of thermal degradation of cocaine by boiling of the leaf during preparation of 
coca tea could also be disregarded as a cause for the presence of anhydroecgonine 
methyl ester in oral fluid samples. If anhydroecgonine methyl ester was produced as 
an artefact throughout the production of coca tea, again the positives would have 
been expected to appear at a less random pattern.  
When samples were reanalysed one year post collection of the oral fluid samples, the 
amount of anhydroecgonine methyl ester positives increased significantly (Table 
4.11). This indicated that anhydroecgonine methyl ester was formed during storage 
of oral fluid samples which were collected following the consumption of coca tea. 
There is no information available on the stability of anhydroecgonine methyl ester in 
oral fluid neither is there any information on the stability of coca tea. Therefore more 
research should be undertaken to investigate the formation of anhydroecgonine 
methyl ester and its stability further.  
The investigation into concentrations of cocaine and its derivatives strongly 
supported the hypothesis that drugs consumed orally either via solution (tea), smoked 
or snorted can result in elevated concentration of drug in oral fluid. This information 
needs to be kept in mind depending on the application to which the result is being 
applied. In order to further research the effects of oral deposition of drugs and the 
effects it has on its subsequent collection and analysis of oral fluid, research was 
undertaken to investigate the concentrations of opiates following swirling of codeine 
linctus and Collis Browne’s solution. In the work undertaken for this thesis, high 
concentrations of opiates were observed in oral fluid following the swirling of either 
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of the two solutions. Both, Codeine Linctus and Collis Browne’s solution were 
discarded from the mouth following swirling (without swallowing) and therefore 
concentrations can be explained by oral contamination rather than originating from 
blood to saliva gland transfer. Elevated concentrations were observed for up to 3 
hours post exposure to either of the both solution. Previous studies in the literature 
have reported oral deposition to affect the correlation between saliva and blood 
concentrations for 30 to 60 minutes post consumption (Bosker and Huestis 2009). 
The research undertaken in this thesis clearly indicates that drugs which are exposed 
to the oral cavity as a solution have the potential to contribute to oral fluid drug 
levels for up to three hours post exposure (Table 5.2, Table 5.3).  
Additionally, results indicated that a large amount of cavities can increase the 
deposition through when drugs are consumed orally via solution. The principle of 
contamination suggests that the drug solution can linger in the cavities within the 
mouth in addition to the increased presence of drug in the oral mucosa. Only one 
volunteer who participated in the Collis Browne’s / Codeine Linctus exposure study 
had reported to have a large amount of dental work and cavities. A large increase in 
opiate concentration, in comparison to volunteers with less dental work, was 
observed in samples collected from this volunteer. Although the validity of data from 
one volunteer being different to that from the other subjects is questionable, results 
suggest that increased oral fluid concentrations can be observed following exposure 
to a drug solution especially in volunteers with large amounts of cavities. This 
strongly supported the hypothesis that drugs can accumulate in oral tissues, however 
the effects of such a build-up of drug on the oral fluid collection has not yet been 
widely investigated. When oral fluid is collected, the collection device is placed in 
the mouth according to each manufacturer’s instructions. In addition to trace 
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amounts of lipids and proteins, oral fluid contains food residues and cellular debris. 
Drug depots in oral tissue could lead to an increased amount of drug within the 
cellular debris and hence result in elevated drug concentrations in oral fluid. 
However, when oral fluid collectors were scraped firmly around the oral cavity 
during oral fluid collection following exposure to Collis Browne’s mixture or 
Codeine Linctus, no significant increase in opiate concentration were observed in 
comparison to samples which were collected according to the manufacturer’s 
collection instructions (Figure 5.6).  
The investigation of elevated drug concentrations in oral fluid following 
administration via snorted, smoked or oral routes has the potential to accumulate 
drugs in mouth tissues. Elevated drug concentrations can be observed following the 
consumption of coca tea (Chapter 4) and Codeine Linctus and Collis Browne’s 
(Chapter 5).  Both studies strongly support the hypothesis that oral deposition can 
occur when drugs are consumed orally i.e. via solution.  
In addition to deposition by external drug consumption, the hypothesis that 
microbleeding of the gums could contaminate the oral fluid was raised in this thesis. 
As a result of the microbleeding, drug may be released into oral fluid and potentially 
interfere with the interpretation of oral fluid drug concentrations. (Chapter 6). During 
the investigation into the effects of microbleeding on oral fluid drug detection, 
transferrin was utilised as a marker for microbleeding. The study looked to determine 
whether increased microbleeding correlates to elevated drug concentrations. 
Transferrin is a large blood glycoprotein (molecular weight 80,000) that transports 
iron. It would not normally be present in oral fluid, (trace amounts) and hence is a 
useful marker for blood presence in saliva.  
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The research undertaken showed that there was no relationship between transferrin 
concentration and drug concentrations. Additionally, microbleeding did not result in 
an immediate increase in oral fluid drug concentration when bleeding was stimulated 
following the consumption of 15 mg of codeine.  These results can be explained 
when considering that only minute amounts of drug would leak into oral fluid during 
microbleeding. Assuming that the average microbleed is between 5 µL to 20 µL, the 
quantity of drug entering into oral fluid would be minimal in comparison to the 
concentration detected in oral fluid following codeine consumption. When applying 
the average S/P ratio of 3.32 to the average plasma concentration reported following 
a dose of 30 mg/mL, it results in the quantity of drug being released into the oral 
fluid to range between 0.17 ng and 0.68 ng (Scharp et al 1983, Schramm et al 1992, 
Cone 1993, O’Neal et al 1999, Kim et al 2002). This amount is insignificant when 
considering the much higher concentration of 250 ng/mL of opiates at three hours 
post consumption on one 15 mg dose of codeine. Therefore when considering both 
the results from the drug clinics and the results from the controlled codeine exposure 
study, microbleeding can be excluded to be a contributing factor to elevated drug 
concentrations.  
The work undertaken in chapters 4 and 5 demonstrated that drugs which can be 
consumed orally, i.e. coca tea, Collis Browne’s solution or Codeine Linctus can 
contribute to the oral fluid concentration and hence influence the interpretation of 
results.  With elevated concentrations reported for up to one hour following the 
consumption of coca tea and four hours following the consumption of Codeine 
Linctus or Collis Browne’s, the question of  how deep drugs can penetrate into the 
tissue and whether there are subsequently released over time was  investigated.  
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The work undertaken in this thesis successfully showed the development of an 
immunohistochemical method for the detection and visualisation of cocaine, heroin 
and their metabolites. The immunohistochemical method utilised an antigen-antibody 
detection system and was successfully developed for cocaine and heroin in porcine 
and mouse tissue. The immunohistochemical method (Chapter 6) was applied to 
visualise drugs in in vitro and in vivo tissue.  Porcine tongues exposed to a range of 
concentrations of cocaine or heroin showed that the presence of drug was observed 
following tissue exposed to concentrations ranging between 100 ng/mL and 10 
µg/mL.  The immunohistochemistry revealed that the degree of drug entry was 
concentration dependent. Staining in tongues which were exposed to cocaine was 
weaker in intensity in comparison to that of heroin. Heroin is more lipophilic than 
cocaine resulting in a much higher estimated volume of distribution of heroin (~ 60 – 
100 L/kg) in comparison to the volume of distribution of cocaine (~ 1 – 3 L/kg) 
(Moffat et al 2011, Urso et al, 2012). The higher the volume of distribution, the more 
the  drug which travels into the tissue, which is clearly supported by the result of the 
immunohistochemical staining.  This is further supported when comparing the logP 
value for cocaine and heroin. Heroin has a much lower logP value suggesting that the 
drug distributes more freely into the tissue than cocaine.  
No staining was observed in the blood vessel walls of the treated porcine tongue 
sections following external exposure to cocaine or heroin solution indicating that the 
drugs do not cross the blood vessels walls and hence would not elevate blood 
concentrations. Of note was the staining around the epithelium in porcine tongue 
tissue. The epithelium showed positive staining on the outside layer. However the 
inside of the epithelium (closest to the muscle) the staining appeared to be negative. 
This is yet to be explained but the hypothesis is that this is a result to the epitheliums 
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fast rate of repair and renewal of tissue in response to abrasions in the mouth which 
results in a cluster of nuclei around the inside layer of the epithelium. A high 
concentration of nuclei in close proximity to each other resulted in a negative 
appearance for cocaine or heroin.  
The presence of cocaine and heroin in tissue suggests that they have the ability to 
enter into and subsequently bind to tissue to form depots which can subsequently be 
released over time. This also indicates that drugs can enter the oral fluid by 
mechanisms other than via the surrounding blood.  
In addition to immunohistochemical analysis, the artificial saliva washes and 
homogenates of tongues were analysed using LC-MS. Positive results of artificial 
saliva washes from tongues exposed to cocaine concentrations showed that the 
presence and concentration of cocaine and its metabolite benzoylecgonine increased 
with increasing concentration. No cocaine or benzoylecgonine were detected in 
washes from tongues which were exposed to the lowest concentration of 100 ng/mL 
of cocaine. With the exception of the highest exposure dose of 10 µg/mL of cocaine, 
washes were negative by the last wash, suggesting that all external contamination 
had been removed. When relating the analytical results to the immunohistochemical 
staining, it was noted that although no drug was detected during the wash steps, 
significant staining was still observed in tongues.  The positive staining suggested, 
that cocaine had entered and bound to the tongue tissue to form a depot and could 
subsequently be released over time.  
In comparison to cocaine, heroin was not detected throughout the washes and 6-
MAM and morphine were only detected in washes 1 and 2 following exposure to 
1000 ng/mL or 10 µg/mL. In comparison to the analytical results, 
immunohistochemical results of tongues exposed to heroin solutions showed 
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significant staining in all tongue tissue. This indicated that although no drug is being 
released during the wash steps, drug is still present within the tissue and has hence 
bound to the oral tissue from where it subsequently could be released over time. 
Tongues were washed during the work undertaken in this chapter as in the mouth 
saliva is constantly renewed and oral tissue washed with new fresh saliva at an 
average rate of 0.5 mL/min to 1 mL/min. The results support the hypothesis that 
some drug had loosely bound to the tongue surface which was gently and 
progressively removed, potentially leaving significant binding and transfer to the 
tissue itself.    
Furthermore, a section from each tongue was removed at the end of the seventh wash 
step for homogenisation and analysis using LC-MS. The transverse cross section was 
divided into five parts (Chapter 7). Cocaine and benzoylecgonine were detected in all 
homogenates from tongues which were exposed to cocaine in artificial saliva. The 
observed concentrations were highest in the S1, S2, S4 and S5, which made up the 
outside of the tongue transverse cross section. Lowest concentrations for cocaine and 
benzoylecgonine were observed in section 3, which was removed from the centre of 
the tongue indicating that although the drug penetrated the tissue section to the centre 
of the tongue, less drug reached the centre than on the external sections of the 
tongue.  
Homogenates from tongues exposed to heroin showed that morphine and 6-MAM 
concentrations were detected in all sections removed from tongues. Similarly to 
cocaine, morphine and 6-MAM concentrations observed were lowest in section 3 
which was removed from the centre of the tongue. Concentrations of morphine and 
6-MAM observed in tissue were higher in comparison to cocaine and 
benzoylecgonine concentrations which further supported the hypothesis that heroin 
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penetrates the tissue easier than cocaine in addition to the more intense staining 
observed following exposure to heroin.  
Following completion of wash steps pre-wetted AlereTM Certus oral fluid collectors 
were brushed against the tongue to identify whether the contact between collector 
and tongue tissue could result in a contamination of oral fluid by extraction drug 
from the mouth tissue.   
When collectors were brushed against tongues exposed to cocaine, it was observed 
that cocaine and benzoylecgonine were detected in samples collectors with the 
AlereTM Certus collector. The presence of cocaine and benzoylecgonine in samples 
collected using a pre-wetted AlereTM Certus collector following seven washes after 
the original exposure to various concentrations of cocaine solution, indicated that the 
brushing the collector against the tongue can potentially extract drug from the oral 
tissue. The seventh wash was negative for cocaine and benzoylecgonine when 
exposed to cocaine spiked into artificial saliva, with the exception of the 10 µg/mL 
dose, indicating that all excess external contamination of cocaine had been washed 
off by wash seven. Therefore the presence of cocaine and benzoylecgonine in 
samples collected with the Certus collector, are not a direct result of external 
contamination, but the drug must have been released from the oral tissue.  
In contrast, heroin was not detected in samples collected with the AlereTM Certus 
device. The absence of heroin, morphine and 6-MAM in collection devices suggest 
that the collector does not extract either of the compounds from the oral tissue. This 
further supports that heroin binds tightly to the tissue, as immunohistochemical 
staining resulted in intensive staining throughout the tissue. The lack of drug when 
swiping the collector against the tongue, also supports the results in chapter 5, where 
no change in drug concentrations were observed following scraping of the AlereTM 
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Certus device against the tongue following consumption of Codeine Linctus or Collis 
Browne’s solution. Results from chapter 5 further indicated that opiates such as 
morphine and codeine can bind to oral tissue and subsequently be released over time.  
In a separate study the release of drugs from tongue tissue was investigated. Tongues 
were exposed to either 100 ng/mL or 1000 ng/mL of cocaine or heroin and then 
washed for either 1 hour, 6 hours, 24 hours or 48 hours in artificial saliva. 
Immunohistochemical results of the transverse cross sections of the tongue showed 
that following cocaine exposure, specific staining was still observed 48 hours post 
exposure. Although staining weakened with prolonged washing, significant staining 
was still observed after washing 48 hours. Additionally, when homogenate sections 
were analysed, it was observed that concentrations of cocaine and benzoylecgonine 
decreased with prolonged washing time and 48 hours post exposure, only 
Benzoylecgonine were detected.  
Similarly, following heroin exposure, as with the initial exposure study, the staining 
observed following immunohistochemical staining, was more intense in comparison 
to cocaine. Analysis from homogenates showed that concentrations of morphine and 
6-MAM were higher than cocaine and benzoylecgonine which hence further 
supported the hypothesis that following the exposure to heroin, drug enters the tissue 
more easily. Positives for morphine and 6-MAM were still detected following 48 
hours of washing which indicated that the drug binds tightly to the tissue and can 
subsequently be released over time.  
Additionally, in a separate study, porcine tongues were exposed to smoke from a 
dose of 100 mg or 200 mg of either crack cocaine or street heroin and stained using 
the same immunohistochemical methods. Results showed, that drug was present in 
all of the tongues exposed to drug via the smoking route. Similar to the porcine 
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tongues exposed to drug solutions, porcine tongues showed a difference in intensity 
depending on whether they were exposed to crack cocaine or street heroin. This 
further supports that heroin penetrates the tissue more than cocaine does as a result of 
its lipophilicity.  
Cocaine was only present in the connective tissue following exposure to smoke from 
a 100 mg dose of crack cocaine and did not penetrate the muscle bundles at all. At a 
higher dose, cocaine began to surround the muscle bundles and was seen to start to 
enter the muscle bundles. In comparison, heroin started entering the muscle bundles 
at a lower dose of 100 mg and had nearly fully penetrated the muscle bundles at the 
higher dose of 200 mg.  
Blood vessel walls also did not show any positive staining in concurrence with 
porcine tongues exposed to a drug solution rather than drug smoke. The same pattern 
of staining in the epithelium was observed with the inner layer of the epithelium 
showing no positive staining whereas the outside layer was positively stained.  
The presence of drugs in tissue following exposure to smoke from either crack 
cocaine or street heroin, further supports the hypothesis that drugs with are consumed 
by either snorting, smoking or solution have the potential to form depots in tissue 
which can subsequently be released from the tissue over time.  
In-vitro studies in porcine tissues gave promising results for the visualisation of 
drugs in oral tissue. However, the challenge with any in vitro study is to determine 
how this would apply to an in vivo study. Therefore an in vivo was designed in order 
to test the immunohistochemical staining technique and identify whether morphine 
could be visualised in oral tissue such as tongue and salivary glands after injection in 
mice.   
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Mice were injected with either a low (3 mg/mL) or a high dose of morphine (9 
mg/mL) and humanely killed 30 minutes post injection. Staining was observed 
tongues for both low and high concentrations of morphine. Staining was observed in 
the connective tissue, muscle bundles and epithelium although no difference was 
observed between the centre of the tongue and the outside of the tongue indicating 
that morphine was evenly distributed throughout the tongue. Both injection doses 
resulted in positive staining of epithelium. However in the inside layer (closest to 
muscle) a negative stain was observed indicating that this was negative whereas the 
outside layer of the epithelium was specifically stained. Similar to the in-vitro study 
this could be explained by the epitheliums rate of repair and renewal of tissue in 
response to abrasion in the mouth.  
As mice were exposed to morphine via injection rather than oral ingestion, no 
external oral contamination occurred.  Therefore an additional difference observed 
between in vitro porcine tongues, which were exposed to solution, and in vivo mice 
tongues, which were from mice injected with morphine, was that the specific staining 
was observed in the blood vessel walls indicating that the drug travelled from the 
blood through the blood vessel wall into the tissue.  
Overall the specific staining in tongues for mice which were injected with the higher 
dose of morphine (9 mg/mL) was more intense in colour than the staining observed 
in following an injection with a lower dose (3 mg/mL) suggesting that more drug has 
entered the tongue tissue.  
In addition to the tongues, salivary glands were removed from mice which were 
injected with a saline control, low concentration or high concentration of morphine. 
Mice, like humans have three salivary glands – the sublingual gland, parotid gland 
and submaxillary gland. All three glands are located in clusters below fat tissues and 
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submandibular lymph nodes. Salivary glands were removed 30 minutes post 
injection of morphine and fixed immediately for immunohistochemical staining. 
Immunohistochemical analysis confirmed that all three salivary glands managed to 
be collected during the procedure. Following application of an immunohistochemical 
staining method that utilised a morphine-3-glururonide antibody, it was visually 
observed that specific staining appeared to be present in all three salivary glands. 
Specific staining did not occur in the acini of the glands, but was only detected in the 
salivary ducts of the gland as well as the blood vessels. All saline controls, were 
negative for drug staining.  
Although staining was present in salivary glands of both groups, from mice injected 
with low or high concentrations of morphine, staining was more intense when mice 
were injected with a higher dose of 9 mg/mL indicating that more morphine has 
travelled into the structures of the salivary gland. This further supports the hypothesis 
that the larger the dose of the drug consumed, the greater is the potential that drug 
depots can form within the oral tissue.  
Drug was also visualised in the blood vessels / capillaries confirming that the drug 
travels across the blood vessel wall into the salivary gland. The presence of morphine 
in the salivary ducts strongly support the hypothesis that drug is excreted 
simultaneously to the excretion of saliva into the oral cavity hence leading to a 
contamination of drug and hence potentially contributing to the elevated drug 
concentrations observed in oral fluid. Although, similar to the acini, the salivary duct 
consist of epithelium, the epithelium is the thinnest layer of epithelium present in the 
salivary gland and hence allowing an easy transfer across the epithelium. 
To sum up, the research described in this thesis enhanced the understanding of the 
factors and processes concerning the depositions of drugs in oral tissue and oral 
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fluid. Results of this thesis showed that elevated drug concentrations were observed 
where drugs are consumed via oral routes such as solution or smoking. 
Immunohistochemical staining in combination with analytical analysis demonstrated 
that drugs such as cocaine and opioids can bind to oral tissue and be subsequently 
released over time and hence have to potential to interfere with the interpretation of 
drug concentrations in oral fluid. This is not an issue under legislation that forbids 
the presence of drugs or as a check for drug compliance or abstinence as for these it 
is not relevant where the drug has come from, just that the drug is present. However, 
the formation of drug depots and the subsequent slow release of drugs from tissue 
must be considered in relation to the interpretation of results where cut off 
concentrations are used to determine whether a person is positive or negative in an 
oral fluid drug test.   
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Chapter 11.0  - Limitations 
 
Table 11.1 Summary of limitations to the work undertaken in this research 
Limitation: Comment: 
Due to time constraints, the work 
undertaken in Chapter 3 focussed solely 
on the potential that foods and 
adulterants can affect the immunoassay 
screening system and subsequently 
cause false positives 
A secondary study to investigate the potential of food 
and adulterants to cause false negatives would have 
been beneficial as drug users often try to adulterate 
samples with substances such as lemon juice, tea, milk 
or vinegar in order to mask a positive result in the drug 
test. However, due to time constraints for the research 
undertaken, it was not possible to investigate this 
further.   
Additional samples of coca tea could 
not be collected due to limitation of 
time during this research and lack of 
collaborators within Peru. Additionally, 
it was not possible to import coca tea 
leaves due to the lack of a Home Office 
Import licence (Chapter 4). 
Samples were only collected for one hour post 
consumption of coca tea. Results showed that coca tea 
samples were positive for cocaine and its derivatives for 
up to 60 minutes. Therefore it would have been 
beneficial to repeat the collection process in Peru and 
collect sample for a longer time period in order to 
determine the time point at which concentrations 
dropped below the SAMHSA cut off for cocaine and its 
derivatives. Additionally the presence of 
anhydroecgonine methyl ester and cocaethylene has yet 
to be explained fully. However, due to a lack of a Home 
Office Import licence it was not possible to import coca 
tea leaves within the UK and hence prepare the coca tea 
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Limitation: Comment: 
in the same manner than when samples were originally 
collected in Peru.  
Mass spectra were unobtainable for 
results of cocaine and its derivatives 
detected in oral fluid following a 
consumption of coca tea 
Mass spectra were unobtainable due to loss of data 
following a computer fault.  
 
Limited information available during 
the analysis of the coca tea which was 
prepared from a ready-to-use teabag that 
contained ground coca tea leaves as 
well as green tea powder (Chapter 4) 
The quantity of coca leaf within the tea bag was 
unknown and therefore it is difficult to compare the 
concentrations of cocaine and its metabolites within the 
tea from the tea bag with those observed in oral fluid 
following the consumption of coca tea.  Additionally it 
is unknown whether the species of coca leaf was the 
same in both instances. Some species of the coca plant 
have been reported to contain anhydroecgonine methyl 
ester within the leaf which would explain its presence 
within the tea.  
Samples for transferrin analysis were 
collected by Alere Toxicology as part of 
their routine analysis before key 
information could be recorded. 
Additional information such as route of 
administration, drug use and drug dose 
Route of administration: As discussed in other 
chapters, the contribution to oral fluid drug levels is 
significant from smoking, intranasal and chewing 
routes of administration whilst intravenous and 
intramuscular routes result in higher blood levels 
compared to oral fluid. It would have been 
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Limitation: Comment: 
would have benefitted with the 
interpretation of the results 
(Chapter 6) 
advantageous to know the route of administration to 
further segregate the groups into oral versus injection 
routes. This would have provided further evidence of 
whether observed elevated concentrations are related to 
the route of administration.  
 
Drug Use: It would have also been beneficial to have 
known the time of between last drug use and collection 
of sample. This information would have given some 
insight as to whether the sample was in early or late 
elimination phase. In early phase we would expect to 
see high oral fluid levels resulting from contamination 
of the mouth cavity whereas in late phase elevated 
concentrations might be relating to drug deposition 
within and release from the oral cavity.   
 
Drug dose: The final missing information in this data 
set is dose of the drug consumed and drug purity. The 
missing detail on the dose hinders the correct 
interpretation of the oral fluid concentrations in relation 
to the drug consumed.  
Because of the large number of unknowns associated 
with the drug clinic data, a study was undertaken 
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Limitation: Comment: 
involving oral fluid collection under controlled 
conditions following the consumption of a codeine 
tablet. (Chapter 6 – Study 2)  
 
The amount of blood released during 
microbleeding has not been reported in 
the literature (Chapter 6) 
All calculations on the estimated quantity of drug 
released into oral fluid during microbleeding were 
based on an estimated volume of microbleeding ranging 
between a minimum volume of 5 µL and a maximum 
volume of 20 µL.  
Although the development of a method 
for the use of GMA resin was 
successfully achieved, the method was 
deemed unsuitable for the use in any 
further study due to the small sample 
size that could be embedded (Chapter 7) 
Important features, such as blood vessels and 
epithelium were destroyed during the removal of the 
biopsy samples from transverse cross sections. These 
features were vital to identify whether the drug is able 
to easily travel across the blood vessel wall and hence 
contaminate the blood.  
The staining could not be quantified as 
the staining counter-software was not 
specific enough to identify all the 
staining during image analysis (Chapter 
7, Chapter 8, Chapter 9) 
The software is based on a filter by which it quantifies 
the brown pixels in the image and simultaneously 
translates them into red pixels which are then identified 
by the software. However, the identification of the 
brown pixels is dependent on the light intensity used in 
the microscope, the magnification employed and 
intensity of staining. Additionally, the software 
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Limitation: Comment: 
accounts for staining at low and high intensity, and 
quantifies both in the same manner hence cannot 
differentiate between the low and the high drug 
concentrations. These factors resulted in the 
quantification method being deemed unsuitable for use. 
Porcine tongues varied in size during 
the work undertaken in Chapter 7 and 
Chapter 8 
Porcine tongues varied in size during this experiment as 
tongues are proportionate to the size of the animal it 
was removed from. As tongues were provided directly 
by the butcher, there was no way to individually 
selecting each tongue depending on its size. Therefore 
large variations in concentrations between two tongues 
exposed to the same drug concentrations could be a 
direct result of the difference in size between tongues. 
For any future work, the weight and size of the tongues 
should be recorded to aid with the interpretation of 
results.  
Tongues were stored frozen prior to 
treatment and immunohistochemical 
analysis (Chapter 7, Chapter 8) 
The butcher received the tongues from an abattoir and it 
was therefore not known how long the tongues were 
stored frozen before the use in the work undertaken in 
Chapter 7 and Chapter 8. Therefore it was difficult to 
assess the damage that could have occurred during the 
freezing and thawing process. Histological analysis 
however showed that the tissue structure was intact in 
all tongues, suggesting that tongues were suitable for 
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Limitation: Comment: 
the use in the work undertaken in those chapters.  
Due to time restrictions during this 
project, no studies were undertaken to 
investigate the release of drug and its 
detection  time for smoked tongue 
(Chapter 8) 
The presence of drugs, visualised by 
immunohistochemical staining (Chapter 8) in tissue 
following smoking also strongly supports the 
hypothesis that drugs can enter the oral fluid via routes 
other than via the surrounding blood. Drugs enter the 
muscle and form depots within the tissue when smoked 
which indicates that they can linger in the tissue and 
subsequently be released over time.  
The secondary antibody for the use 
during immunohistochemical staining 
was a biotinylated rabbit-anti-goat 
antibody 
Although the primary antibody was raised in sheep, the 
secondary antibody selected was biotinylated rabbit-
anti-goat antibody. This anti-goat antibody can generate 
more non-specific binding than an anti-sheep antibody; 
however no anti-sheep antibody was 
available/accessible during this study.  
The sample size in Chapter 9 was 
limited as the study was undertaken in 
collaboration with the School of 
Physiology & Pharmacology, 
University of Bristol.  
A larger sample size would allow analysing tongue 
tissue using LC-MS/MS in keeping with Chapter 7 and 
Chapter 8, to show some statistical evidence in addition 
to the visual examination of the sections. Due to time 
restrictions during this research, it was not possible to 
repeat the experiments in chapter 9 to obtain additional 
tongue and salivary gland tissue.  
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Chapter 12.0 - Future recommendations 
12.1 Adulterants and Food contaminants  
The work undertaken in this thesis showed that foods such as vinegar have the 
potential to affect the immunoassay screening system and cause false positives. 
Future research should be focussed on whether these foods or adulterants can also 
mask positive results and hence result in false negatives. Drug users have claimed 
that foods such as lemon juice, vinegar, tea and milk can invalidate an oral fluid drug 
test (Mikkelsen and Ash 1988) and hence mask a positive test result. This hypothesis 
should be further tested to follow on from the adulterant and contaminant work 
undertaken in Chapter 3.  
12.2 Microbleeding of the gums 
Microbleeding of the gums was shown not to be a contributing factor to elevated 
drug concentrations following controlled codeine exposure. However, for further 
research this should be further investigated for drug such as benzodiazepines which 
are highly protein bound. Benzodiazepines have reported S/P ratios between 0.01 and 
0.1 which suggests that any microbleed would significantly add to the oral fluid 
concentration.  
12.3 Oral contamination  
The research undertaken in this thesis clearly showed that drugs which have been 
consumed orally have the ability to contaminate the oral cavity and hence affect the 
interpretation of oral fluid drug results. Elevated concentrations of cocaine and its 
metabolites above the recommended SAMHSA cut off were observed for up to one 
hour post consumption of one single cup of coca tea. Further work should extend the 
time of collection to identify how long concentrations are reported positive before 
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dropping below the recommended SAMHSA cut off. Additionally, the work 
undertaken showed that concentrations of anhydroecgonine methyl ester and 
cocaethylene following consumption of one cup of coca tea which were detected at 
random time points throughout the collection timeline. Samples were reanalysed one 
year post the initial analysis. During the second analysis no cocaethylene was 
detected and the number of positive samples containing anhydroecgonine methyl 
ester increased. Possible explanation for the disappearance of cocaethylene positives 
could be instability of cocaethylene in oral fluid or the presence of esterase enzymes. 
Only limited information is available in the literature on the stability of cocaethylene 
in oral fluid, hence it should be further investigated to fully explain the 
disappearance of cocaethylene from the oral fluid samples.  
The repeat analysis one year post the initial analysis resulted in an increased number 
of samples testing positive for anhydroecgonine methyl ester. This indicates that 
anhydroecgonine methyl ester was formed within the sample during the one year of 
storage. The stability of anhydroecgonine methyl ester in oral fluid has not been 
documented in the literature. Although anhydroecgonine methyl ester has been 
reported to form through thermal degradation of cocaine as a pyrolysis product of 
smoking crack cocaine, formation due to storage conditions or instability have not 
previously been reported in the literature (Jacob et al 1990, Kintz et al 1995, Kintz et 
al 1997, Toennes 1999). Therefore the formation and stability of anhydroecgonine 
methyl ester should be further researched in order to identify whether storage 
conditions can result in the formation of anhydroecgonine methyl ester as a result of 
instability.  
Additionally, during the research undertaken throughout this thesis it was not 
possible to analyse the coca tea as a result of restrictions for the import of coca tea or 
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coca tea leaves. Future work to investigate drug concentrations in coca tea would 
provide essential information of the presence and concentration of constituents. This 
information could assist with the explanation of the presence of anhydroecgonine 
methyl ester and the subsequent interpretation of results.  
12.4 Drug depots 
The work described in this thesis showed the successful development and application 
of an immunohistochemical technique for visualising cocaine and opiates in tongue 
tissue and salivary glands. The presence of staining could not be quantified in 
transverse cross sections of porcine tongue tissue. The results of the application of 
the DDS staining software showed that staining could be identified but that the 
quantification of staining was depending on the light intensity used in the 
microscope, the magnification employed and the intensity of staining. For any future 
research in this field it would be beneficial to develop a quantification method which 
is able to account for low and high intensity of staining and quantify accordingly. 
The quantification of staining would enhance our understanding of the distribution 
and facilitate more informed interpretation of oral fluid drug analysis.   
The immunohistochemical staining technique was only developed for cocaine and 
opiates but could be further expanded to other commonly used drugs to enhance our 
understanding of how drugs are excreted into oral fluid. Cannabis is one of the most 
commonly smoked drugs and thus should be a prime candidate for further work. The 
in vivo study in mice successfully demonstrated that drug can travel into the tongue 
tissue and salivary gland following peritoneal injection of morphine. The study was 
undertaken in collaboration with Bristol University, School of Pharmacology. The in 
vivo study in mice was hence limited to morphine because Bristol University only 
had a licence for injecting morphine and not cocaine. Future research should be 
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expanded to explore the application of more drugs in in vivo studies using 
immunohistochemical staining.   
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Researcher Details 
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Eva Reichardt 
 
School 
 
Faculty of Science & Technology 
 
Status 
 
Postgraduate Research (PhD, MPhil, 
DProf, DEng) 
 
Course 
 
Postgraduate Research 
 
Have you received external funding to 
support this research project? 
 
 
No 
 
 
Project Details 
 
 
Title 
 
Investigation of the effects of common food and beverages on oral 
fluid drug detection 
 
Proposed Start 
Date 
 
February 2011 
 
Proposed End 
Date 
 
June 2012 
 
 
 
Summary (including detail on background methodology, sample, outcomes, 
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As part of this study each volunteer will be requested to consume, or swirl, each of 
the adulterants listed below around in the mouth. An oral fluid sample will then be 
collected immediately. The pH ( acidity or alkalinity) of the oral fluid sample will 
be measured. A second oral fluid sample will be collected after 10 minutes. Again, 
the pH of this sample will be measured.  
As part of this study the time it takes for each device to collect a sufficient amount 
of oral fluid will recorded. Samples will then be stored and send to Cozart 
Bioscience Ltd. for analysis.  
 
The Intercept device follows a simple process. Firstly, in order for the device to 
absorb a sufficient amount of oral fluid the device will be kept in the mouth for 
around 2 to 5 minutes. The pad is then inserted into the vial containing a buffer and 
the wand is snapped. The sample will then be re-sealed and send to Cozart 
Bioscience Ltd. for further analysis. The following adulterants have been chosen for 
this study: 
 
1. Mouthwash 
2. Toothpaste  
3. Chewing Gum 
4. Sour Sweets (Lemon Sherberts) 
5. Sugar Coated Sweets 
6. Spicy Food 
7. Fried/Oily Food 
8. Apples 
9. Oranges 
10. Grapes 
11. Yoghurt 
12. Fruit Juice (unsweetened) 
13. Coke 
14. Coffee 
15. Tea 
16. Fruit juice (sweetened) 
17. Cheese 
18. Milk 
19. Vinegar 
20. Cranberry Juice 
Red Bull 
 
 
External Ethics Review 
Does your research require external review through the NHS National 
Research Ethics Service (NRES) or through another external Ethics 
Committee? 
No 
 
Research Literature 
Is your research solely literature based? No 
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Human Participants 
 
 
Will your research project involve interaction with human 
participants as primary sources of data (e.g. interview, observation, 
original survey)? 
 
 
Yes 
 
Does your research specifically involve participants who are 
considered vulnerable (i.e. children, those with cognitive impairment, 
those in unequal relationships—such as your own students, prison 
inmates, etc.)? 
 
 
 
No 
 
Does the study involve participants age 16 or over who are unable to 
give informed consent (i.e. people with learning disabilities)? NOTE: 
All research that falls under the auspices of the Mental Capacity Act 
2005 must be reviewed by NHS NRES. 
 
 
 
No 
 
Will the study require the co-operation of a gatekeeper for initial access 
to the groups or individuals to be recruited? (i.e. students at school, 
members of self-help group, residents of Nursing home?) 
 
 
No 
 
Will it be necessary for participants to take part in your study without 
their knowledge and consent at the time (i.e. covert observation of 
people in non-public places)? 
 
 
No 
 
Will the study involve discussion of sensitive topics (i.e. sexual activity, 
drug use, criminal activity)? 
 
Yes 
 
 
Are drugs, placebos or other substances (i.e. food substances, vitamins) 
to be administered to the study participants or will the study involve 
invasive, intrusive or potentially harmful procedures of any kind? 
 
 
Yes 
 
Please explain why your research project does not require ethical review by a 
NHS REC. Solid foods and beverages are totally consumed whilst liquids such as mouthwash and 
vinegar (n = 30 mL) are swirled around the mouth for 30 seconds and then discarded. 
All substances for testing are not harmful to the volunteer. Volunteers will provide 
informed consent and can withdraw from the study at any time. Volunteers can also 
choose not to have a certain substance if they feel in any way uncomfortable in doing 
so.  
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Will tissue samples (including blood) be obtained from participants? 
Note: If the answer to this question is ‘yes’ you will need to be aware of 
obligations under the Human Tissue Act 2004. 
 
 
Yes 
 
Please explain why your research project does not require ethical review by a 
NHS REC. 
 
Samples will be collected using the Intercept Orasure or Concateno Certus Oral Fluid 
collection device. Both devices are non-invasive and samples will be fully anonymised. 
Volunteers will be provided with consent. Participation in this research study is 
voluntary. If volunteers chose to take part, they have the right to stop at any time.  
  
 
Could your research induce psychological stress or anxiety, cause harm 
or have negative consequences for the participant or researcher (beyond 
the risks encountered in normal life)? 
 
 
No 
 
Will your research involve prolonged or repetitive testing? 
 
No 
 
Will the research involve the collection of audio materials? 
 
No 
 
Will your research involve the collection of photographic or video 
materials? 
 
No 
 
Will financial or other inducements (other than reasonable expenses and 
compensation for time) be offered to participants? 
 
 
No 
Please explain below why your research project involves the above 
mentioned criteria (be sure to explain why the sensitive criterion is essential 
to your project’s success). Give a summary of the ethical issues and any 
action that will be taken to address these. Explain how you will obtain 
informed consent (and from whom) and how you will inform the 
participant(s) about the research project (i.e. participant information sheet). 
A sample consent form and participant information sheet can be found on 
the Research Ethics website. 
 
The non-invasive sample collected will be fully anonymised. Before participating in 
the study, participants will be provided with a patient information sheet that details 
the purpose of the study, why it is important to undertake the work, what will 
happen to them and how the information they provide will be used. If the 
participants are willing to volunteer for the study they will be asked to sign a 
consent form. The participants in this study will all be over 18 and able to read and 
write English. It is important to. Any information the participants provide will be 
kept strictly confidential and all data will be fully anonymised.  (Consent form 
attached below) 
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Final Review 
 
 
Will you have access to personal data that allows you to identify 
individuals OR access to confidential corporate or company data 
(that is not covered by confidentiality terms within an agreement or 
by a separate confidentiality agreement)? 
 
 
 
No 
 
Will your research involve experimentation on any of the following: 
animals, animal tissue, genetically modified organisms? 
 
 
No 
 
Will your research take place outside the UK (including any and 
all stages of research: collection, storage, analysis, etc.)? 
 
 
No 
 
Please use the below text box to highlight any other ethical concerns or risks 
that may arise during your research that have not been covered in this form. 
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Consent Form for Collection of Oral Fluid 
 
Bournemouth University, United Kingdom 
 
Title of Project:  Investigation of the effects of Adulterants and Food on Oral 
Fluid Drug Test Devices (Intercept and Cozart devices) 
 
Principal Investigators: 
 
 Professor David Osselton, Director of the Centre for Forensic Sciences, 
University of Bournemouth. 
 Eva—Maria Reichardt, Bournemouth University 
 Dr Dene Baldwin, Technical Director, Cozart Bioscience Ltd. 
 
 
This is a research study.   Research studies include only people who want to take part 
and you do not have to give consent for participation if you do not wish to do so.  
Your oral fluid sample is being collected to act as a control from someone who does 
not participate in recreational drug use. This form provides information about this 
research, which will be discussed with you. It may contain words or procedures that 
you do not understand. Please ask questions about anything that is unclear to you. 
Discuss it with your family and friends if you wish and take your time to make your 
decision.   
 
1. Purpose of the Research 
 
Oral fluid drug testing has become increasingly popular over the past years. 
Oral fluid drug testing is a non-invasive process which can be administered 
quickly anytime and anywhere. The process of oral fluid testing is reduces 
risk of tampering as the process can be monitored directly. Adulterants such 
as food are used as dilution tactics in order to beat the oral fluid drug tests. 
This study will look at the effects of common foods and adulterants on oral 
fluid drug testing procedures. In this study the effects of the adulterants on 
the “Intercept” and “Cozart” oral fluid collection devices.  
 
As part of this study each volunteer will be requested to consume, or swirl, 
each of the adulterants listed below around in the mouth. An oral fluid sample 
will then be collected immediately. The pH ( acidity or alkalinity) of the oral 
fluid sample will be measured. A second oral fluid sample will be collected 
after 10 minutes. Again, the pH of this sample will be measured.  
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As part of this study the time it takes for each device to collect a sufficient 
amount of oral fluid will recorded. Samples will then be stored and send to 
Cozart Bioscience Ltd. for analysis.  
 
The Intercept device follows a simple process. Firstly, in order for the device 
to absorb a sufficient amount of oral fluid the device will be kept in the 
mouth for around 2 to 5 minutes. The pad is then inserted into the vial 
containing a buffer and the wand is snapped. The sample will then be re-
sealed and send to Cozart Bioscience Ltd. for further analysis. You will also 
be requested to provide details of your age, sex and whether you are taking 
any drugs or medications. 
The following adulterants have been chosen for this study: 
 
21. Mouthwash 
22. Toothpaste  
23. Chewing Gum 
24. Sour Sweets (Lemon Sherberts) 
25. Sugar Coated Sweets 
26. Spicy Food 
27. Fried/Oily Food 
28. Apples 
29. Oranges 
30. Grapes 
31. Yoghurt 
32. Fruit Juice (unsweetened) 
33. Coke 
34. Coffee 
35. Tea 
36. Fruit juice (sweetened) 
37. Cheese 
38. Milk 
39. Vinegar 
40. Cranberry Juice 
41. Red Bull 
 
 
2. Discomforts and Risks:  
   
One risk of giving samples for this research may be the release of your name that 
could be linked to the stored samples and/or the results of the tests run on the 
samples. To prevent this, these samples will be given a unique identification 
code.  Only the study staff will know the code.  The name that belongs to the 
code will be kept in a locked file or in a computer with a password.  Only 
authorized members of the research team will have access to your name.  
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3. Statement of Confidentiality: 
 
a. Privacy and confidentiality measures 
 Each sample will be given a unique code for which the samples will 
hereby be known.   
 Samples are going to be analysed at Cozart Bioscience Ltd. The 
information provided throughout this study i.e. (sex, health, drug 
use) will not identify you by name.  
 
The results of this research study may be presented at scientific / medical 
meetings or in scientific / medical publications. The identity of donors will 
not be disclosed in those presentations.  
  
If you agree, samples and results will be stored along with information about 
yourself obtained in the course of this research study (age, sex, health, drug / 
medication use). The information stored will not identify you by name.  
  
If you agree to participate in this study you will receive a signed and dated 
copy of this consent form for your records.  
 
In the event of any publication or presentation resulting from the research, no 
identifiable information will be shared. 
 
We will keep participation in this research study confidential to the extent 
permitted by law. However, it is possible that other people may become aware 
of study participation. For example, the following people/groups may inspect 
and copy records pertaining to this research.  
 
 The Bournemouth University Institutional Ethics Review Board (a 
committee that reviews and approves research studies)   
 
The possibility of identification is very low and every effort will be made to keep 
your personal information in the research record private and confidential but 
absolute confidentiality cannot be guaranteed. 
 
4. Costs for Participation: 
 
 a. Costs:   
There are NO costs for participation in this research 
 
b. Rights: 
Signing this form will lose no legal rights. 
        
       c. Compensation:  
   No payment or compensation will be received for participation in this 
research study. 
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5. Voluntary Participation / Withdrawal:  
 
Participation in this research study is voluntary. You do not have to participate in 
this research. If you choose to take part, you have the right to stop at any time. If it 
is decided not to participate or if it is decided to stop participation in the research at 
a later date, there will be no penalty. 
 
6. Contact Information for Questions or Concerns:      
 
You have the right to ask any questions you may have about this research.  If you 
have questions, complaints or concerns about this research, contact Professor David 
Osselton, Centre for Forensic Sciences, Bournemouth University. 
 
 
 
 
Consent:  
I have read the information in this consent form. All my questions about this study 
and my participation in it have been answered to my satisfaction.  
 
I authorize the collection of oral fluid samples for analysis for the purpose of the study 
by the investigation team at Bournemouth University. 
 
By signing this consent form, no legal rights have been waived, which would otherwise 
have been had for participation in a research study.  
 
Please initial the following option:  
 
 
I would like scientists to study my oral fluid sample only to complete the study outlined  
above and then to discard the oral fluid sample so that other studies cannot be 
done. 
 
 
Signature__________________________________                    Date___________ 
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Name (please print) _______________________________________ 
 
Signature of Person Conducting  
Informed Consent Discussion____________________________          
 
Date___________ 
 
Name (please print) ________________________________________ 
 
  
Signature of Witness ____________________________________  Date 
___________ 
(Required)  
 
Name (please print) ________________________________________ 
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Appendix B 
 
 
 
 
 
Status 
 
Approved 
 
 
Researcher Details 
 
 
Name 
 
Eva Reichardt 
 
School 
 
School of Applied Sciences 
 
Status 
 
Postgraduate Research (PhD, MPhil, 
DProf, DEng) 
 
Course 
 
Postgraduate Research 
 
Have you received external funding to 
support this research project? 
 
 
No 
 
 
Project Details 
 
 
Title 
 
Concentrations of cocaine, benzoylecgonine and ecgonine methyl 
ester in oral fluid following the consumption of coca tea 
 
Proposed Start 
Date 
 
February 2011 
 
Proposed End 
Date 
 
December 2012 
 
 
 
Summary (including detail on background methodology, sample, outcomes, 
etc.) 
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Most scientific studies examining oral fluid cocaine appearance have been  
restricted to relatively small doses of drug for ethical and safety reasons. For the 
purpose of this study, oral fluid samples following the consumption of coca tea will 
be collected in Lima, Peru. Coca tea is widely consumed in a number of South 
American countries where its use is both legal and socially acceptable. The tea is 
prepared from an infusion of the leaves obtained from the coca bush Erythroxylum 
coca . Following local custom, coca tea will be prepared by soaking 10 whole coca 
leaves in boiling water for 5 minutes prior to straining to remove the leaf tissues. 
Volunteers will be asked to drink 1 cup (~250 mL) of coca tea immediately post 
straining of the leaves over a period of approximately 5 minutes and afterwards 
provide a sample of oral fluid immediately following completion of tea drinking. 
Oral fluid will subsequently collected at 15, 30, 45 and 60 minute intervals. Oral 
fluid collection was facilitated using the AlereTM Certus device 
 
External Ethics Review 
Does your research require external review through the NHS National 
Research Ethics Service (NRES) or through another external Ethics 
Committee? 
No 
 
Research Literature 
Is your research solely literature based? No 
 
 
Human Participants 
 
 
Will your research project involve interaction with human 
participants as primary sources of data (e.g. interview, observation, 
original survey)? 
 
 
Yes 
 
Does your research specifically involve participants who are 
considered vulnerable (i.e. children, those with cognitive impairment, 
those in unequal relationships—such as your own students, prison 
inmates, etc.)? 
 
 
 
No 
 
Does the study involve participants age 16 or over who are unable to 
give informed consent (i.e. people with learning disabilities)? NOTE: 
All research that falls under the auspices of the Mental Capacity Act 
2005 must be reviewed by NHS NRES. 
 
 
 
No 
 
Will the study require the co-operation of a gatekeeper for initial access 
to the groups or individuals to be recruited? (i.e. students at school, 
members of self-help group, residents of Nursing home?) 
 
 
No 
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Will it be necessary for participants to take part in your study without 
their knowledge and consent at the time (i.e. covert observation of 
people in non-public places)? 
 
 
No 
 
Will the study involve discussion of sensitive topics (i.e. sexual activity, 
drug use, criminal activity)? 
 
Yes 
 
 
Are drugs, placebos or other substances (i.e. food substances, vitamins) 
to be administered to the study participants or will the study involve 
invasive, intrusive or potentially harmful procedures of any kind? 
 
 
Yes 
 
Please explain why your research project does not require ethical review by a 
NHS REC. 
Coca tea is widely consumed in a number of South American countries where its use is 
both legal and socially acceptable. The tea is prepared from an infusion of the leaves 
obtained from the coca bush Erythroxylum coca. The consumption of coca tea is legal 
in Peru and tea only contains low concentrations of cocaine which should not result in 
impairment. The amount of cocaine and its metabolites present in coca leave can vary 
depending on species and origin of the Erythroxylum plant (Jenkins et al 1996). The 
Peruvian Erythroxylum species, as used by Jenkins et al, contains 5.11 mg of cocaine, 
0.11 mg of benzoylecgonine and 1.15 mg of ecgonine methyl ester in 1 g of leaf 
material. The tea will be prepared by a Peruvian colleague, Karina Gerdau-Radonic,  
which will ensure that the tea is prepared correctly.   
 
 
Will tissue samples (including blood) be obtained from participants? 
Note: If the answer to this question is ‘yes’ you will need to be aware of 
obligations under the Human Tissue Act 2004. 
 
 
Yes 
 
Please explain why your research project does not require ethical review by a 
NHS REC. 
 
Samples will be collected using the Concateno Certus Oral Fluid collection device. 
Both devices are non-invasive and samples will be fully anonymised. Volunteers will 
be provided with consent. Participation in this research study is voluntary. If volunteers 
chose to take part, they have the right to stop at any time.  
  
 
Could your research induce psychological stress or anxiety, cause harm 
or have negative consequences for the participant or researcher (beyond 
the risks encountered in normal life)? 
 
 
No 
 
Will your research involve prolonged or repetitive testing? 
 
No 
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Will the research involve the collection of audio materials? 
 
No 
 
Will your research involve the collection of photographic or video 
materials? 
 
No 
 
Will financial or other inducements (other than reasonable expenses and 
compensation for time) be offered to participants? 
 
 
No 
Please explain below why your research project involves the above mentioned 
criteria (be sure to explain why the sensitive criterion is essential to your 
project’s success). Give a summary of the ethical issues and any action that 
will be taken to address these. Explain how you will obtain informed consent 
(and from whom) and how you will inform the participant(s) about the 
research project (i.e. participant information sheet). A sample consent form 
and participant information sheet can be found on the Research Ethics 
website. 
 
The non-invasive sample collected will be fully anonymised. Before participating in 
the study, participants will be provided with a patient information sheet that details 
the purpose of the study, why it is important to undertake the work, what will happen 
to them and how the information they provide will be used. If the participants are 
willing to volunteer for the study they will be asked to sign a consent form. For those 
volunteers who do not speak and understand fluent English, the consent form will be 
translated to Spanish. Karina Gerdau-Radonic will be present at all times throughout 
this study in order to be able to translate and assist in answering any questions or 
concerns. The participants in this study will all be over 18.  Any information the 
participants provide will be kept strictly confidential and all data will be fully 
anonymised. (Consent form attached below)  
 
Final Review 
 
 
Will you have access to personal data that allows you to identify 
individuals OR access to confidential corporate or company data 
(that is not covered by confidentiality terms within an agreement or 
by a separate confidentiality agreement)? 
 
 
 
No 
 
Will your research involve experimentation on any of the following: 
animals, animal tissue, genetically modified organisms? 
 
 
No 
 
Will your research take place outside the UK (including any and 
all stages of research: collection, storage, analysis, etc.)? 
 
 
No 
 
Please use the below text box to highlight any other ethical concerns or risks 
that may arise during your research that have not been covered in this form. 
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Consent Form for Collection of Oral Fluid following Consumption 
of Coca Tea 
 
Bournemouth University, Inglaterra, Reino Unido 
 
Investigadores Principales: 
 Professor David Osselton, Director, Centro de Ciencias Forenses y 
Biologicas, Bournemouth University 
 Eva—Maria Reichardt, Bournemouth University 
 Benni Juckes, Bournemouth University 
 
 
Este es un proyecto de investigación y su participacion es voluntaria. No tiene que 
hacerlo si asi no lo desea.  
 
El siguiente documento expica la naturaleza del proyecto y el por que se estan 
colectando muestras de saliva. Si contiene palabras o expresiones que no entienda, por 
favour pida una aclaracion.  
 
Proposito de la Investigacion 
 
La hoja de coca contiene varios alcaloides, entre elleos “cocaine”. Estudios con otras 
substancias han demonstrado que estas se pueden acumular en los tejidos bucales 
despues de su consume oral, lo que llevaria a indicar que se pueden formar depositos de 
estas substancias en la boca. Este studio busca investigar si el consume de mate de coca 
conlleva la formacion de depositos de “alcaloides” en los tejidos bucales.  
 
Metodo 
 
Este studio se lleva a cabo de forma anonima. Cada voluntario recibira un codigo de 
identificacion unico para proteger su identidad. Se les pedira solamente sue dad, sexo e 
historial medico y de drogas. Toda informacion sera tratada de manera confidencial.  
 
1. Las muestras bucales se tomaran por medio de un hisopo 
2. Una muestra se tomara antes del consume de mate de coca 
3. Despues se ofrecera el mate de coca 
Validation of Oral Fluid as a Matrix for Drug Detection - Appendices 
 
428 
 
4. Luego de beber el mate se tomaran muestras a los 0,15,30, 45 y 60 minutos 
despues del consume 
Las muestras seran analizadas por la empresa Concateno, ubicada en Abingdon, 
Inglaterra, Reino Unido.  
 
Confidencialidad 
 Cada muestra llevara un codigo unico de identificacion 
 Ningun dato proporionado (sexo, edad, historical medico, consume de drogas) 
estara relacionado con su nombre 
 Los resultados de este studio pueden ser presentados en conferencias 
profesionales pueden ser publicados. En ningun momento se identificara a los 
participantes por sus nombres.  
 
 
Contactenos 
 
Eva Reichardt, Centre for Forensic and Biological Sciences, Bournemouth University, 
Inglaterra, Reino Unido (ereichardt@bournemouth.ac.uk) 
 
Autorizacion 
 
He leído este document y mis preguntas han sido respondidas.  
 
Autorizo que mis muestras de saliva sean usadas en el marco de este proyecto de 
investigación, y que no sirvan para otros estudios.  
 
Nombre (en letra de imprenta) ___________________________________________ 
 
Firma _________________________________  Fecha _______________________ 
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Appendix C 
Non-cross reacting compounds for the AlereTM Cocaine Metabolite EIA Kit (Chapter 
4) 
Benzoylecgonine 
6 Monoacetylmorphine Fentanyl Norpropoxyphene 
Alprazolam Heroin Oxymorphone 
Amobarbital Hexobarbital Pentazocine 
Barbital Ibuprofen Pentobarbital 
Butabarbital Ketamine Phentermine 
Caffeine LAAM (+) Pseudoephedrine 
Carbamazepine Lidocaine (-) Pseudoephedrine 
Chlordiazepoxide Lorazepam Phenylpropanolamine 
Clonazepam MDEA PCP 
Codeine MBDB Ranitidine 
Cyclobenzaprine MDMA Salicylate 
D9-THC MDA Secobarbital 
Dextromethorphan Meperidine Temazepam 
Dextropropoxyphene Medazepam Tramadol 
Diazepam Mephobarbital Tyramine 
Diphenhydramine Methaqualone Venlafaxine 
(+) Ephedrine Morphine Zolpidem 
(-) Ephedrine Naltrexone   
EMDP Naloxone   
EDDP 11-nor-9-Carboxy-D9-THC   
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Appendix D 
 
 
 
 
 
Status 
 
Approved 
 
 
Researcher Details 
 
 
Name 
 
Eva Reichardt 
 
School 
 
School of Applied Sciences 
 
Status 
 
Postgraduate Research (PhD, MPhil, 
DProf, DEng) 
 
Course 
 
Postgraduate Research 
 
Have you received external funding to 
support this research project? 
 
 
No 
 
 
Project Details 
 
 
Title 
 
Oral fluid opiate concentrations following oral consumption of 
Codeine Linctus® and Collis Browne’s® mixture 
 
Proposed Start 
Date 
 
February 2011 
 
Proposed End 
Date 
 
December 2012 
 
 
 
Summary (including detail on background methodology, sample, outcomes, 
etc.) 
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The purpose of the work described in this was to examine drug deposition in oral 
fluid and potentially the surface of the mouth cavity by investigating concentrations 
of opiates following oral consumption of Codeine Linctus® ® and Collis 
Browne’s® ® mixture.  
The elevated drug concentrations in oral fluid over a prolonged period suggest that 
drugs such as cocaine and opioids can bind to oral tissue. Collected oral fluid can 
contain cell and food debris which can be collected by the abrasion of the collector 
against the oral tissues. The presence of drug depots in tissues suggests that the cell 
debris present in oral fluid also contains drugs, which can potentially contribute to 
and hence increase oral fluid concentrations.    
The work undertaken in this chapter aimed to investigate characteristics of 
deposition in the oral fluid using observed concentrations such as the length of time 
drug can be detected in oral fluid and the effect of cell abrasion during collection. 
Volunteers will be invited to swirl 5 mL of Collis Browne’s®  or Codeine Linctus®  
around the mouth for one minute before discarding the liquid from the mouth. The 
calculated dose for Codeine Linctus®  was 15 mg and 5 mg for Collis Browne’s®  
mixture. Oral fluid was subsequently collected at 15, 30, 45, 60, 90, 120, 150 and 
180 minutes after mouth emptying using the AlereTM Certus oral fluid collection 
device. Oral fluid was collected in accordance with the kit manufacturer’s 
instructions.  
In addition to the collection according to the manufacturer’s guidelines, a second 
AlereTM Certus collector was brushed against the oral cavity to identify whether the 
increased presence of cellular debris can increase the amount of drug detected in 
oral fluid. Brushing was undertaken until the adequacy indicator showed that 
sufficient oral fluid had been collected.  
 
 
External Ethics Review 
Does your research require external review through the NHS National 
Research Ethics Service (NRES) or through another external Ethics 
Committee? 
No 
 
Research Literature 
Is your research solely literature based? No 
 
 
Human Participants 
 
 
Will your research project involve interaction with human 
participants as primary sources of data (e.g. interview, observation, 
original survey)? 
 
 
Yes 
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Does your research specifically involve participants who are 
considered vulnerable (i.e. children, those with cognitive impairment, 
those in unequal relationships—such as your own students, prison 
inmates, etc.)? 
 
 
 
No 
 
Does the study involve participants age 16 or over who are unable to 
give informed consent (i.e. people with learning disabilities)? NOTE: 
All research that falls under the auspices of the Mental Capacity Act 
2005 must be reviewed by NHS NRES. 
 
 
 
No 
 
Will the study require the co-operation of a gatekeeper for initial access 
to the groups or individuals to be recruited? (i.e. students at school, 
members of self-help group, residents of Nursing home?) 
 
 
No 
 
Will it be necessary for participants to take part in your study without 
their knowledge and consent at the time (i.e. covert observation of 
people in non-public places)? 
 
 
No 
 
Will the study involve discussion of sensitive topics (i.e. sexual activity, 
drug use, criminal activity)? 
 
Yes 
 
 
Are drugs, placebos or other substances (i.e. food substances, vitamins) 
to be administered to the study participants or will the study involve 
invasive, intrusive or potentially harmful procedures of any kind? 
 
 
Yes 
 
Please explain why your research project does not require ethical review by a NHS 
REC. 
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Collis Browne’s mixture and Codeine Linctus are available over the counter in most 
UK pharmacies.  
Collis Browne’s®  mixture, manufactured by Thornton & Ross Ltd, Huddersfield, UK 
contains two principal active ingredients, morphine hydrochloride at a dose equivalent 
to 1.0 mg/5 mL anhydrous morphine and 1.5 µL/5mL of peppermint oil. Collis 
Browne’s®  mixture also contains ethanol, benzoic acid, sorbitol sucrose and fructose.  
Collis Browne’s®  mixture is available for purchase as an over-the-counter medication.  
  Codeine Linctus®, Care+, Thornton & Ross Ltd, Huddersfield, UK, contains only one 
active drug ingredient, Codeine phosphate at a dose of 15 mg/5 mL. Other ingredients 
include citric acid monohydrate, ethyl and propyl parahydroxybenyzoates, sodium 
methyl, ethanol, sugars, food colourings and flavouring. Codeine Linctus® is available 
for purchase as an over-the-counter medication. 
Both Collis Brownes mixture and Codeine Linctus will be administered at a dose as 
recommended by the manufacturer. Additionally, both substances will be discarded 
from the mouth prior to oral fluid collection.  
 
  
 
Will tissue samples (including blood) be obtained from participants? 
Note: If the answer to this question is ‘yes’ you will need to be aware of 
obligations under the Human Tissue Act 2004. 
 
 
Yes 
 
Please explain why your research project does not require ethical review by a 
NHS REC. 
 
Samples will be collected using the Concateno Certus Oral Fluid collection device. 
Both devices are non-invasive and samples will be fully anonymised. Volunteers will 
be provided with consent. Participation in this research study is voluntary. If volunteers 
chose to take part, they have the right to stop at any time.  
  
 
Could your research induce psychological stress or anxiety, cause harm 
or have negative consequences for the participant or researcher (beyond 
the risks encountered in normal life)? 
 
 
No 
 
Will your research involve prolonged or repetitive testing? 
 
No 
 
Will the research involve the collection of audio materials? 
 
No 
 
Will your research involve the collection of photographic or video 
materials? 
 
No 
 
Will financial or other inducements (other than reasonable expenses and 
compensation for time) be offered to participants? 
 
 
No 
Please explain below why your research project involves the above mentioned 
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criteria (be sure to explain why the sensitive criterion is essential to your 
project’s success). Give a summary of the ethical issues and any action that 
will be taken to address these. Explain how you will obtain informed consent 
(and from whom) and how you will inform the participant(s) about the 
research project (i.e. participant information sheet). A sample consent form 
and participant information sheet can be found on the Research Ethics 
website. 
 
The non-invasive sample collected will be fully anonymised. Before participating in 
the study, participants will be provided with a patient information sheet that details 
the purpose of the study, why it is important to undertake the work, what will happen 
to them and how the information they provide will be used. If the participants are 
willing to volunteer for the study they will be asked to sign a consent form (consent 
form attached below). The participants in this study will all be over 18.  Any 
information the participants provide will be kept strictly confidential and all data will 
be fully anonymised.  
 
Final Review 
 
 
Will you have access to personal data that allows you to identify 
individuals OR access to confidential corporate or company data 
(that is not covered by confidentiality terms within an agreement or 
by a separate confidentiality agreement)? 
 
 
 
No 
 
Will your research involve experimentation on any of the following: 
animals, animal tissue, genetically modified organisms? 
 
 
No 
 
Will your research take place outside the UK (including any and 
all stages of research: collection, storage, analysis, etc.)? 
 
 
No 
 
Please use the below text box to highlight any other ethical concerns or risks 
that may arise during your research that have not been covered in this form. 
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Consent Form for Collection of Oral Fluid and Buccal Swabs 
 
Bournemouth University, United Kingdom 
 
Title of Project:  Investigation of the effects of oral contamination on 
Interpretation of Opiate Oral Fluid Results 
 
Principal Investigators: 
 
 Professor David Osselton, Director of the Centre for Forensic Sciences, 
University of Bournemouth. 
 Eva—Maria Reichardt, Bournemouth University 
 Benni Juckes, Bournemouth University 
 
 
This is a research study.   Research studies include only people who want to take part 
and you do not have to give consent for participation if you do not wish to do so.  
Your oral fluid sample is being collected to act as a control from someone who does 
not participate in recreational drug use. This form provides information about this 
research, which will be discussed with you. It may contain words or procedures that 
you do not understand. Please ask questions about anything that is unclear to you. 
Discuss it with your family and friends if you wish and take your time to make your 
decision.   
 
2. Purpose of the Research 
 
Oral fluid drug testing has become increasingly popular over the past years. 
This is largely due to the advantages it has over conventional matrices such as 
blood and urine. Oral fluid collection is an observed, non-invasive proves that 
can be undertaken in any location and is less susceptible to adulteration. Oral 
fluid results are extremely elevated by the presence of oral contamination 
caused by smoked, insufflated or orally administered drugs. This 
contamination is thought to cause formation of drug depots in cheek tissue. 
Furthermore, blood contamination through induction of microbleeding will 
also be investigated as this also has the potential to increase oral fluid drug 
concentrations. This study will look at the effects of drug depots and blood 
contamination on oral fluid drug test results and their interpretation.  
 
As part of this study volunteers will be requested to consume a 15 milligram 
codeine tablet, swill liquid codeine and swill J. Collis Browne’s mixture in 
their mouth and spit it out. Attendance at multiple sessions will be required 
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and volunteers are requested not to eat within the half hour preceding each 
session. An oral fluid sample will be collected 15 minutes prior to 
administration and consecutive samples along with buccal swabs from the 
inside of the cheek will be taken following administration. These will be 
collected at the following time points: 15, 30 minutes, 1, 1.5, 2, 2.5 and 3 
hours.  
 
The Concateno Certus device will be used for collection of oral fluid. This 
process is non-invasive and will involve the device being kept in the mouth 
for approximately 2 minutes or until the detector turns blue indicating a 
sufficient volume has been collected. The pad is then inserted into a vial 
containing buffer. Samples will then be stored and analysed at the University 
laboratory.  
 
You will also be requested to fill in a questionnaire providing details of your 
age, sex and whether you are taking any drugs or medications. The 
concurrent use of two or more central nervous system depressant drugs can 
increase drowsiness and reduce alertness. These drugs include opioid 
analgesics, alcohol, antidepressants, antiepileptics, antihistamines 
antipsychotics, anxiolytics, hypnotics and skeletal muscle relaxants. 
Volunteers currently taking medication containing opiates or any of the drugs 
mentioned above and who have allergies to morphine or codeine will not be 
eligible to take part in this study.  
 
 
 
7. Discomforts and Risks:  
   
One risk of giving samples for this research may be the release of your name that 
could be linked to the stored samples and/or the results of the tests run on the 
samples. To prevent this, these samples will be given a unique identification 
code.  Only the study staff will know the code.  The name that belongs to the 
code will be kept in a locked file or in a computer with a password.  Only 
authorized members of the research team will have access to your name.  
 
Another potential risk is the ingestion of codeine. Codeine is a medication 
available over the counter for use in mild to moderate pain relief and as a cough 
suppressant. Volunteers will be required to take a single 15 milligram tablet. 
Participants are warned that these medicines may cause drowsiness. If affected 
do not drive or operate machinery. Alcohol should be avoided. This low dosage 
and route of administration will minimise any potential adverse drug effects. J. 
Collis Browne’s is an opium tincture containing morphine that for the purpose of 
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this study, along with the codeine linctus, will not be swallowed therefore risk of 
adverse effects should be minimal.  
 
8. Statement of Confidentiality: 
 
a. Privacy and confidentiality measures 
 Each sample will be given a unique code for which the samples will 
hereby be known.   
 Samples are going to be analysed at Bournemouth University. The 
information provided throughout this study i.e. (sex, health, drug 
use) will not identify you by name.  
 
The results of this research study may be presented at scientific / medical 
meetings or in scientific / medical publications. The identity of donors will 
not be disclosed in those presentations.  
  
If you agree, samples and results will be stored along with information about 
yourself obtained in the course of this research study (age, sex, health, drug / 
medication use). The information stored will not identify you by name.  
  
If you agree to participate in this study you will receive a signed and dated 
copy of this consent form for your records.  
 
In the event of any publication or presentation resulting from the research, no 
identifiable information will be shared. 
 
We will keep participation in this research study confidential to the extent 
permitted by law. However, it is possible that other people may become aware 
of study participation. For example, the following people/groups may inspect 
and copy records pertaining to this research.  
 
 The Bournemouth University Institutional Ethics Review Board (a 
committee that reviews and approves research studies)   
 
The possibility of identification is very low and every effort will be made to keep 
your personal information in the research record private and confidential but 
absolute confidentiality cannot be guaranteed. 
 
9. Costs for Participation: 
 
 a. Costs:   
There are NO costs for participation in this research 
 
b. Rights: 
Signing this form will lose no legal rights. 
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       c. Compensation:  
   No payment or compensation will be received for participation in this 
research study. 
 
 
10. Voluntary Participation / Withdrawal:  
 
Participation in this research study is voluntary. You do not have to participate in 
this research. If you choose to take part, you have the right to stop at any time. If it 
is decided not to participate or if it is decided to stop participation in the research at 
a later date, there will be no penalty. 
 
11. Contact Information for Questions or Concerns:      
 
You have the right to ask any questions you may have about this research.  If you 
have questions, complaints or concerns about this research, contact Professor David 
Osselton, Centre for Forensic Sciences, Bournemouth University. 
Consent:  
I have read the information in this consent form. All my questions about this study 
and my participation in it have been answered to my satisfaction.  
 
I authorize the collection of oral fluid samples for analysis for the purpose of the 
study by the investigation team at Bournemouth University. 
 
By signing this consent form, no legal rights have been waived, which would 
otherwise have been had for participation in a research study.  
 
 
Please initial the following option:  
 
 
I would like scientists to study my oral fluid sample only to complete the study 
outlined  above and then to discard the oral fluid sample so that other studies 
cannot be done. 
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Signature__________________________________                    Date___________ 
 
Name (please print) _______________________________________ 
 
 
Signature of Person Conducting  
Informed Consent Discussion____________________________          
 
Date___________ 
 
Name (please print) ________________________________________ 
 
  
Signature of Witness ____________________________________  Date 
___________ 
(Required)  
 
Name (please print) ________________________________________ 
 
 
 
 
 
 
 
 
Validation of Oral Fluid as a Matrix for Drug Detection - Appendices 
 
440 
 
Appendix E 
Non-cross reacting compounds for the AlereTM Opiate Metabolite EIA Kit (Chapter 
5) 
Methadone 
Alprazolam Fentanyl Norburprenorphine 
Amobarbital Hexobarbital Norpropoxyphene 
Barbital Ibuprofen Pentazocine 
Benzoylecgonine Ketamine Pentobarbital 
Butabarbital LAAM Phenobarbial 
Caffeine Lidocaine Phentermine 
Carbamazepine LSD (+) Pseudoephedrine 
Chlordiazepoxide Lorazepam (-) Pseudoephedrine 
Clonazepam Medazepam Phenylpropanolamine 
Cocaethylene Mephobarbital PCP 
Cocaine Methaqualone Salicylate 
D9-THC MDEA Secobarbital 
Dextropropoxyphene MBDB Temazepam 
Diazepam MDA Tramadol 
(+) Ephedrine MDMA Tyramine 
(-) Ephedrine Naltrexone Venlafaxine 
EMDP Naloxone Zolpidem 
EDDP 11-nor-9-Carboxy-D9-THC   
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Appendix F 
Protocol for the production of 1000 mL synthythic saliva (Cozart Bioscience 2008) 
(Chapter 7).  
Materials Required  Quantity  Supplier 
De-ionised water 800 mL Fisher Scientific 
Di-Sodium hydrogen 
orthophosphate anhydrous 
2.3 g BDH 
Potassium dihydrogen 
orthophosphate 
0.4 g BDH 
Sodium Chloride 8.77 g BDH 
Bovine Serum Albumin  (BSA) (1.0 
% w/v) 
3.0 g Sigma - Aldrich 
Glucose 0.01 g Fisher Scientific 
Mucin 0.5 g Sigma - Aldrich 
Amylase Type II - A 0.25 g Sigma - Aldrich 
Sodium Azide (0.05 %) 0.5 g BDH 
5-Bromo-5-Nitro-1,3 Dioxane  0.1 g  Sigma - Aldrich 
Polyvinyl Alcohol 4.5 g Sigma - Aldrich 
De-ionised water Make up to 1000 mL Fisher Scientific 
Preparation instructions:     
1. Add the above ingredients but allow the BSA to dissolve before adding 
additional ingredients 
2. Mix on a magnetic stirrer until the PVA has dissolved 
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Appendix G 
Cross reactivity data for the monoclonal benzoylecgonine antibody used for the 
detection of cocaine during immunohistochemical staining (Chapter 7) 
Compounds Cross 
Reactants 
Concentration 
ng/mL 
Apparent 
Benzoylecgonine 
Reactivity (%) 
Cocaine 
300 277.1 92.4 
50 46.4 92.8 
10 10.2 102.0 
Cocaethylene 
300 290.9 97.0 
50 59.9 119.7 
10 13.0 129.7 
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Appendix H 
Cross reactivity data for the monocolonal morphine antibody used for the detection 
of cocaine during immunohistochemical staining (Chapter 7) 
Compounds Cross 
Reactants 
Concentration 
ng/mL 
Apparent 
morphine Reactivity (%) 
6 MAM 
500 434 86.8 
100 88 88.0 
10 9.3 93.0 
5 4.7 94.0 
Codeine 
100 186 186.0 
10 18 180.0 
5 9 180.0 
1 2 200.0 
Dihydrocodeine 
500 432 86.4 
100 93 93.0 
10 10 100.0 
5 5 100.0 
Heroin 
500 623 124.6 
100 81 81.0 
10 8 80.0 
5 5 100.0 
1 2 200.0 
Morphine 3 glucuronide 
500 532 106.4 
100 150 150.0 
10 10 100.0 
5 5 100.0 
 
 
Validation of Oral Fluid as a Matrix for Drug Detection - Appendices 
 
445 
 
Appendix I 
Images of stained slides of mice injected with a saline control using an 
immunohistochemical technique (Chapter 9) 
Mice Tongue of Saline group Stained section (salivary gland) 
1 
  
  
2  
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Mice Tongue of Saline group Stained section (salivary gland) 
3  
  
4  
  
5 
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Mice Tongue of Saline group Stained section (salivary gland) 
  
6  
 
 
 
 
